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GABAA receptors are ligand-gated ion channels principally responsible for inhibitory 
neurotransmission in the mammalian CNS. GABA binding initiates a series of 
conformational changes causing the receptor to transition from inactive (shut/closed) 
to active (open) ion channel states; and during prolonged agonist exposure, to a 
desensitized (closed) state. Critical to the fine-tuning of inhibitory responses in vivo is 
the allosteric modulation of GABAA receptors by an array of compounds, many of 
which impart their effect through binding within the receptor’s transmembrane 
domain.  
Beyond the importance of GABA-mediated inhibition in maintaining nervous system 
function, GABAA receptors are established therapeutic targets for psychiatric and 
neurodevelopmental disorders. Despite this, an understanding of the structure of 
these receptors at atomic resolution is crucially lacking; particularly with regards to the 
structural elements underpinning channel gating and allosteric modulation. Therefore, 
GABAA receptor ion channels were subjected to atomic-resolution structural analyses 
using chimeric receptors, in addition to comparative studies with bacterial ion channel 
homologues. 
A functional receptor was formed from chimeras between the extracellular domain of 
the prokaryotic ion channel GLIC and the transmembrane domain of GABAA receptor 
α1 subunits. These receptors exhibited GABAA receptor-like properties with respect to 
their response to brain neurosteroids. The amenability of this receptor to high-level 
expression and purification was assessed. The baculovirus-insect cell expression 
system was identified as an appropriate system for generating receptor of sufficient 
quantity and purity to generate diffracting protein crystals.   
Additional studies of GABAA receptor modulators at the bacterial homologs GLIC and 
ELIC identified previously unreported effects prompting further structural investigation 
using X-ray crystallography, cryo-electron microscopy and native mass spectrometry.  
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In conclusion, these studies reveal a new system for atomic structural resolution 
investigation of GABAA receptor subunits, likely to be applicable to other receptors. 
These receptors are potentially powerful tools for understanding the mechanism of 
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LC   Locally-closed 
LGIC   Ligand gated ion channel  
MS   Mass spectrometry 
nAChR   Nicotinic Acetylcholine Receptor 
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NMDA   N-Methyl-D-aspartate 
NMR   Nuclear Magnetic Resonance 
nMS   Native Mass Spectrometry 
pH50 The pH (or concentration of protons) eliciting 50% of the maximal response 
PDB Protein Data Bank 
PEG   Polyethylene glycol 
pLGIC   Pentameric-ligand gated ion channel 
PNS   Peripheral Nervous System 
POPC    1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
PS   Pregnenolone Sulphate 
PTX   Picrotoxin 
RMSD   Root-Mean-Square Deviation 
SA   Spontaneous activity 
SDS PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC   Size exclusion chromatography 
TEVC   Two-electrode voltage-clamp  
THDOC   Tetrahydrodeoxycorticosterone 
TMD   Transmembrane Domain 
TRP   Transient Receptor Potential channel 
UDM   n-Undecyl-β-D-Maltopyranoside 








Chapter 1: Introduction 
1.1. Pentameric-ligand gated ion channels 
Underpinning neuronal activity in the central and peripheral nervous systems (CNS and 
PNS) are neurotransmitter-gated ion channels and metabotropic receptors. Amongst 
these neurotransmitter receptors is the pentameric-ligand gated ion channel (pLGIC) 
superfamily, comprised of anionic Type-A γ-aminobutyric acid receptors (GABAAR) and 
glycine receptors (GlyR); cationic nicotinic acetylcholine receptors (nAChR) and type 3 
5-hydroxytryptamine receptors (5-HT3; serotonin); and additionally zinc-activated 
cation channels (ZAC; Smart and Paoletti, 2012). Upon the release of neurotransmitter, 
these receptors rapidly respond to enable ion flow across the plasma membrane and 
effect neuronal cell excitation (mediated by acetylcholine and serotonin) and inhibition 
(mediated by GABA and glycine). Formerly defined as “Cys-loop” receptors (owing to a 
highly conserved Cys-containing structural loop), the pLGIC superfamily extends to 
anionic-invertebrate receptors activated by glutamate and serotonin (as well as 
cationic-GABA gated invertebrate receptors) and the recently identified bacterial 
homologs from Gloeobacter violaceus (GLIC) and Erwinia chrysanthemi (ELIC; Miller 
and Smart, 2010; Corringer et al., 2012; Smart and Paoletti, 2012). In order to 
understand the normal functional role of these receptors, their pharmacology and how 
dysfunction confers disease states; substantial efforts have been made to obtain high-
resolution three-dimensional structures of pLGICs. From the ensemble of available 
structures X-ray structures of GLIC, ELIC, Glutamate-gated chloride channel (GluCl) 
from C. elegans, human homomeric GABAA β3, human α3 GlyR and mouse 5-HT3 
receptors, plus electron microscope (EM) structures of torpedo nAChR and zebrafish 
α1 GlyR one can begin to appreciate the concerted rearrangement of atoms that occur 
at pLGICs following transmitter release and binding to their orthosteric sites (Unwin, 
2005; Hilf and Dutzler, 2008; Bocquet et al., 2009; Hilf and Dutzler, 2009; Hibbs and 
Gouaux, 2011; Althoff et al., 2014; Hassaine et al., 2014; Miller and Aricescu, 2014; Du 
et al., 2015; Huang et al., 2015). 
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The main focus of this thesis is the mechanistic details of ionotropic GABAA receptor 
activation, and how this is allosterically modulated. The structural elements underlying 
these events are likely conserved across pLGIC family members. In light of this, the 
GABAA receptor family is introduced first, emphasizing its physiological function and 
pharmacology. Given the limited structural information for GABAA receptors, the 
mechanistic details of ligand binding, channel gating and allosteric modulation in the 
framework of the currently available structural and functional information across the 
pLGIC family is also considered.  
 
1.2. GABAA receptors 
The complex interplay of excitatory and inhibitory LGICs is crucial for maintaining 
normal neural network activity. In the mammalian CNS the neurotransmitter GABA is 
the predominant mediator of inhibition (Moss and Smart, 2001). GABA release 
activates ionotropic (GABAA) and metabotropic (GABAB) receptors. In the context of 
the mature neuronal network, activating GABAA receptors causes fast inhibition, 
resulting from an increased transmembrane flux of anions, membrane 
hyperpolarization (usually) and an electrical shunt of the neuronal membrane (Nicoll et 
al., 1990; Staley and Mody, 1992).  
This, however, is an oversimplification of GABAergic transmission. During 
development, GABAA receptor activation plays a pivotal role in synapse formation and 
refinement of neuronal networks. In the immature nervous system, where neuronal 
transmembrane chloride levels form a depolarising electrochemical gradient, 
activation of GABAA receptors results in a membrane-depolarizing effect (Ben-Ari et al., 
2012; Hubner and Holtoff, 2012). Thus early in development, these receptors mediate 
the main excitatory drive in neuronal networks. Moreover, this depolarizing GABA-
mediated response can be sufficient to trigger calcium influx, which has been 
implicated in modulating neuronal cell migration and growth as well as synapse 
formation (Ben-Ari, 2002; Farrant and Nusser, 2005). As the nervous system matures, 
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and concurrent with a change in intracellular chloride levels to lower concentrations, 
there is a shift in the typical functional response to GABA release, which now drives 
neural inhibition (Farrant and Kaila, 2007).  
1.2.1. GABAA receptor structure 
As for other pLGIC-family members, GABAA receptors are characterized by the 
pentameric arrangement of subunits around a central pore that constitutes the 
integral ion channel (Fig 1.1 A). The GABAA receptor family is highly diverse with eight 
subunit families, yielding 19 subunits, identified in the genome. These consist of α1-6, 
β1-3, γ1-3, δ, ε, π, θ and ρ1-3 (Olsen and Sieghart, 2008; Olsen and Sieghart, 2009). 
Moreover, alternative splicing of RNA of certain subunits (e.g. splicing of the γ2 subunit 
producing short and long variants) ensures even greater receptor subunit diversity 
(Möhler, 2006; Farrant and Nusser, 2005). Between subunits of the same family there 
is ~70% sequence identity, whilst between members of the different families, ~20-40 % 
sequence identity (or 50% sequence similarity) is observed (Sigel and Steinmann, 
2012). 
Despite this diversity, GABAA receptor subunits share a common core of structurally 
defined domains (Fig 1.1). Indeed, this core is observed across all pLGIC family 
members (and is described later in greater detail), emphasizing the modular nature of 
these receptors. The large N-terminal domain is normally exposed to the extracellular 
space and consequently is referred to as the extracellular domain (ECD; Fig 1.1 B). 
Extensive studies reveal that this domain houses the orthosteric agonist (GABA) 
binding site (formed at the β-α subunit interface), as well as binding constituents for 
allosteric modulators including for example, the benzodiazepines (at the α-γ subunit 
interface). Additionally, the ECD is the location of the characteristic Cys-loop (formed 
by a disulphide bond between Cys-residues) which is juxtaposed to the cell membrane. 
Spanning the cell membrane are four (α-helical) transmembrane segments (M1-M4), 
which are arranged within a single subunit to form a four α-helical bundle and are 
referred to as the transmembrane domain (TMD; Fig 1.1 A). In the pentameric 
assembly the M2 domains combine to form the channel pore, which allows for 
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selective permeation of anions across the membrane (principally chloride and 
additionally bicarbonate ions). Extending from the base of M3 and M4 helices in to the 
intracellular space is a large stretch of amino acids which form a presumably 
unstructured loop and is now defined as the intracellular domain (ICD; Fig 1.1 B). As 
the most variable feature across GABAA receptor subunits (and indeed pLGICs), this 
domain can vary substantially in length (in excess of 100 amino acid residues for some 
subunits). Though without appreciable secondary structure (on the basis of structural 
predictions), this domain forms the binding locations of interacting and accessory 
proteins, as well as influencing receptor activity through modulation via post 
translational modification, such as phosphorylation and ubiquitination (Moss and 
Smart, 2001; Lüscher et al., 2011).  
 
 
Figure 1.1 – GABAA receptor structure 
A. Native α1β2γ2 GABAA receptor assembly in a 2:2:1 subunit stoichiometry with an “anticlockwise” 
arrangement of βαβαγ (as viewed from the extracellular space). The arrangement of M1-M4 helices is 
shown, with the M2 helix lining the channel. Binding of GABA and benzodiazepines occurs in the ECD at 
β-α and α-γ subunit interfaces respectively.  B. Global architecture and arrangement of subunits shows 
approximate location of orthosteric agonist binding site (at β-α interface), “Cys-loop” (loop 7) and ICD.  




) flow passively across the cell membrane.  
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1.2.2. GABAA receptor composition and assembly 
While these core domains are observed across all subunit families, energetic 
interactions at subunit interfaces dictate the allowed composition and arrangement of 
subunits in the pentameric assembly. Ultimately the final composition of a receptor 
critically influences receptor function and pharmacology, as well as regional and 
subcellular expression profiles in the brain. Despite the multiplicity of subunit isoforms 
and possible combinations, in vivo studies suggest probably less than ~20 GABAA 
receptor native subtype combinations exist with αβγ (in a 2α:2β:1γ stoichiometry; 
Fig1.1) and αβδ amongst the prominent combinations (Möhler, 2006; Olsen and 
Sieghart, 2008). The majority of native GABAA receptors are composed of α1β2γ2, 
accounting for ~40 – 60% of all expressed receptors (Sieghart and Sperk, 2002; Möhler, 
2006).  
In vitro, GABAA receptors can assemble in to considerably more diverse combinations 
comprising homopentamers of a single subunit (e.g. ρ or β subunits) and 
heteropentamers of two or three subunit classes. It is notable that α subunits are 
presumably unable to assemble as homopentameric receptors, even in recombinant 
expression systems, though a functional chimeric receptor between the ECD of ρ1 and 
the TMD of α1 has been reported (Martínez-Torres et al., 2000; Gielen et al., 2015). 
This emphasizes the importance of specific, energetically favoured interactions that 
govern receptor assembly. Indeed receptor imaging studies reveal that native (single) 
α-subunits are expressed and retained in the ER, requiring association with β subunits 
(and normally β and γ subunits) as the minimal subunit assembly cohort for trafficking 
to the cell surface (Connolly et al., 1996; Kittler et al., 2000). The formation of αβ 
heterodimers is reported to precede the formation of the receptor heteropentamer, 
and is determined by specific interactions in the N-termini of receptor subunits 
(Lüscher et al., 2011). Studies of heterologously-expressed β3 homomers reveal the 
role of N-terminal amino acids (G171, K173, E179 and R180) in mediating functional 
homomeric receptor expression (but not of αβ heteromers; Taylor et al., 1999). Studies 
of α1-subunits further suggest a role for two invariant tryptophan residues (W69 and 
W94 residues located in the N-terminus; Srinivasan et al., 1999) in forming the α-β 
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subunit interface and of an N-terminal residue “cassette” (residues 58-67) in formation 
of α1 and α6 containing receptors (in combination with β and γ subunits; Taylor et al., 
2000). Currently, it is unclear as to what interactions prevent receptor (homo-) 
oligomerization and subsequent trafficking to the cell surface.  
1.2.3. Phasic and tonic inhibition 
In addition to setting the pharmacological profile of a receptor, subunit composition 
plays an important role in defining GABAA receptor populations at the levels of brain 
region, neuronal cell type and subcellular localisation. In concert with the specific 
functional properties of different receptor composition, this allows for differential 
responses dependent on local GABA and modulator concentrations. This is most 
noteworthy for receptors targeted to the synapse, and those excluded from this 
region, termed extrasynaptic (Fig 1.2). The former, composed principally of α(1-3)βγ 
subunits, respond to the transiently high synaptic concentrations of GABA (in the mM 
range) in the synaptic cleft, mediating phasic (fast synaptic) inhibition (Jones and 
Westbrook, 1995; Rudolph and Möhler, 2004). The latter, extrasynaptic, receptor 
populations (including αβ, α5βγ, α4βδ and α6βδ compositions; notably δ-containing 
receptors are apparently exclusively extrasynaptic) respond to low ambient GABA 
levels (in the low nM to μM range) outside of the synaptic cleft. The results of this 
response is to provide low intensity, persistent inhibition, termed tonic inhibition 
(Farrant and Nusser, 2005; Brickley and Mody, 2012). Additionally presynaptic GABAA 
receptors have been reported, though with less clearly defined pharmacological 
properties and physiological role (Draguhn et al., 2008; Ruiz et al., 2010). 
The functional response to GABA is distinct amongst receptors mediating phasic and 
tonic inhibition, in terms of receptor kinetics (Fisher and Macdonald, 1997), and likely 
sets the tone for the inhibitory response. It should also be noted that distinct 
sensitivities to endogenous (e.g. neurosteroids) and exogenous (e.g. anaesthetics) 
allosteric modulators are observed at synaptic and extrasynaptic receptors (Fig 1.2; 
Brickley and Mody, 2012). Maintaining a fine balance between the two major forms of 





Figure 1.2 - GABAergic transmission and neurosteroid modulation in the CNS 
Presynaptic GABA release activates synaptic and extrasynaptic populations of GABAA receptors and 
GABAB receptors on postsynaptic neurons. Activation of synaptic GABAA receptors results in phasic 
inhibition of postsynaptic nerve cells, while continuous activation of extrasynaptic receptors contributes 
to tonic inhibition. The role of pre-synaptic GABAA receptor activation is not clearly defined. Release of 
endogenous neurosteroids from neurons and glial cells and binding to GABAA receptors positively 
modulates receptor function (prolonging the decay of the inhibitory response).   
 
1.2.4. GABAA receptor trafficking  
Underlying the precise control of inhibitory GABAergic transmission is tight regulation 
of the number of GABAA receptors trafficked to and clustered at the synapse. 
Mechanisms that influence trafficking of receptors to and from the cell surface 
involves a variety of receptor associated molecules and their respective post-
translational modifications (Moss and Smart, 2001; Jacob et al., 2008). The binding 
sites for many of these accessory proteins, as well phosphorylation consensus 
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sequences are found within the large subunit ICD between M3 and M4 (Lüscher and 
Keller, 2004; Lüscher et al., 2011). 
GABAA receptors are anchored at the inhibitory synapse by gephyrin and dystroglycan, 
whilst binding with GABARAP (GABA receptor associated protein), Plic-1 and 
Huntingtin-Associated Protein 1 is believed to affect surface stability and receptor 
trafficking (Kittler et al., 2004; Lüscher and Keller, 2004; Jacob et al., 2008; Lüscher et 
al., 2011). Additionally, phosphorylation of receptors and receptor binding proteins 
influences trafficking (Smart and Paoletti, 2012). Phosphorylation consensus 
sequences have been identified for α4, β(1-3) and γ2 subunits (within the ICD), where 
they act as substrates for serine-threonine and tyrosine kinases, and modulate cell 
surface receptor expression (Comenencia-Ortiz et al., 2014). Moreover receptor 
phosphorylation has been shown to alter the functional (e.g. β subunit 
phosphorylation alters receptor desensitization and deactivation) and pharmacological 
(e.g. neurosteroid binding enhances phosphorylation of α4-containing receptors) 
profile of GABAA receptors (Hinkle and Macdonald, 2003; Comenencia-Ortiz et al., 
2014; Adams et al., 2015). Notably, receptors are dynamic entities within the plasma 
membrane and are able to exchange with extrasynaptic/perisynaptic receptors, 
transferring via lateral mobility in the cell membrane (Thomas et al., 2005; Bogdanov 
et al., 2006). As with the previous mechanisms, this assists in maintaining receptor 
number at the synapse 
1.2.5. GABAA receptor pharmacology 
A defining feature of the GABAA receptor is the diverse pharmacological profile 
displayed across receptor subunit subtypes. Unsurprisingly, this profile is dramatically 
altered by the differential arrangement of subunits, rendering receptors sensitive or 
insensitive to a range of endogenous and synthetic compounds. Moreover, the 
receptor pharmacology allows for clear identification of the functional effects of 
specific GABAA receptors over other ionotropic and metabotropic (notably GABAB) 
receptors of the CNS.   
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Crucial to the definition of receptor pharmacology is an understanding of the 
mechanism of binding and action. One can also differentiate between pharmacological 
agents solely on the basis of where they bind; either at sites within the receptor ECD or 
TMD, and their functional effect; to directly activate the receptor or modulate receptor 
function in a positive or negative manner. 
1.2.6. GABAA receptor ECD pharmacology 
The ECD houses the orthosteric agonist (GABA) binding site, formed at the interface of 
β-α subunits of native α1β2γ2 GABAA receptor (forming two sites per receptor; Fig 
1.1). Homopentameric ρ1 receptors are similarly GABA-gated, bearing five analogous 
agonist binding-sites at all subunit interfaces (Smart and Paoletti, 2012). The structure 
of this site, largely conserved across pLGICs, is discussed in greater detail in Section 1.4. 
Other key receptor agonists, binding at the GABA-binding, site are the high-affinity 
agonist muscimol and partial agonist 4,5,6,7-Tetrahydroisoxaolo[5,4-c]pyridine-3-ol 
(THIP).  Selective receptor antagonism is imparted by the binding of bicuculline and 
gabazine at the orthosteric site (Johnston, 2013).  
Of the compounds that bind at sites homologous to the orthosteric site (i.e. at non-
agonist binding subunit interfaces), the best characterised (in terms of binding and 
functional effect) are the benzodiazepine class of drug (Fig 1.1 A). These drugs have 
high clinical significance and are widely prescribed owing to their profound effects in 
treating insomnia, anxiety, and convulsions (Rudolph and Knoflach, 2011). 
Benzodiazepines (e.g. diazepam) are positive allosteric modulators of GABAA receptors 
and act to potentiate submaximal GABA responses through increasing the apparent 
affinity of a receptor to GABA (Rudolph and Knoflach, 2011). Binding is mediated by 
residues at the interface of α and γ subunits and is proposed to promote the formation 
of a pre-activation state prior to channel gating (presumably through global 
rearrangement of receptor structure; Gielen et al., 2012). Although there is a 
requirement of an α-γ subunit interface, benzodiazepines are selective to the extent 
that modulation is restricted to α1,2,3,or 5-containing receptors, excluding modulation 
of δ-containing receptors, which nominally replaces the γ2 subunit in 
26 
 
heteropentameric GABAA receptors. Moreover the relationship between binding and 
receptor potentiation can be further refined (from knock-in mouse studies)by the 
requirement of a critical histidine residue in α subunits (α1H101, α2H101, α3H126 and 
α5H105; Wieland et al., 1992; Benson et al., 1998), the absence of which in α4 and α6 
subunits renders them insensitive to benzodiazepines. Further expansion of the 
structure of the benzodiazepine-binding pocket (principally by homology modelling, 
molecular docking and mutagenesis studies) will ultimately assist in the generation of 
specific α-selective compounds with fewer side effects (Richter et al., 2012) 
 
1.2.7. GABAA receptor TMD pharmacology 
The TMD contains the pore-forming and lipid-bilayer interacting elements of the 
GABAA receptor and, unsurprisingly, the binding sites for a wide range of endogenous 
and synthetic compounds that can directly activate or modulate channel function.  The 
list contains compounds exhibiting great diversity in chemical structure, and includes 
volatile and intravenous anaesthetics (including etomidate, propofol and barbiturates), 
Zn2+, protons, and neuroactive steroids (Wilkins et al., 2002; Franks, 2008; Hosie et al., 
2009; Hosie et al., 2003).  
Many of these compounds, particularly anaesthetics, impart their effect through 
binding to the β subunit in heteromeric receptors, and more precisely at a site 
proximal to the 15’ M2 residue (Miller and Smart, 2010). Though introduced in greater 
depth in Section 1.3 the prime numbering system has been established to identify 
residues in M2 (the pore lining α-helices); starting at 0’ (at the cytoplasmic side, a 
conserved arginine) to 20’ (at the extracellular end). This 15’ residue is ideally situated 
to translate binding and/or transduction of a binding signal to the M2 helix and affect 
channel conformation. Evidence for the former (coordination of binding) is provided 
from studies comparing the sensitivity of β1 versus β2/3 containing GABAA receptors 
to modulation by anticonvulsants, a non-steroidal anti-inflammatory agent 
(mefenamic acid) and the anaesthetic etomidate (Miller and Smart, 2010). The 
equivalent 15’ residue of the α-subunit (Ser260) is widely recognised as a major 
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determinant of general anaesthetic and alcohol action in GABAA receptors and Gly 
receptors (Mihic et al., 1997). 
While the aforementioned compounds typically enhance receptor function, acting as 
allosteric agonists or positive allosteric modulators (PAMs), inhibition of the GABAA 
receptor at the level of the TMD is provided by distinct classes of compounds, termed 
negative allosteric modulators (NAMs). Channel blocking agents, including picrotoxin 
and t-butyl-bicyclophosphoro-thionate (TBPS) bind within the channel pore and 
prevent ion flow (Van Renterghem et al., 1987; Bali and Akabas, 2007; Gielen et al., 
2015) (Fig 1.3 A). Block by these compounds can subsequently be relieved at high 
GABA concentrations.  
While the channel-block effects of picrotoxin are clearly defined, allosteric inhibition of 
GABAA receptors by a class of endogenous (inhibitory) neurosteroids (including 
pregnenolone sulphate (PS), dehydroepiandrosterone sulphate (DHEAS)) is apparently 
more complex and consequently poorly understood. In contrast to the potentiating 
neurosteroids (discussed below), inhibitory steroids are less potent effectors at GABAA 
receptors and inhibit receptor function in a complex kinetic manner (Seljeset et al., 
2015). Extensive electrophysiological studies of receptors expressed in recombinant 
systems have yet to provide a unanimous description of preferential binding for PS to a 
distinct activation state of the receptor (with binding observed for receptors in both 
inactive and active states; Akk et al., 2001; Eisenman et al., 2003). Moreover apparent 
promotion of the desensitized form of the receptor upon binding adds further 
complexity to the kinetic profile of these steroidal compounds (Wang et al., 2002; 
Eisenman et al., 2003). While efforts have been made to ascertain a mechanism of 
binding for inhibitory steroids, the location of a site remains elusive. A point of note, 
however, being that a transmembrane-located intrasubunit site mediating the effects 
of positive modulatory steroids (introduced below) does not overlap with a site 





Figure 1.3 - GABAA receptor transmembrane domain pharmacology 
A. Picrotoxin acts in a non-competitive manner by blocking the pore and preventing the flow of ions 
(Bali and Akabas., 2007; Hibbs and Gouaux., 2011). Anaesthetics bind at the interface formed with β 
subunits; propofol at α-β, β-α and γ-β and etomidate at β-α (Chiara et al., 2012). Endogenous positive 
neurosteroids, e.g. THDOC binds at an intrasubunit site within α-subunits and potentiates receptor 
function. B. Mutagenesis studies suggest THDOC potentiation is coordinated by α1 M1 (Q241) and M4 
(N407 and Y410) residues and activation by different α1 M1 (T236) and β2 M3 (Y284) residues (Hosie et 
al., 2006) C. Photo-affinity labelling studies suggest that residues forming the presumed neurosteroid 
activation site are unlikely to be positioned at the β-α interface when etomidate is bound. Azi-etomidate 
photo-labelled residues at the interface are found at α1 M1 Met236 and β3 M3 Met286 (Li et al., 2009). 
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1.2.8. Neurosteroid modulation of GABAA receptors 
An important class of endogenous GABAA receptor allosteric modulators is the 
potentiating neurosteroids, e.g. allopregnanolone and tetrahydrodeoxycorticosterone 
(THDOC). These are metabolites of progesterone and deoxycorticosterone, which 
directly bind to and enhance the GABA response at GABAARs(Belelli and Lambert, 
2005; Lambert et al., 2009). Experiments in the 1940’s characterized the sedative and 
anaesthetic effect of pregnane steroids (reviewed by Lambert et al., 2009). Their 
mechanism and site of action however remained unknown for many years until 
Harrison and Simmonds (in the 1980’s) used the synthetic steroidal anaesthetic 
alphaxalone and demonstrated that, as for other sedatives such as barbiturates and 
benzodiazepines, the site of steroid action was the GABAA receptor (Harrison and 
Simmonds, 1984; Reddy, 2010). This was confirmed by studies of endogenously 
synthesized steroids (in electrophysiological recordings and 36Cl- flux into 
synaptosomes), showing that they were potent modulators of GABAA receptors 
(Lambert et al., 2009). 
Neurosteroids modulate GABAA receptors in a biphasic manner. At low nanomolar 
concentrations they potentiate the GABA response, whilst at higher submicromolar-to-
micromolar concentrations they directly activate the receptor (Hosie et al., 2006; 
2009).  Interaction studies with the barbiturate pentobarbital suggested that 
neurosteroids bind at a distinct site (Lambert et al., 2009). This led to the postulate 
that these low and high concentration effects for neurosteroids were mediated by two 
distinct binding sites on the GABAAR. Electrophysiological studies of recombinant 
GABAARs using point mutations (guided by homology modelling and receptor 
chimeras) provided initial insight into the location of these two sites (Hosie et al., 
2006). An intrasubunit potentiation (low steroid concentration) site, conserved 
amongst the α-subunit family, lies within a cavity of the TMD (normally occupied by 
membrane lipids) where steroid binding is coordinated by residues in M1 and M4 (Fig 
1.3 B). At higher neurosteroid concentrations an additional site was proposed; an 
interfacial-binding pocket (between α subunit M1 and β subunit of M3) to initiate 
direct activation of the receptor (Fig 1.3 B). Subsequent studies on the binding of the 
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general anaesthetic etomidate have however questioned the precise location of the 
activation site, with the residues identified as forming an activation site no longer 
ideally located at the subunit interface for neurosteroid binding when a photoactive 
derivative of etomidate (azietomidate) is also bound to the receptor (Li et al., 2009) 
(Fig 1.3C). Further analysis is evidently required to probe the location of an activation 
site. 
The need to better define the specific sites of neurosteroid action comes from the 
experimental and clinical evidence that suggest an endogenous role for neurosteroids 
in neurological and psychiatric conditions. During stress, pregnancy and following 
ethanol consumption there is an up regulation in steroid synthesis, and the resulting 
(local) nanomolar levels of steroid are able to potentiate the GABA response(Belelli 
and Lambert, 2005). Disruption of this endogenous neurosteroid response potentially 
results in a number of disorders including depression, anxiety, alcoholism and epilepsy 
(Reddy, 2010; Wang, 2011).The treatment of these conditions therefore represents an 
area for the development (and then clinical application) of synthetic neurosteroid 
analogs with improved pharmacokinetics and efficacy. Our ability to generate potential 
new candidates will benefit from a clearer understanding of the molecular 
mechanisms of steroid mediated responses.    
In the framework of recently solved receptor structures, and on the basis of structure-
function studies, we will further discuss the determinants of binding for a number of 
these modulators in Section 1.6. 
 
1.2.9. GABAA receptors as therapeutic targets in disease states 
GABAA receptors have been implicated directly in the etiology of many disorders of the 
brain, including: anxiety disorders, cognitive disorders, epilepsies, mood disorders, 
schizophrenia and sleep disorders (Johnston, 2005; Möhler, 2006; Smart and Paoletti, 
2012; Rudolph and Möhler, 2014; Braat and Kooy, 2015). It is beyond the scope of this 
thesis to introduce all these disorders in detail. It is of little surprise that GABAA 
31 
 
receptors form the target for a variety of pharmacological and therapeutic agents, as 
introduced above, which act to modify receptor activity in a manner often dependent 
on specific receptor subunit combinations (Rudolph and Möhler, 2014). Although a 
number of drugs in widespread clinical use are effective for the provision of 
anaesthesia and sedation, as well as in treating anxiety and insomnia (Rudolph and 
Knoflach, 2011), it might be reasoned that detrimental drug side-effects could be 
better understood by establishing how these agents act at the atomistic level. 
Ultimately, this will only be possible with further high-resolution structural studies, 
which might form the template for rationale design of compounds exhibiting greater 
subunit specificity.  
 
1.3. Structural basis for pLGIC activation and allosteric modulation 
As established pLGICs play a pivotal role in responding to the major neurotransmitters 
in the brain and mediating intracellular communication between nerve cells (Katz and 
Miledi, 1966). Neurotransmitter release stimulates ion flux through either cation-
selective channels (principally nACh and 5-HT3 receptors), inducing an excitatory 
(membrane depolarizing) response, or anion-selective (principally GABAA or Gly 
receptors), inducing an inhibitory (hyperpolarizing) response (Miller and Smart, 2010). 
Common to all these receptors is the pentameric assembly of receptor subunits 
around a central ion channel. Moreover, and as introduced for the GABAA receptor 
family, a common feature of complexity and diversity results from the multiple subunit 
isoforms observed across pLGICs. For GABAARs, eight subunit families have been 
identified; GlyRs have two subunit families (α and β); nAChRs are formed from five 
subunit families (yielding 19 subunit isoforms); and 5-HT3 are typically formed from 





pLGICS are typically found as heteromeric arrangements under physiological 
conditions (Unwin, 1995), displaying distinct functional and pharmacological profiles 
dependent on the specific subunit isoforms present. Ultimately this complexity and the 
consequential difficulty in obtaining high yields of purified protein has precluded many 
of these receptors from being subjected to extensive high-resolution structural studies. 
The identification of receptor orthologs across wider metazoan life (from invertebrates 
to fish; as well as humans and mammals), and in the genomes of a few bacterial 
species, has ultimately provided a greater source of receptors from which to build a 
repertoire of pLGIC structures (Tasneem et al., 2005; Corringer et al., 2012). Indeed the 
first crystal structures of full-length pLGICs were from bacterial sources; Erwinia 
chrysanthemi (ELIC) and Gloeobacter violaceus (GLIC) (Hilf and Dutzler, 2008; Bocquet 
et al., 2009; Hilf and Dutzler, 2009). Unsurprisingly, given their early appearance in 
evolution, these bacterial receptors exhibit a simplified subunit composition, being 
formed of a single subunit type in a homopentameric arrangement, while exhibiting 
the common core of structural elements observed across the pLGIC family. More 
recently, and in line with advances in biochemical techniques and structure 
determination methods, there has been an influx of full-length (or minimally modified) 
receptor structures of eukaryotic lineage, including: X-ray structures of a glutamate-
gated chloride channel from C. Elegans (GluClα), human homomeric GABAA β3, human  
α3 GlyR and mouse 5-HT3 receptors; and cryo-EM structures of zebrafish α1 GlyR 
(Hibbs and Gouaux, 2011; Althoff et al., 2014; Hassaine et al., 2014; Miller and 
Aricescu, 2014; Du et al., 2015, Huang et al., 2015). From this ensemble of structures, 
common principles of signal transduction and receptor modulation can be identified, 








Figure 1.4 - Overview of allosteric transitions from structures of pLGICs 
A simplified conformational model of signal transduction is shown in this schematic diagram derived 
from a summary of crystal and EM structures of receptors solved in distinct conformational states. 
These are based on four states: Resting, Active, Desensitized (Fast) and Desensitized (Slow), with the 
position of a pre-activation or “flip” state also shown. The structures are complemented by a simplified 
pair of subunits (rectangles) showing the ion channel gate, with (green circles) or without agonist 
binding. For simplicity, direct isomerisation between non-adjacent states is not shown. The position of 
various pLGICs shows the likely conformational state in which these were first solved. Structures of  
Torpedo nAChR, GLIC and GluClα have been generated in resting and active conditions. The 5-
HT3receptor is very similar to other published open channel structures, though with a more constricted 
pore conformation. ELIC and GABA β3 receptor structures are proposed to represent pLGICs in distinct 




1.3.2. Conformational transitions in pLGIC gating 
Despite the evolutionary distance between neurotransmitter-gated channels  
(mediating fast synaptic neurotransmission) and their bacterial orthologs (for whom 
physiological roles are still poorly understood), there appears to be a common 
allosteric scheme for receptor function (Cecchini and Changeux, 2014).  At rest the ion 
channel is closed, preventing the flow of ions. Upon agonist binding, the receptor 
undergoes rapid conformational changes, resulting in channel opening allowing the 
passive flow of ions across the membrane (Colquhoun, 2006) (Fig 1.4). Typically during 
prolonged agonist exposure, the flow of ions diminishes as the receptor enters 
desensitized state(s) (in which the channel transitions to a closed state despite the 
presence of bound agonist; Katz and Thesleff, 1957). Eventually the receptor returns to 
an agonist unbound-resting form (Fig 1.4). Ultimately this is an over-simplified picture 
of events, and the allosteric transition between states is characterised by the presence 
of receptor intermediates. These states and the intermediates have been extensively 
studied by electrophysiological and computational methods and can be distinguished 
by their life times (Auerbach, 2015). Ultimately, obtaining high-resolution 
crystallographic structural information of a single receptor in all states has not yet 
been possible; unsurprising given that some intermediates are likely short-lived and 
thermodynamically unstable (and consequently refractory to crystallization).   
Given the apparent conservation of three-dimensional structure across the pLGIC 
superfamily we can assign individual receptor structures to distinct allosteric states 
(Fig 1.4) allowing for an ensemble interpretation of receptor activation and 
modulation (in light of complementary functional studies). In introducing a mechanism 
for pLGIC activation and modulation, we have focused principally on GluClα and GLIC, 
which provide the most extensive repertoire of crystallographic structures for single 
receptors in distinct states and in complex with orthosteric agonist and allosteric 
modulators (Hibbs and Gouaux, 2011; Althoff et al., 2014; Sauguet et al., 2014a; 
2014b). We also introduce a recent development in high-resolution structural studies 
of allosteric transitions of a single pLGIC (of the zebrafish α1 GlyR), made possible by 
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recent developments in electron cryo-microscopy (cryo-EM) (Cheng et al., 2015; Du et 
al., 2015).  
 
1.3.3. General architecture of pLGICs 
As epitomized by early electron micrographs of Torpedo nAChR (at 4Å) and latterly of 
GluClα (at 3.3Å, in complex with stabilizing Fab antibody fragments and ivermectin), 
we can define a general architecture for pLGICs (Unwin, 2005; Hibbs and Gouaux, 
2011). While (pentameric) receptors can vary in molecular mass from 150 – 300 kDa 
(Corringer et al., 2012), the receptor is formed of five subunits, with each subunit 
bearing a core “modular” structure comprised of an ECD, TMD and ICD (the latter 
exhibiting greatest structural variability). The resulting receptor is typically 110Å in 
length (excluding the ICD) and 60Å wide (Fig 1.5).  
 
1.3.4. The extracellular domain 
The ECD of GluClα, in agreement with earlier structures of isolated-soluble pentameric 
ECDs of the acetylcholine-binding protein from molluscs (Brejc et al., 2001; Celie et al., 
2004), is folded in an antiparallel-arrangement of β-sheets (Fig 1.5). The inner 
hydrophobic residues stabilize this immunoglobulin-like β-sandwich. While this 
arrangement is a common feature across prokaryotic and eukaryotic pLGIC structures, 
there is notable variation in the length of the connecting loops between the sets of β 
sheets and also in the presence of one or more N-terminal α-helices in eukaryotic 
receptors (that are absent in prokaryotic structures; Hibbs and Gouaux, 2011; Hassaine 
et al., 2014; Miller and Aricescu, 2014; Du et al., 2015, Huang et al., 2015). These 
connecting loops form critical intra- and intersubunit contacts involved in determining 
receptor assembly, the formation of an agonist binding site and in generating signal 
transduction elements (Taylor et al., 1999; Corringer et al., 2000). Additionally, a role 
for the N-terminal α-helices in receptor assembly has been proposed (from a crystal 
structure of the homopentameric GABAA β3 subunit) through formation of 
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intersubunit electrostatic interactions (Miller and Aricescu, 2014). Though discussed in 
greater detail in Section 1.4, the ECD is the site of the orthosteric agonist binding site 
which forms at the interface between principal (P, +) and complementary (C, -) 
subunits (Corringer et al., 2000) (Fig 1.5 A). Facing the extracellular solution, the ECD 
forms the access point for ions, which are able to enter a wide water-filled vestibule 
before reaching the ion channel (Fig 1.5 B & C). Within this structure lie negatively-
charged residues (in cationic nAChRs) and positively-charged residues (in anionic 
channels), likely to be involved in ion selectivity and permeation (Hansen et al., 2008; 
Smart and Paoletti, 2012) 
 
1.3.5. The ECD-TMD (coupling) interface 
At the point at which the ECD is juxtaposed to the plasma membrane, connecting loops 
form a network of critical interactions between the receptor ECD and TMD and couple 
agonist binding to channel gating (discussed in Section 1.4; Fig 1.5 A). At the base of 
the ECD, sits the highly conserved Cys-loop, or loop 7, which is a loop of residues 
between β6-β7 strands contained within a disulphide-bridge formed between two Cys 
residues (Bouzat et al., 2004). While this Cys-bridge is not observed in prokaryotic 
pLGICs, a critical role for Loop 7 in receptor gating is still retained (Sauguet et al., 
2014b). Loop 7 forms the main contributor to the ECD-TMD interface, and carries a 
canonical ΦPΦD (where Φ is typically an aromatic residue; Cecchini and Changeux, 
2014). Additionally the pre-M1 linker (M1 being the first transmembrane spanning α-
helix), loop 2 (between β1-β2), loop 9 and M2-M3 loop form the remainder of the ECD-
TMD interface (Lyford et al., 2003; Newell et al., 2004). It is noteworthy that while 
primary sequence might differ in this region, the three-dimensional structure of this 
interface is strongly conserved across all pLGICs and is critical to the mechanisms of 
receptor signal transduction. This concept is supported by the generation of a range of 
functional pLGIC ECD-TMD chimeras, most notably of a prokaryotic-eukaryotic chimera 
between the ECD of GLIC and the TMD of the α1GlyR subunit (Duret et al., 2011; 




Figure 1.5 - General architecture of a pLGIC: GluClα from C. elegans 
A. GluClα from C. elegans solved in complex with L-glutamate, ivermectin and Fab antibody fragments is 
shown viewed parallel to the membrane. Fab fragments have been removed in this representation. The 
principal subunit is displayed in green and complementary subunit is in blue. The left panel shows the 
structure of the extracellular domain of the principal subunit. The position of the binding loops and the 
N-terminal α-helix is shown. The inner and outer β-sheets of the ECD are indicated. Right panel shows 
the ECD-TMD interface, involved in coupling agonist binding to channel gating. Crucial structures are 
highlighted: Loop 2 formed by β1-β2, Loop 7 (“Cys-loop”, light blue) formed by β6-β7, the pre-M1 region 
and the M2-M3 loop (teal). Interactions in this region underlie the “coupling” process B. The 
arrangement of subunit ECDs when viewed from the extracellular space down the five-fold pseudo-
symmetry axis (pore position shown by the grey circle). Colouring as in A. C. Pentameric arrangement of 
TMDs around the pore (grey circle) and relative position of M1 – M4 helices and M2-M3 loop. Colouring 
as in A. 
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1.3.6. The transmembrane domain 
As observed in early EM structures of tnAChR, and in all subsequent high resolution 
(full-length) pLGIC structures, each subunit exhibits four transmembrane spanning 
segments that fold into the α-helices M1-M4 (Fig 1.5 C; Miyazawa et al., 2003). These 
four helices are arranged to form a bundle distinct to that observed in ionotropic 
glutamate receptors and inverted potassium channels (Zhou et al., 2001; Kumar and 
Mayer, 2013; Karakas and Furukawa, 2014; Lee et al., 2014). The second M2 α-helices 
form the channel pore, which are stabilised through interactions with neighbouring M2 
helices and buttressed by M1 and M3 helices of the same subunit (Miyazawa et al., 
2003; Corringer et al., 2012). The identity of M2 residues lining the pore is similar or 
identical across members of the pLGIC family, including hydrophobic residues at the 
mid-point of M2 forming a channel gate (at 9’) and charged residues (conserved 
amongst cationic or anionic channels) forming the selectivity filter (Miller and Smart, 
2010; Smart and Paoletti, 2012). The orientation of the M2 helices is dependent on the 
receptor’s activation state. Conformational changes in M2 occur as a result of both 
rigid-body motions and bending or “kinking” of the M2 helix, which must therefore 
exhibit a degree of inherent flexibility (Miller and Smart, 2010; Prevost et al., 2012; 
Sauguet et al., 2014b; Bera and Akabas, 2005). Positioned at the periphery of the four 
helix-bundle lies the M4 α-helices. These face the lipid bilayer, and forms crucial 
interactions with membrane lipids to modulate receptor function (Barrantes, 2015; 
Carswell et al., 2015).  
 
1.3.7. The intracellular domain 
Extending into the intracellular space of the cell is the large and variable M3-M4 loop, 
or intracellular domain (ICD). Though not conserved in prokaryotic pLGICs (where short 
linkers are observed), the M3-M4 loop can be in excess of 100 residues in eukaryotic 
pLGICs and forms the binding site for receptor accessory and trafficking proteins (Moss 
and Smart, 2001; Smart and Paoletti, 2012; Stokes et al., 2015). While much of this 
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forms an unstructured mass, EM-structures of tnAChR and crystal-structure of mouse 
5-HT3 receptor reveal an additional intracellular MA helix (and also shorter MX helix for 
5-HT3 receptor; Unwin, 2005; Hassaine et al., 2014). The MA helix extends the ion 
permeation pathway beyond the channel formed by the TMD M2 helices, and likely 
plays additional roles in ion conductance (Kelley et al., 2003). While missing from 
anionic-receptor crystal and EM structures; GluClα, GABAA β3, GlyREM (noting that the 
native ICD was replaced with shorter linkers), the existence of such secondary 
structure in anionic pLGICs is less clear.  
 
1.4. Mechanism for agonist binding and channel gating (from GluClα and GLIC) 
Within the general framework of crystal structures of GluClα, it is possible to formulate 
a mechanism of how agonist binding at a site in the ECD is able to gate the ion channel. 
 
1.4.1. Orthosteric agonist binding 
The first step in channel activation is the binding of agonist. Early studies revealed that 
agonist binding occurs at an interfacial site between neighbouring subunits, with 
contributions from three binding loops on the “principal” subunit (Loops A, B and C) 
and three loops (Loops D, E and F) on the “complementary” subunit (Corringer et al., 
2000; Brejc et al., 2001). 
Largely conserved across all pLGICs, the rules governing the formation of an agonist 
binding interface is dependent on subunit composition and stoichiometry. For 
example, in heteromeric α1β2γ2 GABAA receptors binding strictly occurs at the two the 
β-α interfacial positions (Smart and Paoletti, 2012), while binding at all five equivalent 
positions is possible in homomeric arrangements, as observed in GABAA ρ1, Gly α1 and 






Figure 1.6 - The orthosteric agonist binding site: Glutamate bound GluClα 
The principal and complementary subunit interface of GluClα with bound L-glutamate shown in stick and 
sphere representation. L-glutamate binds at the orthosteric agonist binding site formed by Loops A, B 
and C of the principal subunit (green) and Loops D, E and F of the complementary subunit (blue).  Panel 
top right; view of the binding site parallel to the membrane following rotation of the structure in the 
main figure. Dashed lines indicate hydrogen bonding between residues of the binding pocket and L-
glutamate. Panel bottom right; a view of the binding site from the extracellular space following rotation 
of the structure shown in the top panel. The network of interactions orientating the agonist in the 
binding pocket can be clearly observed. Cation-π interaction between α-amino nitrogen of glutamate 





Crystallographic structures of the soluble Acetylcholine-binding protein (AChBP) 
confirmed the position of the agonist binding site and provided the first high-
resolution details of ligand recognition(Brejc et al., 2001; Celie et al., 2004). An 
“aromatic box” of residues (contributed by the binding loops) stabilized the agonist 
molecule (ACh) through cation-π interactions(Thompson et al., 2010); in AChBP these 
are Loop A – Tyr, Loop B -Trp, Loop C - two Tyr and Loop D – Trp. This arrangement is 
essentially observed in full-length agonist bound receptor structures. In GluClα, L-
glutamate (the endogenous agonist) is coordinated by aromatic residues on Loops A, B 
and C, though Arg (and Lys) residues on loops D and E of the complementary subunit 
also coordinate agonist binding through electrostatic interactions with the glutamate 
carboxylate moiety (Fig 1.6; Hibbs and Gouaux, 2011). 
Surprisingly, the general mode of agonist binding is conserved even in receptors 
separated considerably in evolution. ELIC, from the plant pathogen E. chrystanthemi, is 
gated by primary amines and the neurotransmitter GABA (Spurny et al., 2012). Co-
crystallization studies have revealed that binding occurs at the orthosteric site, with 
GABA caged by aromatic residues of binding loops from the principal and 
complementary subunits. Moreover, a crystal structure of the GABA β3 
homopentameric receptor reveals further details of the agonist-binding pocket.  
Though not gated by the orthosteric agonist GABA, this receptor was crystallized in the 
presence of a novel agonist, benzamidine (which functionally gates the channel; Miller 
and Aricescu, 2014). In agreement with the consensus model, the agonist was 
coordinated at the neurotransmitter binding pocket by stacking interactions between 
the benzyl ring (of benzamidine) and aromatic residues of the binding loops, and 
further coordinated by putative polar, electrostatic and cation-π interactions (Miller 
and Aricescu, 2014).  
It is notable that this aromatic support is broken in the prokaryotic pLGIC homolog 
GLIC (Bocquet et al., 2009; Hilf and Dutzler, 2009; Nury et al., 2010). In contrast to 
other members of the pLGIC family, the orthosteric agonist of GLIC is protons (Bocquet 
et al., 2007). These do not bind at a site overlapping with Loops B and C, and are likely 
to bind at one or more sites elsewhere in the ECD (Duret et al., 2011; Gonzalez-
Gutierrez et al., 2013). Despite this, antagonism of the proton-elicited current of GLIC 
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has been observed by cinnamic acid derivatives, with molecular docking studies 
suggesting that binding (via interactions with the carboxylate moiety of the acid) 
occurs at a interfacial site in the ECD slightly below the orthosteric site (Prevost et al., 
2013).  
 
1.4.2. Loop C capping 
Following agonist binding but prior to the global reorganization of the receptor 
resulting in channel opening, it is postulated that the receptor occupies an 
intermediate preactivation or “flip” state (Fig 1.4; Lape et al., 2008). In this state the 
channel remains closed, and apparently stabilized by the occupancy of (full) agonists 
(but incompletely by partial agonists). It is proposed that the C-loop, and more 
specifically a capping motion (i.e. repositioning itself closer to the agonist molecule), 
might stabilize this intermediate (Miller and Smart, 2010). Ultimately without further 
structural information it is difficult to determine whether this “flip” state forms a 
discrete structural state or series of states prior to full activation (Mukhtasimova et al., 
2009).  
 
1.4.3. Rigid body motions of the ECD of GluClα 
Following agonist binding (and passage through an intermediate pre-activation or 
“flip” state) a wave of conformational transitions occurs resulting in channel opening. 
In light of crystal structures for GluClα and GLIC in ascribed resting and active states we 







Figure 1.7 - Loop C closure and ECD-TMD transitions during activation of GluClα 
A. Superposition of principal subunits (viewed parallel to the membrane) of apo- and ivermectin-GluCl. 
Subunits are colour-coded to show distances between equivalent Cαatoms in transition from closed to 
open and from open to closed states (using the colorbyrmsd.py script in Pymol). The ECD and TMD of a 
complete pentamer were aligned individually. Residues 103-105 were missing in the apo-GluCl structure 
and were excluded from these calculations. Notable regions of low (e.g. binding pocket) and high (e.g. 
top of TMD) movement are indicated. B. Superposition of a single subunit of apo- and L-
glutamate/ivermectin-GluCl (PDB 3RIF) shows global movement on transition from the closed to 
agonist-bound open state. C. Binding site closes after agonist binding through rigid body motions. 
Movement of arginine residues on the complementary face are shown (Apo-magenta) and (L-Glut-Blue) 
D. Superposition of TMD of complementary subunit shows movement at the ECD-TMD interface in the 
principal subunit, as viewed across the channel pore. For clarity only the TMD of the complementary 
subunit is shown.  
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Superposition of the principal subunits of GluCl in the apo (resting) and 
ivermectin/glutamate-bound (active) states reveal that the ECD and TMD move largely 
as rigid bodies (Fig 1.7 & 1.8; Hibbs and Gouaux, 2011; Althoff et al., 2014). Notable 
hotspots of movement (following agonist binding) are seen at the top of the pore 
lining M2 helix and the M2-M3 loop (as defined by fluctuations in Cα-Root Mean 
Square Deviation (RMSD) between open and closed states; Fig 1.7 A). Movement of 
the β-sandwich of the ECD reveals a twisting of the entire subunit around the pore axis 
and simultaneous tilting towards the centre of the pore. This consequently results in a 
compaction of the subunit interface. At the level of the agonist binding site loops A, B 
and, most notably, loop C close the binding pocket around glutamate as a result of 
(rigid body) twisting of the extracellular domain (Fig 1.7B & C). Notably Loop C does 
not appear to move as an independent entity, as had been proposed from agonist 
bound structures of AChBP (Celie et al., 2004; Hansen et al., 2005). In closing the 
binding pocket, glutamate is stabilized through the interactions described previously. 
Additional displacement of arginine residues on the complementary face allows for 
accommodation of glutamate in the compacted binding pocket (Fig 1.7 C), and 
subsequently reinforces binding through hydrogen bonding (Althoff et al., 2014).   
 
1.4.4. Coupling at the ECD-TMD interface of GluClα 
The coupling interface, formed by connections between the ECD and TMD, undergoes 
significant reorganization during channel activation, consistent with extensive 
functional data (Reeves et al., 2005; Lee et al., 2008). Interactions are observed 
between the (inner) β1-β2 loop (Loop 2) and M2-M3 loop, as well as the Cys-loop (loop 
7) and extracellular ends of the transmembrane spanning helices (Fig 1.7 D). In 
transitioning from the resting to active state of GluClα, loop 2 moves towards the M2-
M3 loop, which in turn is displaced away from the channel pore (towards the 





1.4.5. GluClα activation opens the ion channel 
Superposition of the transmembrane domains further reveals how these 
conformational rearrangements result in channel opening. In the apo state M2 helices 
lining the channel are orientated perpendicular to the plane of the membrane (Fig 1.7, 
1.8 and 1.9). A hydrophobic gate is formed by the side chains of 9’ Leu (L254) residues, 
restricting the pore radius to ~1.4 Å and occluding the channel (Fig 1.9).As chloride 
ions having a Pauling radius of 1.8 Å ion flow is restricted in this state (Hibbs and 
Gouaux, 2011). Upon activation, the TMD expands at the extracellular side following 
clockwise rotation of M3 and M4 (around the centre of the helical bundle) and tilting 
of the M2 helix away for the pore (Fig 1.8). The channel gate formed by side chains of 
9’ Leu residues is now removed, moving out of the channel pore and allowing for the 
passage of chloride ions.  Notably the channel remains constricted at the intracellular 
side (at the level of the -2’ proline), though with a diameter of 4.6 Å still able to allow 
the passage of chloride ions (Fig 1.9).  
It should be noted in interpreting structures of GluClα that active-open channel forms 
of the receptor were determined in the presence of the allosteric modulator 
ivermectin. Ivermectin, as discussed below, wedges itself between M1 and M3 helices 
of adjacent subunits to stabilize an open channel. The open channel structure is 
essentially identical in both the absence and presence of orthosteric agonist L-
glutamate (Hibbs and Gouaux, 2011). Moreover the orthosteric agonist-binding site is 
near identical regardless of whether glutamate is bound or not. To corroborate the 
interpretations of GluCl structures, one can compare the global architecture and 
relative re-arrangements to those observed for the prokaryotic homolog GLIC, solved 
under resting (neutral pH) and active (acidic/low pH) conditions. These structures are 
free of the constraints that ivermectin and/or antibody fragments (used as 
crystallization aids) may have imposed on GluClα structures (Hibbs and Gouaux, 2011; 









Figure 1.8 - ECD and Ion channel conformational changes during GluClα activation 
Apo-GluCl (red) and Ivermectin-GluCl (green) were globally aligned (using the entire pentamer) to show 
overall changes in conformation in the ECD and TMD. There is a counter-clockwise twist of ECDs, 
resulting in compaction of the subunit interface. N-terminal α-helices move towards the five-fold 
symmetry axis upon activation (though there is an overall expansion of the extracellular access pore). In 
the TMD there is an apparent clockwise rotation of the entire domain (around the pore axis) and within 
the helical bundle. Upon activation M2, M3 and M4 helices rotate in clockwise manner around the 
centre of the bundle. The M2 α-helices are in a straight conformation (in the apo-state) and are tilted 
away from the pore axis (at the extracellular end) in the active state. Constriction and expansion at the 
extracellular end of M2, and at the hydrophobic gate formed by M2 9’ Leu residues is shown by dotted 










Figure 1.9 - Ion channel profile across pLGIC activation states 
Side view of M2 helices for indicated states of various pLGICs (Hilf and Dutzler., 2008; Bocquet et al., 
2009; Hibbs and Gouaux, 2011; Althoff et al., 2014; Hassaine et al., 2014; Miller and Aricescu, 2014; 
Sauguet et al., 2014b; Du et al., 2015, Huang et al., 2015). M2 residues are shown in stick formation. 
Volume accessible to solvent is shown as spheres (analysed using Caver software with probe radii of 0.9 
Å (Petrek et al., 2006)). Red shaded boxes show constriction of <1.8Å radii and blue boxes of 1.8 – 3.3 Å 
radii.    
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1.4.6. Mechanism for activation from GLIC 
By superposing the principal subunits of GLIC solved in a resting state at neutral pH 7, 
and in an active state (PDB 4HFI) at acidic pH 4, reveals distinct similarities and 
differences to GluClα with regards to the global domain reorganization associated with 
channel gating (Fig 1.10). The ECD, as in GluClα, behaves as an approximate rigid body, 
whilst the TMD in contrast displays reduced global reorganization compared to GluClα, 
but with a pronounced movement of the M2 helix.  
 
1.4.7. Rigid body movements of the ECD close the orthosteric binding site 
The ECD domain under resting conditions adopts an extended conformation, with each 
subunit’s β-sandwich positioned away from the five-fold symmetry axis. In contrast to 
GluClα, this positions the ECD in a relatively loose arrangement, with each subunit 
distal to neighbouring subunits and the orthosteric binding site expanded in volume. 
Upon activation, after exposure to low pH, the entire ECD undergoes global 
anticlockwise twisting and “un-blooming” motions (Fig 1.10 A and B). This brings the 
ECD in to a less extended configuration, with the β-sandwich positioned closer to the 
central axis of the receptor. Through these twisting and “un-blooming” motions the 
subunit interface becomes compacted, and there is apparent closure of the orthosteric 
binding site loops B and C (which follows the global rotation of the ECD; Fig 1.10 A).  
In the context of pLGICs which display agonist binding at the orthosteric site, closure of 
loop C would act to facilitate agonist binding and stabilization, whilst movements in 
loop B likely serve to transmit structural information to initiate channel opening 
(Sauguet et al., 2014b; Auerbach, 2015). This might explain the observation that 
substitution of residues in loop B of GABAA receptors is capable of initiating 
spontaneous channel opening (Newell et al., 2004). Whilst the global closure of the 
binding pocket of GLIC (upon proton activation) is consistent with the wealth of 
knowledge for agonist binding in AChBP structures, as observed for structures of 
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GluClα, it reveals a contraction based upon quaternary rearrangements, rather than 
flexing of loop C. 
 
Figure 1.10 - ECD and Ion channel conformational changes during GLIC activation 
A. Superposition of single subunits for resting (neutral pH 7, red) and active (pH 4, green) GLIC shows 
global movement on transitioning from closed to an agonist-bound open state. In the resting state the 
ECD forms an extended conformation, increasing the interface volume between neighbouring domains. 
B. Superposition of the ECD (pentamer) reveals twisting of the β-sandwich upon channel activation and 
radial movement towards the pore-axis thereby reducing the volume of ECD-ECD interface. C. 
Rearrangement of the TMD during activation (closed – red to open – green). M1 and M2 helices rotate 
in clockwise manner, while M3 and M4 are largely immobile. The upper end of M2 tilts away from the 
pore axis revealing a global iris-like opening of the channel. Constriction and expansion at the 
extracellular end of M2 and at the hydrophobic gate formed by M2 9’ Leu residues is shown by dotted 
lines between subunits.       
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It is notable that the binding site for protons in GLIC has yet to be identified. While it is 
thought to reside in the ECD  (though at a site not overlapping the orthosteric agonist 
binding pocket), there is also an argument that protonation of an M2 Histidine (H235) 
is sufficient to stabilize the open channel, which closes upon deprotonation in 
molecular dynamic simulations (Duret et al., 2011; Wang et al., 2012; Prevost et al., 
2013). Of similar note, it is significant that in structures of GluClα in the absence of 
orthosteric agonist (glutamate), but presence of allosteric agonist (ivermectin) a 
compaction of the orthosteric binding pocket is still observed. Regardless of the 
location of proton binding, it is maybe not surprising that the orthosteric site 
undergoes rearrangement in GLIC. This might be considered to be a structural 
consequence of the quaternary rearrangement of the ECD upon activation and is 
inherently required for the transfer of information across the receptor(i.e. from the 
ECD to the TMD; Auerbach, 2015). 
 
1.4.8. Coupling at the ECD-TMD interface of GLIC 
At the coupling interface between ECD and TMD there is transition of key structural 
elements which underpin signal transduction. During the transition from resting to 
active states there is a redistribution of hydrophobic interactions between loop 2, pre-
M1 and loop 7, which serves to increase connectivity to the TMD via the M2-M3 loop. 
At the global level the M2-M3 loop moves (horizontally) away from the pore axis, 
towards the receptor periphery (Fig 1.10 C). This position (in the open form) is 
stabilized by a steric block of a conserved proline (23’) in the M2-M3 loop by residues 
at the tip of loop 2 (as also proposed for GluClα; Calimet et al., 2013).  
 
1.4.9. Proton activation of GLIC opens the ion channel 
In contrast to the global rotational rearrangement of all helices in the TMD of GluClα 
(on transition from closed to open state), activation of GLIC at the level of the TMD is 
characterized by localized rearrangements. As in the apo-structure of GluClα, under 
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resting conditions M2 helices lining the channel are orientated perpendicular to the 
plane of the membrane, forming a constriction of the channel at the level of the 9’ Ile 
residue (the hydrophobic channel gate; Fig 1.9 and Fig 1.10). This constriction, though 
less narrow than that observed in GluClα, is not compatible with hydrated ion flow, 
thus delineating a non-conductive state. Upon activation, M3 and M4 helices remain 
largely stationary, while M1 tilts in the uppermost half, towards the pore. The channel 
lining M2 helices tilt at the extracellular end, opening the channel with an iris-like 
motion (Fig 1.10). The direction of this flexure follows the line of horizontal movement 
of the M2-M3 loop, and is tangential to the channel axis (rather than the radial 
movement of M2 helices observed in GluClα). As a result of M2 tilting, the extracellular 
side of the channel expands, with Ile 9’ residues moving out of the pore, and the 
channel adopting an open conformation (Fig 1.9 & Fig 1.10). As in structures of GluClα, 
the intracellular end of M2 is largely immobile during this process.  
In summary, the mechanism of channel gating (at least in transition from closed to 
open conformations) appears largely conserved, and is consistent with EM-structures 
of tnAChR captured by plunge-freezing methods (Unwin and Fujiyoshi, 2012). 
Underlying this is the re-configuration of M2 helices from a straightened conformation, 
in the closed form, to a locally tilted or flexed conformation, in the open form, and 
consequential displacement of hydrophobic 9’ residues forming the channel gate. 
Indeed an array of functional studies across the pLGIC superfamily emphasise the 
importance of this 9’ position in gating, and more specifically in stabilizing the channel 
in a closed state under resting conditions (Revah et al., 1991; Chang and Weiss, 1998; 
1999; Bocquet et al., 2007).  Mutation of the hydrophobic 9’ residue to polar residues 
induces gain-of-function, stabilizing the channel in the active state and characterised 
by spontaneous channel activity (than can be antagonized by channel blocking agents).  
 
1.5. A mechanism for pLGIC desensitization 
While structures of GLIC and GluClα provide means for high-resolution structural 
analysis of receptors in closed and open states, they do not suggest a mechanism for 
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the structural re-configuration that occurs upon transition through to a desensitized 
state. At the functional level, neither GLIC nor GluClαcryst exhibit properties (in 
macroscopic electrophysiological recordings) to suggest that these receptors undergo 
pronounced desensitization during prolonged “crystallization” agonist exposure (e.g. 
pH 4 and ivermectin; Etter et al., 1996; Bocquet et al., 2007; Hibbs and Gouaux, 2011; 
Laha et al., 2013). This possibly provides a reason as to why these receptors are 
stabilized in the open channel conformations in the crystal form. Unravelling the 
structural re-arrangements underpinning desensitization has ultimately proved to be 
more elusive. 
Desensitization represents a reduction in receptor response during prolonged agonist 
exposure, and is a conserved property amongst most pLGICs (Katz and Thesleff, 1957). 
At the level of the ion channel this state reflects the transitions from an active-open 
channel to desensitized closed-channel conformation (where agonist is bound 
continuously), and a consequential reduction in ion flow (Papke et al., 2011). At the 
physiological level, desensitization is likely to play roles in reducing postsynaptic 
currents, and thereby protecting nerves cells to repetitive transmitter release.  
Moreover, desensitization can serve to modulate the time-course of decay of the post-
synaptic currents and additionally play a role in tuning the (tonic) response of 
extrasynaptic receptors to low, ambient concentrations of agonist (Jones and 
Westbrook, 1995; Bianchi and Macdonald, 2002).  
Single-channel electrophysiological recordings of nAChRs suggest that there are at 
least two distinct kinetic components to the desensitization response (Sakmann et al., 
1980). Receptors transition to a fast desensitized state, with a lifespan of the order of 
10-100 ms, and subsequently into a slow desensitized state, in which the receptor can 
reside over a timescale of seconds. Elucidating the likely structures of these states 
proved difficult for a long period of time. However, on the basis of recent functional 
and structural evidence we can begin to understand the potential re-arrangements 




1.5.1. Re-arrangement of the ECD-TMD occurs during desensitization 
Previous functional data has suggested structural elements in the ECD and at the ECD-
TMD are responsible for setting receptor desensitization(Bouzat et al., 2008; Wang and 
Lynch, 2011). In the latter case, and on the basis of voltage fluorimetry experiments of 
the α1-GlyR, conformational changes are observed in pre-M1, loop 2 and M1 α-
helix(Wang and Lynch, 2011). While these changes were reported to be specific to 
desensitization, it is pertinent to note that these regions are also important in setting 
the efficacy of channel gating, which might obscure whether observed changes relate 
to the macroscopic or microscopic rates of desensitization (Pless and Lynch, 2009b; 
Gielen et al., 2015). Though macroscopic electrophysiological recordings of GLIC do not 
reveal receptor desensitization, double electron-electron resonance (DEER) 
experiments of GLIC reconstituted into liposome reveals a proton-induced desensitized 
state (Velisetty and Chakrapani, 2012; Dellisanti et al., 2013). This response is 
apparently mediated by rearrangement of interfacial loops; loop 2, M2-M3 loop and 
loop 9. During the transition from closed to desensitized state loop 2 becomes less 
mobile and loop 9 shows considerable mobility (Dellisanti et al., 2013). Moreover, 
DEER experiments confirm that the GLIC pH 4 structure does not correspond to a 
desensitized state (Dellisanti et al., 2013). 
 
1.5.2. A desensitization gate is located in the ion channel 
While it is likely that the ECD-TMD undergoes substantial rearrangement during 
desensitization, functional studies have pointed towards a second model for receptor 
desensitization. This model proposes that receptor desensitization proceeds from the 
open state of the channel and suggests the involvement of a “desensitization” gate 
located within the channel (Auerbach and Akk, 1998). This gate would be distinct to 
the “activation gate” formed by the ring of hydrophobic residues at the 9’ M2 position. 
Affinity labelling studies of nAChR with a hydrophobic probe 3-(trifluoromethy)-3-(m-
iodophenyl) diazirine (TID) revealed a decrease in labelling at the level of the M2 9’ 
residue during the transition from open to fast desensitized states, suggesting local 
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conformational change in the channel (Yamodo et al., 2010). Moreover electron 
paramagnetic resonance (EPR) spectroscopy experiments (to measure distance 
between spin–labelled Cys residues) of GLIC reconstituted into liposomes proposes 
that desensitization involves a distinct gate between 2’ and 9’ M2 residues (albeit with 
experimental caveats that should be accounted for, including the size of the 
introduced spin labels and restrictions on motion; Velisetty and Chakrapani, 2012). 
These studies all point towards the existence of a distinct desensitization gate, the 
location of which being mid-way up the channel pore. Recent studies of a 
desensitization gate in α1β2γ2 GABAA and α1 Gly receptors suggest a distinct pore 
location (Gielen et al., 2015).  Given that open channel structures (GLIC and GluClα) 
reveal a narrowing of M2 helices down to the (intracellular) -2’residues and that at a 
functional level desensitization likely proceeds from an open channel state, it was 
postulated that desensitization might result from an ‘extension’ of the activation 
process. The likely location of a ‘desensitzation gate’ would by this principal be 
proximal to the cytoplasmic portion of the channel. Indeed mutagenesis of residues 
along the cytoplasmic end of M2/M3 interface had a pronounced effect on receptor 
desensitization. Additionally, the channel blocker picrotoxin (which binds at the level 
of 2’ Thr and -2’ Pro residues in crystal structures of GluClα) was shown to prevent 
desensitization, in accord with an overlap of a picrotoxin binding site and 
‘desensitization gate’ (Hibbs and Gouaux, 2011). Moreover, the model proposed would 
be consistent with experimental data to suggest that picrotoxin is trapped in the 
resting, but not desensitized, state of the GABAA receptor(Bali and Akabas, 2007). 
Capturing a single receptor in a number of gating states (with different life spans and 
thermodynamics) provides a significant challenge. With regards to receptor structure 
during desensitization, we can however use existing experimental data to assist in 
interpretation of crystallographic (and more recently cryo-EM) structures of receptors 
in distinct states. 
While nearly 20 crystal structures of the prokaryotic pLGIC ELIC have been solved, and 
in the presence of orthosteric agonists including GABA, cysteamine and 
(bromo)propylamine, the conformation of the channel always delineates a closed non-
conductive state (Zimmermann and Dutzler, 2011; Gonzalez-Gutierrez et al., 2012; 
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Spurny et al., 2012). Structures of ELIC are characterized by a hydrophobic constriction 
of the channel at the M2 9’ Leu and 16’ Phe residues (Fig 1.9). Whilst this was initially 
interpreted as a resting form of the receptor, DEER spectroscopy studies have 
subsequently suggested that ELIC is not an appropriate model of a resting pLGIC 
(Dellisanti et al., 2013). Given that co-crystallization of ELIC with orthosteric agonists 
exhibits a closed channel structure, it is speculated that this conformation may 
correspond to that observed during slow receptor desensitization (Cecchini and 
Changeux, 2014).   
 
1.5.3. An intracellular desensitization gate in inhibitory pLGICs 
Notably, the recent crystal structure of the GABA β3 homopentamer (solved in the 
presence of the novel agonist benzamidine) revealed a unique pore structure, with 
respects to the configuration of M2 helices (Miller and Aricescu, 2014; Fig 1.9 & 1.11 
A-D). The channel is expanded at the extracellular side and M2 helices taper down as 
they approach the intracellular side of the plasma membrane (Fig 1.11 A). The 
“hydrophobic gate” at the 9’ M2 Leu residue reveals a similar diameter to that 
observed in open channel structures, though curiously with Leu side-chains rotated out 
of the pore (when compared to the configuration in GluClα (Fig 1.11 B Hibbs and 
Gouaux, 2011). At the -2’ M2 residue the channel forms its narrowest constriction of 
3.15 Å. In this state chloride ions would not be passed, with the channel in a closed 
configuration (distinct to that observed in ELIC, GLIC-pH 7, apo-GluClα and tnAChR; Fig 
1.9). Given that agonist was bound in the structure, this was proposed to represent a 
receptor in a desensitized form. The location of this constriction is in strong agreement 
with location of a “desensitization gate” proposed by mutagenesis studies of the 
GABAA (and Gly) receptor (Gielen et al., 2015). Indeed mapping critical desensitisation 
residues of the M2/M3 interface on the crystal structure reveals a strong network of 
interactions, with residues lodged along this interface perfectly positioned to induce 
rearrangement of the channel lining M2 helix (Fig 1.11 C). Moreover this network is 
well positioned to interact with and cradle the side chain of a conserved aromatic 
residue at the base of M3 (Tyr 299 in GABA β3cryst) that was proposed to induce 
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localized desensitization through a side chain conformational switch (Miller and 
Aricescu, 2014).  
The local constriction of the GABA β3 channel represents an “extension” of the 
intracellular narrowing observed for pore lining helices in active-receptor structures 
(GluClα-IVM and GLIC-pH 4; notably minimal rearrangement is observed for the M1, 
M3, M4 helices and M2-M3 loop when superposed with GluClα-IVM Fig 1.11 D). 
Therefore we might speculate that the intracellular desensitization gate is responsible 
for initiating transition through the fast-desensitized state (Cecchini and Changeux, 
2014).  
In corroboration of this, recent nuclear magnetic resonance (NMR) and EPR 
spectroscopy studies of reconstituted-ELIC revealed that in the transition from a 
resting to a desensitized state, an expansion of extracellular and contraction of 
intracellular portals of the channel pore occurs (Kinde et al., 2015). While in agreement 
with the proposed desensitized structure of GABA β3 receptor, and functional studies 
of GABAA and α1 Gly receptors, this is in stark contrast to crystal structures of agonist 
bound ELIC. This would add weight to the argument that agonist-bound structures of 
ELIC are a reasonable model for the slow-desensitized receptor. 
While there is now a strong agreement between functional desensitization data (for 
ELIC, GABAA and Gly receptors) and the crystal structure of the GABA β3 receptor, it 
should be noted that the crystallized form of the GABA β3 receptor is not one of 
physiological relevance (given that it not activated by GABA). Moreover the observed 
response to the novel agonist, benzamidine, has not yet been fully characterised. 
Additional caveats regard the reported spontaneous activity previously reported for 
GABAA β3 homopentamers and the potential effects this might have on channel 
structure (Wooltorton et al., 1997). Of similar note, it is also unclear what effect 
truncation of the receptor ICD, and replacement with shorter linkers, has on 
constraining receptor structure (Papke and Grosman, 2014). Finally, and as apparent 
from studies of ELIC, it is notable that crystal packing may (artificially) affect the 










Figure 1.11 - Desensitization gate at the intracellular end of the ion channel in pLGICs 
A. Surface profile and orientation of pore lining M2 residues (stick representation) in GABA β3 (orange) 
and GluCl-ivermectin (blue). The constriction formed by the extended confirmation of M2 helices at the 
intracellular end of GABA β3 TMD is apparent from superposition of individual TMDs. This surface 
profile clearly shows the channel constriction at -2’. B. Rotation of M2 helices in GABA β3 receptor 
moves 9’ residues out of pore, resulting in an expanded global channel profile below 16’. C. Location of 
critical desensitization residues identified in a study of native α1β2γ2 GABAARs (Gielen et al. 2015) and a 
conserved aromatic residue (Ty299 in GABA β3) in stick and sphere representation. The nearest subunit 
is removed for clarity. D. Superposition of single TMD of GluCl-ivermectin reveals minimal movement of 
helical bundle in GABA β3. The M2-M3 loop moves towards the pore axis and extension of the lower 
end of M2 closes the channel. E. and F. Location of critical desensitization residues identified in study α1 
GlyR (Gielen et al., 2015) mapped on to the α1 GlyR cryo EM structures  (strychnine (Str) – closed and 
glycine/ivermectin (IVM) – desensitized-like) as viewed from the extracellular space (E) and 
perpendicular (F) to the membrane plane at the base of the TMD. The near subunit is removed for 
clarity.  Individual subunits of the pentamer were superpositioned.  
 
 
1.5.4. An allosteric modulator induces a ‘desensitized-like’ channel structure 
Despite the aforementioned caveats, the structure of a Zebrafish α1 Gly receptor in 
the presence of orthosteric agonist glycine (Gly) and allosteric modulator ivermectin 
(IVM) determined by cryo-EM would suggest a potential mechanism for (fast) 
desensitization consistent with that proposed for the GABA β3 receptor(Du et al., 
2015). Free from the constraints of crystal packing, solubilized receptors are now 
directly imaged in the electron microscope, in a near native state. This approach 
reveals that the α1 GlyR-Gly-IVM structure has a tighter constriction of the intracellular 
portal of the pore, when compared to α1 GlyR-glycine structure (which reveals a fully-
open active form, Fig 1.9 and Fig 1.11 E & F). With a radius of 2.5Å this is too narrow to 
permit passage of a hydrated chloride ion (Du et al., 2015). In electrophysiological 
recordings the glycine/ivermectin bound receptors exhibit reduced susceptibility to 
picrotoxin block (consistent with the findings from functional studies of native α1 
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GlyRs (Gielen et al., 2015)). Given that the pore-profile of this receptor resembles 
those of the GABA β3 receptor (and in light of the functional data), the α1-GlyR-Gly-
IVM complex would apparently reflect an agonist-allosteric modulator-bound 
desensitized state of a pLGIC.  
Superpositioning the EM structures for a closed-strychnine bound and Gly-IVM bound 
α1 Gly receptor further reveals the tight-knit network of interactions formed by 
residues lining the M2/M3 interface (as identified by mutagenesis studies). In 
transitioning from a closed to partially open/desensitized channel configuration, there 
is a displacement of residues at the intracellular-most end of the interface (Fig 1.11 E & 
F). The Gly-IVM cryo-EM structure reveals a mechanism whereby allosteric modulators 
(e.g. ivermectin) binding at an intersubunit cavity are able to promote desensitization. 
Conversely, modulators binding at intrasubunit cavities (formed by M1, M2 and M3) in 
nAChRs are able to prevent desensitization (Dacosta et al., 2011; Gill et al., 2011).    
While recent crystal and EM structures, as well as functional data, shed new light on 
the structures underpinning desensitization, a clear consensus regarding receptor 
desensitization has yet to be reached. Ultimately high-resolution structural studies of a 
single receptor in both the fast and slow desensitized states will likely assist in 
interpretation of the existing data. 
 
1.5.5. What role does the ICD play in channel gating? 
From the ensemble of available structures we can build a plausible mechanism for 
agonist activation. However a significant caveat is that, with the exception of the 5-HT3 
receptor (and nAChR), high-resolution structures have only been obtained for 
receptors lacking the large M3-M4 loop (Unwin, 2005; Hassaine et al., 2014). Typically 
truncated and replaced with a short linker sequence, it is far from clear as to the role 
that this loop may play in channel gating, and particularly its involvement in the 




1.6. Allosteric modulation at the TMD 
Clinical and endogenous compounds are able to modulate pLGIC function through 
binding at allosteric sites distinct to the orthosteric binding pocket. These compounds 
display a range of properties; from intrinsic (agonist) activity to potentiation or 
inhibition of receptor function. The TMD of pLGICs, and the GABAA receptor in 
particular, appears to be the likely target for a wide variety of modulators including 
general anaesthetics, neurosteroids, channel block agents and lipids (Hosie et al., 
2006; Franks, 2008; Hosie et al., 2009; Barrantes, 2015; Gielen et al., 2015). In the 
framework of recent high-resolution crystal structures we can begin to further 
understand how some of these might bind and impart their effects. 
 
1.6.1. The channel block sites 
Channel blocking agents are non-competitive inhibitors that occlude the aqueous pore 
of the ion channel and thereby prevent the flow of ions. The functional effects of the 
pore-blocker picrotoxin (PTX) have been extensively studied across pLGIC, and in the 
case of GABAA receptors block the active state of the receptor, though are also trapped 
in a resting receptor conformation (Bali and Akabas, 2007; Gielen et al., 2015). Co-
crystallization of GluClα with PTX reveals a binding site deep in the channel pore, at the 
level M2 2’ Thr and -2’ Pro residues(Hibbs and Gouaux, 2011; Fig 1.12 D). This binding 
site likely overlaps with the location of a desensitization gate in GABAA and Gly 
receptors.  Anaesthetic barbiturates though typically thought to bind outside of the 
channel pore in anionic-GABAA receptors have been shown to inhibit cationic-nAChRs 
through preferential binding within the channel of a desensitized receptor (Hamouda 
et al., 2014a; Sauguet et al., 2014a; Hamouda et al., 2014b). Moreover in the cation 
selection ELIC, the anaesthetic bromoform was found to bind within the channel pore 




1.6.2. Anaesthetic binding sites 
The wealth of functional and structural evidence points towards anaesthetic binding 
sites located outside of the channel pore for both anionic and cationic pLGICs. At 
cationic nAChRs anaesthetics typically display inhibitory properties (Sauguet et al., 
2014a). Photo-affinity labelling studies of tnAChR with a photoactivatable propofol 
analog reveal binding at a channel site and an intrasubunit site within the helical 
bundle of the δ-subunit (Jayakar et al., 2013). Curiously the latter site partially overlaps 
with a crystallographically identified binding site for propofol at GLIC, where propofol 
acts as an inhibitor (Weng et al., 2010; Nury et al., 2011).  
It is unlikely that an equivalent site exists in GABAA receptors, at which propofol 
potentiates channel function. Indeed photo-affinity labelling studies have identified 
binding sites for photo-reactive propofol and etomidate analogs at interfacial 
transmembrane sites in GABAA receptors (Li et al., 2009; Yip et al., 2013). In studies of 
α1β3γ2 it was found that etomidate binds selectively at the β-α subunit interface, with 
propofol binding at β-a, α-β and β-γ sites with apparently equal affinity(Chiara et al., 
2012; Olsen et al., 2013). It was subsequently found that propofol binds at a site 
located within the GABAA receptor β-subunit, but positioned at the interface of subunit 
TMDs (Yip et al., 2013). This was proposed following photo-labelling of an apparently 
critical His (267) residue in β3 homopentamers and α1β3 heteropentamers. The 
location of the proposed site does not overlap with the intrasubunit anaesthetic site 
identified for propofol in GLIC, but does however partially overlap with an intersubunit 
anaesthetic site identified crystallographically for bromoform binding at a ethanol-
sensitized mutant GLIC receptor(Nury et al., 2011; Sauguet et al., 2013a). The crystal 
structure of the homopentameric GABA β3 receptor (though not bound in situ with 
anaesthetics) reveals putative binding pockets for etomidate and propofol in close 
proximity to residues previously identified by photo-affinity labelling studies (Fig 1.12 
B; Miller and Aricescu, 2014). It has subsequently been suggested for propofol that 
high- and low-affinity binding sites reside in vicinity of this pocket (in GABA β3 
receptors), and that they would both be inaccessible in the closed channel state (Eaton 
et al., 2015; Franks, 2015).  
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1.6.3. Intersubunit binding sites 
Structures of GluClα and more recently α1 GlyR (by crystallography and cryo-EM 
respectively) in complex with the insecticide ivermectin reveal a mechanism of pLGIC 
modulation through binding at an intersubunit TMD site (Hibbs and Gouaux, 2011; Du 
et al., 2015). Ivermectin typically acts in an irreversible manner to potentiate or inhibit 
channel function (depending on the type of pLGIC; Corringer et al., 2012). At GluClα it 
acts as an allosteric agonist, while at α1 GlyRs it potentiates agonist activity (Etter et 
al., 1996; Hibbs and Gouaux, 2011; Du et al., 2015). Ivermectin binds similarly in both 
structures, wedging between the interface of M3 and M1 helices for principal and 
complementary subunits respectively (Fig 1.12 C). It forms multiple contacts with 
residues of M2, notably polar interactions with the M2 15’ Ser residue, M3 (principal), 
M1 (complementary) and in the case of the α1 GlyR with the M2-M3 loop. Of 
particular note is that the homologous M2 15’ residue in GABAA and Gly receptors has 
been shown be a key determinant of general anaesthetic and alcohol modulation 
(Mihic et al., 1997; Miller and Smart, 2010). It appears in the case of ivermectin that 
binding at this site (which is located proximal to the M2) is capable of stabilizing the 
active state of the channel for GluClα, while in the GlyR it apparently stabilizes a low 




Figure 1.12 - Allosteric modulation in the TMD of pLGICs: GluClα and GABA β3 
A. Central panel shows two subunits of GluClα with ivermectin bound at the interface of subunit TMDs. 
B. Top centre: Binding cavities for propofol and etomidate as observed in the GABA β3 structure. The 
propofol cavity (P) is lined by M2 His267 and formed within a subunit TMD facing the interface. The 
etomidate cavity (E) is at the subunit interface and lined by M2 (15’ N265) and M3 residues of one 
subunit and M1 of the facing subunit. C. Right panel; view of the ivermectin binding site from the 
extracellular side of the membrane. Polar interactions with M2 15’ Ser residue is shown by dotted lines. 
D. Bottom centre; Picrotoxin (stick and sphere representation) binding deep in the pore of GluClα at the 
level of 2’ Thr and -2’ residues E. Left panel; POPC-lipid binding cavity in GluClα, analogous to the 
ivermectin binding site, viewed approximately parallel (tilted slightly) to the plane of the membrane.   
64 
 
1.6.4. Lipophilic modulators 
Given that this site is freely accessible from the lipid bilayer it opens new avenues for 
potential mechanisms of allosteric modulation of pLGICs, for example, by lipophilic 
modulators. At the GABAA receptor one such class of endogenous lipophilic 
modulators, introduced previously, are the neurosteroids. These compounds act in a 
biphasic manner; potentiating at low nanomolar concentrations and acting as allosteric 
agonists at high micromolar concentrations (Hosie et al., 2006). In contrast to 
ivermectin and other synthetic compounds, neurosteroid binding is not mediated by 
the M2 15’ residue. Neurosteroid potentiation is likely to occur upon binding at an 
intrasubunit site within the TMD of α-subunits. Mutagenesis studies reveal that a 
conserved α-subunit Gln residue is critical, which from homology models, can be 
mapped to the base of M1 facing M4 of the same subunit. This aqueous cavity can 
accommodate a neurosteroid molecule, when it is orientated perpendicularly to the 
plane of the membrane. By this approximation, the steroid molecule forms other 
binding site contacts with residues in the upper part of M4 (Hosie et al., 2006).  
By contrast, the location of a site mediating the direct activating effects of 
neurosteroids remains unclear, though it is likely to be formed by TMD residues at the 
subunit interface(Hosie et al., 2006). Given the allosteric agonist properties displayed 
by ivermectin and its binding location in GluClα, it will be of interest to determine 
whether neurosteroids (both potentiating and inhibitory) can interact at GABAA 
receptors via a similar site. Ultimately, structure determination (by crystallography or 
cryo-EM) of a steroid-bound receptor will provide further mechanistic insight.  
Endogenous molecules in the lipid bilayer may also use this ‘interfacial avenue’ to 
interact with and allosterically modulate pLGIC function (Barrantes, 2015). Indeed 
cholesterol and anionic lipids have been shown to impart stabilizing and modulatory 
effects on nAChRs (Labriola et al., 2013). Though GABAAR-active endogenous 
neurosteroids are synthesized from cholesterol, it is unclear as to what effect the 
parental sterol has on GABAA receptors (Sooksawate and Simmonds, 2001). Molecular 
dynamic simulations suggest that cholesterol may stably bind at a site analogous to the 
GluCl-ivermectin-binding site (Hénin et al., 2014). During these simulations cholesterol 
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is able to promote channel opening. Ultimately, direct experimental evidence will be 
needed to corroborate these findings.   
While crystal structures of GLIC reveal bound membrane lipids (in a crevice formed by 
the upper parts of M1 and M4), functional-reconstitution reveals that GLIC is 
inherently insensitive to its lipid environment when compared to its eukaryotic 
counterparts (Bocquet et al., 2009; Nury et al., 2011; Labriola et al., 2013). Further 
structural evidence for lipid-modulation of pLGICs comes from a crystal structure of 
GluClα with bound 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
molecules (Althoff et al., 2014). POPC occupies a site overlapping the ivermectin 
binding site, and is able to penetrate the helix interface with phosphocholine head 
groups juxtaposed to M2 helices (Fig 1.12 E). Surprisingly, this interaction alone is 
sufficient to induce a distinct expanded, open-like channel confirmation. It will be of 
interest to determine whether this site displays specific lipid selectivity and whether a 
common mode of allosteric modulation is observed across different classes of lipids.   
 
1.7. Overcoming the barriers to pLGIC structure determination 
An array of high-resolution structures for full length pLGICs in various conformational 
states have been determined, with some bound to agonists and allosteric modulators. 
Despite this, the amount of structural data for GABAA receptors is still very limited. This 
is largely due to the inherent difficulty in purifying and crystallizing eukaryotic 
membrane proteins. Developments in pre-crystallization screening (to optimize 
detergent extraction and purification of receptors), crystal optimization and structure 
solution techniques will ultimately assist in the generation of further high-resolution X-
ray pLGIC models. Of equal interest will be the application of alternative approaches, 
including cryo-EM and native mass spectrometry for characterising protein in its native 
state. In the case of cryo-EM, direct imaging of purified protein can now (with the 
advent of developments in direct electron detection cameras and image processing) 
allow high-resolution structure determination. In comparison, native mass 
spectrometry can reveal different modes of lipid and small molecule binding to 
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membrane proteins in their native states. In addition to crystallography, these two 
approaches have been applied during this study. Short “primers” can be found in the 
Appendix, which summarise the steps involved in structure determination by cryo-EM 
(Appendix Primer 1) and the structural questions that can be addressed by mass 






















1.8. Thesis Aims 
While significant progress has been made in advancing our understanding of the 
structural mechanisms underpinning GABAA receptor activation and modulation, to 
date there is only one high-resolution structure of a GABAA receptor in the Protein 
Data Bank (PDB), the homopentameric β3 receptor (Miller and Aricescu, 2014). Indeed 
at the start of this study, this was not even the case, with high resolution structures 
available only for the receptor homologs GLIC, ELIC and GluClα (as introduced in 
Chapter 1). While these form useful templates for homology modelling to guide 
structure function studies, there will likely be grey areas in the ‘structural’ 
interpretation of data. Ultimately, the generation of more high-resolution data for 
GABAARs will provide the greatest detail regarding receptor function and modulation.  
The ability to generate high-resolution structures for pLGICs is inherently dependent 
on the ability to express and purify the full length receptor at both high yield and 
purity, and then grow strongly diffracting protein crystals for structural determination. 
For eukaryotic pLGICs, such as GABAARs, this is far from trivial.  
As emphasized in Chapter 1, pLGICs are modular receptors, comprised of an ECD, TMD 
and ICD. Owing to this property, it has been possible to generate receptor chimeras, 
whereby domains of distally related receptors have been fused to form functional 
proteins, e.g. a chimera between the ECD of the prokaryotic GLIC and TMD of the 
human α1 GlyR subunit (Duret et al., 2011). The question was therefore raised; can we 
use the domains of previously crystallized receptors, e.g. the ECD of GLIC, as a 
surrogate host for other eukaryotic receptor domains, e.g. the TMD of the GABAAR? 
Given the evident amenability of the ‘surrogate host’ to high-level purification and 
crystallization, one might postulate that this could coerce the eukaryotic domain to 
pack in the crystal form for high-resolution structural analyses. In doing so, 
fundamental questions regarding domain structure, role in receptor function and 
allosteric modulation could be assessed. 
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We therefore choose to explore the potential for generating chimeric GABAA 
receptors, principally targeting the TMD of the GABAAR α1 subunit for fusion with the 
ECD of GLIC. This GABAAR subunit was chosen due to a current lack of high-resolution 
structural information and its apparent role in setting critical receptor properties, such 
as desensitization, and allosteric modulation by neurosteroids. We reason that 
‘breaking’ the GABAA receptor subunit into its individual core components, such as the 
TMD, would improve the potential for successful purification and crystallization (that 
might otherwise be hindered in studies of the full-length, glycosylated receptor 
complex).       
We set about designing chimeric GABAA receptors and assessed functionality and 
allosteric modulation of receptors expressed in Xenopus oocytes for 
electrophysiological recordings (Chapter 3). In order to generate sufficient yield of a 
chimeric receptor for crystallization, a number of purification strategies were assessed 
on their ability to stabilize GLIC-GABAAR α1 chimeras in detergent micelles (Chapter 4).  
Additionally, we probed the different pharmacological properties of native GABAARs, 
their prokaryotic homologs and receptor chimeras. These revealed previously 
unreported allosteric modulator responses at GLIC (to the barbiturate, pentobarbital; 
Chapter 5) and ELIC (to the inhibitory neurosteroid, pregnenolone sulphare; Chapter 
6), which we have assessed in further structural studies to ascertain binding sites. 
Finally, as the field of membrane protein structural biology develops, we have begun 
to assess the use of non-crystallographic techniques, cryo-EM and mass spectrometry 








Chapter 2: Material and Methods 
2.1. Reagents 
Sources for the reagents used in this study are provided throughout the materials and 
methods along with relevant experimental details. 
 
 
2.2. Molecular Biology 
Extended details of the constructs generated and used in this study are given in 
Appendix Tables 1-3.  
  
GLIC, ELIC, GluClcryst, GABAAR and chimeric subunits were subcloned in to pRK5 for 
mammalian expression, with a Kozak consensus sequence inserted upstream of the 
native signal peptide sequence. The mature GLIC and ELIC protein-encoding sequences 
were flanked by the signal peptide from the 7 nAChR. The plasmid containing the 
gene for GluClcryst (originally in pGEM)was a gift from Eric Gouaux (Addgene plasmid 
number 31488) and that containing GLIC (originally in pMT3) was a gift from Pierre-
Jean Corringer.  
 
 
2.2.1. PCR amplification and analysis 
Chimeric subunits were generated by an overlap PCR protocol and subcloned in to 
pRK5 for expression. The procedure consists of four-steps, with PCR products purified 




1. PCR amplification of the amino-terminal end of the receptor was generated using 
the forward primer SP6 and a reverse primer (Table 2.1) that overlapped the junction 
between the parental receptor DNAs.  
2. PCR amplification of the carboxyl-terminus end of the receptor was generated using 
the reverse primer P5 and a forward primer (Table 2.1) that overlapped the junction 
between the parental receptor DNAs.  
3. The PCR products from steps 1 and 2 were assembled following a PCR amplification 
using SP6 and P5 primers.  
4. The PCR product of step 3 was sublconed into pRK5 using the restriction enzymes 
ClaI and EcoRI and T4 DNA ligase.  
 
Table 2.1 PCR primers for GABAA receptor chimeras with GLIC and GluClα 
 
Primer Sequence 5’- 3’ Template 
GLIC-GABA α1 F GATTTCTCGTCAATATGGCTACTTTGTTATTCAAACATATC GABAA α1 
GLIC-GABA α1 R TAACAAAGTAGCCATATTGACGAGAAATCCGCAA GLIC 
GLIC-GABA β2 F GGATTTCTCGTCAATATGGCTACTTCATCCTGCAGAC GABAA β2 
GLIC-GABA β2 R GCAGGATGAAGTAGCCATATTGACGAGAAATCCGCAAC GLIC 
GluClα-GABA α1 F CAGCTCAAAAGAGAATTCGGCTACTTTGTTATTCAAACATATC GABAA α1 
GluClα-GABA α1 R TTGAATAACAAAGTAGCCGAATTCTCTTTTGAGCTGGATCGTG GluClα 
 
Primers are shown for the receptor chimeras where F = Forward primer (used in combination with P5 
primer for pRK5 vector) and R=reverse primer (used in combination with SP6 primer for pRK5 vector). 
 
 
Receptor fragments and full-length genes were generated by PCR using Phusion DNA 
Polymerase (Thermo Fischer, Rockford, Illinois, USA). PCR was performed using a G-
StormThermal Cycler (Somerton, Somerset, UK) using the following generic protocol, 







1. Activation: 98°C for 30s 
2. DNA Denaturation: 98°C for 10s 
3. Annealing: Variable temperature (typically 55-72°C) for 30s 
4. Extension: 72°C for variable time of 15-30s/kb 
5. Return to step 2, 25-40x (dependent on reaction) 
6. Final extension: 72°C or 10 min 
 
For all reactions; PCR products were run on an agarose gel (0.8-2% depending on the 
fragment size to be isolated) for reaction analysis. Bands equating to PCR products of 
the expected size were excised and DNA was isolated using a QIAquick Gel Extraction 
Kit (Qiagen).  
 
Single-point mutations of receptor subunits and affinity tag-insertions were generated 
by inverse PCR using Phusion DNA polymerase. The PCR product of this amplification 
reaction was isolated following gel extraction and purification; (5’) phosphorylated 
using a T4 polynucleotide kinase (New England Biolabs, UK) and ligated using a T4 DNA 
ligase (New England Biolabs, UK or Roche, Basel, Switzerland). All plasmids were 
transformed in to DH5α E. coli cells (New England Biolabs, UK) unless otherwise stated 
and plated on to Luria Broth (LB) agar plates supplemented with the appropriate 
antibiotic (see Table 2.2 and Appendix Table 1-3); ampicillin at 100 μg/ml or kanamycin 
at 30-50 μg/ml) and incubated overnight at 37°C. Colonies were picked and incubated 
in 3-5 ml of LB supplemented with antibiotic with shaking (overnight at 37°C). Plasmid 
DNA was purified using QIAprep Spin Miniprep kit (Qiagen). The concentration of DNA 
was determined using a spectrophotometer (BioPhotometer; Eppendorf, Hamburg, 
Germany) or Nanodrop (Thermo Fischer). Where necessary, the volume of bacterial 
culture for DNA purification was scaled up in order to carry out Midi scale plasmid 
preparation (HiSpeed Plasmid Midi Kit (Qiagen)).  Coding regions of all construct genes 






Table 2.2 Antibiotics and reagents for bacterial culture and selection 
 
Reagent Source Solvent [Stock] [Final] 
Ampicillin Melford Water 100 mg ml-1 100 µg ml-1 
Kanamycin 
sulphate 
MP Biochemicals Water 50 mg ml-1 50 µg ml-1 
Gentamicin 
sulphate 
Sigma Water 7 mg ml-1 7 µg ml-1 
Tetracycline Sigma Ethanol 10 mg ml-1 10 µg ml-1 




Melford Water 100 mM 0.1-0.2 mM 
 




2.2.2. Bungarotoxin-tagged construct design and generation 
For live-cell imaging of surface-expressed receptors, the nucleotide sequence encoding 
a 13 amino acid -bungarotoxin binding site (BBS) mimotope was introduced into the 
receptor subunit gene; WRYYESSLEPYPD (Wilkins et al., 2008). This sequence was 
positioned such that the site would be introduced 7 amino acid residues from the start 
of the mature protein. Complementary DNA fragments for the 13 residues BBS were 
incorporated into oligonucleotides, such that the site could be introduced into the 





Table 2.3 PCR primers for inserting α-bungarotoxin binding site 
 
Primer Sequence (x=Gene of interest) 
BBS Forward 5 -GTTTAGAACCATATCCAGATx-3  
BBS Reverse 5 -TACTTTCATAATATCTCCAx-3  
 
 
2.2.3. Bacterial expression constructs 
Chimeric subunits were subcloned into a modified pET26 vector for bacterial 
expression under the T7 promoter as a fusion protein with the maltose-binding protein 
(Fig 2.1). The final construct encoded the pelB signal sequence followed by a (His)10 
tag, maltose binding protein (MBP), a Herpes simplex (HRV) 3C protease site and the 
chimeric subunit sequence. The genes encoding GLIC and ELIC as MBP-fusion proteins  
(in the pET26 vector described above) were gifts from Raimund Dutzler (Addgene 





Figure 2.1 – Schematic of MBP-fusion protein for bacterial expression and 
purification 
Schematic representation of the MBP-fusion protein construct used for bacterial expression and 
purification of GLIC, ELIC and GLIC-GABAAR chimeras. A pelB signal peptide sequences targets the 
protein to the inner membrane of bacteria. The His-MBP fusion tag is inserted at the N-terminus of the 





2.2.4. Baculovirus-Insect cell expression constructs 
The gene encoding chimeric subunits and a C-terminal (His)8 tag was subcloned in to 
pFastBac1 vector for baculovirus-driven expression in insect cells. Transposition of the 
gene of interest into recombinant bacmid DNA was carried out using DH10 Bac cells 
(following manufacturers guidelines, with minor modifications. Invitrogen/Life 
Technologies Ltd). Cells were plated on kanamycin/gentamicin/tetracycline/Bluogal 
/IPTG LB agar plates (Table 2.2) for blue/white colony selection (allowing up to 48 hrs 
for colour selection). White colonies containing the recombinant bacmid were selected 
for isolation of recombinant bacmid DNA.   
 
Briefly, single white colonies were picked and inoculated in 2YT broth supplemented 
with kanamycin/gentamicin/tetracycline and grown at 37 C (overnight with shaking). 
Cells were harvested by centrifugation, lysed and bacmid DNA isolated by isopropanol 
precipitation. Due to the large size of recombinant bacmid DNA (>135 kb), it was 
therefore analysed by PCR using a combination of M13 Forward or Reverse primers (as 
detailed in the Bac-to-Bac Handbook, Invitrogen, Table 2.4) and by using a primer 
specific to the gene of interest (to confirm successful transposition). PCR products 
were analysed by gel electrophoresis.  Recombinant bacmids (exhibiting successful 
transposition) were stored at 4 C prior to use.  
 
Table 2.4 PCR primers for analysis of recombinant bacmid DNA 
 
Primer Sequence  
M13 Forward 5 -CCCAGTCACGACGTTGTAAAACG-3  






2.3.1. Preparation of Xenopus oocytes  
Xenopus laevis were housed in the Biological Services Unit or at Royal Free College 
Hospital (UCL). Segments of ovaries were taken using a Schedule 1 procedure 
(following terminal anaesthesia with tricane methane sulphonate MS 222) and 
prepared for electrophysiological recordings as previously described (Gielen et al., 
2012). Briefly, segments of the ovaries were incubated in a (Calcium-free) collagenase-
type 1 solution (OR2 + collagenase) for approximately 2-4 hrs (OR2; 85mM NaCl, 5mM 
HEPES, 1mM MgCl2, pH 7.6 with 1M KOH). Oocytes were washed several times in OR2 
(without collagenase), followed by washing in Barth’s solution (88mM NaCl, 1mM KCl, 
0.33mM Ca(NO3)2, 0.41mM CaCl2, 0.82mM MgSO4, 2.4mM NaHCO3, 10mM HEPES pH 
7.6 with NaOH). Defolliculated oocytes were stored in Barth’s solution supplemented 
with gentamicin at 16-18 C.    
 
For receptor expression in oocytes, plasmid DNA was diluted to 1-30 ng/ l in TE buffer. 
Single oocytes were subsequently injected with 27.6 nl of receptor subunit cDNA into 
the nucleus. Oocytes were incubated at 17 C in Barth’s solution for 1-4 days prior to 
recordings (depending on the receptor subunits to be expressed).  
 
Oocytes expressing homomeric wild-type (WT), mutant or chimeric subunits were used 
between 1-4 days after injection. Wild-type homomeric receptors typically showed 
robust expression after 1 day, whist chimeric receptors typically showed robust 
currents after 2-4 days.  Injected oocytes were transferred to an in-house designed and 
fabricated recording chamber and viewed and positioned under optical magnification 
(Fig 2.2). During recordings oocytes were continuously superfused with the following 
recording solutionfor proton-gated receptors: 100 mM NaCl, 2mM KCl, 2mM CaCl2, 
1mM MgCl2, 10 mM MES, 10 M EDTA; and for GABA and glutamate-gated receptors: 
100 mM NaCl, 2mM KCl, 2mM CaCl2, 1 mM MgCl2, 5 mM HEPES, adjusted to pH 7.4 
with 1M NaOH). Recording pipettes (borosilicate glass) were fabricated using a two-
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stage vertical puller (resistance 0.8-2 MOhms) and filled with 3M KCl. Oocytes were 
voltage clamped at -60 mV, and experiments carried out at room temperature. 
Receptor activated currents were induced by application of the appropriate agonist 
using a gravity flow perfusion system for fast-application. For pH sensitivity 
experiments, 10 mM MES buffered recording solution was adjusted to the appropriate 
pH with 1M NaOH. Currents were recorded using an Axoclamp 2B amplifier, a Digidata 
1322A interface and pCLAMP (Version 8) and recorded to disk (Dell Computers). 





Figure 2.2 - Schematic of Two-Electrode Voltage Clamp recording set up and 
application system 
Oocytes were continuously perfused using a gravity flow system and vacuum pump (for perfusion out of 
bath). Drugs were applied by gravity flow and a two-way manually operated switch. Under normal 
conditions the wash/bath line (e.g. recording solution) is channelled in to the recording chamber (and 
drug to the waste line). For drug application, rapid rotation of the switch through 90° directs the drug 




Table 2.5 Drug solutions used for electrophysiology 
 
Drug Source [Stock]  Stock solvent 
GABA Sigma 1M Water 
Ivermectin Sigma 1mM DMSO 
Pentobarbital Sigma 100mM DMSO/Water 
Picrotoxin Sigma 10 mM DMSO 
Pregnenolone sulphate Sigma 10 mM DMSO/Water 
S97617 Sigma Up to 100mM DMSO/Water 
THDOC Sigma 10mM DMSO 
 
Drugs were sourced from Sigma-Aldrich (Steinheim, Germany) and prepared as described. Where DMSO 
was used as solvent, the final concentration of DMSO in recording solution did not exceed 0.1% (v/v). In 
the cases where DMSO concentration was > 0.5%, recordings in the presence of an equivalent 
concentration of vehicle alone were carried out to ensure specific effects of the drug (over DMSO). 
Pentobarbital was a sodium salt.  
 
Drug application was dependent the type of experiment. For peak recordings, agonist 
(GABA/glutamate/protons) was applied in combination with other drugs (either co-
applied, or pre-applied, or applied following receptor-activation. Drug details in Table 
2.5). In constructing concentration-response relationships, a normalising concentration 
of agonist was frequently applied (to assess run-up or run-down of membrane 
currents). For assessment of receptor activation and desensitization rates, the 
response to prolonged agonist exposure (40-60 s) was recorded.  
 
2.3.2. Electrophysiology data analysis  
Concentration response data were typically generated from 6 to 8 data points. The 
amplitudes of peak currents were measured and then normalised to the response 
amplitudes evoked by a normalising agonist concentration (in Clampfit, Molecular 
Device, USA). If agonist-induced currents resulted in a loss of voltage clamp (and hence 
underestimation of actual membrane current) this was accounted for prior to analysis. 
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Individual data sets were fitted with the Hill equation (see below), and a variation was 
also used that enabled two-component fits and inhibition-response relationships to be 
described using Origin 6.0. The concentrations causing half-maximal effects (EC50/IC50) 
and Hill slope (nH) values were generated from individual data fits. For mean fits; 
pending on feasibility, relative membrane currents were normalised to either an 
experimentally- or theoretically-derived maxima, and then fitted with the Hill 
Equation.   
 
Equation 2.1 Hill Equation 
 
 
Where Imax, proton is the maximum response to a saturating concentration of protons, 
EC50 is the concentration of protons ([A]) inducing a half-maximal current, nH is the Hill 
coefficient and i is the number of components where j typically = 1-3.  
 
 




Antagonism was evaluated through constructing inhibition-concentration relationship 
curves and a data fit generated using the equation above. IC50 is the concentration of 
























2.3.3. Activation and Decay Analysis 
Agonist current rise times were determined as the time for the current amplitude to 
increase from 20% to 80% of the maximal response. For analysis of receptor decay 
kinetics, oocytes were exposed to agonist for prolonged period (ideally 45-60, but due 
to an endogenous oocyte response to protons this was not always possible and data 
sets exhibiting considerable “noise” in the decaying phase were discarded). Weighted 
decay time constants for desensitization were determined by fitting the decaying 
phase with 2 or 3 exponential components (in Clampfit version 8) and using the 




Figure 2.3- Agonist-evoked response with a bi-exponential decay function 
Current (red trace) recorded from an oocyte expressing GluCl-GABAA upon application of a saturating 
concentration of agonist, glutamate. Cursors (vertical teal lines) were placed at the approximate start 
and end of the decaying phase and fitted with a bi-exponential decaying function. Function parameters 





























Equation 2.3 Weighted time decay constant 
 
w = (A1. 1 + A2. 2) / (A1 + A2); 
 
 
Where τ1 and τ2 represent the time constants for a bi-exponential decay (see above 
figure for example of fit to data), and A1 and A2 are relative amplitude contributions of 
τ1 and τ2.  
 
 
2.3.4. Spontaneous Channel Activity Analysis 
Given that picrotoxin block could not be measured for some receptors, in order to 
compare relative spontaneous channel activity between mutant receptors, activity was 
measured as a percentage of the maximum current induced by high agonist 
concentration. 
 







Where IHolding is the stable standing current (e.g. spontaneous activity; SA) observed 
immediately following oocyte voltage clamp (at resting pH) and Imax, proton is the max 
current size induced by a high (maximal) proton concentration.   
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2.4. HEK Cell Electrophysiology and Imaging 
2.4.1. HEK Cell Culture and transfection 
HEK293 cells were maintained in Dulbecco’s modified Eagle’s media supplemented 
with 10% v/v fetal bovine serum, penicillin-streptomycin (100 units/100 g/ml) and 2 
mM glutamine (all from Gibco, Invitrogen Ltd.) at 37°C in humidified 95 % air and 5 % 
CO2. For imaging and electrophysiology experiments cells were plated on to 18 mm 
glass coverslips (VWR International) coated with poly-L-lysine (Sigma), and in 10 cm 
culture dishes (Greiner-Bio-One GmbH, Frickenhausen, Germany) for routine culture or 
cell lysate preparations. For passaging, cells were washed with Hank’s Balanced salt 
solution (HBSS: Gibco), detached from the dish with trypsin-EDTA (Gibco) before 
quenching the trypsin in culture media and replating. HEK293 cells were transfected 
using a calcium phosphate protocol at ~4-18 hrs post plating (depending on the 
application). For imaging and electrophysiology experiments cDNAs encoding receptor 
subunits was mixed with eGFP (except in the case of eGFP-tagged receptor constructs, 
which were mixed with monomeric DsRed). DNA mixtures (~2-4 μg total cDNA) were 
diluted in 340 mM CaCl2 (20 μl/coverslip) and 2x HBSS (24μl/coverslip), and the 
suspension applied to cells. Cells were used 18-48 hrs post transfection. For cell lysate 
preparations, the above protocol was scaled-up for the addition of 10-20 μg cDNA per 
10 cm culture dish. 
 
2.4.2. HEK Cell Imaging 
For (live-cell) imaging of surface-expression of receptors, a BBS was introduced in to 
receptor subunit gene as described previously. To image -bungarotoxin labelling of 
live transfected HEK293 cells (co-transfected with eGFP), cells were washed in Krebs 
Ringer buffer (140mM NaCl, 4.7mM KCl, 1.2mM MgCl2, 2.52mM CaCl2, 11mM Glucose 
and 5mM HEPES, adjusted to pH 7.4 with 1M NaOH), followed by application of 
Alexa555-conjugated -bungarotoxin (Molecular Probes, ThermoFisher, Waltham, MA, 
USA) for 5 min. Cells were washed (briefly) in Krebs and then imaged immediately 
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using a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss Ltd., Welwyn, Garden City, 
Hertfordshire, UK) equipped with a 488 nM argon and 543 nM He-Ne laser line and a 
40x water-immersion objective. Images were later analysed with ImageJ (Fiji). An 





Figure 2.4 - Cell surface labelling of BBS-tagged receptors with α-Bungarotoxin 
(conjugated to Alexa555) 
 
A. Example of cell surface labelling of HEK293 cells expressing BBS-tagged GLIC-GABAAR α1 chimeric 
receptor as revealed following incubation with α-Bungarotoxin (Bgtx) conjugated to Alexafluor 555. 
Transfected cells were identified by co-transfection with eGFP. Cell surface expression is clearly visible 
as a fluorescent signal around the edge of cells (i.e. the plasma membrane). A strong band of labelling is 
shown by the white arrowhead. Apparent intracellular labelling (as indicated by the yellow arrowhead) 
is likely to be contributed by labelled-receptors embedded in the membrane but outside of the image 
focal plane. We do not expect to observe receptor internalization under the imaging conditions used in 
this study. B. Analysis of the profile of the fluorescent signal along a line (white line in A) reveals clear 
demarcation between intracellular expression of soluble eGFP and plasma membrane embedded 
bungarotoxin-labelled receptors. The position of the plasma membrane is shown by arrows. Note: BBS is 
inserted into the receptor’s N-terminus at a position exposed to the extracellular space. Fluorescent 





2.4.3. HEK Cell Electrophysiology: Whole-cell patch clamp 
Transfected HEK293 cells (on glass coverslips) were placed in a recording chamber, and 
visualized using phase-contrast optics. Transfected cells were identified using eGFP 
signal (visualized under epifluorescence optics). During recordings cells were 
continuously perfused at room temperature with a Krebs recording solution (in mM; 
140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.52 CaCl2, 11 glucose and 5 HEPES, adjusted to pH 7.4 
with 1M NaOH). Whole-cell currents were recorded from cells voltage-clamped at -20 
mV. Whole-cell currents were filtered at 5 kHz and digitized at 50 kHz via a Digidata 
1332A (Molecular Device, USA) and recorded to disk (Dell Computers). Patch pipettes 
(borosilicate glass) were fire polished to 2-4 mOhms and filled with an intracellular 
solution (in mM; 120 KCl, 1 MgCl2, 11 EGTA, 10 HEPES, 1 CaCl2, 2 ATP, adjusted to pH 
7.2 with 1M NaOH). The osmolarity of intracellular solution was typically 300 mOsm/l.  
 
 
2.5. Expression and purification of receptor in bacterial cells 
2.5.1. Expression and purification of GLIC and chimeric receptors in E. coli 
For expression of GLIC and chimeric receptors in E. coli, receptors were expressed as a 
fusion protein with Maltose Binding Protein as previously described (Nury et al., 2011). 
Proteins were overexpressed in E. coli C43 cells (Lucigen, Middleton, WI, USA). For a 
typical large-scale expression: An overnight culture in LBKan30 (50-100 ml) was used to 
inoculate 5l of 2YT media (~8.5 ml of 850 ml 2YT in 2.5l Erlenmeyer flasks) and grown 
with shaking (180-220 rpm) at 37 C. Expression was induced by addition of 0.1 mM 
IPTG (Sigma-Aldrich) once cell density reached an absorbance (OD600) of ~1.0. Cells 
were cooled to 20 C and expression was carried out overnight at 20 C (shaking at 180 
rpm). Cells were harvested and resuspended in Buffer A (300 mM NaCl, 20 mM Tris-
HCl pH7.6) supplemented with EDTA-free Inhibitor Cocktail Complete (Roche). Cells 
were disrupted by sonication (Soniprep 150 – 9mm probe) and unlysed cells and debris 
cleared by centrifugation at 15,000g for 30 min at 4°C (JA20 rotor. Beckman Coulter, 
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High Wycombe, UK). The membrane fraction was isolated by centrifugation of the 
cleared lysate at 200,00g (45Ti or 70Ti rotor) for 2 h at 4 C. Membrane pellets were 
resuspended in Buffer A and proteins extracted with 40 mM n-Dodecyl- -D-
Maltopyranoside (DDM) (Affymetrix-Anatrace, Generon Ltd, UK) overnight under 
gentle agitation. Insoluble material was removed by centrifugation at 200,000g and 
solubilized protein purified by affinity chromatography with amylose resin (New 
England Biolabs) or by immobilized metal affinity chromatography (IMAC) with TALON 
Co2+ resin (ClonTech, Takara Bio, France). Initial screens of chimeric receptor 
expression in bacteria used purification on amylose resin.  
 
For purification on an amylose resin, the resin was pre-equilibrated in Buffer A 
supplemented with 0.02% DDM (w/v) prior to binding of the fusion protein.  Protein 
was batch bound to the resin for 2-4 hrs at 4 C and then packed in to an Econo-Pac 
column (Bio-Rad, Hercules, CA, USA). Unbound material was collected in the flow-
through, and resin washed thoroughly with 0.1% and 0.02% DDM (w/v) in Buffer A. 
Fusion protein was eluted in 0.02% DDM in Buffer A with 20 mM maltose. Eluted 
proteins were concentrated and further purified by gel filtration on a Superose 6 
10/300 GL column (GE Healthcare, Bucks, UK), equilibrated in Buffer A supplemented 
with 0.02% DDM, attached to an AKTA FPLC (at 4°C; GE Healthcare, Bucks, UK) 
operating under Unicorn Control Software. Sample was run over the column at a 
constant flow rate of 0.3 ml/min and the A280nm of the eluent monitored by an in-line 
UV detector. Fractions of the peak corresponding to the pentameric fusion-protein 
were pooled and the fusion tag cleaved in solution with PreScission Protease (purified 
“in-house” and kindly provided by Dr Matthew Gold, Dept of NPP UCL, cleaving at an 
LQVLPQ/GP consensus sequence). His-tagged MBP and a contaminating (amylose-
binding) protein were removed by running the sample over TALON Co2+ resin 
(Clontech, Takara Bio, France) and amylose columns respectively. The cleaved native 
pentameric protein was purified by a final gel filtration step, concentrated with a 
100kDa MWCO Amicon-Ultra centrifugal filter unit (EMD-Millipore) and flash-frozen in 




For purification of GLIC on TALON Co2+ resin a modified protocol was used to that in 
(Gonzalez-Gutierrez et al., 2013). Resin was pre-equilibrated in Buffer A supplemented 
with 0.5 mM DDM prior to binding of fusion protein. Protein was batch bound to resin 
for 2-4 hrs at 4°C in the presence of 10 mM Imidazole, and then packed in to a Bio-Rad 
Econo-Pac column. Unbound material was collected in the flow through, and resin 
subsequently washed with Buffer A supplemented with 0.5 mM DDM and 30 mM 
Imidazole. Fusion protein was eluted in a single step with 300 mM Imidazole (in Buffer 
A supplemented with 0.5 mM DDM). Eluted proteins were concentrated and imidazole 
removed using a PD10 Desalting column (GE Healthcare) before overnight cleavage of 
the fusion tag using dual tagged His/GST-PreScission Protease (Pierce/Life 
Technologies). His-tagged MBP was removed by binding to amylose resin for an hour 
and cleaved GLIC collected in the flow through. Cleaved GLIC and PreScission protease 
were further separated by gel filtration on a Superose 6 10/300 GL column (GE 
Healthcare) equilibrated in Buffer A supplemented with 0.5 mM DDM attached to an 
AKTA FPLC. Peak fractions corresponding to cleaved pentameric GLIC were pooled and 
concentrated to 10 mg/ml for crystallization trials. Fractions at all stages were 
analysed by SDS-PAGE and western blot (as described below).  
 
 
2.5.2. Expression and purification of ELIC in E. coli 
For expression of ELIC in E. coli, receptors were expressed as a fusion protein with 
Maltose Binding Protein largely as previously described (Hilf and Dutzler, 2008). 
Purification additionally used a modified version of the protocol described in 
(Gonzalez-Gutierrez et al., 2012). Proteins were overexpressed in E. coli C43 cells 
growing in 2YT media at 37  C, as carried out for GLIC, and expression was induced by 
addition of 0.2 mM IPTG once the cell suspensions reached an absorbance (OD600) of 
~1.6-1.8. Cells were cooled to 20 C and expression carried out overnight at 20 C 
shaking at 180 rpm. Cells were harvested by centrifugation and resuspended in ELIC 
Buffer A (150 mM NaCl, 50 mM Sodium Phosphate pH 7.9) supplemented with EDTA-
free Inhibitor Cocktail Complete (Roche). Cells were disrupted by sonication and 
unlysed cells and debris cleared by centrifugation at 15,000g for 30 min at 4°C. The 
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membrane fraction was isolated by centrifugation of the cleared lysate at 200,00g 
(45Ti or 70Ti Rotor) for 2 h at 4 C. Membrane pellets were resuspended in ELIC Buffer 
A and proteins extracted with 40 mM n-Undecyl- -D-Maltopyranoside (UDM) 
(Affymetrix-Anatrace, Generon Ltd, UK) overnight under gentle agitation. Insoluble 
material was removed by centrifugation at 200,000g and solubilized protein purified by 
immobilized metal affinity chromatography with Ni-NTA. Solubilized membranes were 
passed through a 0.45 μm filter before loading on to a 1ml HisTrap HP (GE Healthcare) 
column using a peristaltic pump P-1 (GE Healthcare) at 4°C in the presence of 10 mM 
imidazole. Flow through was recycled at least one further time over the column. The 
column was washed with ~20 column volumes of ELIC Buffer A supplemented with 3 
mM UDM and 30 mM imidazole. Bound proteins were eluted in a single step with 300 
mM imidazole. 1 ml fractions were collected and protein-containing fractions pooled, 
concentrated and desalted using a PD-10 column to remove imidazole. Fusion-protein 
was digested overnight at 4°C using His/GST-HRV 3C protease (Pierce/Life 
Technologies). A second round of affinity chromatography (by TALON Co2+ resin) was 
used to remove His-tagged MBP and protease. The flow through from this step 
contained cleaved ELIC. ELIC was concentrated and further purified on gel filtration 
column (Superose 6 10/300) equilibrated in ELIC Buffer B (150 mM NaCl, 10 mM 
Sodium Phosphate pH 7.9) supplemented with 1.2 mM UDM. Peak fractions 
corresponding to the pentameric protein were pooled and concentrated (for 
crystallization typically at 9-11 mg/ml). See further details regarding the preparation of 
ELIC for EM experiments.  
 
2.6. Expression and purification of chimeric receptors in Sf9 insect cells 
2.6.1. Insect cell culture 
Sf9 insect cells (Invitrogen/Gibco) were cultured using standard methods. In brief, cells 
were cultured in suspension in Erlenmeyer flasks at 27 C shaking at 130 rpm in an 
Inova 42R shaking incubator (New Brunswick/Eppendorf), under no further 
atmospheric control, in two types of media: Sf900 SFM (Invitrogen/Gibco) or 
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InsectXpress with L-glutamine (Lonza/SLS, UK). After screening the effect of media on 
protein expression, InsectXpress media was used for scale-up experiments.  
 
2.6.2. Transfection and Baculovirus-generation 
Transfections were carried out on adherent cells, cultured in 6-well plates. Cells were 
seeded at ~1x106  cells/well and transfected using PEI Max (MW 40,000. Polysciences). 
Briefly, for each well 12 g PEI in PBS was mixed with 4 g of bacmid DNA, incubated 
at room temperature for 20 min and then added to the cells. Cells were incubated for 
5-7 days at 27 C without shaking prior to harvest of the P1 virus. Culture media 
containing recombinant virus particles was collected and clarified by centrifugation.  
P1 virus was either used immediately for ‘P2 viral’ amplification or stored at 4 C in the 
dark. P2 virus was generated through infection of cells in suspension at a density of 1-
2x106 cells/ml. Cells were infected with P1 virus at a dilution of 1:100 (v/v). Cells were 
incubated at 27 C shaking at 130 rpm for 72 hrs prior to harvesting P2 virus. Cell 
suspensions were centrifuged and supernatant containing P2 virus collected. Protein 
expression in transfected and infected cells was analysed by SDS-PAGE and western 
blot. 
 
For protein expression experiments cells were grown in suspension to 1-2 x 106 
cells/ml in 850 cm2 roller bottles (400 ml cells/ bottle). Cells were infected with P2 virus 
at a dilution of 1:100 (v:v) and incubated at 27 C (unless otherwise stated) shaking at 
130 rpm for 48-72 hrs.  
 
 
2.6.3. Small-scale expression and detergent screening 
In order to screen a number of constructs for expression, or a panel of detergents for 
their efficiency of extraction, a small-scale purification scheme was implemented. 
Starting material for purification was typically the biomass of 3-10 ml of insect cells 
(from a 30 ml culture infected with P2 virus). The following protocol was adapted from 
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one developed by the Joint Center for Innovative Membrane Protein Technologies 
(JCIMPT) for small scale screening of GPCRs and other membrane protein complexes. It 
should be noted that in this study, the procedure was used primarily to monitor 
construct expression and provide preliminary results for detergent extraction 
efficiency. It should also be noted that the effect of preparing cell membranes using 
the “high-salt/hypertonic wash” procedure prior to detergent extraction of receptors 
has not, at this stage, been explored in scale up studies in this study.     
 
Insect cells were harvested by centrifugation and one time washed with cold PBS. Cell 
pellets were resuspended in Lysis Bufer (20 mM HEPES pH7.5, 20 mM KCl, 10 mM 
MgCl2) and homogenized on ice (20 strokes of a dounce homogenizer). The amount of 
cell biomass and volume of lysis buffer used typically depended on the number of 
variables to be screened (e.g. screening of one construct against 10 detergents; 30 ml 
cells biomass resuspended in 3 ml of lysis buffer, homogenized and split between 10 
1.5 ml eppendorf tubes ~0.3 ml/tube).  Cell suspensions were centrifuged at 16,000-
18,000 g for 30 min at 4°C. The supernatant was discarded and the pellet resuspended 
in buffer A (50 mM HEPES pH7.5, 500 mM NaCl, 10% glycerol) before centrifugation at 
16,000 g for 30 min at 4°C. This step was subsequently repeated at least 3 more times. 
Cell pellets (crude membrane preparation) were resuspended in detergent extraction 
buffer and mixed at 4° C for 1-2 hrs. Detergents (see Table 2.7) were used at a final 
concentration of 1% final and cholesterol hemisuccinate (CHS) at 0.1% (w/v). Insoluble 
material was removed by centrifugation at 16,000 g for 30 min at 4°C, and solubilized 
proteins purified by TALON Co2+ resin (in the presence of 20 mM imidazole) at 4°C for 
at least 2 hrs. 25 μl of TALON resin (equilibrated in buffer A supplemented with 20 mM 
imidazole) was used per sample.  Following incubation, TALON resin (and bound 
protein) was pelleted at 700 g for 5 min at 4°C, and washed three times in Buffer A 
supplemented with 0.05% detergent (and 0.005% CHS) and 20 mM imidazole. Bound 
protein was eluted in a single step with 200 mM imidazole (typically 60 μl of elution 
buffer supplemented with detergent/CHS was used to elute protein from 25 μl of 
TALON resin). Eluted proteins were analysed by SDS PAGE and coomassie blue stain. 
Given that an equal mass of starting material was used per sample, we could assess 
and compare on a semi-quantitative level the extent to which various detergents 
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extracted a single protein of interest. Constructs (and individual virus stocks) could be 
rapidly assessed on the strength of their expression using this small-scale purification 
approach.   
 
 
2.6.4. Large-scale expression and purification 
Strong candidate receptors for structural studies identified from small-scale screens 
(and detergents potentially capable of extracting an appreciable yield of protein) were 
introduced in to scale-up expression studies.  
 
Cells were harvested for purification after 72 hrs and collected by centrifugation at 
3,220 g and washed once with cold PBS. Cell pellets were either used immediately or 
flash-frozen in liquid nitrogen and stored at -80°C. Pellets were resuspended in Buffer 
TBS (20 mM Tris pH 8, 300 mM NaCl) and EDTA-free protease inhibitor cocktail 
complete. Cells were disrupted by sonication on ice (10x using 15 s on/off cycles) with 
a Soniprep 150 equipped with a 9 mm probe. The homogenate was clarified by 
centrifugation at 8,000 g for 20 min at 4°C (JA-12 rotor) and the supernatant 
transferred to a chilled ultracentrifuge tube. The membrane fraction was isolated by 
centrifugation at 125,000 g for 1.5 hrs at 4 C (45Ti or 70Ti rotor). Membranes were 
resuspended in a volume of TBS corresponding to one volume per mass of the 
membrane pellet and homogenized with a dounce homogenizer on ice, and 
transferred to a chilled glass beaker. DDM was added at 0.1 g/g membrane and CHS at 
0.1% final, and membranes solubilized (under gentle agitation by stirring) at 4°C for 2 
hours. Insoluble material was removed by centrifugation at 125,000 g for 1 hr at 4°C 
(various rotors). Solubilized protein was bound in batch to TALON Co2+-affinity resin 
overnight at 4 C in the presence of 10 mM imidazole. TALON resin was pre-
equilibrated in Buffer TBS supplemented with 0.03% DDM. Resin bound protein was 
subsequently exchanged in to TBS containing DMNG/CHS in two-steps. Resin was first 
washed with 10 CVs of TBS supplemented with 0.04% DMNG, 0.002% CHS and 25 mM 
Imidazole, followed by washing with 20 column volumes (CV) of TBS supplemented 
with 0.02% DMNG, 0.001% CHS and 25 mM imidazole. Protein was eluted by a single-
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step with 250 mM Imidazole (0.02% DMNG, 0.001% CHS). Eluted proteins were 
concentrated using an Amicon centrifugal filtration device exhibiting a 100 kDa cut-off 
membrane. Precipitated material was removed by centrifugation (16,000 g, 10 min, 
4°C) and proteins further purified by gel filtration on a Superose 6 10/300 GL column 
equilibrated in Buffer TBS with 0.02% DMNG and 0.001% CHS. Peak fractions were 
analysed by SDS PAGE, and fractions corresponding to the pentameric protein pooled 
and further concentrated to ~3-7 mg/ml, and either used immediately for 
crystallization trials or flash frozen in liquid nitrogen and stored at -80°C.  
 
 
2.6.5. SDS PAGE and Western Blotting 
Protein samples were prepared in Laemmli buffer or LDS sample buffer and incubated 
briefly at room temperature. Samples were separated by SDS PAGE (Tris-Glycine gels) 
and either stained immediately with Coomassie Brilliant Blue (Sigma Aldrich) or 
transferred to a nitrocellulose membrane (0.45 M pore) for western blot analysis.  
For western blot analysis membranes were initially blocked in 5% milk in PBS-T (PBS 
supplemented with 0.1% Tween-20), followed by incubation overnight at 4 C in 
primary antibody (in PBS-T + 5% (w/v) milk, Table 2.6). Blots were washed in PBS-T and 
then incubated in secondary antibody (in PBS-T + 5% milk). Blots were once again 
washed in PBS-T and then exposed to ECL reagent (Pierce Protein Biology, Thermo 
Fisher). Bands were detected using an ImageQuant LAS4000 Analyser (GE Healthcare).  
Table 2.6 Antibodies used for western blot (WB) analysis 
 
Antibody Source (Cat. 
No) 














Table 2.7 Detergent and lipid solutions used for purifications and crystallography 
 
Detergent/Lipid Abbrev. FW (Da) CMC (mM) CMC (%) 
n-Decyl-β-D-Maltopyranoside DM 482.6 ~1.8 0.087 
n-Undecyl-β-D-Maltopyranoside UDM 496.6 ~0.59 0.029 
n-Dodecyl- β-D-Maltopyranoside DDM 510.6 ~0.17 0.0087 
n-Octyl- β-D-Maltopyranoside OM 545.4 ~19.5 0.89 
Octyl Glucose Neopentyl Glycol OGNG 568.7 1.02 0.058 
Decyl Maltose Neopentyl Glycol DMNG 949.1 0.036 0.0034 
Lauryl Maltose Neopentyl Glycol LMNG 1005.2 0.001 0.01 
Lauryldimethylamine N-oxide LDAO 229.4 ~1-2 0.023 
Sodium lauryl sulphate SDS 288.4 8.2 0.23 
Anapoe-C10E6 C10E6 Avg. 423 ~0.9 0.038 
Anapoe-C12E8 C12E8 Avg. 539 ~0.09 0.0048 
Anapoe-C12E9 C12E9 Avg. 583 ~0.05 0.003 
Fos-Choline-12 FC12 351.5 ~1.5 0.047 




Cymal 7 522.5 ~0.19 0.0099 
     
Digitonin - 1229.3 < 0.5mM  
Cholesteryl Hemisuccinate CHS 486.73 - - 
Cholesteryl Hemisuccinate Tris Salt CHS 607.9 - - 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocholine 
POPC 760.08 - - 
1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphocholine 
DPPC 734.04 - - 
     
Amphipol A8-35 A8-35 ~8 kDa - - 
 
All detergents were sourced from Anatrace (Generon, Maidenhead, Berkshire, UK), with the exception 
of SDS (Sigma-Aldrich Steinheim, Germany), Digitonin (Calbiochem, Merck-Millipore, Darmstad, 
Germany), Cholesteryl Hemisuccinate (Sigma-Aldrich). CMC is the Critical Micelle Concentration, and 
values are for detergent in water (as provided by the supplier). Lipid (POPC and DPPC) solutions were 
typically prepared in 80% gel filtration buffer and 20% DMSO.  
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2.6.6. CPM Fluorescence Thermal Stability Assay 
CPM assays were carried out at the Membrane Protein Laboratory, Harwell Research 
Campus (Didcot, UK) 
 
Purified receptor protein (GLIC-GABAAR α1 chimeras in DMNG and CHS and ELIC in 
UDM) was mixed with a panel of detergents to assess thermal stability using an 
unfolding assay, (Alexandrov et al., 2008). Thermal stability was quantitatively 
characterised by changes in fluorescence output of the thiol specific fluorochrome N-
[4(7-dimethyamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM).  
 
Detergents were prepared in assay buffer (20 mM Tris pH 7.5, 150 mM NaCl) at a final 
concentration equivalent to 3x CMC (as detailed in Table 2.7). For example, DDM has a 
CMC of 0.0087%, and was used at 0.026% (i.e. 3x CMC) in CPM assays. CPM dye 
((Sigma-Aldrich) was prepared as a 4 mg/ml stock in DMSO, and then further diluted 
1:20 in assay buffer (supplemented with DDM) before dilution to a final working 
concentration as detailed below. Protein samples were typically diluted to ~4 mg/ml. 
For CPM assays the “reaction” was composed as follows (per well of a 96 well PCR 
plate): 
 
Reaction Buffer 47 µl 
Protein  1 µl 
CPM Dye  2 µl 
Total Volume  50 µl 
 
The reaction mixture was mixed and briefly incubated at room temperature before 
transfer to a qPCR machine (Agilent Mx3005P, Agilent Technologies, Santa Clara, CA, 
USA) equipped with excitation/emission filter sets to monitor CPM fluorescence (Ex 
384 nm/Em 470 nm). The experimental protocol consisted of a temperature ramp (in 
1°C increments) from 25°C to 95°C. At each temperature step three fluorescence 




For qualitative purposes raw data was plotted as temperature versus fluorescence 
readout. For quantitative purposes an inflection point of the melting curve, which is 
assumed to equal the melting temperature (Tm) was calculated. In order to calculate 
the Tm, a Boltzmann sigmoidal function was used to fit the experimental data. Data 
analysis was guided (and constrained) by visual inspection of the data, especially 
where fluorescent signals show considerable variability at high temperature.         
 
 
2.7. Protein Crystallography 
Protein crystallization was dependent on the purified receptor sample, e.g. GLIC-
GABAAR α1 chimera, GLIC or ELIC and on the experiment type, e.g. co-crystallization, 
seeding, etc. General protocols for crystallization plate setup were followed for all 
purified receptors. Any variations in protocol have been detailed. Briefly, GLIC-GABAAR 
α1 chimeras were screened for crystal growth using sparse matrix screens and 
conditions previously reported for GLIC. WT GLIC was crystallized in previously 
reported conditions (Nury et al., 2011) and WT ELIC was also co-crystallized in 
previously reported conditions (Hilf and Dutzler., 2008), and under new crystallization 
conditions identified using sparse matrix screens.  
 
 
2.7.1. General crystallization notes 
Crystallization was carried out by vapour diffusion in either the sitting drop (e.g. 96 
well MRC 2 drop plates/Swissci; Molecular Dimension, Suffolk, UK) or hanging drop 
configuration (e.g. 24 well plates and silicon coverslips). Plates were maintained at 4°C, 
16°C or 22°C.  Protein samples were concentrated with centrifugal filter devices (with 
molecular weight cut-offs of 50 or 100 kDa) either as the last step of purification or 
immediately prior to crystallization. Bacterial receptors, GLIC and ELIC, were typically 
concentrated to 6-10 mg/ml for crystallization trials, while GLIC-GABAAR α1 chimeras 
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were used in crystallization trials at 1-7 mg/ml. Prior to crystallization protein samples 
were centrifuged for 10 mins at >16, 000 g to remove any precipitated material.  
 
Crystallization sitting drops in 96 well plates were set up using a TTP Labtech Mosquito 
robot. 80 µl of reservoir solution was transferred from a 96 well deep block (containing 
either “Sparse matrix” or optimization screen, as detailed below) to the reservoir well 
of a 96 well MRC 2 drop plate (Fig 2.5) using a Liquidator Pipetting System (Mettler 
Toledo, Leicester, UK). The plate was transferred to the plate position of the Mosquito 
robot and protein sample dispensed manually in to an 8 well disposable strip for 
automated transfer. A protocol was run which allowed for automated dispensing of 
crystallization drops (typically 100 nl of protein plus 100 nl of reservoir or 150 nl 
protein plus 75 nl reservoir).  
 
Crystallization hanging drops (Fig 2.5 A) on siliconized circle coverslips (18 x 0.22 mm; 
Hampton Research, CA, USA) in 24 well plates were set manually. 500 µl of reservoir 
solution was dispensed in to the well of a 24 well plate. Drops (total volume of 1-2 µl) 
were composed of protein and reservoir mixed in 1:1 ratio. Coverslips were inverted 
over the reservoir solution and sealed with grease (see Fig 2.5 A).  
 
2.7.2. Sparse matrix and additive screens 
In initial crystal growth screening of chimeric receptors and ELIC, commercially 
available “sparse matrix” screens were used. These screens are generated from a 
range of crystallization conditions that have previously supported successful crystal 
growth (for subsequent X-ray diffraction studies). These conditions can be sampled for 
new proteins, if no previous information about crystallization exists. Sparse matrix 
screens specific to α-helical type transmembrane proteins have been designed, 






Figure 2.5 - Crystallization optimization set up and schematic of (vapour diffusion) 
sitting and hanging drop configurations 
 
A. Sitting drop well configuration in MRC 2 Well plates (arrow represents vapour diffusion event) and 
hanging drops set on a coverslip. B. A broad screen around an initial crystallization condition hit (green 
box) is shown, in which [PEG %] and buffer pH has been varied. Variations of this configuration can be 
used to vary salt concentration.   
 
 
Additionally additive and detergent screens can be used in optimizing crystal growth. 
These are used after identification of crystal “hits”, i.e. a condition which supports 
crystal growth, and following initial rounds of optimization. Their use can prove helpful 
in improving crystal quality, e.g. size, shape and diffraction limit. Additive screens 
typically include ligands, detergents, multivalent salts, volatile and non-volatile 
organics as identified from data mining (of crystallization conditions in the PDB). 
Successful hits from additive and detergent screens can be used to design further 
optimization experiments. Indeed in the case of newly identified detergents, these 
might also be implemented during the final stages of purification. The commercially 
available screens used (in the 96 well sitting drop format) during this study are detailed 
in Table 2.8. For additive screens, the reservoir solution was composed of 72 µl 




Table 2.8 Sparse matrix, detergent and additive screens 
 
Screen Name Screen 
Type 















(Newstead et al., 2008; 
Parker and Newstead, 
2012) 
MemAdvantage Additive Molecular 
Dimensions 








2.7.3. Optimization screens 
After identification of conditions yielding “crystal hits, optimization screens (Fig 2.5 B), 
or grid screens, are set up around the conditions yielding the crystal hits. In 
optimization screens of a condition containing a precipitant (e.g. PEG), salt and buffer, 
two of the components are varied while one is kept constant.  An example of a broad 
screen (in 24 well format) around an initial hit, in which PEG concentration and pH 
have been varied is shown in Fig 2.5 B. Broad screens are often used to try to 
reproduce the initial hit, and if successful the range of concentrations or pH is further 
narrowed down (e.g. varying [PEG] in increments of 0.5% rather than 2%). Ideally, 
optimization trays should refine crystallization conditions to those which minimize 
crystal nucleation and maximise crystal size and quality.  
 
During this study we carried out optimization screens in both 24 well and 94 well plate 
formats (i.e. crystal hits identified in sitting drops were also assessed by hanging drop). 
Initial hits were positioned close to the centre of a screen (Fig 2.5 B). Optimization 
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screens in the 24 well plate format were manually prepared from reagent stock 
solutions. Reagents were either prepared in house or obtained from the supplier of 
initial sparse matrix screens.  For optimization screens in the 96 well format, a Perkin 
Elmer Multiprobe II Robotic liquid handling system was used. Solutions for the four 
corner points of a screen were prepared (e.g. comprising all components of the 
crystallization conditions in the minimal and maximal concentrations and pH to be 
used in the screen). These solutions were used (in varying ratios) to form the entire 96 
well screen (which was prepared in a 96 deep well block). Screens were kept at 4°C for 




For co-crystallization experiments protein was mixed with drug or lipid solutions (at 
twice the final concentration) and incubated on ice prior to crystallization. Once mixed 
with reservoir solution at a 1:1 ratio the desired final concentration of drug was 
achieved. Crystallization experiments were then set up as normal (with the exception 




GLIC was incubated on ice with pentobarbital or a brominated derivative, 5-(2-Bromo-
ethyl)-5-ethyl-pyrimidine-2,4,6-trione (S97617; both prepared in DMSO at 100 mM 
stocks). The concentration of drug solution was 5 mM once the protein sample was 
mixed with the reservoir solution at 1:1. No precipitation of protein was observed 




ELIC was incubated with either DPPC or POPC lipids (with gentle mixing). Lipids were 
prepared as 2% stocks in gel filtration buffer (with UDM) and added to a final 
concentration of 0.02%. The agonists GABA or propylamine (250 mM stock in gel 
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filtration buffer; Sigma-Aldrich) were then added at 30 mM or 5mM respectively. The 
antagonist pregnenolone sulphate was added at 250 µM (from a 10 mM stock). 
 
2.7.5. Micro-seeding strategies 
Where crystallization trials yielded crystals with unfavourable properties (small, ill-
defined shapes and weakly diffracting), a seeding strategy was used. This technique 
has been used in a number of membrane protein crystallization studies to improve 
crystal size and reproducibility, and eventually yield high quality diffracting crystals 
(Dürr et al., 2014; Sauguet et al., 2014b).  
 
Under normal crystallization conditions, the sample (e.g. pLGIC in buffer, salt and 
detergent) starts in a stable, undersaturated state. In this state crystals cannot 
nucleate. Upon addition of a crystallization reagent the relative supersaturation of the 
sample increases, and can result in three events (defined as zones of the crystal phase 
diagram; Fig 2.6). In the metastable zone nuclei cannot form but crystals can grow; in 
the labile zone crystals can both form and grow; and in the precipitation zone the 
sample precipitates and crystal formation is not possible. Using a seed stock formed 
from a crushed small crystal or crystal fragment, one can control the extent of crystal 
nucleation (bypassing the need for spontaneous nucleation) and in doing so grow 
crystals of increased size and with greater reproducibility. The seed stock is added to a 
fresh protein sample and reservoir solution, in varying ratios, at the point of setting 
new crystallization drops. As under normal conditions, the addition of seeds in an 
unsaturated solution, or in the precipitation zone, does not support crystal growth. 
However addition of seeds to a drop saturated to the metastable phase can support 
crystal growth (where originally spontaneous nucleation could not occur, Figure 2.4). 
By serially diluting the seed stock the number of crystals that grow in this zone can be 
manipulated, ideally supporting the growth of fewer large crystals. Similar results can 
be achieved by streaking a crystalline material (dislodged from an existing crystal by 
means of seeding tool, e.g. cat whisker) drawn across a recipient drop. Ideally the 






Figure 2.6- The crystallization phase diagram and the effect of crystal seeding 
The crystal phase diagram is shown (adapted from Luft & De Titta, Acta Cryst. 1999). The solubility of a 
protein (macromolecule) in solution is shown as a function of the concentration of the precipitant 
(crystallization reagent) present. The metastable, labile and precipitation zone all represent states of 
supersaturation. Crystal nucleation can only occur from the labile zone, however growth is supported in 
the metastable zone. Addition of crystal seeds (ideally to a crystallization drop in the metastable zone) 
bypasses the need for spontaneous nucleation of crystals.   
 
 
2.7.6. Seeding strategies applied to GLIC (co-)crystallization 
In “normal” crystallization experiments, GLIC had a tendency to form plate-shaped 
crystals, lacking substantial size in all dimensions. Plate-shaped crystals were used to 
generate a seed stock for seeding experiments. Crystallization drops containing plate 
crystals were opened, and crystals crushed using a glass probe. Then, 5 µl of the 
crystallization reagent was added to the well containing crushed crystal slurry and 
transferred to an eppendorf tube on ice containing a bead. A further 5 µl of 
crystallization reagent was added to the well and transferred to the tube. This process 
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was repeated until all crystal fragments had been transferred (~40-50 µl). The tube 
containing the bead and crystal seed slurry was then vortexed for 3 min, periodically 
stopping and returning the tube to ice. The final slurry formed the seed stock. Seed 
solutions were typically used in an undiluted form (a process termed Microseed Matrix 
Screening) to set new crystallization drops. Seeding experiments were carried out in 24 
well optimization screens. Drops were manually set and were composed of 1.2 µl 
protein, 0.8 µl reservoir solution and 0.4 µl seed stock (equivalent ratios were also 
maintained in different drop volumes). Seeds prepared from apo-GLIC were also used 
as seed stocks for drops set with GLIC incubated with drug.  
 
Streak seeding was also carried out for GLIC, using a seeding tool (composed of a 
natural fibre). Donor crystals were touched with the seeding tool, and seeds deposited 
in a recipient drop by running the seeding tool in a straight line across the middle of 
the drop. Recipient drops were composed of GLIC protein and crystallization reagent in 





Throughout this study X-ray diffraction data was collected at cryogenic temperatures (-
173°C). Crystals were therefore rapidly cooled by plunging in to liquid nitrogen (and 
stored) prior to diffraction data collection. Crystals were typically transferred using a 
nylon loop (Hampton Research) or micro-loop (Mitegen, Ithaca, NY, USA) to a solution 
composed of the mother liquor supplemented with 20% glycerol, and allowed to 
briefly equilibrate. During this period, crystals were monitored for visible changes in 
their physical properties, e.g. cracking. For ELIC 30% glycerol or ethylene glycol was 
also used as cryoprotectant. Crystals of GLIC-GABAAR α1 chimeras, GLIC and ELIC were 
also assessed for diffraction without cryoprotectant, but the lack of cryoprotectant 
having detrimental effects in all cases. After incubation in cryoprotectant, crystals 
were rapidly plunged into liquid nitrogen and stored in vials under liquid nitrogen prior 
to X-ray diffraction experiments.  
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2.7.8. Diffraction Data Collection Strategies 
X-ray diffraction of crystals was screened by a synchrotron radiation source. Diffraction 
data were collected at Diamond Light Source (Harwell, UK) on beamlines I03, I04 and 
I24 (microfocus); the French National Synchrotron Facility – Soleil (Gif-sur-Yvette, 
France) on beamline Proxima 2 (microfocus); and the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France) on beamlines ID23-1 and ID23-2 (microfocus). 
Microfocus beamlines allow for the beam size to be focused down to 5 µm x 5 µm. This 
allows for precise characterisation of the diffraction properties of small crystals and at 
various regions of larger crystals (which would not necessarily be possible with a beam 
of larger dimensions).  
 
For crystal characterisation, short exposure times at 50% beam transmission were 
used, e.g. 0.1-0.5 s exposure times at 50% beam transmission. Typically 3 diffraction 
images separated by 45° were collected (total rotation of crystal of 90°). During image 
acquisition oscillation angles of 0.1-1° were used. Where crystals could not easily be 
identified or to align best diffracting portion of a large crystal, grid scans of crystals 
were used to assist crystal alignment (this is not available on all beamlines used during 
this study). Briefly, a grid is drawn over a region of interest and X-ray diffraction 
pattern recorded for each sector. The strongest diffracting region is aligned to the 
beam centre and crystal rotated through 90°. A second grid scan is carried out and, the 
crystal aligned to the strongest diffracting region. In doing, so the crystal can be 
precisely aligned relative to the beam centre.   
 
Crystal characterisation and (where possible) data collection strategy calculations were 
carried out using automated software pipelines associated with the beamlines (as part 
of the acquisition software). The characterization and strategy program EDNA was run 
for collections of 2-4 images. This program is run automatically with diffraction images 
used as input files to be run in the program Mosflm (Powell et al., 2013). Mosflm 
carries out indexing of reflections and allows for crystal orientation, unit cell 
parameters and a possible crystal space group to be determined. Following complete 
data set collection, Mosflm is used to intergrate images and generate an output (MTZ) 
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file of reflection indices with their intensities and standard deviations. The MTZ file 
format can be used in programs of the CCP4 program suite (Collaborative 
Computational Project No. 4 suite of software for macromolecular X-ray 
crystallography (Winn et al., 2011)).     
 
 
2.7.9. Data Processing and Model Building and Refinement for GLIC 
During this study a data set (from a single crystal) of GLIC (grown in the presence of a 
pentobarbital-derivative) at a resolution of 3.2 Å was collected at 0.954 Å on beam 
ID23-1 at ESRF (Data set: 1225 images of 0.2° oscillation, 100% beam transmission, 
0.04 s exposure; Table 2.9). The model presented in Chapter 5 was generated from an 
MTZ output file from the automatic software pipeline applied to data collections at 
ESRF. Data is indexed and integrated in XDS (X-ray Detector Software, MPI for Medical 
Research, Heidelberg, Germany (Kabsch, 2010)), and fed (via the program Pointless, 
which also checks the assigned symmetry space group) into Aimless for data reduction. 
The resulting MTZ file was used for structure determination by molecular replacement. 
Molecular replacement uses known structures to phase experimental data and provide 
an initial model for structure refinement. This is achieved through rotation and 
translation of the known structure in the unit cell of the collected diffraction data.  
 
Additionally the raw image files were processed manually in Mosflm (following the 
principles described for initial crystal characterisation). As for autoprocessed data, 
indexed and integrated data was reduced using the Aimless program in CCP4 (Winn et 
al., 2011). The resulting MTZ file was also used for structure solution by molecular 
replacement in Phaser (as described below). Results from manually and auto-
processed data were identical.  
 
The structure of GLIC in this study was solved by molecular replacement in Phaser 
(McCoy et al., 2007) using GLIC at 2.4 Å (PDB 4HFI) as a search probe (in which 
detergent and water molecules were removed). The translation function Z-score (TFZ) 
in Phaser show that the solution is correct; TFZ = 13.8. As a rule of thumb, a TFZ value 
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>8 shows correct structure solution. For data presented in Chapter 5, an initial round 
of automated model building, structure refinement and density modification was 
carried out using Phenix Autobuild. Given that the space group and unit cell 
dimensions were isomorphous to the apo-GLIC, which was used as a search probe, we 
assessed initial density maps for their quality but also ambiguous peaks in electron 
density and difference maps (an example of “ideal” density maps generated by 
refinement and their interpretation is shown in Fig 2.7).  
Table 2.9 Crystallographic Statistics (values in parentheses are for the highest 
resolution shell) 
 
Data Collection Beamline ID23-1 
Space Group C2 
Cell Dimension a, b, c (Å) 180.7, 132.8, 159.2 
Cell Angles α, β, γ (°) 90, 102, 90 
Wavelength (Å) 0.9537 
Resolution (Å) 49.47 – 3.19 (3.28-3.19) 
Completeness (%) 91.0 (55.1) 
Multiplicity 4.3 (2.8) 
I/σI 7.2 (1.3) 
Rmeas 0.189 
Rmerge 0.147 (0.051) 
CC1/2 0.944 (0.567) 
 
Coordinate files, electron density and difference maps were opened in Coot (a 
molecular graphics application for model building) for visual inspection (Emsley et al., 
2010). Where side chains could not be fit to density or showed poor stereochemistry 
(as assessed by the Ramachandran plot function in Coot), only the Cα-backbone was 
built. Clear electron density was visible for 6 detergent molecules in the channel pore 
(consistent with published GLIC structures), and also visible as positive density in the 
difference map. The position of this density allowed for superposition of detergent 
molecules modelled for GLIC (PDB 4HFI; for purposes of visualization). Initial maps 
revealed positive peaks in the difference map (when contoured at >5 ς) at subunit 
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interfaces. In light of previous observations we modelled these as chloride or acetate 
ions (in Coot). Indeed many of the clear peaks in electron density and difference maps 
(that were not contributed by the protein model) could be interpreted based upon 
previous observations made for GLIC crystal structures. Electron density and difference 
maps were prepared for molecular graphics with FFT program in CCP4 and opened in 
Pymol for image preparation. B-factors stated in the text are those generated in Phenix 
program “auto.refine”. All images and alignments were prepared in Pymol (DeLano 
Scientific, 2002; except for images of α1 GlyR in Chapter 1 which were prepared in 




Figure 2.7-An example of a 2mFo-DFc density map (blue) and mFo-DFc difference 
map (green/red) for published structure of GLIC (PDB 4HFI). 
The 2mFo-DFc map is generated during refinement and is the primary map used for manual inspection 
and model building. Fo and Fc are the experimentally measured and model-based amplitudes for the 
structure.  The map shown is a portion of the structure of GLIC (PDB 4HFI; maps obtained from the 
Electron Density Servers (EDS)). The 2mFo-DFc map is coloured blue and contoured at 1.5 ς, i.e. 1.5 
standard deviations above the mean electron density, and shows where we expect most of the model to 
be (excluding hydrogen atoms). The mFo-DFc (difference) map is coloured green (positive contours at +3 
ς) and red (negative contours at -3ς). The positive density (green) indicates features present in the data 
not accounted for the model (e.g. a drug molecule). The negative density (red) indicates parts of the 
model that are not supported by the data (e.g. an incorrectly modelled residue side chain). This model 
of GLIC (after multiple rounds of model building and refinement) fits well with the density maps. In this 
case positive peaks in the difference map likely represent unmodeled interatomic scattering.     
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2.8. Electron Microscopy 
Electron microscopy was carried out at Birkbeck EM Laboratory. Duncan Laverty 
prepared protein samples, assisted with image collection and project design. Dan Clare 
(Birkbeck) prepared EM grids, collected and analysed images and assisted project 
design. ELIC (negative stain and cryo-EM) and GLIC-GABAAR α1 chimeras (negative 
stain-EM) were used in these experiments.  
 
2.8.1. Sample preparation for EM (exchange in to Tris Buffer or Amphipol) 
Where protein samples were not in Tris-buffered solution, a final buffer-exchange step 
was included in the previously described purification procedure. 300-500 µl of purified 
cleaved-pentameric ELIC was injected on to a Superose 6 10/300 GL column 
equilibrated in 20 mM Tris pH7.6, 150 mM NaCl and 1.2 mM UDM and run at a flow 
rate of 0.3 ml/min. The elution profile was identical to that of ELIC purified in sodium 
phosphate buffer. Peak fractions were analysed by SDS PAGE and coomassie stain, 
pooled and concentrated initially to 3 mg/ml for EM.  
 
For the exchange of ELIC in to Amphipol A8-35; 500 µl of purified pentameric ELIC (in 
SEC buffer + 1.2 mM UDM at 1mg/ml, as described in Section 2.5.2) was mixed with 
Amphipol A8-35. A 50 mg/ml stock of A8-35 was prepared in ELIC SEC buffer (10 mM 
Sodium Phosphate, pH 7.9 and 150 mM NaCl) without detergent. Amphipol A8-35 was 
added to the protein in varying ratios of 1:3, 1:6, etc (protein: A8-35, w/w). The 
protein-amphipol solution was mixed overnight at 4°C.  Following incubation, the 
protein-amphipol solution was added to a tube containing 60 mg of Biobeads (Biorad). 
Biobeads adsorb free detergent and amphipol molecules (removing them from 
aqueous solution). This was mixed for a further 1-2 hrs at 4°C.  Biobeads were 
separated from ELIC in A8-35 by passing over a small EconPac column (; the ELIC/A8-35 
complex was collected in the flow through). The flow through was injected on to a 
Superose 6 10/300 GL column equilibrated in 20 mM Tris pH7.6 and 150 mM NaCl. 
Peaks corresponding to pentameric ELIC-amphiol A8-35 and free amphipol molecules 
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were observed. Peak fractions for the former were pooled and concentrated 1-2 
mg/ml for EM.      
 
 
2.8.2. Sample preparation for Negative Stain EM 
Protein sample in detergent or amphipol was used for negative stain EM at 0.01-
1mg/ml. 3.5 µl of purified protein sample was applied to glow-discharged EM grids 
(6mm) covered with a continuous coating of carbon. Glow discharging renders the 
normally hydrophobic carbon surface more hydrophilic. This was left for 30-60 sand 
then blotted, before staining with 5 µl of 2% uranyl acetate for 1-2 min. The protein 
was removed by blotting and imaged in the electron microscope. EM girds were stored 
at room temperature prior to imaging. Additionally, for certain experiments EM grid 
were pre-treated with poly-lysine (Sigma Aldrich) to positively charge the surface. 
Staining was carried out as normal.  
 
 
2.8.3. Sample preparation for Cryo-EM 
For cryo-EM sample preparation the concentration of purified ELIC (in detergent, 
UDM, or amphipol, A8-35) was adjusted to 0.5-3 mg/ml. 3.5 µl of protein was applied 
to glow discharged holey or lacey carbon coated (copper) grids. An additional 
treatment of with poly-lysine was also used for some grids. After approximately 30 s 
grids were blotted to remove the protein solution and rapidly plunged in to liquid 
ethane for vitrification.      
 
 
2.8.4. Sample imaging and data analysis 
Negative stain EM images were collected on a Tecnai T10 (FEI, Oregon, USA) operated 
at 100 keV, at a magnification of 44,000 x and Tecnai T12, operated at 120 keV, at a 
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magnification of 67,000 x. Cryo-EM images were collected on a Tecnai Polara EM (FEI) 
operated at 200 keV with a K2 direct electron detector (Gatan, Pleasanton, CA, USA) at 
27,000 x magnification. Particles (~4,500) were aligned and classified in RELION 
(Scheres, 2012). 
 
2.9. Mass Spectrometry 
Mass spectrometry was carried out in the laboratory of Konstantinos Thalassinos 
(Structural and Molecular Biology, UCL). Duncan Laverty prepared samples for mass 
spectrometry. Data acquisition and analysis was carried out by Adam Cryar (Peptide 
Fragment Mapping) and Kitty Hendricks (Native Mass Spectrometry) 
 
2.9.1. Tryptic Digest of In-gel Proteins and Mass Spectrometric Analysis 
Tryptic Digest 
 
Identification of purified proteins was confirmed using mass spectrometry. Protein 
samples were separated by SDS PAGE and stained by coomassie. Target protein bands 
were excised and destained with a mixture of acetonitrile and 50 mM ammonium 
bicarbonate pH8 (40% and 60% v/v respectively). Native proteins were subsequently 
reduced with 10 mM DTT at 80 C for 30 min, followed by alkylation with 55 mM 
Iodoacetamide for 20 min at RT in the dark. Gel pieces were washed by swelling and 
shrinking with sequential washes with 50 mM ammonium bicarbonate and 
acetonitrile. Proteins were digested overnight with Trypsin (at 10 ng/ l in 50 mM 
Ammonium bicarbonate) at 37 C. Peptides were extracted in a mixture of formic acid 
(1%) and acetonitrile (2%) (prepared in water) and dried under vacuum. Samples were 







Peptide Fragment Data Acquisition 
 
Nano-Reversed Phase Liquid Chromatography (RPLC) separation of each tryptic digest 
sample prior to analysis by mass spectrometry was performed using a nano-ACQUITY 
UPLC system (Waters Corporation) with the use of a 5 µm SYMMETRY C18, 180 µm x 
200 mm trap column and a 1.7 µm BEH130 C18, 75 µm x250 mM analytical column. A 
two-phase linear gradient was performed where solvent A was 0.1 % formic acid in 
water and solvent B was 0.1 % formic acid in acetonitrile. Sample was applied to the 
trapping column at mobile phase composition of 3 % solvent B with a flow rate of 5.0 
µl/min. The column was then desalted for 2 min at the same conditions. A linear 
gradient was then applied at a flow rate of 0.3 µl/min whereby the concentration of 
solvent B was increased from 3 to 40 % over 29 min. Analysis by mass spectrometry 
was acquired using a Synapt HDMS (Waters Corporation) coupled to the nano-
ACQUITY system. The Synapt time-of-flight mass analyser was calibrated over a 
mass/charge (m/z)range of 175.11 Da to 1285.54 Da  using the fragment ions of the 
peptide [Glu1]-Fibrinopeptide B (GFP). The double charged precursor monoistopic 
peak of GFP was fragmented with a collision energy of 30 eV. During analysis a solution 
of GFP at 500 fmol/µl was delivered at a flow rate of 0.3 µl/min via a NanoLockSpray 
source. This faciltated the post acquisition lockmass correction of data using the 
monoisotopic mass of the doubly charged precursor of GFP. The reference sprayer was 
sampled every 60s. Accurate mass measurements were made using a data 
independent mode (LC-MSE) of acquisition. Briefly, energy in the collision cell was 
alternated from low energy (6 eV) to high energy (energy ramp from 15-35 eV) whilst 
continuously acquiring MS data. Measurements were made over a m/z range of 100-
2000 Da and the time of flight mass analyser was operated in V mode with a scan time 
of 1s. 
 
Peptide Fragment Mapping Data Processing 
 
All data processing was carried out using PLGS v2.5 (Waters Corporation). The 
computational methods used to process the data are explained in detail in 
(Geromanos et al., 2009). Data was searched against a Swissprot specific protein 
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database (generated for Spodoptera frugiperdaSf9 insect cells) appended with the 
sequence of the chimeric receptor to be identified. Carbamidomethyl-C was specified 
as a fixed modification.  Oxidation (M), was specified as variable modifications. A 
maximum of two missed cleavages of the protease were allowed for semi-tryptic 
peptide identification. For peptide identification two corresponding fragment ions 
were set as a minimum criterion whereas for protein identification a minimum of one 
corresponding peptide identification and seven fragment ions were required.  
 
2.9.2. Native Mass Spectrometry (nMS) and Ion-Mobility Mass Spectrometry (IM-MS) 
Spectrometry 
nMS and nIM-MS experiments were carried out on a Synapt G1 Mass Spectrometer 
(Waters, Herts, UK). Ionization of samples was carried by nano-Electrospray Ionization 
(ESI) in IM-nMS experiments. For ionization, samples were loaded in to the mass 
spectrometer using gold-coated glass capillaries (manufactured in-house). Spectra 
were recorded in positive ion mode and time-of-flight mass analyser in V-mode.  Data 
were analysed using MassLynx software version 4.1 (Waters) all spectra smoothed 
using a mean function. Calculation of masses from the mass spectra was carried out 
using a script developed by K. Thalassinos. In brief the script takes observed 
mass/charge (m/z) values and calculates their corresponding mass when given a 
charge state (of 1 to 100). A charge series is made, for which an average mass and 
standard is calculated. Charge states with the lowest standard deviation are taken to 
generate the final experimental mass.  
 
2.10. Homology Modelling 
A 3D homology model of the GLIC-GABAAR α1 chimera was generated using Modeller 
(Version 9.7; Eswar et al., 2008) and the crystal structure of GLIC (PDB 3EAM; Bocquet 




Chapter 3: Generation of functional chimeric GABAA receptors; electrophysiological 
and pharmacological characterisation 
3.1. Introduction 
To increase our understanding of the structural mechanisms underlying Cys-loop 
receptor operation, specifically GABAAR gating and allosteric modulation at the level of 
the ion channel, we based our experimental approach on the design and generation of 
a functional chimeric GABAA receptor. The rationale for this is based on recent work 
demonstrating that structural and functional studies are possible when using a 
prokaryotic-eukaryotic receptor chimera model, which has recently been created 
between the extracellular domain (ECD) of GLIC and the glycine receptor α1 subunit 
transmembrane domain (TMD) (Duret et al., 2011; Moraga-Cid et al., 2015).  
We took a similar approach, exploring the potential use of the ECD of previously 
crystallized receptors, for example the prokaryotic proton-gated receptor GLIC, to act 
as a surrogate host for GABAAR subunit TMDs. While “GLIC-based” chimeras will 
represent our primary focus, we will also use alternative ECD surrogate hosts for 
GABAA receptor TMDs. By taking this approach we might be able generate a functional 
receptor, which is amenable to both high level expression and crystallization, 
particularly where known crystal-packing contacts exist and might be expected. For 
example, interactions between neighbouring ECDs are shown to form principal contact 
points in the crystal packing of GLIC (Bocquet et al., 2009).   
Given that we propose to utilise a chimeric receptor system in this study (rather than 
full-length receptor subunits), it is crucial that the receptors generated represent a 
suitable model for study of native GABAARs by retention of appropriate functional 
characteristics. Therefore, prior to assessment of high-level expression (and 
purification), receptors were characterised at a functional and pharmacological level. 
Those exhibiting characteristic “GABAAR-like” traits would serve as candidate receptors 
to advance forward to further structural studies (in Chapter 4). 
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Upon generation of receptor chimeras, we took advantage of two recombinant 
expression systems, HEK293 cells and Xenopus oocytes, for screening receptor 
assembly, trafficking, ion channel function and pharmacology.  Whilst ion channels 
that are over-expressed and purified from bacteria and insect cells typically form the 
starting material for structural studies (e.g. X-ray crystallography and electron 
microscopy), the construct used in purification protocols is often tested for 
functionality in alternative more amenable recombinant expression systems (Hibbs 
and Gouaux, 2011; Lee et al., 2014). Ion channels expressed and characterised 
electrophysiologically in Xenopus oocytes and HEK293 cells likely represent what might 
be expected to exist in a water-soluble protein-detergent lipid complex following 
extraction from the host plasma membrane.  As a result electrophysiological studies 
and purification rarely use the same expression system. Despite this, recent 
developments in mammalian expression systems for high-level protein expression, 
particularly HEK293 cells (and to a lesser extent insect cells), are notable in that they 
allow for robust functional characterisation and purification of the protein of interest 
from the same membranous environment (Miller and Aricescu, 2014)(Cao et al., 
2013a; Moraga-Cid et al., 2015). In acknowledging these caveats, we have used 
HEK293 primarily to assess trafficking of receptors to the cell surface (using 
fluorescence microscopy) and ion channel expression in Xenopus oocytes with two-
electrode voltage-clamp (TEVC) electrophysiology to assess the function and 
pharmacology of chimeric receptors.  
In addition to assessing efficient expression of functional chimeric receptors, we have 
used site-directed mutagenesis to establish whether chimeric and native receptors 
gate via a common mechanism. Notably, we examined the structural elements 
responsible for receptor desensitization, further testing the notion that a 
desensitization gate, distinct to the activation gate in the ion channel, is responsible 
for defining a closed channel-state during prolonged exposure to agonist. Whilst pLGIC 
desensitization arises from the concerted movements of structural elements at the 
level of the ECD and ECD-TMD interface (Bouzat et al., 2008; Pless and Lynch, 2009a; 
Wang and Lynch, 2011), recent studies suggest that the ion channel adopts a distinct 
intermediary conformation in the transition from active-open through desensitized-
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closed to the resting-closed state of the receptor (Auerbach and Akk, 1998; Velisetty 
and Chakrapani, 2012; Miller and Aricescu, 2014; Gielen et al., 2015; Kinde et al., 
2015). Structure-function studies have identified residues near an intracellular portal 
of the ion channel that form the core of a “desensitization gate”, inducing a 
constriction of the pore during prolonged exposure to agonist (Gielen et al., 2015). 
Despite these recent breakthroughs, the nature of receptor desensitization remains a 
contentious subject, particularly in assigning structures to the fast and slow 
desensitized states of the receptor (and the associated conformational transitions).  
We have introduced single point mutations into M2 and M3 of chimeric receptors and 
monitored their effect on receptor desensitization. In cases where mutations rendered 
the channel non-functional, a well-characterized gain-of-function mutation (at the 
level of the hydrophobic “activation gate” of the receptor, defined as 9’) was 
introduced in rescue experiments (Chang and Weiss, 1999). Through a combination of 
mutagenesis studies and pharmacological assessment of non-mutant bearing forms of 
the chimera, we have been able to establish common structural elements to both 
receptor activation and modulation, when compared to native GABAARs.  
 
3.2. Results 
On the basis of comparative alignments of receptor subunits, homology modelling and 
structure-function data, a chimeric GLIC-GABAA receptor subunit was designed and 
generated using standard molecular biology techniques. Structural “mismatches” 
occurring at the coupling interface (between the prokaryotic ECD and eukaryotic TMD) 
were identified and mutated (to assess their effect on channel gating). Receptor cDNA 
was injected in to Xenopus oocytes and whole-cell proton activated currents recorded 
in the two-electrode voltage-clamp configuration. Agonists and allosteric modulators 
were applied using an in-house gravity flow perfusion system (as described in 
Materials and Methods) for rapid drug application.     
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3.2.1. Homology model and schematics 
We focused our initial studies on generating a functional chimera between the ECD of 
GLIC and the TMD of GABAA receptor α1 subunit. Functional studies of α1-containing 
GABAA receptors in recombinant expression systems have revealed a role for residues 
in the GABAAα1 TMD in coordinating the sensitivtiy to the allosteric modulators, the 
neurosteroids, and in setting the extent of receptor desensitization (Hosie et al., 2006; 
Gielen et al., 2015). 
In designing a chimeric receptor, an extensive sequence alignment of pentameric 
ligand-gated ion channels (; previously generated by Dr M. Gielen) was analysed.  
Existing functional data could be mapped onto known structural elements of the 
receptors (e.g. TM regions, connecting loops at the gating interface and the large 
intracellular loop between M3 and M4; Appendix Fig 3). Additionally a receptor 
homology model (using the crystal structure of GLIC: pdb 3EAM as a template) served 
to guide subsequent mutagenesis at the prokaryotic-eukaryotic interface. The point of 
ECD-TMD fusion was selected at a site preceding M1 where an arginine residue was 
identified that is conserved across the pLGIC family, and a glycine-tyrosine motif that is 
also conserved across many GABAA subunits (Fig 3.1 and Appendix Figure 3). 
Expression and trafficking of the chimeric receptor to the cell surface was under the 
control of the α7 nAChR signal peptide sequence (which has previously been reported 
to enable efficient expression and export of GLIC to the plasma membrane (Bocquet et 
al., 2007). While initial studies focused on a simple domain-switch chimeric receptor, 
structural elements at the coupling-interface (including loop 7; a conserved FPM motif 
and the M2-M3 linker) were assessed as likely areas where residue mismatches might 
affect the efficacy of channel gating. It should be noted that for clarity, residue 
numbering in the ECD and TMD of the receptor is as observed in the native full length 
receptor (e.g. the domain switch occurs at position GLIC Y194 and continues from 






Figure 3.1 - Chimeric GLIC-GABAAR α1 receptor 
Schematic representation of GLIC-GABAAR α1 domain chimera. The ECD (blue) is of GLIC and the TMD 
(red) of the GABAA α1 receptor subunit. Notable structural elements forming the coupling interface are 
Loop 7 (Green) and the M2-M3 loop (Blue). The sequence at the point of domain fusion is shown. The 
large loop between M3 and M4 (forming the ICD) of the GABAA α1 receptor subunit is not observed in 
GLIC.  
 
3.2.2. α-Bungarotoxin binding studies 
In order to assess the expression, assembly and trafficking of receptors (in HEK293 
cells), a mimotope of the binding site for the neurotoxin, -bungarotoxin (hereafter 
referred to as bungarotoxin-binding site; BBS (Wilkins et al., 2008) was introduced near 
the end of the N-terminal. Export of receptors to the surface was monitored in live 
cells by labelling with an Alexa 555 fluorophore-conjugated α-bungarotoxin (as 
described in Materials and Methods: Section 2.4.2). Given that α7 nAChRs, a distant 
relative of GLIC, possess an innate bungarotoxin binding site (Li et al., 2011) 
(coordinated by residues in the ECD) we first assessed toxin-labelling of GLIC lacking a 
BBS in HEK cells co-transfected with enhanced green fluorescent protein (EGFP). In 
contrast to HEK cells expressing α7 nAChR-5-HT3 chimeras (Fig 3.2 A), innate labelling 
of GLIC was not observed. Upon introduction of the BBS, robust cell surface labelling of 
cells expressing BBSGLIC was observed within 24 hrs of transfection (Fig 3.2 B). Labelling 
of BBS-tagged GLIC-GABAA receptor α1 chimeric receptors at the cell surface could also 
be observed, with a peak in labelling approximately 48 hrs after cell transfection (Fig 
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3.2 C). This would suggest that the folding and trafficking process is not as efficient for 
the chimera when compared to wild type GLIC protein. Throughout this study we have 
further utilised this mimitope tagging approach to rapidly screen receptors for efficient 
expression and cell surface export in parallel to functional analyses.  
 
 
Figure 3.2 - α-Bungartoxin binding to BBS-tagged receptors 
Live-cell confocal images of HEK293 cells transfected with the indicated construct following incubation 
with Alexa555 conjugated α-Bungarotoxin. Left panels: eGFP signal, Centre panels: Alexa555 α-
Bungarotoxin, Right panels: merge of two channels. A. Untagged nAChR-5-HT3 receptor chimera B. BBS-
tagged GLIC C. BBS-tagged GLIC-GABAAR α1 chimera. Following incubation in α-Bungarotoxin, 
transfected cells were identified by eGFP signal and surface-specific labelling was imaged.  
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3.2.3. Functional characterisation of proton response of WT-GLIC and GLIC-GABAAR α1 
chimera 
While α-bungarotoxin labelling studies demonstrate that the GLIC-GABAAR α1 chimera, 
like GLIC, is expressed at the cell surface, it does not provide information regarding the 
functional properties of the protein. To determine whether the chimera forms a 
functional proton-gated ion channel we expressed receptors in Xenopus oocytes and 
measured their electrophysiological properties. Xenopus oocytes, rather than HEK293 
(or other mammalian cell lines) were preferred for electrophysiological recordings, 
because we noted that a greater time period was required to obtain robust expression 
of the chimera in HEK293 cells (determined by imaging). We presumed that the 
chimeric receptor folding might be less efficient when compared to GLIC. In addition, 
Xenopus oocytes have been used previously for robust expression of “difficult to 
express” chimeric receptors (e.g. GLIC-GlyR, ELIC-nAChR α7, GABAAρ1-α1 subunit 
chimeras; Martínez-Torres et al., 2000; Duret et al., 2011; Tillman et al., 2014). We 
therefore adopted use of this expression system to assess the functional properties of 
GLIC-GABAAα1 receptors. Furthermore, oocyte injections and TEVC studies can be 
carried out rapidly and in a semi-automated manner enabling the study of a number of 
receptor mutations and truncations.  
Two-electrode voltage-clamp studies of Xenopus oocytes injected with the chimeric 
GLIC-GABAA α1 receptor subunit revealed that, like GLIC (Bocquet et al., 2007), it forms 
a functional proton gated ion channel (Fig 3.3). In agreement with the fluorescence-
imaging experiments with α-Bungarotoxin, maximal current amplitudes evoked 
decreased extracellular pH for the chimera were observed 48-72 hrs after injection, 
whilst wild-type (WT) GLIC exhibited large proton-elicited currents within 18-24 hrs of 
cDNA injection. Current profiles for GLIC and the chimera were distinct to the small 
proton-elicited currents observed as controls in non-injected oocytes (typically <0.05 
μA exhibiting slow onsets to pH 4-5). Furthermore, current profiles of the two proteins 
exhibited contrasting properties.  GLIC is characterized by slow activating currents 
(following a jump of extracellular pH from pH 7.4 to pH 4), which do not desensitize 
during prolonged exposure to protons and are rapidly offset by returning to neutral 
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extracellular pH producing a small inward rebound current (Fig 3.3 A & B). In contrast 
the chimera exhibits comparatively fast onset kinetics, and current decay during 
exposure to low extracellular pH (Fig 3.3 A & C). A rapid recovery of the current 
response is also observed upon returning to high extracellular pH (low proton 
concentration). Whilst these properties are reminiscent of wild type (WT) α1-
containing GABAARs, the time-course of receptor activation and desensitization (when 
compared at the macroscopic level) is slower for the chimera (Fig 3.3 A). Thus the 
chimera retains the proton-gating properties of GLIC, presumably imparted by the 
ECD, and approaches the kinetic properties of the GABAARs, presumably conferred by 
the α1 TMD. 
In order to characterize the gating and channel properties of the chimera, proton-
concentration response and current-voltage relationships were assessed.  I-V 
relationships obtained from voltage-steps (of 10mV) from -60mV to +50mV applied to 
a pH 5.2 elicited current revealed a marked outward rectification (in a manner similar 
to that observed for GABA-activated currents of α1β2 GABAA receptors expressed in 
oocytes; Fig 3.3 E). GLIC, by contrast, exhibits a linear I-V relationship. Currently the ion 
flux contributing to the observed currents has not been studied further, though one 
might postulate, that like native GABAARs, the chimera forms an anionic, specifically Cl⁻
 
selective channel. Ultimately, further studies will confirm this.  
Proton-concentration response curves were generated for WT GLIC and the chimera 
(Fig 3.3 B-D). Consistent with previously published results (Bocquet et al., 2007), the 
threshold for GLIC activation is ~ pH 6, with a pH50 (i.e. pH required to activate 50% of 
the maximal current response) of 5.0 ([H+] = 1.0 ± 0.15 X 10-5 M) and reaches a 
maximum response at ~pH 4 (Fig 3.3 B & D). Contrastingly, the chimera displays 
threshold proton-gated activity at lower proton-concentrations (pH 7.2) and does not 
attain a maximal response up to pH 4, presumably non-saturating proton 
concentrations (Fig 3.3 C & D). The observation of GLIC-GABAAR α1 receptor activation 
at low proton concentrations were also made for another functional chimera formed 
between GLIC and GlyR α1 (Duret et al., 2011), for which application of the channel 
blocker picrotoxinin, at pH 8, produced a significant decrease in holding current in 
chimera expressing oocytes voltage clamped at -60 mV. This would suggest that the 
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GLIC-GABAAR α1 chimeric receptor might also be similarly allosterically stabilized in an 




Figure 3.3 - Functional characterisation of proton-gated response at GLIC and GLIC-
GABAAR α1 chimera 
A. Peak-scaled membrane currents elicited by 10 mM GABA (for α1β2 GABAAR) or pH 4 (for GLIC and the 
GLIC-GABAAR α1 chimera) showing the activation and desensitization phase of the receptor response. B 
and C. Examples of membrane currents recorded from oocytes expressing either GLIC (B) or GLIC-GABAA 
α1 (C) in response to decreasing pH. Horizontal bars indicate the duration of exposure to indicated 
extracellular pH. D. Proton-concentration response curves for GLIC and GLIC-GABAA α1. Points are mean 
± s.d. n = 5-7 oocytes It should be noted that responses at the chimera have been arbitrarily normalized 
to the response at pH 4 to allow for comparison with the proton response curve of GLIC E. Example I-V 
relationships for α1β2 GABAAR, GLIC and GLIC-GABAAα1. Currents where recorded in response to 
voltage steps of 10 mV, and normalised to the current at -60 mV (=-1).     
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In this study, oocytes expressing the GLIC-GABAAR α1 chimera do not exhibit 
substantial holding currents at presumed “resting” proton concentrations (~pH 8), nor 
does picrotoxin application induce changes to the holding current, suggesting our 
chimera is not spontaneously activating. Monitoring current responses at various 
proton concentrations jumps (pH 7.5-9.5) using a modified recording solution buffered 
with tricine (useful pH buffer range 7.4-8.8), rather than MES buffer (useful pH buffer 
range 5.5-6.7), confirmed GLIC-GABAA α1 receptor activity at low pH (data not shown). 
Given that the coupling-interface at the border between the prokaryotic ECD and 
eukaryotic TMD has not been modified in our chimeric receptor, it might be postulated 
that the apparent constitutive activity is the result of residue mismatches between 
critical structural elements responsible for maintaining the receptor in an inactive state 
under resting conditions.  
 
3.2.4. Analysis of receptor structural mismatch mutations and effect on gating 
To ensure that our chimera could be activated and modulated appropriately, without 
any aberrant behaviour caused by mismatches in critical areas of the receptor that are 
important to gating, we sought to identify and minimize a number of potential 
structural mismatches at the interface between the prokaryotic ECD and eukaryotic 
TMD (Fig 3.4). Additionally we assessed the effect of mutating the M3-M4 loop 
(forming the large ICD of the receptor) on setting the levels of receptor activation and 
desensitization.  
Guided by our homology model (Fig 3.4 A) and existing structure-function studies (as 
reviewed in (Miller and Smart, 2010), loop 7 and M2-M3 loop were identified as 
potential candidates for mutation at the coupling interface (Fig 3.4 B & C, and 
Appendix Figure 3). Mutation of 11 residues forming the linker between M2 and M3 
(Appendix Figure 3) to the complementary residues observed in GLIC appeared to 
almost completely abolish proton-gated current responses (Fig 3.4 B). Given the small 
size of currents for the mutant chimera, it is difficult to distinguish this response from 
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the endogenous proton response observed in uninjected oocytes. Thus it was unclear 
if protein expression in the plasma membrane of cells was abolished as a result of 
disruptive changes to protein folding or due to the chimera adopting non-physiological 
non-conductive conformations. Notably the M2-M3 loop is crucial for both folding and 
gating across metazoan members of the Cys-loop receptor superfamily, as well as in 
GLIC, as revealed by recent crystallographic studies of cross-linked variants or loss-of-




Figure 3.4 - Chimera homology model and functional characterisation of M2-M3 loop 
and Loop 7 mutants 
A. Homology model of the chimera using the crystal structure for GLIC (PDB 3EAM) as a template. 
Surface rendering of a single subunit is shown and the following regions highlighted; GLIC ECD – blue, 
GABAAα1 TMD – red, Loop 7 – green, M2-M3 loop – cyan, M3-M4 loop – orange. B. M2-M3 loop and 
proton current evoked for the mutated chimera in which residues in the loop are replaced by those for 
GLIC. C. Loop 7 region, with YPF motif replace by FPM motif from GABAAR α1 subunit, and residues 
shown in stick representation. Proton evoked current of mutant chimera in oocytes elicited by step to 
low pH.  
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Loop 7 formed from connecting strands β6-β7 in the ECD (the characteristic Cys-loop in 
eukaryotic pLGICs) is another key structural component in communication between 
the ECD and TMD. Structure-function studies along with recent crystallographic data 
reveal that loop 7 protrudes down into the TMD where it contacts with M2-M3, the 
top of M3 and post-M4 (Hibbs and Gouaux, 2011; Althoff et al., 2014; Hassaine et al., 
2014; Miller and Aricescu, 2014). We therefore postulated that mutation of the tip of 
loop 7 to the complementary residues of GABAAR α1 (Y-P-F > F-P-M) might serve to 
improve the efficiency of gating of the GLIC-GABAAR α1 chimera. Unsurprisingly, this 
relatively conservative mutation (when compared to the M2-M3 loop modification 
introduced above) did not ablate function of the chimeric receptor (Fig 3.4 C), with 
robust proton-gated responses were observed in Xenopus oocytes. While this 
mutation in loop 7 still enabled the generation of a functional receptor, there was no 
apparent change to the observed proton-concentration response relationship (i.e. 
channel gating at low proton concentrations and failure reach to plateau in activation 
at high concentrations).  
 
3.2.5. Analysis of M3-M4 loop truncation and effect on activation and desensitization 
In addition to mutagenesis studies at the coupling interface, the boundary between 
the prokaryotic ECD and eukaryotic TMD, we assessed both the role of the large ICD, 
between M3 and M4 TMD helices of the GABAA α1 subunit, in receptor function and in 
determining receptor kinetics. A large and variable length M3-M4 loop is a consistent 
feature across the eukaryotic pLGICs, which, in addition to acting as a scaffold for the 
binding of accessory proteins, serves to modulate receptor kinetics (potentially 
through post-translational modifications, e.g. receptor phosphorylation (Moss and 
Smart, 2001). The discovery of prokaryotic pLGIC homologs, revealed significant 
evolutionary truncation of the ICD, with short linker segments joining M3 and M4 with 
no apparent effect on receptor function (Bocquet et al., 2007; Hilf and Dutzler, 2008; 
Bocquet et al., 2009). Subsequent studies confirmed that the largely removable nature 
of the ICD extends to eukaryotic pLGICs, with a recent study reporting the generation 
122 
 
of functional 5-HT3 and GABAA ρ1 receptors in which the respective M3-M4 loop was 
replaced with the short linker segment from GLIC (Jansen et al., 2008).  Furthermore, 
recent expression, purification and crystallization studies of eukaryotic receptors and 
chimeras (including GluClcryst, GABAR β3cryst and GLIC-GlyRα1 (Lily) have used 
constructs lacking the large, structurally unresolved M3-M4 loops (likely to hinder 
receptor crystallization because of perceived structural flexibility; Hibbs and Gouaux, 
2011; Miller and Aricescu, 2014; Moraga-Cid et al., 2015). We therefore assessed the 
functional amenability of our chimeric receptor to truncation of the M3-M4 loop (~75 
amino acids in length), which would likely serve as crucial step in identifying candidate 
receptors for high-level expression and purification. Furthermore these studies would 
allow us to further investigate the role of this loop on receptor activation kinetics.  
Based upon sequence alignments and existing structural data we designed two 
chimeric receptors exhibiting truncation of the M3-M4 loop (Fig 3.5). In exchange for 
the stretch of ~ 75 residues observed in GABAARα1 subunit we included either a short 
tripeptide, -ATG-, linker (akin to that observed in GluClcryst) or heptapeptide, -
SQPARAA-, linker (as observed in GLIC). The point of insertion was positioned so as to 
not potentially exhibit structural constraints on the M3 and M4 helices (Fig 3.5 A and 
Appendix Fig 3), or displaces residues (particularly at the base of M3) involved in 
setting the desensitization kinetics of native α1-containing GABAA receptors.  
Live-cell fluorescence imaging experiments using M3-M4tripeptide or M3-M4heptapeptide 
receptors incorporting a BBS yielded robust cell surface labelling within 24 hrs of cell 
transfection (Fig 3.5 B). The increase in rate of delivery of receptors to the plasma 
membrane would suggest that the large, unstructured nature of the native ICD likely 





Figure 3.5 - Trafficking and functional characterisation of M3-M4 linker truncations in 
the chimera. 
A. Position of M3-M4 linker in chimera homology model. Below, linear sequence detailing the insertion 
of the linkers. B. α-Bungarotoxin labelling of HEK293 cells transfected with EGFP and BBS-tagged 
chimeras with tri- or heptapeptide M3-M4 linkers (Alexa 555 α-Bgtx channel red and merge with eGFP). 
C. Proton-concentration response curves for GLIC and M3-M4 linker chimeras. n= 7-8 oocytes D. Peak-
scaled membrane currents showing activation and decaying phase of proton elicited responses for the 





(F) chimeric recepotrs in response to increasing proton concentrations. 
124 
 
export to the cell surface. Consistent with previous studies deletion of the M3-M4 loop 
and replacement with either tri- or heptapeptide linkers did not ablate receptor 
function when analysed electrophysiologically (Fig 3.5 C-F). Oocytes expressing either 
the M3-M4tripeptide or M3-M4heptapeptide GLIC-GABAAR α1 chimera were activated by low 
external pH within 18-24 hrs of oocyte injection (in accord with the fluorescence-
imaging experiments; Fig 3.5 D). The nature of the mutation has minimal effect on the 
apparent activation kinetics of the receptor (Table 3.1), whilst having an appreciable 
effect on entry into desensitization. Deactivation kinetics upon return to extracellular 
pH 8 were rapid and apparently unaltered.  
Evidently replacing the ICD with the heptapeptide linker, in combination with a less 
conservative conservation of post-M3 and pre-M4 residues (as detailed in linear 
sequence of Fig 3.5 A) gives rise to a receptor which exhibits an increase in rate of 
desensitization (Fig 3.5 D) when compared to replacing the M3-M4 loop with a short 
tripeptide linker and retention of a greater portion of residues post-M3 and pre-M4. It 
is also evident that the activation kinetics of the M3-M4heptapeptide chimera is slightly 
faster, though whether this reflects enhanced receptor gating or an increase in the 
rate of entrance in to desensitization relative to the rate of receptor activation is 
unclear.  
Whilst there is an apparent effect of the M3-M4 linker on receptor kinetics, we also 
observed a change in the proton-concentration response curves of the truncated 
chimeras (Fig 3.5 C, E & F). As observed for a chimera in which the large ICD is 
retained, M3-M4tripeptide and M3-M4heptapeptide chimeras exhibit leftward shifts in the 
proton-concentration curves when compared to the WT GLIC curve, with proton-gated 
currents recorded at pH7.5 and with respective pH50s of 6.18 ([H
+]=6.49 ± 1.78 x 10-7M) 
and 6.69 ([H+]=2.04 ± 0.09 x 10-7 M) (Fig 3.5 C). Additionally there is a clearer maximum 
in receptor activation at low pH (high proton concentrations; Fig 3.5 E & F). This is 
most apparent for the M3-M4heptapeptide chimera. It was notable for the M3-
M4heptapeptide chimeric receptor that significant holding currents, which could be 
blocked by the channel blocker picrotoxin, were observed in oocytes maintained at pH 
8 when voltage-clamped at-60 mV. This observation along with a leftward shift in the 
proton-dose response curve is indicative of an increase in the spontaneous activity of 
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the receptor. This is presumably imparted through structural modifications introduced 
through altering the length and nature of the M3-M4 loop. These results are consistent 
with those observed for the GLIC-GlyRα1 chimera which used a linker of similar length 
and sequence to replace the large M3-M4 loop (~ 75 residues) found in native GlyRα1 
(Duret et al., 2011). Whilst the M3-M4tripeptide chimera construct retains proton-gating 
activity at relatively neutral pH, holding currents at pH 8 were small and similar to 
those observed with forms of the chimera that retained a full length M3-M4 loop. This 
presumably reflects greater stability in a non-conducting state under “resting” 
conditions. It is unclear from concentration-response relationships alone as to whether 
this M3-M4tripeptide receptor exhibits constitutive basal activity as a result of 
mismatches in the structural elements at the gating interface or through truncation of 
the M3-M4 loop.    
3.2.6. Functional analysis of desensitization mutations in GLIC-GABAAR α1 M3-M4 
linker truncated chimeras 
At the macroscopic level two-electrode voltage-clamp recordings of chimeric receptors 
suggest that through a simple domain switch, we have been able to confer similar 
activation and gating properties that might be expected for native GABAARs (e.g. a 
faster rate of activation and entrance into a desensitized state when compared to 
GLIC). To further assess whether the chimera adopts common mechanistic 
arrangements during channel gating to native GABAARs, in particular during receptor 
desensitization, we used site-directed mutagenesis to study residues at the 
intracellular end of M2 and M3, recently proposed to form a desensitization gate at 
the receptor (Gielen et al., 2015). Studies of α1β2(γ2L) GABAARs have revealed that 
introduction of single residue point mutants (altering side chain charge or volume) 
along the M2/M3 interface is sufficient to dramatically enhance the apparent rate of 
receptor desensitization. As a result of these functional studies (supported by evidence 
from recent crystallographic, NMR and DEER spectroscopy data (Miller and Aricescu, 
2014; Kinde et al., 2015)), it is now proposed that receptor desensitization is the result 
of structural rearrangements extending beyond those which occur at the level of ECD 
and ECD-TMD interface (Gielen et al., 2015).  
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Having confirmed that deleting the large M3-M4 loop of the chimera does not ablate 
function, further functional studies were carried out at receptors bearing these 
truncations (given their potential promise for receptor purification and crystallization 
strategies, see Chapter 4). Whilst there is an apparent effect of deletion on setting the 
time course for desensitization, receptor activation kinetics (and crucially, retention of 
a desensitizing phase) remains largely unchanged.   
A question that must, however, be addressed concerns the nature of the structural 
confirmation this M3-M4 linker adopts when spliced in to the sequence of the GLIC-
GABA chimera. Given the point at which we have introduced these linkers (and there 
positioning in published crystal structures) we might predict that they remain in the 
cytosolic portion of the linker rather than being incorporated into the α-helices of M3 
and/or M4. Thus they would not be expected to impart physical constraints on the 
helical bundle of the TMD which would drastically alter receptor kinetics.  
Mutation of the M2 4’ glycine (G258) to alanine, increasing the side chain volume in 
the GLIC-GABAA α1 chimera with either M3-M4 linker, is sufficient to increase the rate 
of desensitization when compared to non-mutant bearing forms of the chimeras (Fig 
3.6 A, B, E & F and Table 3.1). Further mutation to a bulky hydrophobic valine residue 
resulted in a loss-of-function for chimeric receptors bearing the M3-M4tripeptide linker 
whilst currents exhibiting a rapid rate of decay (6-fold increase) were resolvable with 
chimeric receptors bearing the M3-M4heptapeptide (Fig 3.6 B, D & F). 
Mutation of -3’ valine (251) to isoleucine, another residue profoundly affecting 
desensitisation in α1β2 GABAARs (Gielen et al., 2015) was also sufficient to induce an 
increase in the rate of receptor desensitization (for both M3-M4tripeptide and M3-
M3heptapeptide chimeras), whilst mutation to the bulky aromatic phenylalanine (V251F) 
did not yield resolvable currents for either chimeric receptor. Peak normalised 
responses also indicated a shift in the rate of receptor activation, most notable in the 
more profoundly desensitizing mutants (Fig 3.6 C & D). Given the comparatively slow 
onset kinetics of currents mediated by the chimera (when compared to a GABAAR) this 
likely represents a rapid entry into desensitization (greater than the rate of activation), 





Figure 3.6 - Functional analysis of desensitization mutations at chimeric receptors 





(B) and indicated TMD mutations upon exposure to low pH. C-F. Bar 





(D, F) plus the indicated mutations. n 




In a manner similar to that observed in studies of native GABAARs, the selected 
mutations affected both the rate (and extent) of desensitization for currents mediated 
by the chimeras. Furthermore systematic mutation at a single site, which increases the 
rate of desensitization is also apparent on the backbone of the chimeric receptor (e.g. 
M3-M4heptapeptide G258 (WT; τω 11.9s) < G258A (5.86s) < G258V (2.01s). An unexpected 
observation was that the extent to which the apparent desensitization profile was 
affected by the M3-M4 truncation. For example currents exhibiting a rapid decaying 
phase were resolvable for G258V mutation of GLIC-GABAAα1 M3-M4
heptapeptide but not 
the M3-M4tripeptide. Furthermore in the case of profoundly desensitizing mutants (e.g. 
V251F) currents could not could be resolved, regardless of the nature of the M3-M4 
truncation.  
The lack of resolvable currents for profoundly desensitizing mutants, in particular 
V251F (at -3’ position of M2), was maybe not a surprising observation. At α1β2 
GABAARs, introduction of α1
V251F subunits is sufficient to induce a 20-fold increase in 
the rate of desensitization when compared to its wild type counterpart. Introduction of 
the equivalent mutation into the β2 (S247F) and co-expression with α1V251F yields 
receptors with unresolvable currents. As mentioned previously, this likely arises 
through generating a receptor exhibiting rates of desensitization greater than the rate 
of ion channel opening. This is also likely to affect homomeric V251F mutant receptors 
in the present study (i.e. exhibiting mutations at all five -3’ positions), which did not 








Table 3.1 Weighted decay time constants of desensitization and activation rates for 
chimeric GLIC-GABAAR α1 receptors bearing ‘desensitization mutations’. 
 
Construct Rise time20-80% (s) τω (s) n 
GLIC-GABAA α1
Full length
 1.77 ± 0.28 11.93 ± 2.22 5 
    
M3-M4Tripeptide 1.67 ± 0.24 19.3 ± 2.46 9 
M3-M4TripeptideG258A 1.24 ± 0.08 14.7 ± 1.11 5 
M3-M4TripeptideV251I 1.49± 0.34 17.1 ± 3.72 3 
    
M3-M4Heptapeptide 0.89 ± 0.32 11.9 ± 1.25 9 
M3-M4HeptapeptideG258A 0.51 ± 0.25 5.86 ± 0.84 5 
M3-M4HeptapeptideG258V 0.45 ± 0.09 2.01 ± 0.10 5 
M3-M4HeptapeptideV251I 0.60 ± 0.16 8.22 ± 1.18 5 
 
τω is the weighted decay time constant for desensitization (calculated from a bi-
exponential fit of the decaying phase of currents during prolonged agonist exposure, 
as detailed in Materials and Methods). It should be emphasized that these number 
serve to highlight the trend in (increased) rate of desensitization following introduction 
of various point mutations). Values are means ± s.d and n is the number of cells. 
 
 
3.2.7. Trafficking and functional rescue of V251F mutant chimera 
To determine whether the V251F mutation affects assembly or causes the chimera to 
adopt a non-conductive state, we used imaging to track cell surface labeling in HEK293 
cells and electrophysiological recordings, following introduction of a well characterized 
gain-of-function mutation at the level of the hydrophobic gate in the pore-lining M2 
helix (Leucine-9’-Serine; Chang and Weiss, 1999).    
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Previous studies have shown that hydrophilic substitution of the conserved 9’ leucine 
in GABAAR subunits (as for other members of the pLGIC superfamily) results in a 
profound increase in both agonist sensitivity and spontaneous channel openings 
(Chang and Weiss, 1999).  Given this effect, substitution at the 9’ position is often used 
to rescue the function of apparently non-functional receptors, and in doing so confirm 
cell surface presence of a receptor exhibiting an expected bias in the gating 
equilibrium.  
We introduced a BBS into GLIC-GABAAR α1 M3-M4
tripeptide V251F chimeras (for cell 
surface tracking in HEK293 cells) and the L9’S mutation for electrophysiological 
recordings.  Incubation with fluorophore conjugated α-bungarotoxin yielded cell 
surface labeling of receptors in transfected cells, which would suggest assembly and 
export to the plasma membrane (Fig 3.7 C). Notably we also observed robust surface 
labeling of receptors at cells expressing both the (electrophysiologically) functional 
G258A mutant (M3-M4tripeptide) chimera and loss-of-function GLIC-GABAAα1 M3-
M4tripeptide G258V mutant chimera (Fig 3.7 A & B).  
Consistent with previous studies of GABAARs, the M3-M4
tripeptide L9’S mutant chimera 
exhibited spontaneous activity in the absence of agonist (at extracellular solution pH 
8), as inferred from a significant increase in the holding current for oocytes clamped at 
-60 mV (Fig 3.8 A). Picrotoxin blocked a proportion of this current, as did the inhibitory 
neurosteroid pregnenolone sulfate (PS; Fig 3.8 A).  Application of agonist was able to 
induce further channel opening, as reflected by an additional inward current following 
a step to low pH. These results are consistent with the L9’S mutation stabilizing the 






Figure 3.7 - α-Bungarotoxin binding to BBS-tagged desensitization mutant chimeras 
Live-cell confocal images of HEK293 cells transfected with the indicated construct following incubation 
with Alexa555 conjugated α-Bungarotoxin. Left panels: EGFP signal, Centre panels: Alexa555-α-













G258A. Following incubation in α-Bungarotoxin, 
transfected cells were identified by EGFP signal and surface-specific labelling imaged.  
 
The L9’S mutation was able to rescue the function of the V251F mutant chimera, with 
oocytes injected with the double mutant exhibiting currents in response to low pH (Fig 
3.8 B). This confirms that the V251F mutation has not caused the chimera to form a 
non-physiological non-conductive state. Additionally, the current traces revealed 
notable features which might further suggest that the M3-M4tripeptide V251F chimeric 
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receptor is allosterically stabilized in a distinct gating state. Specifically, spontaneous 
activity of double mutants was reduced greater than 2 fold when compared to the L9’S 
mutated chimera. Comparing the spontaneous activity as a percentage of the 
spontaneous current and the maximal proton response (see Materials and Methods) 




Figure 3.8 - Functional analysis of L9’S rescue of non-functional V251F chimera 
Example current responses from A. GLIC-GABA
M3-M4tripeptide 
L9’S receptor and B. GLIC-GABA
M3-M4tripeptide 
L9’S/V251F in oocytes (clamped at -60 mV). Dashed lines represents zero current level, showing 
spontaneous current at pH 8. Inhibition of spontaneous current by 10 μM pregnenolone sulphate (PS) 
and 200 μM picrotoxin (Ptx), and further current activation by pH 4. 
 
Furthermore spontaneous currents of the L9’S/V251F receptor were not blocked by 
picrotoxin (at a concentration shown to reduce a significant portion of the 
spontaneous current observed in L9’S receptors; Fig 3.8 B). By contrast the 
spontaneous current for the L9’S/V251F and L9’S was reduced by PS (Fig 3.8 A & B). 
Whilst (at the macroscopic level) there was no apparent increase in desensitization of 
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proton-elicited currents for the L9’S/V251F receptor, the reduction in spontaneous 
currents and loss of picrotoxin-block are consistent with the notion that the V251F 
mutation dramatically biases the gating equilibrium constant of the chimera towards a 
closed-desensitized channel conformation when expressed in Xenopus oocytes (and is 
discussed in greater detail below). Not only does this result further confirm that the 
mechanisms underlying channel gating, specifically desensitization, are common 
between native and chimeric GABAARs, but also identifies a strong loss-of-function 
mutant receptor which would serve as an ideal candidate for structural studies of a 
receptor stabilized in a distinct (presumed desensitized) state.  
 
3.2.8. Neurosteroid potentiation and inhibition of chimeric GABAA receptors 
Having established a channel gating profile for the chimera, revealing a common 
mechanism for receptor desensitization in comparison to its native GABAAR 
counterparts, we sought to assess the pharmacological profile of the GLIC-GABA 
chimera and determine whether key sites for allosteric modulator binding have been 
retained in the TMD. We focused primarily on the response to the endogenous 
neurosteroids tetrahydro-deoxycorticosterone (THDOC) and pregnenolone sulphate 
(PS). These steroids impart distinct and opposite effects, but have both been 
characterised extensively at α1-containing GABAARs; THDOC potentiating activity or 
directly gating the channel, and PS inhibiting agonist responses. It was hypothesised 
that within the chimeric receptor, the sites responsible for mediating the binding and 
effect of these two neurosteroids might be retained and a modulatory effect observed 
following agonist activation. With regards to the pharmacological profile of GLIC, 
sensitivity to these two compounds has not been reported. However given that the key 
residues previously reported to mediate the response to potentiating neurosteroids 







Figure 3.9 - Functional analysis of THDOC potentiation of proton-response 
Example current traces of responses induced by pH10-20 and their potentiation by increasing 





(B). Inset panel in A reveals the response induced by 3 μM THDOC in oocytes expressing GLIC-GABA
M3-
M4tripeptide
 at pH 8 (Current calibration bar: 20s/40 nA). 
 
THDOC (across a range of concentrations) was observed to potentiate ~pH10-20 elicited 
currents in oocytes expressing the chimera (Fig 3.9). This response was observed for 
both M3-M4tripeptide and M3-M4heptapetide linker chimeras, exhibiting sensitivities 
(respective ~EC50s for THDOC; 1.16 ± 0.54 μM and 0.99 ± 0.15 μM, n=5 and 3 
respectively) in the high nM-low μM range (Fig 3.9 A & B). Unsurprisingly the response 
recovery is extended at high THDOC concentrations, most likely due to slow washout 
of the steroid. This response is reminiscent of α1β2γ2 GABAARs, though the reported 
sensitivity is slightly greater in native GABAARs (~280 nM in HEK293 cells (Hosie et al., 
2006)). The response of WT GLIC to THDOC was distinct in that the receptor was 
largely insensitive to THDOC (exhibiting a small inhibition of the proton response at 
high μM THDOC concentrations). These results are consistent with a lack of a THDOC 
binding site in GLIC, with a critical glutamine (Q241) in M1 of the GABAA α subunits 
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replaced by a tryptophan (W213) in GLIC. The binding site for THDOC is however 
functionally introduced through a domain switch with GLIC by inserting the GABAAR α1 
TMD, as observed by a potentiation of a proton response in the chimera.  
Given the constitutive activity observed with the chimera even at resting, neutral pH 
we cannot yet conclude that a THDOC response observed at pH 8 (Fig 3.9 A) represents 
a true direct activation of the receptor. THDOC could simply be potentiating 
constitutive channel activity. Moreover, since the direct gating response at the α1β2γ2 
containing receptors is presumed to be coordinated by binding of steroid molecule at 
an interfacial site between alpha and beta subunits (presumably with residues from 
both subunits responsible for binding (Hosie et al., 2006)), we would not expect direct 
activation of the GLIC-GABAAα1 chimera where there is a homomeric configuration of 
α-subunit TMDs. 
Whilst potentiating neurosteroids, have been the focus of extensive studies with 
regard to their mechanism of action, our understanding of how inhibitory 
neurosteroids bind and antagonize the GABAAR is less clear. This class of steroids 
incorporates the sulphated steroids, including pregnenolone sulphate (PS) and 
dehydropiandrosterone sulphate (DHEAS), and like potentiating steroids are naturally 
occurring in the CNS (Seljeset et al., 2015). Whole-cell currents elicited by a 
submaximal proton concentration (~pH80) were recorded from oocytes expressing 
GLIC-GABAA α1 chimeras (and GLIC) in the absence or presence of PS (ranging from 100 
nM to 30 μM; Fig 3.9). Native GABAARs have previously been shown to be inhibited (in 
a use dependent manner) at high nM/low μM concentrations of PS, with greater 
inhibition of steady state currents compared to peak response (Seljeset et al., 2015).  
Furthermore, this inhibitory response is characterised by promoting the receptor’s 








Figure 3.10 - Functional analysis of Pregnenolone Sulphate inhibition of proton-
response 
Example current traces of ~EC80 proton response by increasing concentrations of pregnenolone sulphate 




(B). Inset in A shows 
enlarged, peak-scaled membrane currents for the pH 4.5 response for the chimera and 10 μM GABA 
response for α1β2 GABAAR in the presence or absence of 3 μM PregS.  
 
Whilst not extensively studied, PS exhibited a range of effects at oocytes expressing 
WT GLIC (depending on the co-applied proton concentration). PS exhibited both weak 
potentiation and inhibition of the proton activated response. Furthermore the 
sensitivity of this response to PS (at mid-high μM) was substantially outside of the 
effective concentration range previously reported for a eukaryotic pLGIC, e.g. α1β2γ2 
GABAAR. Given the relatively promiscuous nature of pregnenolone sulphate, which is 
known to modulate, amongst others, the pLGIC superfamily, iGluRs and TRP channel 
(Harteneck, 2013), the observation of a low-sensitivity response at GLIC was not 
surprising. 
In contrast to GLIC, introduction of the α1 TMD in the GLIC-GABA chimeras increased 
the potency of pregnenolone sulphate (Fig 3.10 A & B). Chimeric receptors exhibited 
PS sensitivity in the high nM-low μM concentration range, and in a manner similar to 
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native GABAARs this inhibition was characterized by an increase in the desensitization 
kinetics of the proton response (Fig 3.10 A Inset). It is notable that in contrast to the 
inhibition response observed at a native GABAAR, there was a profound PS mediated 
depression of the peak proton response (during co-application experiments). This may 
reflect the slow onset of proton-elicited response, which in the presence of PS is 
masked by an apparent increase in the rate of entry into a closed-desensitized state.  
Given that studies were primarily carried out on M3-M4 truncated receptors it would 
appear that binding and sensitivity of the chimeric receptor to PS was not dependent 
on structural elements provided by the M3-M4 loop. Whilst we cannot exclude that PS 
imparts its effect through indirect interaction with the ion channel (i.e. lipid 
interactions in the bilayer), it is apparent from these studies that structural elements 
conferred by the GABAAR α1 TMD are likely to be responsible for the increased 
sensitivity to PS.  
 
3.2.9. Picrotoxin block of chimera currents 
We have focused primarily on the inhibitory effects of PS, a compound for which 
relatively little is known regarding its mode of action. In addition, the effects of the 
GABA antagonist picrotoxin at chimeric receptors were also assessed. The antagonistic 
effects of picrotoxin across members of the pLGIC superfamily has been extensively 
studied, and it is widely acknowledged that it acts as a channel-blocking agent binding 
deep within the pore at the -2 to 2’ level (Bali and Akabas, 2007). Moreover, recent 
crystallographic studies of GluCl in complex with picrotoxin provides further weight to 
this proposed mechanism of action (Hibbs and Gouaux, 2011). In agreement with 
previous studies, picrotoxin was able to block proton-activated currents through GLIC  
(Fig 3.11 B; Alqazzaz et al., 2011). As might be expected currents through the chimera 






Figure 3.11 - Functional analysis of picrotoxin block of proton-response 
Representative membrane current traces showing fast dissociation of picrotoxin (PTX) from oocytes 
expressing GLIC-GABA
M3-M4tripeptide 
chimera (A) and GLIC (B) when activated by a high/saturating 
concentration of protons. Note the rebound current in A after washout of PTX, indicating that PTX is 
unlikely to bind to a desensitized state of the receptor (Gielen et al., 2015). 
 
3.2.10. Pentobarbital inhibition at α-containing chimeras and potentiation of β-
containing chimeras 
The pharmacological profile of the chimera (with regards to neurosteroids and 
picrotoxin) exhibits typical properties that might be expected of a α1-containing 
GABAAR. In this respect, the chimeric receptor represents a minimal model of an α-
containing GABAAR at the level of the TMD. Therefore, we might also use this receptor 
to study the effects of other pharmacological agents exhibiting complex mechanisms 
of actions. General anesthetics (GA) have long been implicated as acting through the 
GABAAR, however, an understanding of how these compounds act at the molecular 
level is poorly understood. While a binding site for the intravenous GA propofol has 
been established at the GABAAR β subunit (Yip et al., 2013; Franks, 2015), and also at 
the bacterial homolog GLIC (by co-crystallographic studies; Nury et al., 2011), the 
mechanism by which barbiturates, including pentobarbital, bind and act are not as 
clearly defined. Pentobarbital modifies receptor function in three concentration-
dependent manners; at low concentrations (<100 μM) channel activity (induced by 
sub-saturating agonist concentrations) is potentiated, intermediate concentrations 
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(100μM-1mM) are able to directly activate the receptor, and above 1mM 
pentobarbital exhibits antagonistic effects, blocking currents through the ion channel 
(Akk and Steinbach, 2000; Muroi et al., 2009). The mechanisms underlying these 
distinct modes of action are poorly understood. Given the complex nature of its action, 
it might seem likely that distinct structural elements, contributed by a combination of 
subunits, mediate the different functions of pentobarbital at GABAARs. Studies to date 
have revealed that β-subunit homomers can be directly gated by pentobarbital (Davies 
et al., 1997; Wooltorton et al., 1997). Here we have assessed the pentobarbital 
response at our GLIC-GABAA α1 chimera in order to potentially assign a role for the 
GABAA α1 TMD in barbiturate binding. It should be noted that studies were carried out 
on the chimera including the large, native M3-M4 loop of the GABAA α1 subunit.   
The response of WT GLIC and the chimera to a submaximal proton-gating 
concentration (~pH20) in the absence or presence of pentobarbital (3 μM-1 mM) was 
recorded in oocytes. Pentobarbital co-application at pH 8 did not induce any effect at 
WT GLIC receptors or the chimera. Co-application of PB at an extracellular recording 
pH20 proton concentration revealed an inhibitory action of PB at both GLIC and the 
chimera (IC50s of 113.7 ± 9.4 μM and 272.5 ± 39.5 μM respectively; Fig 3.12 A & C). The 
concentration ranges over which PB imparts this inhibitory effect is equivalent to the 
concentrations inducing potentiating-activating responses at α1β2 GABAARs (which 
exhibits an ~EC50 of 25.4 ± 12.1 μM, from a fit of ‘potentiating’ data points). 
Intriguingly, PB inhibition of proton-gated currents at the chimera were characterised 






Figure 3.12 - Functional analysis of pentobarbital responses at GLIC and α1 and β2 -
GABAA chimeras. 
Example membrane current traces showing the modulatory effect of increasing pentobarbital 
concentration at an ~pH20 proton-gating concentration for GLIC-GABAα1 (A), GLIC-GABAβ2 (B) and GLIC 
(C). D. Pentobarbital concentration response curves at an ~EC/pH20 (as shown in A-C) for the indicated 
GLIC receptor and GLIC-GABAA chimeras and at 1 μM GABA for oocytes expressing α1β2 GABAAR. Points 
are mean ± s.d. n = 4 - 8 cells. A concentration response for α1β2 GABAAR data points is fit to 
‘potentiating’ pentobarbital concentrations (3-100 µM) and not those inducing channel block (>100 
µM).   
 
This response is consistent with pentobarbital rapidly dissociating from a low affinity, 
open channel block site (Wooltorton et al., 1997). Rebound currents were not 
observed for GLIC, though this may reflect the slow kinetics of channel gating observed 
at this receptor. We cannot conclude from these experiments that an inhibitory 
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response was mediated through binding of PB to the TMD (for both GLIC and the α1 
chimera) and not by the ECD of GLIC, which is common to both receptors. However, 
given that binding of PB at β-subunits is presumed to be coordinated by parts of M1, 
M2 and M3 (Amin, 1999) and that other anesthetics have been observed 
(crystallographically) to bind within the TMD of GLIC (Nury et al., 2011; Sauguet et al., 
2013a), it would seem more likely that a (potentially common) inhibitory barbiturate 
binding site of equivalent affinity is found within the TMD of GLIC and the GABAAR α1-
subunit. It might therefore be concluded that the structural elements critically 
responsible for the activating effects of PB are contributed by the β-subunit, and not 
the TMD of the α1-subunit 
Based upon previous observations of PB activation of homomeric β-subunit receptors, 
we reasoned that, if functional, a chimera between the ECD of GLIC and the TMD of 
the GABAA β2-subunit might exhibit a contrasting activity profile with respect to the 
actions of pentobarbital. In a similar manner to that described for the α1 GLIC-GABAAR 
α1 chimera, we constructed a domain chimera between the ECD of GLIC and the TMD 
of the β2 GABAAR subunit (with no exchange of gating residues at the ECD-TMD 
interface or truncation of the M3-M4 loop). Tagging these GLIC-GABAA β2 chimeras 
with a BBS and expressing them in HEK293 cells revealed robust surface expression 
with fluorophore conjugated α-Bgtx (Appendix Figure 4). When expressed in oocytes, 
small proton-gated currents were recorded for the GLIC-GABAA β2 chimera. In contrast 
to the GLIC-GABAA α1 chimera this response exhibited slow onset kinetics, and did not 
decay during prolonged exposure (Appendix Figure 4). Given the well characterised 
proton modulation of GABAARs, mediated by H267 in TM2 of β2 subunit (Wilkins et al., 
2002), it is not immediately clear whether channel gating of the chimera is initiated by 
proton-sensing at the level of the ECD or if protonation of H267 within the pore is 
sufficient to induce channel opening.  
As for GLIC and GLIC-GABAARα1 chimera, the proton mediated response of GLIC-
GABAAR β2 was measured in the presence or absence of pentobarbital (ranging from 3 
μM to 1 mM). Curiously, application of pentobarbital at pH 8 (presumed resting) did 
not initiate direct activation of the ion channel. Co-application of pentobarbital at 
extracellular solutions of low pH evoked currents of increasing magnitude with 
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increasing concentration of pentobarbital (with an EC50 of 142.9 ± 46.5 μM), with a 
response profile (slow onset) reminiscent of pentobarbital potentiation of agonist 
induced currents for native GABAARs (Fig 3.12 B & D). Furthermore, at higher 
concentrations of pentobarbital, removal of drug was preceded by a transient increase 
in current (rebound current). This would suggest that the TMD of the β2-subunit is 
responsible for contributing residues responsible for coordinating the potentiating 
effects of pentobarbital, whilst like the α1 TMD, also retaining a low-affinity, open 
channel block site. From these studies we would infer that structural elements 
responsible for direct gating are presumably not present on the GLIC-GABAA β2 
chimera. While previously published data demonstrates that barbiturates are able to 
directly gate receptors formed by full-length β-subunit homomers, it is notable that 
much of this work has focused on a response at receptors formed of β1 or β3, and to 
lesser extent, β2-subunits (Cestari et al., 1996; Krishek et al., 1996; Davies et al., 1997; 
Wooltorton et al., 1997).  
 
3.2.11. Alternative chimeric GABAA receptors: a GluCl-GABAA chimera 
The study of pentobarbital (presented above) displays the apparently robust nature 
with which the ECD of the prokaryotic channel GLIC is able to act as a surrogate host 
for eukaryotic TMDs across the GABAAR subunit family. This is likely to be case for 
other eukaryotic TMDs of the pLGIC superfamily. Despite the functional nature of 
these chimeric receptors, and retention of “typical” transmembrane domain based 
pharmacology of eukaryotic subunits, the kinetics of receptor activation and 
desensitization are considerably slower than those of its native eukaryotic counterpart.  
The bacterial channel GLIC is speculated to be responsible for playing a role in bacterial 
physiology, acting as a proton sensor in the regulation of photosynthesis at the inner 
membrane of gram-negative cyanobacteria.  GABAA receptors on the other hand are 
critical in mediating fast-inhibition within the CNS. Unsurprisingly therefore, the time-
scale with which these receptors are required to activate and impart their effect on 
membrane potential differs considerably. This is reflected in the response of our 
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chimera with “GABAA-like” receptor kinetics, whilst retaining the proton-sensing 
property of GLIC. It is however a “slow” receptor when compared to native GABAARs. 
The α1-chimeras introduced in this study typically activate on a time scale of seconds 
(in Xenopus oocytes). Whilst profoundly faster than GLIC, native GABAARs typically 
activate on the time course of milliseconds (<50 ms in oocytes). This likely reflects the 
evolutionary separation between the two receptors, and the changes that have 
occurred at the level of agonist binding, signal transduction and channel gating to 
generate a more rapid response.  
One of the major technical challenges of our functional studies to this point was the 
need to activate the GLIC-GABAA chimeras with protons. Repeated and prolonged 
application of low pH solutions caused additional stress on injected oocytes and could 
also induce endogenous acid-sensing channel activity which could prove problematic 
in the analysis of responses to (prolonged) agonist exposure and when screening 
weakly expressing receptors.   
To address this issue and to test the concept that evolution within the pLGIC 
superfamily allows for large domain switches whilst retaining receptor function, we 
generated a chimera between the ECD of the glutamate-gated chloride channel (GluCl) 
α subunit from C. elegans and the TMD of the α1 GABAAR subunit (receptors more 
closely related in evolution). We reasoned that such a chimera, given that the ECD of 
GluCl is amenable to crystallization (in the presence of Fab fragments), might also be a 
suitable candidate for high-level expression, purification and crystallization of a 
receptor bearing the TMD of the GABAAR α1 subunit.  
As for GLIC-GABAA chimeras, the point of domain fusion was at a site pre-M1 (at a 
conserved arginine residue). Similarly, sequence and structural mismatches at the ECD-
TMD interface were not altered. Alignment and analysis of primary sequence reveal 
greater conservation of residues at the crucial gating interfaces (loop 7, pre-M1, M2-







Figure 3.13 - Functional analysis of GluClcryst 
A. Membrane currents evoked by 2 μM ivermectin in oocytes expressing GluClcryst. B. Following initial 
activation of GluCl channels with 2 μM ivermectin, application of 100 μM glutamate elicits reversible 
currents. C. Inhibition of ivermectin activated current by 0.5 mM picrotoxin and 1μM pregenolone 
sulphate (PS). Dotted line indicates zero current level.  
 
The construct used to generate the new chimera was GluClcryst, which is the glutamate-
gated chloride channel α subunit with truncations at the N-terminus, M3-M4 loop, and 
C-terminus, as used in crystallization studies (Hibbs and Gouaux, 2011; Althoff et al., 
2014). Consistent with published data on GluCl, ivermectin potently activates GluClcryst 
(exhibiting slow current onset and apparently irreversible binding; Fig 3.13 A). 
Following pre-activation with ivermectin, the subsequent application of glutamate 
resulted in further activation of the receptor, in a reversible manner (Fig 3.13 B). As 
previously observed, pre-activated currents induced by ivermectin are blocked by 
picrotoxin. Intriguingly and previously unreported, the inhibitory neurosteroid 
pregnenolone sulphate potently blocked the ivermectin response (Fig 3.13 C). Given 
that current levels return to those comparable with the pre-acitvated state, we might 
deduce that inhibition mediated by PS is non-competitive and does not displace 
ivermectin, therefore acting via a distinct binding site.   
Expression of chimeric GluCl-GABAA α1 receptors yielded robust glutamate-activated 
currents, which were not dependent on prior application of ivermectin (Fig 3.14). 
Indeed application of 2 μM ivermectin alone elicited no response. Glutamate-gated 
responses exhibited currents with a fast onset of response, which decayed in a 
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pronounced manner during prolonged application (Fig 3.14 A). Current offset upon 
wash off of the agonist was also fast. The macroscopic kinetics observed for the 
chimera are distinct to GluClcryst, being more reminiscent of a native α1-containing 
GABAAR and notably to a greater extent than those observed for GLIC-GABAA α1 
chimeras. Glutamate activated the chimera across a range of concentrations, with 
concentration-response relationships yielding an EC50 of 49.7 ± 7.58 μM (Fig 3.14 B & 
C). The observed glutamate sensitivity is not dissimilar to that observed at full-length 
GluClα receptors (EC50 =7 μM in the presence of ivermectin (Etter et al., 1996)). Given 
that GABAARs are normally insensitive to glutamate, we might conclude that the ECD 
of GluCl provides the glutamate binding site (consistent with crystallographic data) and 
that subsequent transduction of the binding response induces chimera channel gating. 
From this and our previous studies it is clear that an evolutionary conservation of 
common structural elements exists at the ECD-TMD interface (of pLGIC), which allows 
for the generation of functional chimeras between two distinct receptors.  
Beyond agonist activation of the chimera, we were curious as to whether the 
pharmacological profile of the chimera and GluClcryst would exhibit distinct properties 
with regards to neurosteroids. As previously alluded to, a putative binding site for the 
inhibitory neurosteroid PS exists at GluClα.  At the primary sequence level, residues 
critical for mediating the effects of potentiating neurosteroids, e.g THDOC, are not 
conserved between GABAAR α-subunits and GluCl (Q241 in α1 is a tryptophan at the 
equivalent position in GluClα). Indeed, application of THDOC (at high nM-low μM 
concentrations effective at GABAARs) is not sufficient to induce a response in GluCl, 
nor does it enhance ivermectin- or ivermectin-glutamate activated currents. This is 
consistent with GluClα lacking a binding site for THDOC. As for the GLIC-GABAAR α1 
chimera, introduction of the TMD of the GABAA α1-subunit with GluCl, is sufficient to 
restore the binding of THDOC, with co-application of THDOC in the presence of an 
~EC20 concentration of glutamate inducing a potentiation of current (Fig 3.14 D). Once 
again, these results are consistent with an intrasubunit binding site for THDOC being 
located within the helical bundle of a single α1 subunit TMD. Furthermore, 
introduction of point mutations known to ablate steroid binding at native GABAARs 






Figure 3.14 - Functional analysis of GluCl-GABAA α1 chimera 
A. Membrane currents showing activation and decay of GluCl-GABAAR α1 chimera (in oocytes) during 
prolonged exposure to glutamate 300 μM. B. Glutamate-concentration response curve for GluCl-
GABAAR α1 chimera. Points are mean ± s.d. n = 4 oocytes C. Example membrane current responses of 
occytes expressing the chimera upon exposure to increasing concentrations of glutamate. D. Example 
current traces of response induced by ~EC20 glutamate and its potentiation by 2μM THDOC in oocytes 
expressing GluCl-GABAAR α1 chimera E. THDOC mediated potentiation is ablated through introduction 
of the Q241L mutation into the GluCl-GABAAR α1 chimera. 
 
3.3. Discussion 
Previous studies have demonstrated that it is possible to generate functional 
prokaryotic-eukaryotic chimeras, which exhibit channel gating mechanisms and TMD 
pharmacological profiles reminiscent of their native receptor counterparts (Duret et 
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al., 2011; Tillman et al., 2014). Whilst this has been shown for chimeras between GLIC-
GlyRα1 and ELIC-nAChR α7, it has not been investigated for receptors incorporating 
GABAAR subunit TMDs. Here we have sought to generate functional chimeric receptors 
between the ECD of GLIC (and later GluCl) and the TMD of GABAAR α1 (and β2) 
subunits. The TMD pharmacological profile of chimeric receptors was investigated to 
determine whether it reflected the TMD of the native receptor subunit. Furthermore, 
to infer whether common channel gating mechanisms are exhibited by chimeric 
receptors, particularly with regards to receptor desensitization, point mutations known 
to confer pronounced desensitizing properties were introduced into the chimeras.  
Ultimately, these functional studies serve as a starting point in the rationale design of a 
chimeric receptor that might be suited to high level-expression, purification and 
atomic resolution structural studies to infer the molecular mechanisms of allosteric 
modulation and channel gating of GABAARs.  
 
3.3.1. Evolutionary conserved assembly and gating mechanism revealed by chimeric 
receptors 
An assumption made in the generation of GLIC-GABAAR α1 chimera (as introduced in 
this study) was that the receptor would form on obligate homomer. GABAAR α1 
subunits are unable to form functional homomeric receptors at the cell surface, 
requiring association with at least a β-subunit for export from the ER (Connolly et al., 
1996; Taylor et al., 1999; 2000). Despite this, a functional chimera between the ECD of 
GABAAR ρ1 and the TMD of GABAAR α1 has been previously reported, suggesting that 
the α1 TMD is capable of forming a homo-pentameric arrangement (Martínez-Torres 
et al., 2000). Similarly, we have observed that the presence of a receptor ECD capable 
of folding and homo-oligomerizing, e.g. GLIC, is sufficient to constrain the TMD of α1 in 
to a functional homopentameric assembly. This result is consistent with extensive 
studies showing that crucial interactions in the ECD (at subunit interfaces) play an 
integral role in determining receptor assembly (Connolly et al., 1996; Taylor et al., 
1999). Moreover, the isolated ECD of GLIC is capable of oligomerizing (independent of 
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the TMD), though loops that would normally form the ECD-TMD interface are largely 
disordered (Nury et al., 2010). In summation, it is not immediately clear as to whether 
the ECD and TMD fold and assemble independently; though the most reasonable 
hypothesis would suggest folding and assembly of TM spanning helices forming the ion 
channel is followed by assembly of the ECD domain in to a pentameric arrangement 
and subsequent trafficking to the cell surface. On this basis, it is apparent that 
interactions at the interface of GABAA α1 ECDs are energetically unfavourable and 
prevent stable homo-oligomerization.  
For all the functional chimeras generated in this study we can draw a number of 
conclusions regarding the structural integrity of the individually incorporated domains 
and the ECD-TMD interface.  
i) The ECD of GLIC is intact and forms the likely site of a proton-sensing site capable of 
transducing a binding signal to the TMD. Whilst the work of Wang et al (2012) 
proposes a role for protonation of H235 in channel activation, in this study replacing 
the TMD of GLIC with that of the GABAAR α1 subunit removes histidine residues in the 
TMD that might act as potential proton-sensors. The chimera is functionally activated 
in response to protons, as was the case in the previously reported GLIC-GlyRα1 
chimera. This would be consistent with the proton-sensing capacity being provided by 
the ECD of GLIC rather than the TMD. Similar conclusions can be drawn for chimeras 
incorporating the ECD of GluCl. The glutamate binding site at GluClα is well established 
through crystallographic studies (Hibbs and Gouaux, 2011); with glutamate binding at 
the classical neurotransmitter binding site capped by loop C. Our results of a 
glutamate-gated response through the channel of a GluCl-GABAAR α1 chimera would 
confirm that the ECD is structurally intact when fused to alternative TMDs.  
We must make more cautious conclusions in the case of the GLIC-GABA β2 chimera 
with regards to channel activation. This is due largely to previous observations 
regarding both proton modulation of GABAAR receptors (mediated by the β(2) subunit) 
and channel gating mechanisms in homomeric β-subunit receptors. For a long time, 
the consensus view has been that GABA could not gate β-subunit homomers, whilst 
allosteric compounds including anaesthetics, pentobarbital and propofol, could induce 
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direct channel gating (Krishek et al., 1996; Wooltorton et al., 1997). Moreover, in the 
case of homomeric β3 receptors, spontaneous activity was reported. It might therefore 
be concluded that the homomeric β-receptor lacks one or both of the elements 
responsible for binding GABA or transduction of a binding signal from the ECD to the 
TMD. From our studies, when compared to the GLIC-GABAAR α1 chimera, proton 
gating of the chimeric receptor incorporating the β2 subunit via a proton-sensor in the 
ECD is not immediately apparent. The presence of a previously reported proton 
modulation site, His267, in M2 of the β2 subunit may in fact be responsible for any 
proton-mediated effects (as observed for the proton-dependent pentobarbital 
response reported in this study; Wilkins et al., 2002). It should be noted however that 
recent crystallographic studies, of a GABAAβ3-homomer, has further confounded views 
of agonist binding and action at β3-homomers (Miller and Aricescu, 2014). Despite 
previous reports suggesting these receptors are insensitive to GABA, an X-ray structure 
reveals binding of a previously unreported agonist benzamidine at the classical 
neurotransmitter-binding site which is capable of gating the receptor (and also 
observed in electrophysiological recordings; Miller and Aricescu, 2014). This would 
suggest β3 homomers are presumably capable of binding agonist and gating in the 
“normal manner” established across the pLGIC superfamily.     
ii) The ECD-TMD interface forms a structure that is part of the signal pathway initiaing 
receptor gating. As initially proposed by Duret et al, following studies of the GLIC-
GlyRα1, the work presented here is in accordance with the principle that underlying 
gating at the ECD-TMD interface is the interaction of surfaces with complementary 
shapes (Duret et al., 2011). This concept is supported by the array of functional pLGIC 
chimeras previously reported; GLIC-GlyRα1, ELIC-nAChR, α7 nAChR-5HT3 and the GLIC-
GABAAR α1 and GluCl-GABAAR α1 chimeras reported in this study (Eiselé et al., 1993; 
Duret et al., 2011; Tillman et al., 2014). The extent to which elements at the ECD-TMD 
have been mutated (either for correct folding or improved receptor kinetics) varies in 
each of these studies. In the grand scheme though, minimal modifications are required 
to generate a functional receptor. The altered (often unfavourable) receptor kinetics 
observed for many of these chimeric receptors likely represent (at an atomic level) the 
disruption of specific and complex intra- and intersubunit interactions at the coupling 
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interface (contributed by loops2 and 7, pre-M1, M2-M3 linker, and post-M4), which 
are normally responsible in setting the efficacy of receptor gating at native pLGICs 
(Miller and Smart, 2010; Smart and Paoletti, 2012). This work goes some way to 
confirm these observations, and ultimately highlights the evolutionary conservation of 
a common gating mechanism.    
iii) This study provides strong evidence that the TMD of GABAAR α1 forms an intact ion 
channel. Though single channel conductance and ionic selectivity have not been 
determined, it is likely that the TMD forms an intact channel (with I-V relationships 
revealing a marked outward rectification of proton-elicited currents, reminiscent to 
the I-V relationship observed for GABA-gated currents through α1β2 receptors). 
Furthermore, pharmacological profiling revealed that picrotoxin blocked the chimera, 
in a manner consistent with it binding deep within the pore of the channel (Bali and 
Akabas, 2007; Hibbs and Gouaux, 2011). Whilst this does not necessarily confirm an 
expected organisation of individual TMDs as a four alpha-helical bundle, the 
potentiating effect of the endogenous THDOC at the chimera provides the strongest 
evidence of structural intactness in the TMD. An established binding model for 
potentiating neurosteroids shows the steroid molecule to be coordinated within an 
aqueous intrasubunit cavity, spanning between a glutamine (Q241) in the lower half of 
M1 and residues in the upper half of M4 (asparagine and tyrosine residues of the α 
subunit; Hosie et al., 2006). This cavity, and consequently steroid response, would 
presumably only be retained within a structurally intact TMD. The high-affinity steroid 
response of the chimera, contributed by the α1 TMD would provide further support to 
this model of steroid binding at GABAARs.  
 
3.3.2. A common mechanism for receptor desensitization 
Desensitization of receptors during prolonged agonist exposure is a common 
phenomenon across the pLGIC superfamily, and plays a critical role in shaping receptor 
response and, at the wider level, neural network activity. Single channel recordings of 
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nAChRs reveal that receptors transition from an active (open channel state) to an 
inactive (closed channel) through two distinct phases of desensitization exhibiting fast 
and slow kinetics (Sakmann et al., 1980).  Whilst mutagenesis studies (Bouzat et al., 
2008; Wang and Lynch, 2011) and EPR spectroscopy studies (of solubilized and 
reconstituted GLIC; Dellisanti et al., 2013) have implicated the role of structures within 
the ECD and at the ECD-TMD interface in determining receptor desensitization, recent 
structure-function studies of native GABAARs suggest that desensitization is 
characterised by constriction of the ion channel by a physical “desensitization gate”. 
Residues at the interface of the lower-halves of M2 and M3 are likely to undergo 
rearrangement in forming this structure (Gielen et al., 2015). Recent crystallographic 
and NMR studies have added further weight to this theory (Miller and Aricescu, 2014; 
Kinde et al., 2015).  
Using our chimeric receptor as a model for GABAAR channel gating, we sought to 
determine whether they exhibit a common mechanism for desensitization. Consistent 
with previous studies (Gielen et al., 2015), a number of systematic mutations of 4’ 
glycine and -3’ valine in M2 (of the α1 TMD) had a pronounced effect on the 
desensitization of the chimera. It should be noted these mutations were introduced in 
to receptors bearing truncations of the M3-M4 loop, which have been shown in this 
study and in the work of Papke and Grosman on GlyRα1, to affect the kinetics of entry 
into desensitized states (potentially through post-translational modulation; Papke and 
Grosman, 2014). Given that both these studies were carried out on receptors lacking 
the large M3-M4 loop would suggest that this domain does not have a direct effect on 
desensitization. From this we might conclude that our studies of chimeric receptors 
exhibiting desensitization mutations, but lacking the large ICD, are a representative 
model of a receptor in a desensitized state at the level of the channel.  
An intriguing finding of this study was the apparent loss of picrotoxin sensitivity on a 
chimeric receptor bearing a profound desensitization mutation (conferring loss of 
function), valine 251 to phenylalanine (in M2 of α1). It was possible to rescue function 
of this receptor through introduction of a well-characterised gain-of-function mutation 
at the 9’ position of M2, leucine 9’ serine (Chang and Weiss, 1999). Whilst (at the 
macroscopic level) spontaneous currents of L9’S mutant alone were sensitive to block 
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by picrotoxin, double L9’S/V251F mutants exhibited smaller spontaneous activity and 
were less sensitive to picrotoxin. Given that a desensitization gate is thought to 
physically overlap the picrotoxin-binding site (Gielen et al., 2015), it might be deduced 
that a receptor allosterically stabilized in a desensitized state (i.e. where the pore is 
constricted at the intracellular end) would occlude the binding of picrotoxin and thus 
explain the observations made in this study. This theory is complicated firstly by the 
observation of spontaneous activity, and therefore ion flux through a channel 
proposed to be allosterically stabilized in a desensitized (and thus non-conducting) 
state. Secondly, what are the resultant effects of introducing a second mutation in the 
M2 helix (at the level of the “activation” gate) on the pore profile and orientation of 
pore-lining residues, particularly near the desensitization gate?   
We might be able to make a rationale case that the double mutant has no, or minimal 
effect on pore residues and overall profile in the active state. This is based upon recent 
crystallographic studies of gating mutants in GLIC (which manifest themselves as loss-
of-function in electrophysiological experiments). Whilst single mutants were 
crystallized in the “locally-closed” conformation, Gonzalez-Gutierrez and Grosman 
were able to solve the structure of a double mutant (bearing the equivalent 9’ rescue 
mutant described here) at low pH (Gonzalez-Gutierrez et al., 2013). The structure of 
this receptor was identical to that of the WT open- channel conformation and thus 
presumably receptors respond to low pH and gate in a normal manner. We might 
therefore conclude that in our electrophysiological experiments, V251F/L9’S receptors 
are expressed in a partially desensitized (low-conductance) state under resting 
conditions, but are able to gate in response to agonist (high proton) as normal. While 
these data go some way to confirm that the non-functional V251F receptor is fixed in a 
desensitized state, high-resolution structural studies will ultimately be needed to 
provide greater detail.  
3.3.3. Pregnenolone sulphate inhibition is characterised by increased desensitization 
When compared to the potentiating neurosteroids, the role(s) of inhibitory 
endogenous steroids in the CNS and their mechanism of action at GABAARs is largely 
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unknown. However, a member of this steroidal subclass, pregenolone sulphate, can 
also modulate other members of the pLGIC superfamily, iGluRs, including NMDARs as 
well as members of the Transient Receptor Potential (TRP) channel family (Harteneck, 
2013). Never the less, given the affinity with which these steroids apparently bind and 
impart their effect at GABAARs it remains a relevant goal to identify the determinants 
of an inhibitory steroid-binding site. This would shed light on the role of these 
compounds in GABAergic inhibition at the neuronal level. 
Intriguingly, the presence of the TMD of the α1 GABAAR was sufficient to dramatically 
enhance chimeric receptor inhibition by PS compared to the variable, low-sensitivity 
effect observed at WT GLIC. Furthermore this inhibition mimicked the response 
observed at native GABAARs, with an apparent increase in the rate of entry in to the 
desensitized state (Akk et al., 2001; Eisenman et al., 2003). Given the comparatively 
slow onset kinetics of the chimera, in comparison to native GABAARs and the 
complicated kinetic profile of PS block (Seljeset et al., 2015), the nature of this 
inhibitory response cannot be fully deduced. 
It might seem reasonable to assume that a binding site for PS has been incorporated in 
to the chimera through the addition of the α1 TMD. However, with no consensus view 
regarding a binding model of PS at GABAARs, this does not discount GLIC retaining a 
low-affinity binding site that is merely masked by the slow (non-desensitizing) 
response of this receptor when compared to both chimeric and native GABAARs. 
Furthermore, previous studies have identified a role for the 2’ residue in the M2 of α1 
(V256) in the signal transduction of a PS binding response (Wang et al., 2006; 2007). 
Mutation to a polar serine residue is sufficient to reduce PS sensitivity 30-fold at 
α1β2γ2 GABAARs (Wang et al., 2006). Given that GLIC exhibits a similar polar residue, 
threonine, at this 2’ position might simply indicate that the lack of a transduction 
element at this position is responsible for the weak PS response.  
However, we have observed for the first time high-affinity PS binding at GluCl, which 
further confounds the picture. PS was able to inhibit an ivermectin activated channel 
response. Given that GluCl, like GLIC, exhibits a polar (threonine) residue at 2’ in the 
M2 lining helix, it is difficult to deduce whether a mechanism of PS binding and/or 
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transduction at pLGICs does indeed involve a common role for the 2’ M2 residue. The 
nature of PS inhibition not only at GABAARs, but also other members of the pLGIC 
superfamily, is a complex one, and may not even involve direct interaction with the 
protein (potentially acting through modulation of the surrounding lipid environment). 
Ultimately high-resolution structural studies are again likely to provide the clearest 
evidence regarding the determinants of a PS binding site. Later in this study we 
describe attempts to co-crystallize the bacterial homolog, ELIC, in the presence of PS in 
order to identify its binding site (Chapter 6).                        
 
3.3.4. Pentobarbital acts differentially at structurally distinct chimeric receptors 
We have shown in this study that the inhibitory and potentiating effects of the 
barbiturate, pentobarbital, can be separated by the presence of either an α1 or β2 
TMD (in a “GLIC based” chimera). At native GABAARs pentobarbital exhibits 
potentiating, activating and inhibitory effects. Previous studies have suggested a role 
for residues in M1, M2 and M3 of β-subunits in forming the binding sites for 
pentobarbital. Indeed one study observed that introduction of M3 of β2 subunit in to 
ρ1 GABAARs, was sufficient to impart sensitivity to pentobarbital (Amin, 1999). In line 
with these observations, we show that the GABAAR β2 TMD is able to impart binding of 
pentobarbital necessary for the potentiating effects of this anaesthetic on a chimeric 
receptor. In contrast, the TMD of the α1 appears to play no role in the potentiating 
(and presumably activating) effects of pentobarbital. This conclusion is drawn from the 
assumption that binding is mediated by individual subunits within the heteromeric 
arrangement observed in native GABAARs (which we cannot easily study in our 
chimeric receptor model). This however is unlikely to be the case for receptor 
heteromers, with photolabeling studies of anesthetic barbiturate analogs reveal 
binding at α-β and β-γ subunit interfaces (Chiara et al., 2013; Jayakar et al., 2015). 
Notably both the β2 and α1 TMD chimeras retain low-affinity pentobarbital channel-
blocking sites. A site responsible for the antagonistic effects of pentobarbital has not 
yet been identified, however previous single channel studies argue for both a single 
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low-affinity channel-blocking site as well as two or more sites for potentiation and 
activation (Rho et al., 1996; Akk and Steinbach, 2000).   
The bacterial homolog GLIC appeared to retain an inhibitory site for pentobarbital. This 
result is consistent with the inhibitory effect observed for other normally positive 
modulatory anesthetics, including propofol, desflurane and bromoform, at GLIC and 
nAChRs (Violet et al., 1997; Weng et al., 2010; Sauguet et al., 2013a). In the case of the 
former, co-crystallographic studies have revealed a number of GA binding sites at the 
level of the TMD (Sauguet et al., 2014a). Moreover, screens of a range of GABAAR 
modulators at the bacterial homolog ELIC revealed that PB application at 1 mM had no 
effect on this bacterial channel (Spurny et al., 2012). The inhibitory response we 
observed in this study therefore appears to be specific (with an IC50 = ~110 μM), 
comparable to concentrations of PB known to induce a response at GABAARs in vivo. 
We have addressed this observation in mutagenesis and co-crystallization studies to 
further assess the mechanism of action of pentobarbital at GLIC (Chapter 5). 
 
3.3.5. GLIC (and GluCl)-GABAAR chimeras are strong candidates for expression and 
purification trials 
Crucially, through these functional studies we have shown the capacity to generate 
chimeras between the ECD of GLIC or GluCl and the TMD of GABAAR subunits 
(principally that of α1). These receptors retain the important TMD pharmacological 
and functional properties, such as desensitization, that is expected at native 
heteropentameric GABAA receptors. More over, truncation of this receptor in the 
region of the large M3-M4 loop does not ablate receptor function. This is likely to be 
important for structural studies, and validates the receptor chimeras introduced in this 
chapter as strong candidates for expression and purification trials (as addressed in 





The ECDs of GLIC and GluCl are capable of acting as surrogate hosts for GABAAR TMDs. 
Receptor truncations in the M3-M4 loop are likely to prove essential for high-level 
expression, purification and crystallization of receptors and do not alter chimeric 
receptor function. 
GLIC-GABAAR α1 chimeras exhibit a mechanism of desensitization similar to that for 
native GABAARs. 
GLIC and GluCl chimeras containing the α1 TMD are functionally gated by protons and 
glutamate respectively, and exhibit TMD pharmacology (with respect to neurosteroids) 
that is typical of α1-containing GABAARs.  
The differential effects of pentobarbital are mediated by residues contributed by 
different GABAARs TMDs.  







Chapter 4: Expression, purification and crystallization of chimeric GABAA receptors 
4.1. Introduction 
In this chapter, the amenability of chimeric GLIC-GABA receptors to high-level 
expression and purification was assessed in two recombinant expression systems; 
bacteria and insect cells (the latter under baculoviral infection). This step is a critical 
one on the path to receptor crystallization for high-resolution structural studies.    
The low number of membrane protein structures deposited in the PDB epitomizes the 
challenge of membrane protein structural biology. Whilst membrane proteins 
constitute at least 30% of the genome, and an even greater proportion of known drug 
targets, they comprise less than 3% of the PDB (~2,450 of 111,000 structures in August 
2015). This “poor showing” when compared to soluble proteins is a reflection of the 
difficulties that arise at each stage in the path from project conception through to 
successful crystallization and structure determination (Carpenter et al., 2008). 
Essential experimental techniques to be addressed include, but are not limited to; 
choosing an appropriate expression system, identifying stabilizing detergents, 
purification strategy, crystallization method, diffraction data collection strategy and 
model building. Whilst general protocols exist (Newby et al., 2009), and serve as a 
strong starting point, each membrane protein is different and critically dependent on 
it’s preferred lipidic environment for stable expression. Subsequently the rules for 
purification of a protein are often non-transferable, even between similar proteins, 
and thus reliant on substantial experimental optimization. Unsurprisingly, significant 
steps have been taken to allow experimental variables to be rationalized in a high 
throughput manner both at the level of pre-crystallization screening (e.g. Fluorescence 
Size Exclusion Chromatography (FSEC; Kawate and Gouaux, 2006; Hattori et al., 2012)) 




Members of the pLGIC family have proved particularly challenging to study at high-
resolution, and only in the past few years have a number of pioneering studies allowed 
for a gradual expansion of our understanding of how these receptors function at the 
atomic level (reviewed by Cecchini and Changeux, 2014). High-resolution studies of 
full-length receptors are often hindered by the presence of a large ICD of 70-200 
residues, observed across metazoan receptors (Smart and Paoletti, 2012; Stokes et al., 
2015). This domain is typically excluded during construct design and functional 
screening, and thus will likely prove elusive to crystallographic structure determination 
(in the context of the full length receptor). Recent structural studies of the mouse 
5HT3R do however prove an exception to the rule (Hassaine et al., 2014) Never-the-
less, the remaining domains, the ECD and TMD, are the site of action of orthosteric 
ligands and allosteric modulators (as introduced in Chapter 1), and the coupling 
interface between domains critical in mediating receptor activation and also the site of 
pathological mutations (Smart and Paoletti, 2012). Thus the wealth of knowledge that 
can be gained from studying these truncated receptors is considerable.  
The modular nature of pLGICs, as emphasized by our functional studies in Chapter 3, 
highlights a new approach to structural studies. By generating domain chimeras with 
receptors previously expressed to high yield and crystallized, we can begin to use 
studies of individual eukaryotic domains, e.g. GABAAR TMD, to advance our 
understanding of allosteric modulation and channel gating. This approach circumvents 
some of the inherent problems of studying full-length eukaryotic receptors. For 
example; post-translational modification (e.g. glycosylation) of the ECD acts in both 
receptor assembly and activity regulation (Dellisanti et al., 2007; Miller and Aricescu, 
2014), but introduces heterogeneity at the level of purified receptors that prevents 
energetically-favoured crystal contacts from  forming. Chimeric receptors bearing the 
ECD of prokaryotic homologs will not exhibit such sites, and presumably be more 
amenable to purification to homogeneity and crystallization. Whilst we might predict 
that the exposed regions of pLGICs are most likely to form points of contact in the 
crystal form, identifying specific atomic interactions is more difficult. Exploring the use 
of chimeras with previously crystallized domains might allow for rationale prediction of 
crystal packing contacts and increased likelihood of generating well-ordered crystals.  
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The principal aim of this study was to use crystallographic approaches for structure 
determination of chimeric receptors. As introduced previously, this is rate limited by 
the ability to purify large quantities of protein and generate strongly diffracting 
crystals. Recent advances in electron cryo-microscopy (cryo-EM; discussed briefly in 
Appendix Primer 1) reveal a rival method for structure determination, obviating some 
of the challenges inherent to X-ray crystallography (Cheng, 2015; Cheng et al., 2015). In 
seminal studies, cryo-EM was used in determining the structures of TRP channel 
members (TRPV1 and TRPA1; Liao et al., 2013; Cao et al., 2013b; Paulsen et al., 2015). 
While significant advances in sample preparation, electron detection and imaging 
allowed (near) atomic resolution structures to be generated, TRP channels at 300-400 
kDA were considered to be at the lower molecular size limit for structure 
determination by cryo-EM, even though the inherent four-fold symmetry of TRP 
channels assisted model-building and overall resolution. However the rapid and 
continual development of direct electron detectors and image processing software is 
likely to make cryo-EM accessible to the study of smaller membrane proteins, including 
pLGICS (typically 150-300 kDa in size). We might therefore reason that purified 
chimeric receptor preparations could provide the starting material for multiple 
structural techniques (e.g. X-ray crystallography and cryo-EM).  
 
4.2. Results 
4.2.1. Identifying an expression system capable of generating appreciable yield of 
chimeric receptor: Bacterial expression 
Using the GLIC-GABAAR α1 chimera introduced in Chapter 3, our first challenge was to 
identify a recombinant expression system capable of generating stable receptors in 
sufficient quantity for downstream processing. The prokaryotic receptor GLIC is 
strongly expressed in bacterial cells as an N-terminal fusion construct with Maltose-
Binding Protein (MBP) (Fig 4.1 A). Therefore, we reasoned that a chimera exhibiting 
the ECD of GLIC and the TMD of the GABAAR α1 subunit would be similarly expressed 
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in E. coli, assembled as a pentamer and targeted to the periplasmic membrane when 





Figure 4.1 - Bacterial expression of MBP-GLIC and chimeric MBP-GLIC-GABAAR β2 
A. Workflow for bacterial expression of MBP-GLIC (and chimera), receptor purification and analysis. B. 
Representative size-exclusion profile of MBP-GLIC following solubilization in DDM and purification on 
amylose resin. Peaks correspond to large aggregates (in the column void) (1), pentameric MBP-GLIC (2) 
and endogenous porin protein (3). Coomassie-blue stain and western blot analysis of peak fractions is 
shown on the right, revealing migration of MBP-GLIC as a band of ~70 kDa. C. Representative size-
exclusion profile of MBP-GLIC-GABA β2 following solubilization in DDM and purification on amylose 
resin. Peaks correspond to void (1), aggregate of MBP-GLIC (2) and endogenous porin protein (3). 
Coomassie-blue stain and western blot analysis of peak fractions are shown right, revealing migration of 




Consistent with previous studies, we also found that the fusion protein of MBP-GLIC is 
well expressed in the C43 strain of E. coli (Bocquet et al., 2007; 2009). GLIC receptors 
form a stable pentamer (as well as higher order aggregates) when solubilized in n-
Dodecyl-β-D-maltopyranoside (DDM) and purified on an amylose resin. This is 
apparent from size exclusion chromatography (SEC) where prominent peaks 
corresponding to larger aggregates (which elute in the column void volume, ~8 ml) and 
pentameric MBP-GLIC (~13ml elution volume) are observed (Fig 4.1 B). SDS PAGE and 
coomassie blue-stain (and western blot) confirm that these peaks correspond to MBP-
GLIC, with material from peaks migrating as a single, homogenous band of ~70 kDa. 
The third peak component observed in SEC experiments corresponds to an 
endogenously expressed porin-family member, which binds with high affinity to the 
amylose resin. At a volume of ~15 ml this elutes in a clearly defined, symmetrical peak, 
which can be separated from MBP-GLIC (as assessed by SDS-PAGE analysis of peak 
fractions; Fig 4.1 B). Later in this study (Chapter 5) we show how purified MBP-GLIC 
can be used in further purification strategies, yielding cleaved WT-GLIC (for receptor 
crystallization trials).  
We speculated that GLIC-GABAAR chimeras might be similarly expressed in E. coli (as a 
fusion protein with MBP). However, subsequent attempts to express chimeric MBP-
GLIC-GABAA α1 chimeras (lacking the large M3-M4 loop) proved unsuccessful. During 
screening we noticed poor bacterial cell growth following induction of expression, 
which would suggest that chimera constructs showed increased cell toxicity when 
compared to wild MBP-GLIC. Possibly this was due to recombinantly expressed 
proteins being misfolded and forming inclusion body aggregates (though this was not 
assessed further).This indicated that bacteria are unlikely to be suitable for production 
of chimeras containing eukaryotic elements, such as the α1 subunit TMD, which 
probably require a more complex membranous environment for stable expression. 
Indeed the composition of a eukaryotic membrane differs profoundly from that of the 
bacterial inner (and outer) membranes, crucially lacking lipids including cholesterol 
known to interact with and stabilize eukaryotic pLGICs (Hénin et al., 2014; Barrantes, 
2015). Further receptor mutations may have improved the expression of the GLIC-
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GABAAR α1 chimera in bacteria. However, the maximum yield achievable was unlikely 
to be conducive for crystallization trials. 
Our only minor success in bacterial expression screens was for a truncated GLIC-
GABAAR β2 chimera (introduced in chapter 3). This was expressed as a fusion protein 
with MBP and lacking the large M3-M4 loop. Affinity purification on amylose resin, 
following DDM solubilization of isolated membranes, revealed a faint band of the 
expected mass for monomeric receptor subunit when assessed by SDS PAGE and 
coomassie stain (and confirmed by western blot analysis with an α-MBP antibody) (Fig 
4.1 C). The receptor yield is considerably lower than that of WT GLIC. A lower mass 
band (exhibiting immuno-reactivity) would suggest that a C-terminally degraded 
species is also purified. Size exclusion chromatography (of affinity-purified proteins) 
shows a poorly defined peak spanning a significant volume of the column. Analysis of 
material from this peak suggests that it corresponds to the chimeric receptor (Fig 4.1 
C). In contrast to WT-MBP-GLIC, the profile of this peak is unlikely to correspond to a 
pentameric form of the protein and most likely represents receptor in an aggregated 
or high-order oligomeric state. At this stage we did not optimize the expression and 
purification of chimeric receptors from E. coli. 
4.2.2. Identifying an expression system capable of generating appreciable yield of 
chimeric receptor: Baculovirus-insect cell expression 
In order to improve expression and purification of our chimeric receptor we next 
considered use of a higher eukaryotic cell line for protein production. Insect cells, and 
more specifically the baculovirus-insect cell expression system, has been successfully 
used for the production of eukaryotic ion channels for structural studies, including the 
rat AMPAR GluA2, C. Elegans glutamate-gated chloride channel (GluClcryst) and 
zebrafish P2X4 receptors (Sobolevsky et al., 2009; Hibbs and Gouaux, 2011; Hattori and 
Gouaux, 2012). Given that insect cells, unlike stably expressing mammalian cell lines, 
e.g. HEK293, can be grown easily in suspension with no-atmospheric control, 
establishing an insect cell line for protein expression is not as costly or time-
consuming. We therefore chose to test expression and purification of chimeric 
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receptors by baculoviral infection of Spodoptera frugiperda Sf9 insect cells, using 
established protocols (Trowitzsch et al., 2010) (Fig 4.2).  
Initial expression studies with regards to construct design were guided by functional 
experiments (as detailed in Chapter 3) and focused on GLIC-GABAAR α1 chimeras. Our 
initial rationale for construct design and purification was also guided by the existing 
data for crystallized pLGICs (GLIC, ELIC and GluCLcryst) and the wider field of eukaryotic 




Figure 4.2 - Workflow for pre-crystallization screening of chimera constructs by 
baculovirus-insect cell expression system 
Receptor chimera candidates identified in functional experiments (Chapter 3) were subcloned in to 
vectors for insect cell expression. Stage 1: PCR reaction analysis by DNA gel electrophoresis was used to 
confirm gene transposition in to a baculovirus shuttle vector (bacmid). Stage 2: Purified bacmid DNA 
was used in transfection and recombinant virus generation. Subsequent rounds of viral amplification 
were used to increase the viral titre. Protein expression and viral titrewasthen assessed by SDS PAGE 
and coomassie blue-stain and/or western blotting. Stage 3: Expression of stable pentameric receptors 
was assessed in scale-up experiments prior to large-scale expression, purification and crystallization. 
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As previously discussed, the large intracellular loop linking M3 and M4, forming the 
ICD of eukaryotic pLGICs, is likely to hinder high-level receptor expression, purification 
and subsequent crystallization. In Chapter 3 we developed two M3-M4 truncated 
variants of the chimera, defined as: M3-M4tripeptide and M3-M4heptapeptide. Both exhibited 
similar proton gating properties and TMD pharmacology for a GLIC-GABAAR α1 
chimera. Here we focused on constructs bearing the M3-M4tripeptide linker for high-level 
expression. For clarity we have refined this construct as GLIC-GABAAR α1
∆ICD (where ∆ICD 
represents truncation of the M3-M4 loop by the “tripeptide” linker).The decision to 
focus on this chimera was principally due to its previous successful incorporation into a 
homologous receptor, GluClcryst, for expression in Sf9 cells and successful crystallization 
(Hibbs and Gouaux, 2011; Althoff et al., 2014). Additionally we chose this construct on 
the basis that a shorter linker (replacing the ICD) might impart greater structural 
rigidity on the TMD and thus facilitate crystallization. In line with recent structural 
developments in the pLGIC field, occurring during the time-course of this study 
(namely structures for the GABAA β3 homomer and GLIC-GlyR α1, LiLy; Miller and 
Aricescu, 2014; Moraga-Cid et al., 2015), we have begun to assess in greater depth the 
effects of the M3-M4 linker mutation on receptor expression and purification. 
Interestingly both of the aforementioned studies use the heptapeptide linker sequence 
from GLIC.  
In addition to truncating the M3-M4 loop (∆ICD), preliminary purification experiments 
were of a construct bearing a second truncation, of 13 amino acids at the C-terminus 
(post-M4) of the receptor (Fig 4.4 A); we define this additional truncation as ‘∆Ct’. As 
before, this was guided by the requirement of a similar truncation for expression, 
purification and crystallization of GluClcryst. For purification of chimeric receptors by 
immobilized-metal affinity chromatography, a C-terminal octa-Histidine tag was 
introduced using standard molecular biology techniques. This chimera was still 
activated by protons and functionally indistinguishable from a receptor that retained 






Figure 4.3 - PCR and DNA gel electrophoretic analysis confirms transposition of 
receptor chimera genes in to bacmid DNA. 
DNA gel electrophoresis of PCR products amplified from recombinant bacmids containing the indicated 
receptor genes. PCRs were carried out with either gene specific primers (e.g. annealing at a site located 
in the nucleotide sequence of the GLIC ECD) in combination with M13 F/R primers (as described in 
Materials and Methods), yielding fragments of ~1.2 or ~2.5 kilobases (kb), or M13 F and R primers. For 
latter primer combinations a PCR product of 2.3 kb + size of insert was expected for successful 
transposition. Chimeric receptors containing the tripeptide M3-M4 linker and His-tag are defined as 
GLIC-GABAAR α1
∆ICD
His and with the additional C-terminal truncation as GLIC-GABAAR α1
∆ICD ∆Ct
His. 
GluClcryst is the construct used in previously published crystallization studies (Hibbs and Gouaux, 2011). 
 
Following design and generation, the receptor chimera geneswere integrated into the 
baculovirus (AcMNPV) genome and propogated in E. coli. PCR analysis of “bacmid 
DNA” was used for analysis of successful transposition. Using primers annealing at sites 
unique to the gene-of-interest (i.e.chimeric receptors) we were able to confirm 
successful incorporation of our receptors into the baculovirus genome in preparation 




4.2.3. Determination of expression levels of chimera in virally transduced insect cells 
In preliminary experiments, the expression of the chimeric receptor containing the 
M3-M4 tripeptide linker, C-terminal truncation (of 13 residues) and C-terminal octa-
Histidine tag, GLIC-GABAAR α1
∆ICDΔCtHis, was assessed in whole insect cell extracts 
following transfection; first round of virus amplification (infection with P1virus and 
generation of P2virus); and after a test expression using high titre virus(P2virus). SDS 
PAGE (under reducing conditions) and western blot analysis against the receptor His-
tag was carried out (Fig 4.4). A band of ~38 kDa corresponding to the chimeric receptor 
was observed at all stages of virus generation/amplification. As might be expected, 
signal intensity increased progressively from cells taken following the initial virus 
generation (P1virus) through to expression with high titer virus (P2virus Test Exp) (Fig 4.4 
B). Using a high-titer P2virus we next determined the time-course of receptor expression 
(again by western blotting of crude cell extracts). Western blotting allowed the 
detection of nanogram amounts of protein and thus enabled protein expression to be 
assessed from small amounts of starting material (typical biomass from ~1 x 106 cells). 
Receptor expression was only apparent after 28 hrs and reached an apparent plateau 
in expression levels between 44 and 72 hrs (Fig 4.4 C). Initial screening of expression in 
insect cell shows appreciable production of the chimeric receptor, which contrasted 
with our expression studies in E. coli.  
Using P2virus, we next carried out experiments to determine the efficiency of receptor 
extraction (following detergent solubilization of membranes) and purification (Fig 4.4 
D & E). The membrane fraction was isolated, and proteins extracted using DDM and 
His-tagged chimeras then purified by Immobilized Metal Affinity Chromatography 
(IMAC) using a Co2+ resin. Coomassie blue-stain of SDS PAGE gels of material from 
elution fractions from IMAC experiments revealed a prominent band of ~38 kDa, 
presumably corresponding to our His-tagged chimera. Without further purification 





Figure 4.4 - Preliminary screening of GLIC-GABAAR α1
∆IC D∆CtHis chimera: viral 
amplification, protein expression and purification 
A. Schematic representation of receptor construct; ECD of GLIC (blue) and TMD of GABAA α1 (red). M3-
M4 loop is truncated (∆ICD) and replaced by tripeptide linker (
∆ICD
; linker sequence and insertion site 
shown), C-terminus truncation of 13 residues (
∆Ct
; asterisk) and octa-histidine tag (8x His; for affinity 
purification). B. Western blot analysis with α-His antibody shows chimera expression during P1virus and 
P2virus generation. C. Time-course analysis of protein expression (using P2virus) reveals plateau peak 
between 44 and 72 hrs.  D. and E. Protein-expression (using P2virus), solubilization and affinity 
purification using Co
2+
resin, followed by SDS PAGE and coomassie blue stain reveals a band of the 
expected size for reduced-monomeric chimera receptor subunit. Loading increasing amounts reveals 
affinity purified-protein to be relatively pure. Band (shown by arrowhead was excised) for mass 
spectrometry (MS) and peptide-mapping analysis. F. Colour map of the 56 peptide fragments (on 




To confirm that the major band (of ~38 kDa) was not a contaminant, we excised gel 
bands for tryptic-digest of proteins and mass spectrometric analysis of peptide 
fragments. Mapping of 56 peptide fragments was sufficient to give 64.6% primary 
sequence coverage (Fig 4.4 F), and provide convincing evidence that the chimera is the 
major species purified on Co2+resin. Though this was encouraging, further purification 
of affinity-purified material on a size-exclusion column revealed that this material does 
not exist in a single homogenous state. Presumably the receptor is unstable as a 
pentamer in DDM-micelles. 
Whist we cannot discount that alternative detergents are capable of stabilizing this 
truncated variant of the GLIC-GABAAR α1 chimera, we were curious as to whether 
exclusion of the C-terminal residues was responsible for destabilizing the chimera in 
detergent micelles (Fig 4.5 A). Furthermore, we reasoned that by re-introducing the 13 
post-M4 residues, access to the preceding octa-Histidine tag in affinity 
chromatography steps would be improved, potentially increasing receptor recovery.   
SDS PAGE-coomassie stain and western blot analysis of crude extracts from virally-
infected cells revealed that a receptor including the full C-terminal sequence (GLIC-
GABAAR α1
∆ICDHis) was expressed at equivalent levels to that bearing the C-terminal 
truncation (ΔCt). As expected, this receptor migrated as a band of marginally greater 
mass, ~39 kDa (Fig 4.5 B). Using biomass from increased culture volume as our starting 
material, cell membranes were isolated and detergent solubilized with DDM. Following 
affinity-purification to recover His-tagged chimera, size-exclusion chromatography was 
used to further purify and assess the relative homogeneity of the sample (Fig 4.5 D). 
When loaded on to a Superose 6 10/300 column, affinity purified material elutes as 
two major species. Large aggregates eluted in the void volume (~8 ml) of the column, 
whilst a second broad peak was observed, bearing a shoulder at ~15 ml (previously not 
observed for the ΔCt construct). We reasoned that the latter shoulder corresponds to 
the expected elution volume of the pentameric form of our protein (Fig 4.5 C). Indeed, 
when material from peak fractions was separated by SDS PAGE and stained, a band of 
expected mass for the chimera was observed, and was even more prominent in 
material taken from the fraction corresponding to an elution volume of 15 ml (Fig 4.5 
D). Given that the shoulder is not the major species it is difficult to draw firm 
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conclusions regarding the oligomeric state of our protein in detergent-micelles. We 
might speculate that it is principally expressed as an unstable pentamer which is in 
dynamic-equilibrium with higher-order oligomers. On this basis the latter state is 
favoured and the pentamer is poorly resolved by SEC.  
 
Figure 4.5 - Preliminary screening of GLIC-GABAAR α1
∆ICDHis protein expression and 
purification 
A. Schematic representation of receptor construct; Receptor as in Fig 4.4A however the C-terminus of is 
no longer truncated (asterisk) B. Coomassie blue-stained SDS PAGE andwestern blot analysis with α-His 
antibody shows chimera expression level is unaltered by inclusion of 13 residues at the C-terminus 
(post-M4). Asterisks indicate band corresponding to chimera. Soluble MBP-His was a positive control (in 
α-His blots). C. SEC profileof DDM-solubilized chimera (blue trace) following purification on Co
2+
 resin. 
Indicated peaks correspond to void volume and a shoulder at elution volume of ~15 ml likely to be 
pentameric protein. A sharp symmetrical peak for a pentameric receptor, GluClcryst in DDM (overlay 
green trace) is observed at ~15 ml elution volume. D.  Coomassie blue-stained SDS PAGE analysis of 
affinity-purified receptor (IMAC Eln) and SEC fractions. Prominent band of ~38 kDa clear during affinity 
purification and from SEC fractions. Notably a second lower mass band also present (asterisks) 
throughout, potentially contributed by degraded receptor subunit.  
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To validate this important result, before being used as a starting point from which to 
optimize detergent stabilization of this receptor construct, we first needed to confirm 
that the observed shoulder was likely to represent the pentameric form of the 
chimera. One might expect a homologous pLGIC protein (of similar structure and 
mass), in complex with DDM, to exhibit an elution profile to be expected for the 
pentameric chimera. We therefore expressed and purified GluClcryst in DDM using 
previously reported methods (Hibbs and Gouaux, 2011). Affinity-purified proteins 
eluted in two peaks (when loaded on to a gel filtration column). Large-aggregates elute 
in the column void volume, whilst the major species exists as a well defined 
symmetrical peak, with a retention volume of ~15 ml (Fig 4.5 C). SDS PAGE (under 
reducing-conditions) and coomassie stain revealed that material from this peak 
migrates as single band of ~35 kDa (likely corresponding to the monomeric-GluClcryst 
subunit). Given that GluClcryst is known to exist as a pentamer in DDM, we used this 
result as a benchmark for assessing the generation of stable detergent-solubilized 
pentameric chimeras. 
 
4.2.4. Small-scale detergent-screening of “wild type” GLIC-GABA α1 chimeras 
Having identified a receptor-construct (Fig 4.5 A) from which to optimize detergent 
stabilization, we sought to generate a procedure for screening many detergents on 
their ability to efficiently extract receptor protein. Identifying a detergent capable of 
extracting an appreciable yield of receptor, whilst retaining stability, is critical in ion 
channel purification and subsequent crystallization. Using high-throughput screening 
of detergents by FSEC or small-scale purification paired with SEC-MALS (Multi-Angle 
Light Scattering) has greatly assisted various studies in successfully purifying ion 
channels for crystallography. However, without access to such resources (in the initial 
stages of this study), we were only able to determine the efficiency of detergent 
extraction (using small culture volumes) and not the monodispersity of solubilized 
receptors. Consequently, to assess the purity, homogeneity and stability of detergent-
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solubilized receptors, we used standard purification approaches (IMAC followed by 
SEC). 
In order to screen a panel of detergents (often in combination with cholesterol 
hemisuccinate (CHS); a cholesterol “mimic” which has been found to dramatically 
enhance the stability of many membrane proteins in detergent micelles) we developed 
a micro-purification approach originally used in screening GPCR samples prior to large-
scale production (Fig 4.6 A). The procedure is summarized in greater depth in Material 
and Methods (Section 2.6.3). We used the harsh, ionic detergent Fos-Choline 12 (FC-
12; in which only a few bacterial membrane proteins are capable of maintaining 
structural integrity) as a gauge of total protein extracted. Since FC-12 is equally capable 
of extracting both folded and misfolded protein, we can use it to provide estimation 
(when compared with other detergents) of the relative ratio of correctly folded: 
misfolded protein. By contrast to FC-12, mild-detergents, including DDM, are much less 
efficient at solubilizing misfolded protein (Thomas and Tate, 2014).  
Crude membranes were prepared from insect cell pellets and split in to equal aliquots 
(~5ml biomass/condition) for detergent extraction and purification; the panel used (Fig 
4.6 A) ranged from mild (e.g. DM), to so-called crystallization detergents (e.g. Maltose 
Neopentyl Glycols, MNGs), and harsh-ionic detergents (e.g. FC-12; full list of detergent 
names are in Materials and Methods Table 2.7). FC-12 extraction confirmed strong 
expression of the chimera, and its purification on Co2+ resin, with a dense band 
observed at the expected mass of the (monomeric) chimera subunit (Fig 4.6 B). 
Solubilization in DDM yields a largely homogenous band (migrating at ~39kDa), though 
of reduced intensity when compared to that for FC-12.  
Assuming that equal sized populations of receptors were present in DDM and FC-12 
samples, this would suggest that while a proportion of expressed receptors might be 
misfolded, the mild detergent DDM is capable of extracting ~50% of expressed 
receptors in a (presumably) correctly folded state.  This appreciable yield is consistent 
with our previous results (Fig 4.5 C and D), though we know from SEC experiments that 
much of this purified material represents receptors in a non-pentameric, aggregated 




Figure 4.6 - Small-scale detergent screening of GLIC-GABAAR α1
∆ICDHis and analytical 
scale protein purification 
A. Small-scale workflow for detergent screening. Viral-infected insect cells are harvested and crude 
membranes prepared by homogenization and high-salt wash, before solubilization in one of a panel of 
detergents. Solubilized material is incubated with TALON Co
2+
resin and His-tagged receptors recovered 
by affinity purification before analysis by SDS-PAGE. B.Coomassie blue-stained SDS PAGE of affinity 
purified chimera following detergent screening.. Arrowhead denotes prominent band of ~39 kDa 
corresponding to monomeric chimera subunit. C.Receptor solubilized in DDM +/- CHS was affinity 
purified and further purified by SEC. CHS (cyan trace) is able to further stabilize the presumed 
pentameric form (elution volume of ~15 ml) of the chimera in DDM micelles. SDS PAGE and coomassie 
blue-stain analysis of affinity purified receptor (Inset, left) and of material from peak fractions 
(delineated by horizonetal cyan bar), which runs as homogenous band of ~39 kDa (Inset, right).      
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Faint bands were also (most notably) observed for DDM/CHS, DMNG, LMNG and C12E9. 
Extraction in C10E6 showed two prominent bands (of ~39 and 30 kDa), potentially due 
to a smaller degradation product (Fig 4.6 B). Whilst the lane for DM/CHS shows a faint 
band (of expected mass), the shortened alkyl-chain (C10) of DM when compared to 
DDM (C12) is unlikely to have favourable, stabilizing effects in initial receptor 
solubilization. We cannot rule out that the additional presence of CHS will not 
compensate for this destabilizing effect.  
Given our previous studies with DDM, we were curious to assess the additional 
stabilizing effects of CHS on chimeric receptors. Scaling up our preparations, starting 
with biomass from a ~250 ml culture, we solubilized the membrane fraction with 
DDM/CHS, and recovered solubilized receptors by affinity-chromatography as 
previously described. Surprisingly, the addition of CHS was sufficient to dramatically 
enhance the stability of the presumed pentameric form of the chimera (by SEC), with a 
clear symmetrical peak at ~15 ml (material from peak fractions showing a band of 
expected mass when analyzed by coomassie blue-stain; Fig 4.6 C). This peak, however, 
is incorporated within a broader species eluting over a larger volume of the gel 
filtration column (between 10-16 ml), and thus presumably the detergent-CHS-
receptor complex exists in multiple oligomeric or aggregation states. Further 
experiments are required to determine whether DDM and other detergents (with CHS) 
identified in small-scale screens are capable of stabilizing the GLIC-GABAAR α1
∆ICDHis 
chimera.   
 
4.2.5. Small-scale detergent-screening of “desensitization mutant” GLIC-GABAARα1 
chimeras 
In parallel to screening detergents for stabilizing properties, we were keen to explore 
an alternative avenue of receptor stabilization by modifying the conformational state 
of the channel. This strategy has been adopted in a number of studies to facilitate both 
purification and crystallization of membrane proteins (in distinct states). Most widely 
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used in the GPCR field, in an approach termed conformational thermostabilization, 
genetic engineering of a membrane protein is often capable of imparting stabilizing 
properties that would not be possible to achieve purely by detergent optimization 
(Warne et al., 2008; 2009). We therefore postulated that engineering point mutations 
into our chimera that alter the gating equilibrium would potentially assist expression 
and purification of a stable pentameric receptor. Given that the active state of the 
receptor is likely to be thermodynamically unfavorable, we focused on desensitization 
mutants, which would shift the gating equilibrium towards a distinct closed channel 
conformation. During preliminary experiments, there was a lack of high-resolution 
structural information for pLGICs in a desensitized state, and thus we speculated that 
studies of chimeric receptors bearing such mutations might assist in uncovering the 
molecular mechanisms for desensitization.  
Both functional and non-functional desensitization mutants (introduced in Chapter 3) 
were engineered in to M2 of the GLIC-GABAAR α1
∆ICDHis chimera (non-functional 
mutants were presumed to be trapped in a desensitized state). Additionally we 
introduced the mutations N307S/V in to M3, which were identified as having a 
profound effect on native GABAAR desensitization (Gielen et al., 2015). Small-scale 
purification and extraction screens were carried out to identify strongly expressing 
candidate receptors (Fig 4.7 A & B). Most of the mutant receptors were expressed (and 
purified following extraction in DDM or FC-12) to equivalent or greater levels than the 
“wild-type” chimera, with bands observed at ~39 kDa by SDS PAGE-coomassie stain 
analysis. This was most notable for G258A (Fig 4.7 A) and V251F (Fig 4.7 B) mutants. 
Moreover, the apparent ratio of correctly folded to misfolded protein was greater for 
desensitization mutants (as determined from an equivalent or stronger band intensity 
for DDM versus FC-12 extraction). This is most obvious for receptor bearing the G258A 
(4’ M2) mutation. These results should however be viewed cautiously; typically 
multiple constructs/detergent conditions are screened per experiment, and whilst 
starting material is split equally between samples, there is no further normalization of 
(total) protein loaded onto the gel. SDS-PAGE analysis does however provide a “rough” 
assessment of extraction-purification efficiency and viral-titre (in a manner that is less 
time consuming or error prone when compared to western blot analysis).        
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In choosing candidate mutants for further detergent screening and analytical scale-up 
experiments, we focused on those exhibiting most pronounced (non-) functional 
effects (and thus stabilized in a distinct conformation). We therefore focused initially 
on the V251F α1 subunit mutation. The V251F (-3’ M2) mutant is electrophysiologically 
non-functional in Xenopus oocytes (Chapter 3), but is expressed at the cell surface (as 
determined by rescue experiments and fluorescent imaging). Small-scale screening in 
insect cells shows strong expression and purification (of a largely correctly folded 
population) of receptors. Expanded small-scale detergent screening reveals that the 
receptor is efficiently extracted by DDM and DMNG and to lesser extent by DDM/CHS, 
LMNG and C12E9.  
In preliminary analytical scale-up experiments (starting from increased biomass) we 
chose to detergent extract mutant receptors in DDM with CHS. Given the profound 
effect of CHS in stabilizing the apparent pentameric form of non-mutant bearing 
chimera, we postulated that it would likely have a beneficial stabilizing effect on 
mutant receptors. It should be noted that later in the purification, during SEC, we 
excluded CHS. Following affinity purification of solubilized protein, we further purified 
material by size-exclusion (Fig 4.7 C). Mutant receptors eluted predominantly in a 
single monodisperse peak at a (column) volume of ~15ml; the expected elution volume 
of a pentameric form of the receptor. A minor peak corresponding to the void volume, 
and small “shouldering peaks” to the major elution species were observed, though to a 
lesser extent than observed for the non-mutant chimera. Reassuringly, SDS-PAGE and 
coomassie stain revealed that material from the major peak fractions migrates as a 
single homogenous band, and would suggest that the receptor is of high-purity. 
Ultimately, this encouraging result provided us with a starting point, a stable receptor, 
from which we could begin to optimize large-scale expression and purification for 







Figure 4.7 - Small-scale detergent screening of desensitization mutant GLIC-GABAAR 
α1∆ICDHis and analytical scale protein purification of GLIC-GABAAR α1
V251F ∆ICDHis 
A.Coomassie-blue stained SDS PAGE of affinity purified mutant chimera following detergent screening 
with DDM or FC-12. The chimera (ΔICD is GLIC-GABAAR α1
∆ICD
His) without or with desensitization 
mutations and detergents used in the solubilization are shown above each lane. Arrowhead denotes a 
prominent band at ~39 kDa corresponding to monomeric chimera subunit. B.Coomassie-blue stained 
SDS PAGE of affinity purified V251F mutant chimera following expanded detergent screening.  
C.Stabilizing effects of V251F mutation assessed by size exclusion chromatography. Receptor solubilized 
in DDM/CHS was affinity purified and further purified by SEC (in DDM). The V251F mutation (red trace) 
dramatically enhances presumed pentameric form (elution volume of ~15 ml) of the chimera in DDM 
micelles. SDS PAGE analysis of affinity purified receptor (Inset, left) and of material from peak elution 
fractions, which runs as homogenous band of ~39 kDa (Inset, right).      
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4.2.6. Preparative scale purification of a “desensitization mutant” GLIC-
GABAARα1
V251F∆ICDHis chimera 
Having established that a chimera bearing the V251F mutation exists in a largely 
monodisperse state in DDM (with CHS), we began to prepare sufficient quantity of the 
receptor for crystallization trials. After optimization of “scale-up” experiments, we 
were consistently able to express and purify appreciable yields of pure receptor (0.2-
0.3 mg/L). Gel filtration profiles of purified receptor reveal that the predominant 
pentameric peak and minor shouldering peaks observed in preliminary purifications 
are not in dynamic equilibrium (and thus, critically, the receptor pentamer forms a 
stable complex in detergent; Fig 4.8 A). For crystallization and further experiments, 
peak fractions were collected, pooled and concentrated using 100 kDa molecular 
weight cut-off (MWCO) ultra centrifugal filter devices. Theoretically, these devices 
should exclude “free” detergent micelles (typically ~70 kDa for DDM), however, it has 
been reported that even with appropriate molecular weight cut-off, detergent 
concentration typically increases two-fold. In initial purification experiments we 
observed that for final gel filtration steps, the exclusion of CHS had no detrimental 
effect on receptor stability (presumably sufficient levels of CHS are incorporated into 
and retained in detergent micelles following initial solubilization). Later studies suggest 
that it is might be beneficial, when extracting receptors in DDM, to also include CHS 
during the final purification steps.  
4.2.7. Sequence and oligomeric analysis of GLIC-GABAARα1
V251f ∆ICDHis using mass 
spectrometric techniques 
As for the previous purifications, it was important to ensure that the purified material 
corresponded to our chimeric receptor. SDS PAGE and coomassie stain (and 
additionally western blotting; data not shown) consistently revealed that peak fraction 
migrated as a single, homogenous band of the expected mass for the receptor subunit 
(under reducing conditions). Reassuringly, band excision and in-gel tryptic digest for 
mass spectrometric analysis generated sufficient peptides for coverage of greater than 




Figure 4.8 - Preparative-scale purification of V251F mutant of GLIC-GABAAR α1
∆ICDHis, 
sequence and oligomerization analysis by mass spectrometric techniques 
A.Size exlusion chromatography profile of purified GLIC-GABAAR α1
V251F ∆ICD
His(Extracted: DDM/CHS & 
SEC: DDM). Major peak of pentameric receptor-detergent complex is shaded red, and was pooled for 
concentration. Inset, left: Coomassie-blue stain/SDS PAGE of material from peak fractions, which was 
pooled and concentrated. Inset, right; Final purified receptor runs as a homogenous single band by SDS 
PAGE (under reducing conditions). B. Colour map of the peptide fragments (on receptor chimera 
primary sequence) identified by MS analysis (following gel band excision and tryptic digest). C. Mass 
spectra of V251F chimera (from native MS experiments) following collision-induced release of 
detergent. Blue circles denote charge states used to calculate experimental mass of 201.6 kDa. 
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Though the gel filtration profile of the mutant chimera is consistent with that of a 
receptor in a pentameric form (5 subunits totaling ~200 kDa in mass) in complex with 
detergent molecules (being of comparable elution volume to two homologous 
channels purified in DDM; GluClcryst (Fig 4.5 C) and cleaved WT-GLIC, introduced in 
Chapter 5), we wanted to assign a definitive oligomeric state to the purified material. 
Typically, size-exclusion molecular weight standards are used in comparative 
experiments of elution volume to infer the mass of a purified protein. A caveat to 
these experiments is that mass standards are typically soluble proteins and will not 
experience the same effects that detergent-association has on a membrane protein 
(i.e. altering their hydrodynamic radius). An effect of this is to alter the interaction of 
membrane protein-detergent complexes with the gel-filtration matrix and subsequent 
retention time and elution volume.  
To obviate the qualitative low-resolution data that SEC provides, we used native mass 
spectrometry to determine with precision the oligomeric state of the chimera 
complex. Native mass spectrometry (though technically challenging) can provide 
accurate assessment of membrane protein complex composition, as well as small 
molecule and lipid binding. With regards to protein complex composition (and mass), 
native mass spectrometry provides greater accuracy in calculating mass when 
compared to more widely adopted techniques including analytical ultracentrifugation. 
In preliminary experiments carried out by Adam Cryar and Kostas Thalassinos (UCL 
ISMB), mass spectra were generated for the intact chimera receptor complex following 
introduction in to the gas phase and release of detergent molecules (Fig 4.8 C). Using a 
series of charge states (observed in the mass spectrum) an experimental mass was 
calculated. The experimental mass of 201.76 kDa is greater than the theoretical mass 
of 198.73 kDa by 3.03 kDa, but would demonstrate unequivocally that the chimera 
does indeed form a pentamer (in DDM). The additional mass may represent bound 
lipids (present in the insect cell membrane) or detergent/CHS molecules (from 




4.2.8. Preliminary screening of crystallization of GLIC-GABAAR α1
V251F ∆ICDHis receptors 
The mutant chimera purified in DDM/CHS (solubilization) and DDM (SEC) was taken 
forward to crystallization screening. The initial assumption was that crystallization 
conditions previously reported for WT-GLIC would also allow for crystal formation of 
the chimera. Presumably, crystal growth would exhibit similar packing contacts 
primarily between copies of the ECD; a common domain between GLIC and the 
chimera. However, membrane protein crystallization rarely follows such predictable 
rules, and often proteins of similar structure require completely different and unique 
crystallization conditions. In parallel to screening previously published “GLIC crystal 
growth” conditions we used sparse matrix screening of crystallization conditions in 
order to identify new buffer compositions, which might yield protein crystals. Whilst 
we were able to generate an appreciable amount of purified protein, limitations of 
starting culture volume and final yield meant that a single purification was often only 
sufficient for setting three or four 96 well-format crystallization plates (using drop sizes 
of 200 nl; 1:1 protein: reservoir or 150 nl 2:1 protein: reservoir). Full details of 
crystallization procedures and screens are given in Material and Methods.  
Initial screens identified only 3 conditions capable of supporting crystal growth. Of 
these conditions; two allowed for reproducible crystal growth whilst one was not 
reproducible (Table 4.1). Whether this highlights preparation-to-preparation variability 
in the purification process is unclear. Reproduction of crystal growth was tested by 
means of a grid screen around the initial “crystal hit” (as detailed in Methods Section 
2.7.3). Curiously one of the “hits” was of conditions used previously in the 
crystallization of WT GLIC. Whilst GLIC robustly forms large parallelepiped (a prism 
with parallelogram faces) or plate-shaped crystals (see Chapter 5), chimeric receptors 
formed showers or clusters of small needle-type crystals (typically <50 μm in the 
longest axis; Table 4.1). This size of crystal is not amenable to analysis using “in-house” 
X-ray sources and CCD detectors. Further optimization allowed for generation of larger 
rod shaped crystals (by vapour diffusion in hanging drops). However, screening of 
crystals by synchrotron-radiation source revealed these were detergent based, and not 
protein crystals; a commonly observed problem in membrane protein crystallization.  
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The remaining crystal growth “hit” was a peculiar one, on account of its buffer and 
precipitant composition. Growth was supported in MOPS (3-(N-morpholino) 
propanesulfonic acid) buffer (pH 7-8) with small quantities of a high molecular weight 
Poly(ethylene) glycol (PEG-8000). Small cuboidal crystals (<30 μm) appeared 1-2 days 
after setting drops (Table 4.1). The lack of further salt solution addition to support 
crystal growth was surprising  as was the use of a large molecular weight PEG (when 
low MW PEGS, e.g. PEG 400, have typically proved more successful for α-helical 
membrane protein crystallization; Carpenter et al., 2008; Parker and Newstead, 2012). 
Of greater interest was that crystals formed at pH 7-8. Given that the chimeric 
receptor is proton gated, the pH of a crystallization condition likely influences the 
receptor conformation (as shown by Sauguet et al., 2014b). Whilst GLIC robustly 
crystallizes at low pH (in open and locally closed-conformations; Bocquet et al., 2009; 
Hilf and Dutzler, 2009; Sauguet et al., 2014b), growth at neutral pH in resting 
conformations has proven more elusive. It was therefore encouraging that chimera 
crystal growth could be supported at neutral pH. 
Given the small size of crystals, they were best suited to diffraction charactertisation 
by microfocus beamline (tunable to a beam size of 10 μm x 10 μm). Chimera crystals 
diffracted maximally to ~25 Å, revealing diffraction spots consistent with crystals 
formed from protein. This served as a starting point from which to further optimize 
crystal growth. However, subsequent additive screening with detergents (Detergent 
Screening HT Hampton) and compounds known to improve membrane protein 
crystallization (MemAdvantageTM, Molecular Dimensions) failed to improve crystal 
growth or diffraction. Given this outcome, we chose to re-assess our protein 
purification procedures prior to crystallization. 
 
4.2.9. Refined purification and crystallization screens for GLIC-GABAAR α1
V251F ∆ICDHis 
To this stage, protein extraction and purification had been carried out in DDM (with 
CHS). Our initial choice of detergent had been influenced by previous use within the 
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pLGIC channel field (GLIC and GluClcryst were both purified in DDM for crystallization). 
Furthermore, solubilization by alkyl maltopyranosides had accounted for more than 
half of successful membrane protein crystallizations, with DDM the most commonly 
used (Parker and Newstead, 2012). However, the latter trend is drawn from studies of 
all membrane proteins and we cannot easily assume that a single detergent, DDM, will 
yield crystals that diffract to high resolution for all pLGICs. Given that the starting 
sample for crystallization drop is protein and associated detergent, it is inherent that 
the choice of detergent will have a vital role in crystallization success. We therefore re-
assessed the choice of detergent (and cholesterol) in which our chimeric receptor was 
purified. 
Preliminary small screens had identified efficient extraction of protein by DMNG. 
DMNG is a member of a new class of detergent amphiphiles, maltose neopentyl glycols 
(MNGs) that have been shown to exhibit favorable stabilizing and crystallization 
properties when compared to conventional detergents (Chae et al., 2010). Preliminary 
scale-up experiments showed that the extraction efficiency of the chimera from insect 
membranes by DMNG was lower than anticipated. Given this, we used an alternative 
strategy to assess chimera stability and crystallization in DMNG, through introduction 
of a detergent exchange step during the latter stages of purification. This exchange 
approach has been proven beneficial in the successful crystallization of other ion 
channels (a bacterial voltage-gated sodium channel, NavM and an NMDAR; Bagnéris et 
al., 2013; Lee et al., 2014). DDM/CHS solubilized chimera was bound to Co2+resin and 
washed extensively with buffer comprising DMNG/CHS, prior to elution and final 
purification by SEC in buffer supplemented with DMNG (once again CHS was excluded 
in the belief it might hinder crystallization). Purified receptors elute in a largely 
monodisperse state, as a symmetrical peak of expected elution volume (Appendix Fig 
5B). In addition to a peak corresponding to the column void volume, a smaller defined 
shouldering peak was observed. However, “re-running” fractions of the major peak 
revealed that the presumed pentameric species (retaining a symmetrical peak eluting 
at ~14.5 ml) was not in dynamic equilibrium with this higher mass species. The protein 
was concentrated and crystallization trials carried out as previously described.  
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Crystallization screens yielded three new conditions capable of supporting crystal 
growth (two of which were similar to those previously reported for GLIC; Table 4.2).  
 
 
Figure 4.9 - Preparative-scale purification of GLIC-GABAAR α1
V251F ∆ICDHis following 
detergent exchange in to DMNG/CHS. 
A.SEC profile of purified GLIC-GABAα1
V251F
 (Extracted: DDM/CHS & exchanged in to DMNG/CHS). Major 
peak of pentameric receptor-detergent complex is shaded pink, and was pooled for sample 
concentration. Inset, left: Coomassie-blue stain/SDS PAGE of material from peak fractions (horizontal 
bar below SEC trace), Peak fractions (solid bar above gel and shaded section of SEC trace) were pooled 
and concentrated.  Asterisk at high MW indicates SDS-resistant dimer of chimera subunits. Inset, right; 




Table 4.1 Crystallization of GLIC-GABAARα1
V251F ∆ICDHis (DDM/CHS) 









0.1M MOPS pH 7.0 
9% PEG 8000 
16°C/SD 
 












0.1M NaAc pH4.5 
11-16% PEG 4000 











0.1M NaCit pH4.5 
30% PEG400 0.1M 
NaCl 0.1M MgCl2 
16°C Broad 
Screen 
96 N/A N/A 
 
Table 4.2 Crystallization of GLIC-GABAARα1
V251F ∆ICDHis (DMNG/CHS) 









0.1M NaCit pH3.5 
28% PEG 400      
0.2M LiSO4 
 
4°C growth     
Mem-
Advantage 





0.1M NaAc pH4.0 
16% PEG 4000      
0.2M (NH4)2SO4 
 
4°C growth     
Mem-
Advantage 





0.1M NaCit pH3.5 
16% PEG 4000      
0.34M (NH4)2SO4 
 






Crystals were typically rod shaped, and exhibit increased size (in longest axis) when 
compared to those grown from chimera purified in DDM/CHS. Furthermore, 
crystallization was only observed in drops buffered to low pH (presumably channel 
activating proton concentrations). One condition (MemGold-2 H4) was capable of 
supporting the growth of two distinct crystal forms; rod/needle or tetragonal crystals. 
Intriguingly, screening crystal diffraction revealed diffraction to ~15-20 Å of the latter 
tetragonal form, whilst rods/needles did not diffract (Table 4.2). This would suggest 
distinct properties regarding the order of receptor packing in the two crystal forms.  
Encouragingly, the other two crystallization conditions also revealed protein diffraction 
following broad grid screens of “crystallization reproducibility” (maximally diffracting 
to ~15-20Å; Table 4.2). Initial efforts to carry out additive screening proved 
unsuccessful (additional chemicals having apparently detrimental effects on crystal 
growth).  
In parallel to optimizing crystallization of receptors in DMNG by grid screens (from 
initial conditions), we also assessed the effect of including CHS (at 0.001%) in final size-
exclusion purification steps. Unsurprisingly, given the stabilizing qualities of CHS, 
receptors purified in a largely monodisperse state, showing no elution of aggregated 
material (column void volume) and substantial reduction in the previously observed 
shouldering peak (Fig 4.9). Material from the symmetrical peak at ~14.5 ml retained its 
elution profile in subsequent chromatographic analysis (following storage at 4°C for 48 
hrs) and ran as a homogenous band by SDS-PAGE and coomassiee stain (a faint higher 
mass band corresponding to an SDS-resistant dimer can be observed).  
Crystallization of receptors under the 3 newly identified conditions was reproducible in 
grid screens. Furthermore, crystals grown in MemGold-2 E9 were of an increased size 
(50-100 μm in longest axis) and preliminary diffraction assessment revealed an 
improvement in maximal diffraction to ~11Å (Table 4.2). In order to fully characterize 
crystals we used a microfocus beamline (for improved crystal alignment relative to 






Figure 4.10 - X-ray diffraction pattern for crystals of  GLIC-GABAAR α1
V251F ∆ICDHis: 
DMNG-CHS complex by microfocus beamline. 
X-ray diffraction pattern (0.5° oscillation range) for a crystal of GLIC-GABAα1
V251F
 in the presence of 
DMNG and CHS (by microfocus beamline, ESRF ID23-2). Resolution rings at ~15Å and 7.6Å are shown as 
blue circles and a faint diffraction spot near the resolution limit (of 8.9Å) is highlighted by a box right. 
Lower panel is a magnified section of the diffraction pattern and shows a section through a series of 
diffraction spots. A plot of intensity through these spots reveals ordered spacing of peaks in the 




By microfocus (beamline ID23-2, ESRF), using grid scans to align crystals, chimera 
crystals diffracted maximally to 8.9Å and showed well-ordered crystal lattice (Fig 4.10). 
Despite this improvement, crystals exhibited anisotropic diffraction (a possible 
consequence of disproportionate growth along one axis). Consequently, and due to 
limited diffraction resolution, we have been unable to assign a three-dimensional 
space group to these crystals.  A final point of note is that crystallization of the 
chimeric receptor in MemGold-2 E9 and MemGold-2 F5 (following grid screen 
optimization) has supported the growth of two distinct crystal forms; typically 2D 
plate-form and rod-shaped crystals.  Further efforts are underway to fully characterize 
the different diffraction properties of both crystal types. 
 
4.2.10. Thermal stability assays to determine the effect of detergents on the chimera 
Whilst the generation of crystals diffracting to beyond 10Å represents an appreciable 
achievement, we were ultimately no closer to our goal of producing a high-resolution 
structure for the GABAAR α1 TMD. We therefore sought to take a rational high 
throughput approach to screening detergents during the pre- and early-crystallization 
stages. Pre-crystallization screening provides information that can guide both 
purification and crystallization. One such technique (developed by Alexandrov et al., 
2008) harnesses the fluorescent signal generated following covalent modification of 
Cys residues by a thiol specific fluorochrome, N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)phenyl]maleimide(CPM), that occurs upon temperature induced protein 
unfolding (Fig 4.11 A). The thermal stability of a purified membrane protein in a range 
of detergents and small molecules can then be assessed rapidly and efficiently, 
providing information that might assist in optimizing final purification steps and 
crystallization. One of the major advantages of the CPM assay is that it requires very 
little material, less than 5 μg of protein (per sample), which is important where protein 
yield is a limiting factor.  
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A major limitation of this assay is that it requires Cys residues to be located within the 
transmembrane core of the target protein.  We postulated that this might not be 
problematic for our chimeric receptor. Sequence analysis and homology modeling 
reveals three Cys-residues per subunit (15 per pentamer). One lies within the GLIC 
ECD, and is buried within the quaternary structure at the subunit-subunit interface, 
and two are in the TMD of α1 subunits, within the helical bundle in M1 and M3 
(possibly forming a stabilizing disulphide bridge). The latter Cys-residues form strong 
candidate reporters of thermal-induced under folding, suited to the CPM assay.  
 
Figure 4.11 - Effect of detergents on GLIC-GABAAR α1
V251 F∆ICDHis thermal stability 
A. Purified chimera-detergent complex is mixed in various detergents and with CPM reagent. 
Fluorescence is monitored during temperature ramp in RT-qPCR apparatus, and a melting curve 
generated. B. Melting curves for mild alky-maltoside and MNG detergents.  C. Fluorescence normalized 
melting curves for receptor in DDM and DDM/CHS shows shift in melting transition. A Boltzmann 
equation fit of the data was used to generate a Tm for DDM (Tm = 58°C) and DDM/CHS (Tm = 72.6°C), 
revealing a 14.6°C shift in Tm  upon addition of CHS. 
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CPM assays were carried out in a 96 well plate format, with a RT-qPCR machine to 
monitor fluorescence over a ramp in temperature from 25°C to 95°C (1°C increments). 
The V251F-mutant chimera (purified in DMNG/CHS) was mixed with a range of 
detergents and CPM reagent and a melting temperature (Tm) calculated (Fig 4.11 A). 
The raw data (Fig 4.11 B and Appendix Fig 6) for a panel of detergents screened shows 
considerable variability in the maximum fluorescence intensity (representing the end 
of the unfolding process).   
Since an equal amount of protein was used per sample, this is not easily explained by 
varying amounts of receptor in starting sample. It is more likely to represent the ability 
or inability of a detergent to protect the protein from both unfolding and aggregation. 
For the purpose of our study we have assessed the shape and slope of curve 
(representative of the unfolding transition) to calculate a Tm (Table 4.3). As might be 
expected, harsh destabilizing detergents including OM and LDAO have a melting 
transition occurring at relatively low temperatures and reach a high maximum 
fluorescence intensity (presumably providing little protection to unfolding). CHS is able 
to improve stability, as implied by a shift in the melting transition. Of the Cymal family 
of detergents, only Cymal 7 in combination with CHS exhibits a melting curve and Tm 
comparable to that of the favoured mild detergents (e.g. alky maltopyranosides and 
maltose neopentyl glycols; Table 4.3 and Appendix Fig 6). 
Assessing the results for commonly used mild detergents revealed a number of 
intriguing observations. Consistent with results inferred from our SEC experiments and 
initial crystallization, CHS has a dramatic effect on the stability of the chimera, inducing 
a rightward shift in the melting transition curve (and thus increase in Tm) for all 
detergents tested (Fig 4.11 B and Table 4.3). This is most apparent for DDM, with a 
14.6°C increase in melting temperature (Fig 4.11 C). It should be noted that in 
crystallization screens of DDM purified chimera, we omitted CHS at the final 
purification stage. The results from CPM assays would suggest that this might in fact 
have had a destabilizing effect, affecting crystal formation. Unsurprisingly the shorter 
alkyl-chain of DM has a destabilizing effect, however addition of CHS dramatically 
alters the onset of melting transition and reduction in fluorescence intensity of the 
upper plateau.  
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Table 4.3 Thermal stability of GLIC-GABAAR α1
V251F ∆ICDHis in various detergents 
assessed by CPM Assay 
 
 Melting Temperature/Tm(°C) 
Detergent -CHS +CHS 
DM 46.6 64.3 
UDM 51.5 68.8 
DDM 58.0 72.6 
DMNG 55.6 66.9 
LMNG 61.9 67.1 
OGNG 47.0 67 
OM 32.3 57.3 
LDAO 37.4 47.9 
C12E8 53.2 58.7 
Cymal 6 43.5 63.0 
Cymal 7 55.0 66.4 
 
A Boltzmann equation was used to fit the fluorescence data and generate Tm values. Raw data (Appendix 
Figure 6) were visually inspected during the data fits to ensure that the calculated Tm represent a “true” 
melting transition (and not of potential experimental artifact which might be observed at >80°C). Note: 
each fluorescence data point at 1°C temperature increments was recorded 3 times and then averaged.   
 
DMNG exhibited similar results to DDM, with a pronounced rightward shift in the 
melting transition curve. This result is consistent with gel filtration experiments 
(showing reduced aggregation and increase in the proportion pentameric species) and 
improved diffraction of crystals grown for receptor purified in DMNG/CHS versus 
DMNG alone (during final SEC purification step). Surprisingly, LMNG (; the conventional 
detergents for comparison are UDM and DDM) gave similar thermal stability results in 
the presence and absence of CHS, providing a similar Tm to its shorter chain 
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counterpart, DMNG (with the inclusion CHS). These assays thus allow for rapid ranking 
of detergents, based on their ability to stabilize the chimera, and provide a rationale 
for specific detergent exchange steps prior to crystallization. Immediately it is clear 
that maltopyranosides and maltose neopentyl glycols are more stabilizing, and that 
this is further improved by the addition of CHS (Fig 4.11 B). This is in agreement with 
the development of our purification (and crystallization) procedure, where we have 
empirically selected DDM and then DMNG/CHS for receptor purification.   
 
4.2.11. Negative-stain electron microscopy of GLIC-GABAAR α1
V251F∆ICDHis 
Whilst CPM assays clearly provide a rapid screen for ranking detergents based upon 
thermostabilizing properties, it does not provide clear information regarding 
aggregation state of the chimeric receptor. Direct visualization of the channel complex 
by electron microscopy provides low-resolution structural information and, crucially, 
reveals the propensity for aggregation. Furthermore, as alluded to above and in 
Chapter 6, cryo-EM is rapidly developing as a rival technique to X-ray crystallography 
for structure determination (Cheng, 2015; Cheng et al., 2015). Since the chimeric 
receptors generated for crystallization are likely to also be suitable for structural 
analyses by EM, we were keen to assess both the quality of our purified receptor 
preparations and their preferential orientations by negative-stain EM.   
Negative-stain EM images of chimera in DMNG/CHS were collected by Dan Clare 
(Birkbeck, University of London) on a Tecnai T10 at 44,000x magnification (Fig 4.12). 
The sample was largely monodisperse, with single receptor particles observed across 
all sections of the carbon-coated grid (with only few clusters of “receptor-doublets”). 
This is consistent with the monodisperse state of the protein by SEC (Fig 4.12 A & B). 
As anticipated, EM revealed, for the first time, that the receptor purified in DMNG/CHS 
exists as an intact (pentameric) channel. Particles clearly resembled rosettes (of 
subunits around a central pore), reminiscent of a pentameric pLGIC. With regards to 
particle orientation, the sample is largely homogeneous, with receptors apparently 
adsorbing to the carbon film in a preferential “end-on” orientation (i.e., observing the 
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channel in a plane view from above or below). Despite this, closer visual inspection of 
collected images reveal protein in multiple distinct orientations, most likely assigned to 
receptors in “side-on” or “tilted” orientations (Fig 4.12 C). Preliminary studies reveal 
that occupation of receptor particles in “side-on” orientations may be by dependent 
upon the surface charge of EM grids (following poly-lysine treatment). The orientation 
of protein particles bears substantial importance with regards to high-resolution cryo- 
EM studies, and negative-stain will serve as a vital tool in screening specimen 




Figure 4.12 - Negative-stain EM of GLIC-GABAAR α1
V251F ∆ICDHis following detergent 
exchange in to DMNG/CHS. 
A. Negative-stain EM images of purified V251F chimera (in DMNG/CHS) at high concentration. B. 
Negative-stain EM images of purified V251F chimera following ten-fold dilution. In both cases receptor 
was applied to an EM grid covered in a continuous carbon film and stained with uranyl acetate. 
Receptors typically adsorb to the carbon film in an “end-on” orientation (red circle, B, is a representative 
end view of receptor particle). Free detergent-CHS micelles are highlighted by yellow circle. C. Panels 
show magnified selection of receptor orientations (Top; end view. Centre and lower panels show side or 




A notable observation from preliminary negative-stain EM studies was the presence of 
additional small background particles in chimera preparations (Fig 4.12 B). Given that 
grids were prepared using material previously stored at -80°C (following flash freezing 
in liquid nitrogen) we were concerned that this might represent protein degradation 
(potentially dissociated subunits). However from the high Tmobserved in CPM assays 
and EM images of grids prepared at higher protein concentrations, this seemed 
unlikely. Negative stain images of gel filtration buffer alone (including DMNG/CHS at 
the relevant concentration used in final SEC step) revealed a similar dispersion of small 
particles. Whilst this buffer was not prepared fresh on the day of imaging, we might be 
confident from this observation that the chimera is not undergoing degradation, and 
observed particles most likely represent DMNG/CHS micelles. It might therefore be 
concluded that during final purification, free detergent-cholesterol-micelles are 
formed and carried over into the final receptor preparation (Fig 4.12 B). Such events 
would not be apparent from SEC monitored by UV detection alone, but would be 
revealed by SEC-MALS (Multi-Angle Light Scattering) which provides a measure of the 
ratio of free detergent micelle: protein detergent complex in a sample. The 
observation of free detergent micelles in a sample taken forward to crystallization 
might also explain the limited diffraction observed in X-ray crystallography 
experiments of the chimera.  Detergent molecules not associated in a protein complex 
are likely to hinder crystal-packing formation. In addressing this issue we might 
potentially reduce the concentration of detergent and CHS used in the final 
chromatographic stages of purification. 
 
4.3. Discussion 
After establishing that a functional chimeric pLGIC between the ECD of GLIC and TMD 
of GABAAR can be formed that retains the typical GABAAR α1 subunit TMD 
pharmacology and gating mechanism, in this chapter we sought to assess its suitability 
for high level expression and purification for X-ray crystallography.  At the start of this 
study, high-resolution structures of pLGICs (and the associated purification strategies) 
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existed only for GLIC, ELIC and GluCl (Hilf and Dutzler, 2008; Bocquet et al., 2009; Hilf 
and Dutzler, 2009; Hibbs and Gouaux, 2011). Of these receptors, GLIC and ELIC are of 
prokaryotic origin. Information on how to purify and solve the structure of a eukaryotic 
pLGICs was distinctly lacking. Having established early on that bacterial expression of 
our chimera was not possible, we had to draw on techniques and methods from across 
the membrane protein field to guide development of a purification strategy. During 
this time, a number of groups have successfully purified and crystallized full-length WT 
and chimeric pLGICs. The results of these studies have provided support for our 
empirically derived protocol, as well as new ideas, which we have incorporated into 
our study.   
 
4.3.1. Receptor chimeras require a “sophisticated” membrane environment for stable 
expression 
We reasoned, as others before, that a receptor chimera between prokaryotic and 
eukaryotic domains would be amenable to high level expression in bacteria.  Whilst 
this has been possible in chimeras incorporating significant prokaryotic components 
(e.g. expression of the mammalian Kir3.1 potassium channel in E. coli required 75% of 
the TM pore to be replaced with the prokaryotic Kir equivalent; Nishida et al., 2007), 
for pLGIC domain switch chimeras this has yet to achieved. Indeed the structure of the 
GLIC-GlyRα1 chimera (which formed the rational basis for this study) was recently 
solved, using receptor purified from Drosophilia Schneider 2 (S2) cells, after finding 
that this chimeric receptor was refractory to expression in bacteria (Moraga-Cid et al., 
2015). In our study we also found that a domain chimera with GLIC (GLIC-GABAAR α1) 
was poorly expressed in bacteria, yet expressed strongly and stably in the confines of a 
more sophisticated membrane environment provided by a higher order eukaryotic cell 
line (in this case Sf9 insect cells). Moreover, recently solved structures for human 
GABA β3 and mouse 5-HT3homomeric receptors used material expressed and purified 
from stable eukaryotic HEK293 cell lines (Hassaine et al., 2013; 2014; Miller and 
Aricescu, 2014). Whilst these latter studies would suggest that a cell line of mammalian 
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lineage is essential for stable full-length receptor expression, more recent structural 
studies of zebrafish GlyR α1 and human GlyR α3 receptors have revealed that Sf9 cells 
are capable of supporting expression of correctly assembled receptors for detergent 
extraction and purification (Du et al., 2015; Huang et al., 2015). It is therefore apparent 
that Sf9 cells exhibit a plasma membrane that provides the lipid components that are 
broadly essential for stable expression of pLGICs, and more importantly, of our 
chimeric receptor.     
 
4.3.2. A combination of genetic engineering and detergent stabilization are required 
for receptor purification 
Insect cells provide a folding/assembly pathway and plasma membrane capable of 
expressing chimeric receptor proteins; however for crystallization, receptors must be 
extracted from these membranes and incorporated into detergent micelles as a stable 
pentameric complex. Although further studies need to be carried out to address 
stability in a wider panel of detergents, we have thus far found that commonly used 
mild-detergents (including DDM and DMNG) in combination with cholesterol 
hemisuccinate (CHS) are not completely sufficient to completely stabilize the “wild-
type” chimera. Notably, CHS dramatically enhances receptor stability on detergent 
micelles. This is consistent with the notion that pLGICs, and GABAARs in particular, are 
inherently dependent on cholesterol in maintaining structure and function under 
physiological conditions (Hénin et al., 2014).  The enhanced stability in CHS was 
reminiscent of the GPCR adenosine A2Areceptor, in which binding of CHS at peripheral 
site(s) stabilized DDM-solubilized receptor for crystallization and structure solution 
(Jaakola et al., 2008). Studies of the GABA β3 homomer by Miller and Ariscescu (2014) 
subsequently validated our use of CHS during extraction and purification. Here stable 
purification of a closely related receptor was enhanced by the addition of CHS, 
allowing for eventual structure determination. The authors were apparently unable to 
observe or assign electron density to CHS (if directly bound), so the precise mechanism 
by which it stabilizes the β3 receptor remains unknown.  
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Where detergent solution alone is insufficient to stabilize a membrane protein, an 
alternative approach of genetic engineering to generate a thermostabilized protein has 
proved beneficial. Once again we drew inspiration from the GPCR field. Extensive work 
on the β1-adrenergic and adenosine A2a receptors has used alanine-scanning 
mutagenesis to identify thermostabilising mutations capable (in combination with 
agonists and antagonists) of allowing for successful receptor crystallization of 
receptors in distinct conformations (Warne et al., 2008; Lebon et al., 2011). In a similar 
vein we reasoned that incorporating gating mutants (desensitization mutations, see 
Chapter 3) into our chimera might bias the gating equilibrium such that a receptor 
could be trapped in a distinct conformation. If these represent inactive or closed 
channel states, then this might exhibit greater stability.  Indeed introduction of the 
profound desensitization mutation, V251F in M2 helices of α1 subunits, was sufficient 
to dramatically improve the stability of the pentameric form of the chimera, allowing 
for eventual receptor purification and crystallization. This approach has been 
successfully applied to prokaryotic pLGICs. Gating mutants in the M2-M3 loop of GLIC, 
though electrophyiologically non-functional, could be crystallized to reveal receptors in 
a locally-closed conformation (Gonzalez-Gutierrez et al., 2013). Furthermore this 
approach proved essential in recent crystallographic studies of heterotetrameric 
NMDA receptors from Xenopus laevis, in which introduction of known desensitization 
mutations (from AMPARs) allowed for channel stabilization in detergent micelles and 
successful crystallization (Lee et al., 2014).  
Equally one can rationalize at a functional level whether a receptor is likely to be 
amenable to expression, extraction and purification in detergent micelles. Thus far, 
chimeric receptors exhibiting a basal level of constitutive or spontaneous activity at 
neutral pH (as observed for non-mutant bearing receptors when assessed by 
electrophysiology) are not easily stabilized in detergent micelles. This might represent 
a potential toxicity effect when overexpressed in insect cells with receptor aggregation 
in the cell membrane (prior to detergent extraction). Whether extensive screening of 
detergents in the presence of cholesterol derivatives (e.g. CHS) and allosteric 
antagonists (e.g. pregnenolone sulfate) is sufficient to dampen this constitutive “noise” 
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and stabilize the receptor in detergent micelles for further structural studies remains 
to be seen. 
 
4.3.3. Chimeric receptors yield weakly diffracting crystals 
Thus far we have been unable to generate crystals that diffract to sufficiently high-
resolution for structural determination. Whilst it is achievable, the extensive amount 
of screening (both crystal growth and diffraction) that is required reveals that this task 
is far from trivial. Recent crystallographic studies of GLIC at neutral pH revealed that 
only 1 in 1000 crystals diffracted strongly enough (Sauguet et al., 2014b). Furthermore, 
even with extensive screening and high-overall resolution, the structure of the GLIC-
GlyR α1 chimera is poorly defined at the level of the eukaryotic TMD (Moraga-Cid et 
al., 2015). In both cases this likely reflects instability of packed receptors within the 
crystal form. Indeed high crystallographic B-factors, particularly in the case of LiLy, 
reveal substantial uncertainity in the position of atoms in the lower half of the GlyRα1 
TMD (in the crystal form). Moreover a number of side chains (and some residues) in 
this region could not confidently be built. We might reason that this represents an 
inherent change in the stability of the protein that arises from, and reflects the effects 
of truncation of the M3-M4 loop which is nevertheless essential for purification and 
crystallization. Indeed whilst we have adopted an “alternative truncation strategy”, 
using a short tripeptide linker and more conservative truncation of post-M3 and pre-
M4 regions, it is possible that our inability to grow strongly diffracting crystals, so far, 
results from the disruptive effects of loop truncation on allowing stable crystal packing 
contacts to form.  
While one might reason that flexible loops (namely between M2-M3 and M3-M4) are 
likely candidates for preventing growth of well-ordered and strongly diffracting 
crystals, it is equally possible that the detergent in the sample is the limiting factor. 
Evidently in a sample composed of receptor protein and associated detergent, both 
constituent parts need to work harmoniously in order to generate well-ordered 
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crystals. Poor choice of detergent results in a protein of low thermal stability, 
increasing the likelihood of aggregation and thus hampering further structural studies. 
Here we have empirically identified a combination of detergent (DMNG) and 
cholesterol derivative (CHS) exhibiting high thermal stability and capable of generating 
diffracting crystals (maximally to 8.9Å). The choice of DMNG is pertinent; since their 
conception, maltose neopentyl glycols (MNG) amphiphiles are becoming more widely 
used in membrane protein structural studies (Chae et al., 2010). Moreover purification 
and successful crystallization of the closely related homopentameric GABAβ3, was also 
achieved through using DMNG and CHS.  
So why have we not been able to generate strongly diffracting crystals? Momentarily 
ignoring construct design and modifications; preliminary negative-stain EM studies 
might have revealed a potential “detergent issue”. While EM images revealed 
characteristic rosette shaped particles of the intact pentameric receptor, and were 
largely monodisperse (with little clustering), images at reduced protein concentration 
revealed a background containing smaller distinct particles. These were also present in 
the final purification buffer (from SEC) and probably represent an accumulation of free 
detergent-CHS micelles. The detrimental effects of enriching detergent in a protein 
sample have been well documented with regards to crystallization and often result in 
the phenomenon of phase separation (Newby et al., 2009). Detergent enrichment 
typically occurs during SEC and protein concentration steps, and can hamper both 
optimization and reproducibility of crystal growth. We must therefore carry out further 
assessment of detergent content (using SEC-MALS) and optimization in the final stages 
of sample preparation prior to crystallization to reveal whether the mutant V251F 
chimera when purified in DMNG/CHS, can be used to generate crystals which diffract 
even further.   
4.3.4. Is structure solution by crystallography the clear path forward? 
Ultimately we have yet to fully address the question of chimera crystallization from all 
potential avenues. Techniques including crystal seeding, in situ diffraction screening, 
crystal dehydration and crystallization in the Lipid Cubic Phase (Cherezov, 2011) have 
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all proven beneficial in various crystallographic studies of membrane proteins and 
should be addressed for their potential application to this project. However, successful 
crystallization is rarely a guaranteed result. It might therefore prove essential to 
address our question by alternative approaches. Single particle cryo-EM has developed 
at a rapid pace in recent years, and now stands as a rival method to X-ray 
crystallography for high-resolution structure determination; particularly for difficult 
proteins that are refractory to crystallization. For membrane proteins, structures of γ-
Secretase at 3.4 Å and more significantly GlyR α1 at 3.8-3.9Å in complex with 
strychnine and ivermectin (Du et al., 2015; Bai et al., 2015b) reveal that this technique 
is becoming increasingly amenable to protein complexes of small size (<200 kDa). In 
parallel to studies of ELIC (in Chapter 6), we have begun to screen sample preparation 
of our chimeric receptor for single particle EM studies and hope to further assess the 
use of this technique for structure determination. 
 
4.4. Conclusions 
GLIC-GABA chimeras are poorly expressed in bacteria, but can be expressed to high-
level in Sf9 insect cells using baculoviral-infection 
Non-mutant chimeras are unstable in detergent micelles in the presence of a 
stabilizing lipid, cholesterol hemisuccinate. 
A single desensitization mutation in M2 of α1, V251F, is sufficient to dramatically 
stabilize the chimera in detergent micelles. 
Negative-stain EM reveals the chimera forms an intact pentameric channel. 
Purified chimeric GLIC-GABAAR α1 receptors are capable of generating protein crystals 




Chapter 5: Binding of the barbiturate Pentobarbital to the prokaryotic pLGIC GLIC 
5.1. Introduction 
Previously in this study we introduced preliminary data describing allosteric 
potentiation and inhibition of different classes of pLGICs by the barbiturate 
pentobarbital. Surprisingly, we found that at clinically relevant concentrations, 
pentobarbital was able to inhibit proton-activated currents at the prokaryotic pLGIC 
GLIC (Chapter 3). The functional effects of this drug have been reported across both 
cationic and anionic pLGICs, and the mechanism of action extensively studied using 
electrophysiological and photo-labelling binding studies (Muroi et al., 2009; Hamouda 
et al., 2014a; Jayakar et al., 2015). Given the obvious structural similarity between 
eukaryotic Cys-loop receptors and their prokaryotic counterparts, we were keen to 
determine whether an evolutionarily conserved pentobarbital binding site exists in 
GLIC. Using X-ray crystallography, we sought to identify at high-resolution a three-
dimensional binding site for this barbiturate anaesthetic. 
Barbiturates, including pentobarbital, have been used clinically owing to their 
anaesthetic, sedative, anxiolytic and anticonvulsant properties (López-Muñoz et al., 
2005). However following the development of safer therapeutics (e.g. 
benzodiazepines) also with lower tolerance levels and fewer withdrawal symptoms, 
the clinical application of barbiturates is less commonplace.  The functional effects of 
these compounds are well known and it is principally considered that they act by 
modulating the activity of members of the pLGIC superfamily, and more specifically via 
GABAA receptors (Krasowski et al., 2002) As introduced previously, they are known to 
bind at and allosterically modulate GABAA receptor activity in three distinct, 
concentration-dependent manners; potentiating (at 10-100 µM), activating (<1 mM) 
and blocking (>1 mM) channel function (Akk and Steinbach, 2000; Muroi et al., 2009). 
In terms of clinically relevant concentrations of pentobarbital required for general 
anesthesia in mammals, this is estimated to be in the range of ~ 50 µM (Franks and 




The role of residues in GABAAR β-subunits has long been implicated in coordinating 
drug binding (largely on the basis of functional studies of β-subunit receptor 
homomers; Amin, 1999). As might be expected in the confines of a physiologically 
relevant receptor subunit combination (αβγ), the mechanism of action is likely to be 
more complex and binding orientated through intersubunit (residue) interactions. 
Indeed, photolabeling studies with photoreactive barbiturate analogs postulate that 
binding at distinct interfacial sites formed between γ-β and β-α subunits are 
responsible for mediating the positive and negative allosteric modulatory effects of 
barbiturates at GABAARs (Chiara et al., 2013; Jayakar et al., 2015). 
While GABAAreceptors form the primary site of activity, it is also well established that 
barbiturates are non-selective with regards to binding at eukaryotic pLGICs. Of the 
pLGIC super family members, excitatory currents through neuronal and muscle nAChRs 
have been observed to be blocked at clinically relevant drug concentrations (Hamouda 
et al., 2014a). Such observations would go some way to explaining the side effects that 
are observed following treatment with high drug concentrations. Once again studies 
with photolabeling barbiturate analogs (in muscle nAChRs) have suggested 
mechanisms for drug binding in cationic pLGICs: by binding at an ion channel pore site 
in the nAChR in a desensitized state; or a γ-α interfacial site in resting nAChR forms 
(Hamouda et al., 2014b). With regards to the wider family of general anaesthetics, it 
has been observed that in contrast to their properties at anionic-GABAARs, compounds 
including propofol and halothane display negative allosteric effects at cationic pLGICs, 
such as nAChRs (Violet et al., 1997).  
Evidently, the non-selective manner in which these compounds act is not an easy one 
to decipher, with distinct sites likely to exist at cationic and anionic channels. The use 
of recently identified prokaryotic pLGIC homologues in high-resolution studies of 
anesthetic binding has begun to shed new light on this subject. X-ray crystallographic 
structures of the (cationic) channel GLIC have now been solved in complex with either 
propofol, desflurane or bromoform (Nury et al., 2011; Sauguet et al., 2013a). Whilst 
these compounds display inhibitory effects at GLIC (in a manner reminiscent of their 




intersubunit site) overlap with residues shown to mediate positive modulatory 
responses at anionic pLGICs such as GABAARs and GlyRs (Nury et al., 2011; Sauguet et 
al., 2014a). We were therefore keen to ascertain whether a barbiturate binding site in 
GLIC could be identified using crystallographic approaches and subsequently 
determine if such a site is compatible/comparable with those observed in either its 
cationic or anionic evolutionary counterparts.         
5.2. Results 
5.2.1. Proton-gated response of GLIC (and GA mutants) is inhibited by pentobarbital 
As detailed in chapter 3, pH20 proton-activated currents at GLIC are inhibited by 
pentobarbital at clinically relevant concentrations, exhibiting an IC50 of ~113 ± 9.4 µM 
(Fig 5.2 A & B). We first wanted to determine if residues which had previously been 
shown to coordinate the binding of propofol and desflurane at GLIC were also 
implicated in mediating a pentobarbital response (Fig 5.1 A & B). Co-crystallization 
studies reveal that propofol and desflurane occupy an intrasubunit cavity at the 
extracellular side of the receptor TMD and thus accessible from the lipid bilayer (Nury 
et al., 2011). Residues from M1, M2, M3 and M4 (of the TMD) as well as the β6-β7 
strand (of the ECD) form this binding pocket, with critical contributions from, I202 
(M1), V242 (M2) and T255 (M3) (Fig 5.1 B). Nury et al., performed site-directed 
mutagenesis at these three positions and electrophysiological studies of GLIC to 
emphasize the importance of these residues in mediating propofol and desflurane 
inhibition. A mutation at T255 (to a neutral non-polar alanine) was sufficient to induce 
a differential 10-fold shift in the inhibition curves for both propofol (to lower 
concentrations, i.e. propofol is more potent) and desflurane (to higher concentrations, 







Figure 5.1 - An intrasubunit anaesthetic (propofol and desflurane) binding site at 
GLIC 
A. The pentameric arrangement of subunits at the TMD illustrates the orientation of M1 – M4 α-helices 
and the location of propofol (green) and desflurane (pale blue) are shown in stick and space filling-
representation at each subunit-subunit interface. B. Close up of the propofol binding site (Nury et al., 
2011) viewed from the extracellular side (left panel) and from the plane of the membrane (right panel). 
Residues contributing to ligand binding are shown in stick from. 
 
We initially speculated that should pentobarbital be acting via a common binding site 
(to propofol and desflurane) then identical mutations at GLIC might alter the 
pentobarbital-inhibition curve. In electrophysiological experiments (carried out in 
oocytes) a previously reported gain-of-function (with regards to proton gating of GLIC) 
was observed for receptors bearing the T255A and I202Y mutation. This manifests as 




pH 8 extracellular solution) and a leftward shift of the proton-concentration response 
curve (towards lower proton concentrations).  
 
Figure 5.2 - Pentobarbital inhibits proton-gated currents at GLIC by binding at a 
distinct site to other general anaesthetics. 
A. Examples of membrane currents recorded from oocytes expressing GLIC or the indicated GLIC 
mutant. Currents are evoked at ~pH20 in the absence or presence of indicated concentration of 
pentobarbital (PB). GLIC I202Y and T255A exhibit gain-of-function and were recorded in a bath solution 
of pH 8 (rather than pH 7.4). B.Pentobarbital inhibition-concentration response curves for GLIC WT and 
the indicated mutants (normalised to the proton activated current in the absence of drug).  Points are 
means ± s.d from n= 4-6 oocytes. C.Inhibition of pH20 proton gated response by co-application of 100 μM 




As in previously published GLIC-propofol/desflurane studies, the pentobarbital-
inhibition curve was constructed at pH20 (i.e. the pH/proton concentration eliciting a 
1/5 maximal response; Fig 5.2 A and B). None of the three mutations had substantial 
effect on the pentobarbital inhibition curve (Fig 5.2B). I202Y and V242M mutation 
induced an approximate twofold shift towards lower pentobarbital concentrations 
(exhibiting respective IC50s of 53.6 ± 7.38 and 39.1 ± 4.98 µM) whilst T255A reduced 
apparent sensitivity to pentobarbital (with an IC50 of 155.7 ± 14.6 µM). Given that in 
previous studies T255A and V242M mutations induced much larger (10-fold) shifts in 
propofol and desflurane IC50s, the lack of an equivalent effect on pentobarbital in this 
study would suggest that residues forming an intrasubunit anaesthetic site in GLIC are 
unlikely to be involved in coordinating pentobarbital binding. Presumably, therefore, 
pentobarbital binds at a distinct site in GLIC. 
 
5.2.2. GLIC can be expressed and purified from bacterial cells for co-crystallization 
In light of these observations and to investigate the structural basis for pentobarbital 
binding to and inhibition of GLIC, we sought to co-crystallize GLIC in complex with 
pentobarbital for X-ray diffraction and structure determination.  
As introduced in the previous chapter, a well-established bacterial expression and 
purification procedure already exists for GLIC (Bocquet et al., 2007), allowing for 
milligram quantities of a MBP-fusion protein to be purified following detergent 
extraction (in DDM). This fusion protein acts as a stabilizing “stepping-stone” in the 
generation of the mature protein. Evidently, for crystallographic studies, the large 
soluble MBP-portion of the fusion protein will likely be refractory to the formation of 
well-ordered receptor protein crystals for X-ray diffraction. Consequently MBP is 
proteolytically cleaved from the mature GLIC protomer, yielding a stable pentameric 
GLIC-detergent complex that is further purified by SEC for crystallization trials (see full 




Using published protocols as a starting point, we carried out large-scale expression of 
MBP-GLIC for DDM-detergent extraction and receptor purification. In contrast to the 
procedure introduced in Chapter 4, we used IMAC to recover solubilised-receptors on 
a Co2+ resin. We used this approach, rather than purification on amylose resin, to 
exclude the undesirable purification of a strongly expressed endogenous porin-protein. 
We were consistently able to purify 5-10 mg of fusion protein, which was relatively 
pure (and free of contaminating proteins) when assessed by SDS-PAGE and coomassie 
blue-stain (Fig 5.3). Following cleavage of the MBP-fusion protein in-solution and 
“reverse IMAC purification” to remove the cleaved His-MBP, analysis by SDS PAGE 
revealed two distinct bands (free of contaminating products) of ~30 and 40 kDa in 
mass. The 40 kDa corresponding to the GST-PreScission protease and ~30 kDa band to 
the monomeric mature GLIC subunit (Fig 5.3). Further purification by SEC allowed the 
pentameric GLIC protein-DDM complex to be isolated from the protease. As observed 
for chimeric GABAARs and GluClcryst, GLIC elutes as a clearly defined symmetrical peak 
at ~15 ml (Fig 5.3) The protease elutes as a shouldering peak at ~17 ml and can be 
cleanly separated from the pentameric GLIC (as determined by assessing SEC fractions 
by SDS PAGE and coomassie blue stain). Peak fractions of the GLIC(pentamer)-DDM 
complex from SEC could then be pooled and concentrated (to 5-10 mg/ml) for 
preliminary co-crystallization studies with pentobarbital.   
5.2.3. GLIC crystallization strategies 
Having established a procedure for generating substantial quantities of purified GLIC 
(in DDM), we began to screen for the crystallization of receptors in complex with 
pentobarbital. In contrast to our efforts to crystallize receptor chimeras, well-defined 
crystallization conditions have already been extensively reported for GLIC (Bocquet et 







Figure 5.3 - GLIC forms a stable pentameric complex in DDM 
SEC profile of (proteolytically) cleaved-GLIC (in DDM). Major peak corresponding to mature pentameric 
GLIC is indicated by red pentagon and the minor peak, indicated by blue hexagon, GST-PreScission. Inset 
left; SDS PAGE of purified PreScission protease, IMAC elution and following cleavage reaction. Black 
arrowhead indicates migration of monomeric cleaved GLIC. Right panel; SDS PAGE of SEC fractions 
(volumes are indicated by the horizontal red bar below the SEC trace). Peak shaded portion of SEC 
represents those fractions pooled and concentrated for crystallization.  
 
The most favoured conditions are typically those involving buffering at low pH (high 
proton concentrations) favouring receptor crystallization in an active-open channel 
conformation (Bocquet et al., 2009; Hilf and Dutzler, 2009). Recent studies have 
however shown that crystallization of GLIC is possible at neutral pH, trapping the 
receptor in an inactive-closed channel state (Sauguet et al., 2014b). Previous co-
crystallization studies with general anaesthetics, alcohols and channel blockers have 
favoured the former condition; binding ligand to an active-channel complex at low pH 
(Nury et al., 2011; Sauguet et al., 2013a). It should also be noted that the binding of 




was the case in identifying intra- and inter-subunit sites for the anaesthetic bromoform 
and alcohol ethanol in a “sensitized” F14’A mutant GLIC protein; Sauguet et al., 2013a).  
Using conditions that allowed for successful crystallization of GLIC in complex with 
propofol and desflurane (PEG 4000, NaSCN and Na-Acetate pH 4), we were able to 
replicate robust crystal growth in the absence and following incubation of protein 
solution with an excess of pentobarbital (5 mM). Crystal growth was observed in both 
sitting and hanging drops (by vapour diffusion), typically forming plate shaped (Fig 5.5) 
or needle crystals. Whilst crystals exhibited favourable sizes for diffraction studies in at 
least one dimension (> 50 μm), they were largely two-dimensional. Additionally we 
were able to grow small rectangular cuboid crystals (< 50 μm in the longest 
dimension). Using a microfocus beamline (I24 at Diamond Light Source) we subjected 
our crystals to X-ray diffraction characterisation.  
We observed limited diffraction of needle shaped crystals (10-20 Å), whilst a number 
of small cuboidal and plate crystals revealed diffraction approaching and extending 
beyond 5 Å (maximally to 4.3 Å; Fig 5.4). We were unable however to collect complete 
data sets at this higher resolution due to radiation damage. Though the resolution limit 
of these crystals (Fig 5.4) would be insufficient to build an atomic model of GLIC and it 
would prove difficult to confidently assign density to a bound ligand. Nevertheless we 
were able to observe differences in diffraction quality of plate- and cuboidal-shaped 
crystals. Whilst both showed equivalent maximal diffraction, the former, 
unsurprisingly, exhibited anisotropic diffraction. We were able to assess and 
tentatively assign a three-dimensional space group to GLIC crystals grown in the 
presence of pentobarbital; typically C2 or P212121 crystal forms, as previously reported 









Figure 5.4 - X-ray diffraction pattern for co-crystals of GLIC and Pentobarbital 
X-ray diffraction pattern (0.2° oscillation range) from a crystal of GLIC in the presence of DDM (by 
microfocus beamline, DLS I24). Resolution rings in the main panel at 9.25Å and 4.68Å are shown as blue 
circles. Left panel, is a magnified section showing diffraction spots diffraction limit, ~4.30 Å (resolution 
rings at 3.78Å and 4.68Å are shown as blue circle). The data set collected for this crystal was indexed 
with a space group of P21P21P21. 
 
5.2.4. Optimizing the diffraction limit 
Whilst the general conditions for crystal growth for GLIC are now well established, it is 
evident that crystal growth and cryo-protection requires substantial optimization. To 
date, the large proportion of crystallographic studies of GLIC have been carried out by 
only a few groups (Hilf and Dutzler, 2009; Gonzalez-Gutierrez et al., 2013; Sauguet et 
al., 2014b). Published experimental procedures often only provide limited detail 




apparently critical for the formation of crystals that diffract to high resolution. Namely, 
protein crystallization should be facilitated by using “crystal seeds”, allowing for robust 
growth of large three-dimensional crystals (Sauguet et al., 2014b). Crystal dehydration, 
before cryo-protection, improves the diffraction quality and limit. Despite this a large 
number of crystals must be screened for diffraction before identifying the small 
number capable of generating atomic resolution datasets (Sauguet et al., 2014b; 
Moraga-Cid et al., 2015).  
We therefore sought to optimize and improve the growth of GLIC crystals exhibiting 
increased size in all three dimensions. By testing two well-established seeding 
techniques, we were able to identify a strategy for generating large parallelepiped 
crystals (that would otherwise form 2D plate-shaped crystals under normal conditions; 
Fig 5.5). Small crystals bearing favourable shape and proportionate growth (in each 
dimension) could be grown by the streak-seeding approach (with crystal nucleation 
and growth occurring along the “streak line” (Fig 5.5). Given the small size of crystals it 
is likely that they would only be amenable to diffraction screening and data collection 
on (synchrotron X-ray source) microfocus beamlines. By contrast, a “micro-seeding” 
approach, using seeds from crushed crystals allowed for growth of large three-
dimensional crystals. Plate shaped crystals of GLIC were harvested and crushed to form 
a ”seed slurry” and used to establish fresh crystallization drops. Using this approach we 
were able to manipulate (and reduce) spontaneous nucleation, allowing for crystal 
growth from seeds. This reduced the number of crystals, while enabling growth to 
larger sizes (Fig 5.5). Using this robust crystallization technique, we could further 
explore co-crystallization through a number of strategies, including soaking of large 









Figure 5.5 - Crystal growth optimization by seeding 
Initial crystal growth screens yielded an excess of 2D plate crystals. Using a seed stock (of crushed plate 
crystals) “streak-seeding” and “micro-seeding” were used to generate three-dimensional crystals of 
GLIC. Inset panels show magnified images of three dimensional parallelepiped crystals. More details can 





5.2.5. A brominated-analog of PB exhibits inhibitory effects with similar affinity 
In addition to techniques to improve crystal growth, we were keen to address a 
potential problem commonly observed in crystallographic studies of ligand binding 
proteins. It is often the case that assigning electron density to a bound ligand and 
confidently determining orientation proves problematic particularly if specific 
structural features of the ligand are poorly represented in electron density maps. 
These efforts are further hampered if the protein of interest provides only limited 
diffraction (as is often the case for membrane proteins).  In order to ensure that ligand 
docking results might be more conclusive, it is possible to use the anomalous X-ray 
scattering of specific atoms (e.g. Br) to allow for their definitive identification in 
electron density maps (Spurny et al., 2013; Bagnéris et al., 2014). Drug-derivative 
compounds bearing selenium and bromine atoms have proven particularly useful in 
anomalously assigning density to small bound molecules, and in determining their 
orientation. Indeed in studies of anaesthetics (bromoform), alcohol (bromo-ethanol) 
and channel blockers (bromolidocaine) binding at GLIC, brominated-drug derivatives 
have been employed and used to determine the binding sites (Hilf et al., 2010; Sauguet 
et al., 2013a). It is however important to note that the use of such compounds does 
not obviate the necessity of collecting high-resolution (< 4 Å) data sets.     
We identified a commercially available structurally analogous compound that could 
serve as a pentobarbital derivative; 5-(2-Bromo-ethyl)-5-ethyl-pyrimidine-2,4,6-trione 
(hereafter referred to as S97617). Significantly, this compound contains a bromine 
atom and presumably would be more easily identified in electron density maps (as 
anomalous density peaks). Like pentobarbital, the compound, S97617, is derived from 
barbituric acid, but instead of ethyl and 1-methybutyl groups at position 5 on the 
pyrimidine ring of pentobarbital, it has 2-bromo-ethyl and ethyl R1 and R2 groups (Fig 
5.6 A). In order to justify using S97617 in co-crystallization studies, it was first 
necessary to confirm that its actions resembled that of pentobarbital at both GLIC and 
native GABAAR subunit compositions. Reassuringly, the brominated compound was 
able to directly gate α1β2 GABAA receptors (expressed in Xenopus oocytes; Fig 5.6B). 




IC50 of 157.1 ± 25.8 μM (Fig 5.6A). In both cases the results were reminiscent of those 
observed for pentobarbital, over a similar concentration range. This would suggest 
that this compound is likely to be acting at both GLIC and α1β2 GABAARs in a similar 
manner to pentobarbital and presumably via a common binding site. We have not, at 
this stage, tested the sensitivity of GLIC-anaesthetic mutants, I202Y, V242M and 
T255A, to S97617.   
 
 
Figure 5.6 - Brominated derivative of pentobarbital inhibits proton-gated currents at 
GLIC and activates α1β2 GABAARs 
A. Comparison of pentobarbital and S97617 and inhibition-concentration response curves for GLIC WT 
(activated by pH20 proton concentrations). Points are mean ± s.d and n=6 oocytes. B. Comparison of 
membrane currents evoked by application of 1mM GABA or 1mM S97617 from oocytes injected with 
α1β2 GABAARs.  
 
5.2.6. Crystal structure of GLIC at 3.3 Å 
Having identified a brominated compound that exhibits pentobarbital like properties, 
we sought to co-crystallize GLIC in the presence of S97617. In parallel, crystals grown 




the seeding techniques described above to grow large crystals in the presence of 
drugs, or native crystals that were soaked in drug before cryo-protection. Extensive 
screening of crystals yielded a single crystal grown in S97617 that diffracted sufficiently 
to generate a complete data set at 3.2 Å. It should be noted at this early stage that 
data was not collected at an X-ray absorption optimized to bromine (0.92 Å). 
 
 
Figure 5.7 - C2-type crystal packing of GLIC 
Two views of GLIC crystal packing showing rotation around the indicated axis. Molecules are depicted as 
red or blue cartoons depending on their orientation. The box insert in the right panel indicates a crystal 
packing contact between residues in the ECD, which is magnified in the panel bottom right.  
 
As previously detailed, the crystal was grown at pH 4 and allowed for structure 
solution for GLIC at ~ 3.2Å. The structure of GLIC in the brominated pentobarbital 




GLIC structure (PDB 4HFI; Sauguet et al., 2013b) as a search probe and yielding a 
robust solution (see Materials and Methods Sections 2.7.8 & 9 for more details of 
structure solution and data interpretation). An initial round of automated model 
building and structure refinement was carried out using the Phenix AutoBuild function 
for initial assessment of the quality of the electron density map, and for the 
identification of anomalous peaks in the electron density maps (Terwilliger et al., 
2008). 
The crystals belong to the C2 space group (with one pentamer in the asymmetric unit). 
With regards to the space group and unit cell dimensions, the GLICBrPB crystal 
presented here is isomorphous to 41 of the 45 crystal structures for GLIC reported in 
the PDB. Unsurprisingly, the analysis of crystal packing reveals common contacting 
regions as identified in other GLIC data sets (Fig 5.7). The major contacts are formed 
between the ECDs of neighbouring pentamers (at two points) and the exposed loops at 
the base of the TMD. The second of the two ECD contacting points shows an increased 
degree of structural flexibility in the crystal form (Fig 5.7; as indicated by the high B-
factor in this region with respect to the rest of the protein Fig 5.8).  
The overall architecture of GLICBrPB is identical to that of the native form, GLICnative (i.e. 
grown in the absence of ligand, e.g. PDB 4HFI; Sauguet et al., 2013b). As for GLICnative, 
the structure presented here exhibits structural rigidity in the TMD and the core of the 
β-sandwich of the ECD (as indicated by B-factors for this crystal, 73.7 Å2), with 
increased flexibility in the exposed loops of the ECD (Fig 5.8 A). The structure of 
GLICBrPB was very similar to GLICnative with a α-carbon  (Cα) root mean square deviation 
(RMSD) of 0.267Å over the entire pentamer (by global alignment of all 5 chains; Fig 5.8 
B). This is further confirmed when individual TMD and ECD elements are structurally 
aligned (to GLICnative) with Cα-RMSD in ECD of 0.214Å and in the TMD of 0.260Å (Fig 5.8 
C & Appendix Table 4). Small fluctuations in residue side-chain position are observed in 
more flexible regions of the protein.  This would suggest that structurally, if bound in 
the crystal form, S97617 does not shunt GLIC into a state distinct from the previously 
reported open channel structure. This is consistent with previous studies of GLIC in 
complex with general anaesthetics that bind to receptor in the open form, without 




global and individual domain structural alignments with GLIC in locally closed (LC) and 
resting forms revealed that the structure presented here (GLICBrPB) is comparable only 
to the open form of GLICnative (Appendix Figure 7 and Appendix Table 4). 
 
Figure 5.8 - Global architecture of GLIC grown in Bromo-PB is isomorphous to that of 
GLIC grown under “normal” conditions 
A. GLIC
BrPB
 shown in cartoon-respresentation and colored by B-factor B. GLIC
BrPB
 (red) pentamer aligned 
to GLIC
native
 (cyan, PDB 4HFI) and shown as a ribbon arrangement. In both A and B the proximal two 




ECD (left) and TMD 
(right). Key structural regions are labelled as are residues showing varying degrees of side-chain 




Analysing the electron density maps for GLICBrPB was necessary to assess the quality of 
the structure solution and to identify peaks in density that could be attributed to non-
protein elements (Fig 5.9 and 5.10). Electron density maps were of sufficient quality 
that we could confidently reconstruct the entire peptide backbone and build residue 
side-chains for much of the model (Fig 5.9). At the global level, assessment of electron 
density maps reveals that the peptide backbone satisfies the previously reported open-
active form of GLIC with no ambiguity. This was notably evident at the level of the TMD 
(where we might expect pentobarbital to bind, as discussed below). Electron density 
maps show that side chain positions of pore-lining M2 residues is in agreement with 
those in the open-channel state. Moreover electron density tightly surrounds the 
modelled orientation of the residue side-chains in the M2-M3 loop and β6-β7 loop (the 
critical signal transduction elements at the ECD-TMD interface); notably for Tyr-Pro-
Phe resdues at the tip of β6-β7 loop and aromatic residues of the M2-M3 loop 
(involved in stacking interactions at the interface; Fig 5.9). As expected, in regions of 
the protein exhibiting increased flexibility in the crystal form defining side-chain 
orientation was not possible.          
Having assessed the quality of the electron density maps for the protein main chains, 
we reasoned that it might be possible to identify additional peaks in electron density 
and difference maps that might be assigned to bound ligands. At the limited resolution 
of GLICBrPB this was likely to prove challenging, particularly in terms of defining 
molecular orientation. While we crystallized GLIC in the presence of a brominated-
derivative of pentobarbital, diffraction data was not collected at the peak wavelength 
for bromine (0.919 Å). This would ultimately hamper efforts to identify bound drug 
from the anomalous scattering of bromine (which is considered a “weak scatterer” 
even under optimized experimental conditions”). Indeed generation of an anomalous 
map did not reveal appreciable peaks above the background signal. Subsequently we 
would have to rely on strong signals in difference density maps (contoured at +5ς) to 
determine if S97616 was bound in situ. 
Difference density maps were contoured at 5ς and assessed for strong positive peaks 
(Appendix Fig 8). Visual inspection of results revealed residual electron density in the 




“detergent plug” (formed of 6 detergent molecules) strongly observed across 
structures of active-open GLIC.  
 
Figure 5.9 - Quality of electron density maps for GLIC 
A single subunit in Cα-traceribbon representation is coloured by secondary structure (red; β-strands, 
cyan; α-helices and pink; loops) and blue map representing 2mFo-DFcelectron density map contoured at 
a level of 1ς. Panel left; Cα-trace of the M2-M3 loop and β6-β7 loop and electron density map (as in 
central panel). A number of residues are shown in stick representation to emphasize surrounding 
electron density. Panel right; Cα-trace of a single TMD region and electron density map. Bottom panel; 
The pentameric arrangement of subunits at the level of the TMD illustrates the orientation of the M1 – 





Figure 5.10 - Modelling bounds ions, positioning of (partial) detergent molecules and 
observed density at 6’ Serine level 
A. Detergent density (2mFo-DFcelectron density, blue, and Fo-Fc difference density maps, green, 
contoured at 1.5 ς and 5ς, respectively) in the pore of GLIC
BrPB 
and superposition of detergents (in stick 
representation). M2 lining residues are shown as sticks and labelled for one subunit. The black dashed 
box highlights the ambiguous density at the level of the 6’ Serine residue. B. Location of chloride ions 
(shown in space-fill) in the ECD of GLIC
BrPB 
is shown for pentameric arrangement of subunits. The green-
dashed box is magnified in the top right panel and shows electron density maps as in A. Lower right 
panel black panel) is a magnified view of the chloride binding site and inter-subunit acetate site in the 




Density is apparent for the aliphatic chain of DDM molecules and not for the maltoside 
moiety (Fig 5.10 A and Appendix Figure 8). These molecules form a 6 detergent bundle; 
a pentagonal arrangement with a further detergent molecule orientated centrally. In 
initial structural studies of GLIC it was perceived that the central detergent was 
positioned with the maltoside moiety facing inwards (and the remaining five pointing 
outward; Bocquet et al., 2009). However, more recent structures at higher resolution 
(assisted by use of selenium-derived DDM) provide unequivocal evidence that this 
central detergent also points outwards (Sauguet et al., 2013b). For visualization 
purposes we have superimposed 5 detergent molecules from GLICnative (PDB 4HFI), 
including the maltoside head groups for reference (which were modelled in previous 
structures). Reassuringly, we see a clear overlap in electron density in our maps and 
the positioning of the detergents aliphatic tails (Fig 5.10 B). 
Beyond the observation of electron density in the pore of GLICBrPB we observed the 
presence of strong peaks in all five subunits (ranging from 5.5 to 7.9 ς) at a vestibular 
site in the ECD within loop A (Fig 5.10 B and Appendix Fig 8).  This site overlaps with 
the location of bounds anions, chloride or bromide ions, observed in previous data sets 
(Sauguet et al., 2013b; Fourati et al., 2015). Given the strong positive peaks in 
difference maps (and the presence of NaCl in purification buffers) we can assign and 
model a chloride ion at this site (Fig 5.10 B). We favour a chloride ion (as bromine was 
only included in the crystal drop in form of the compound S97616) though we cannot 
exclude that a bromide ion may be generated by hydrolysis of the “bromo-
pentobarbital” molecule. Regardless of identity, it is likely that the anion is coordinated 
in a position through interactions with residues of the β5 strand and loop A, within a 
positively charged pocket. Three further positive peaks in the difference density map 
(at 6.9 – 7.9 ς) were identified at equivalent positions at three of the five subunit 
interfaces. This site is located below C-loop (the characteristic agonist binding site 
across pLGICs) in a cavity wedged between the adjacent subunits. This position was 
equivalent to a previously identified intersubunit acetate binding site (Fourati et al., 
2015). Given that acetate was present in the crystallization drop (at 100 mM) and on 
the basis of the agreement between our density maps and previous observations, we 




The remaining peak in electron density (contributed presumably by non-protein 
elements) is more difficult to interpret. Residual electron density and a positive peak in 
the difference map were observed at 7.2 ς in the pore, below the detergent plug, at 
the level of the Ser 6’ (M2) residue (Fig 5.10 A). There are three potential hypotheses 
regarding the elements responsible for this density, which in the context of this study 
are discussed in detail below.  
 
5.3. Discussion 
In this chapter we sought to build upon the previous observation that the (cationic) 
prokaryotic pLGIC GLIC is inhibited by the barbiturate, pentobarbital, at clinically 
relevant concentrations. Given the amenability of this receptor to X-ray 
crystallographic studies, we used co-crystallization of GLIC in the presence of 
pentobarbital or a brominated-derivative to identify the molecular determinants of 
drug binding.    
5.3.1. Pentobarbital binds at an inhibitory site distinct to that identified for propofol 
and desflurane 
Since their identification and crystallization, GLIC and ELIC have been used as models 
to identify binding sites for a range of pharmacological agents (recently reviewed in 
Sauguet et al., 2014a). Most notably, the structures of GLIC in complex with the 
general anaesthetics propofol, desflurane and bromoform have been solved at atomic 
resolution, identifying both intra- and inter-subunit binding sites; the latter site likely 
to be conserved from prokaryotic to eukaryotic pLGICs (Nury et al., 2011; Sauguet et 
al., 2013a). However, to date, no high resolution structure exits for a receptor 
structure in complex with anaesthetic barbiturates. Given that barbiturates, including 
pentobarbital, likely target and act at pLGICs (principally GABAARs), we reasoned that 
an inhibitory barbiturate binding site at GLIC (as for previous studies of anaesthetic 




Electrophysiological studies of GLIC revealed that propofol, desflurane and bromoform 
inhibit proton-gated currents. Subsequent crystallographic studies revealed 
overlapping binding of these compounds primarily within an intrasubunit cavity 
formed at the extracellular side of the TMD (Weng et al., 2010; Nury et al., 2011). 
Hydrophobic residues lining this cavity are likely to be responsible for ligand 
recognition and coordinating binding through van der Waals interactions. Notably 
these compounds bound receptor in the open channel form, and thus a mechanism for 
how an anaesthetic promotes channel closure is not immediately apparent.   
Through mutagenesis of residues lining the intrasubunit cavity (namely I202, V242 and 
T255), we found that the inhibitory response to pentobarbital was unlikely to be 
coordinated through binding at a site overlapping with that of the aforementioned 
anaesthetics. Unlike the substantial effects observed in functional studies of propofol 
inhibition at mutant GLIC receptors, we observed little effect on pentobarbital binding 
and inhibition of GLIC. Whilst some of these mutations also imparted basal gain-of-
function effects, we can reasonably assume non-overlapping sites on the basis of our 
mutagenesis studies. Also high resolution structural analysis of anaesthetic binding 
(e.g. propofol, halothane) at soluble surrogate binding proteins of known structure, 
such as human serum albumin and apoferretin, reveal that binding relies on van der 
Waals rather than polar interactions (Bhattacharya et al., 2000; Vedula et al., 2009). 
This is consistent with the nature of residues lining the intrasubunit cavity in GLIC. By 
comparison, pentobarbital has both a distinct aromatic ring structure and increased 
overall polarity compared to these other classes of anaesthetics. In crystallographic 
studies of barbiturate binding to apoferretin, somewhat surprisingly these compounds 
were found to bind at a cavity overlapping with that observed for other anaesthetics, 
with binding now relying on polar interactions (with further contributions from van der 
Waals interactions; Oakley et al., 2012). Whilst the binding site at this surrogate 
protein, apoferretin, evidently exhibits a degree of versatility in anaesthetic binding, 





A further point to note comes from crystallographic studies of mutant GLIC (F14’A) and 
wild-type ELIC receptors in complex with bromoform (Spurny et al., 2013; Sauguet et 
al., 2013a). The F14’A mutation imparts ethanol-sensitivity to the GLIC receptor, as 
well as reversing the direction of the response to bromoform (potentiating rather than 
inhibitory). In mutant GLIC, bromoform now occupies a second, inter-subunit, TMD 
binding site. Intriguingly, this site directly overlaps with residues known to regulate 
allosteric modulation to anaesthetics in eukaryotic plGICs (namely GlyRs and 
GABAARs). While binding of pentobarbital by an inter-subunit site would be in accord 
with the results of photolabeling studies (with photoreactive barbiturate analogs) 
carried out on native GABAARs, that identified labelled M1 and M3 residues at γ-β and 
β-α interfaces (Jayakar et al., 2015), ultimately in GLIC, bromoform binding is still 
coordinated by largely hydrophobic contacts. It should be noted that this inter-subunit 
site is however lined by an increased number of polar residues (when compared to the 
intra-subunit site). Moreover, an alternative inter-subunit bromoform binding site in 
ELIC has also been observed from X-ray crystallography (where bromoform again 
exhibited inhibitory effects in functional experiments; Spurny et al., 2013). Formed by 
a pocket at the intracellular side of the TMD, this site is lined by hydrophobic and 
aromatic residues. As for intra-subunit binding sites in GLIC, the non-polar nature of 
this site would presumably not energetically favour barbiturate binding. We have not 
explored further using mutagenesis whether an inter-subunit site is responsible for 
barbiturate binding in GLIC.       
5.3.2. Pentobarbital binds to ‘activated’ GLIC without affecting global GLIC structure 
In our studies we attempted to use crystallographic approaches to identify a 
barbiturate binding site in GLIC. Whilst we addressed pentobarbital binding, in our 
efforts to optimize crystallography conditions, we also used a commercially available 
brominated-derivative of pentobarbital (S97617). In addition to exhibiting identical 
effects to pentobarbital (inhibition of proton-mediated currents), we also observed a 
direct activation of α1β2 GABAARs in a manner reminiscent of pentobarbital. To our 
knowledge the functional effects of this compound, particularly at members of the 




While we were able to grow crystals in the presence of both pentobarbital and S97617, 
we were only able to identify a single crystal (grown in complex with S97617) capable 
of generating sufficiently high-resolution structural data (by X-ray diffraction). As 
alluded to earlier, we did not collect diffraction data at the X-ray absorption edge of 
bromine (in order to assist localization of this atom in electron density maps). Given 
this and the difficulty of definitively identifying and assigning drug density at the 
maximum diffraction resolution generated (~3.2 Å) we cannot confidently confirm 
whether or not S97617 is present in the atomic model of GLIC presented here. 
However, fluorescence scans of weakly diffracting GLICBrPB (> 5Å) revealed a weak-
bromine specific signal in our sample. At current it is unclear whether this is bound to 
protein-elements within the crystal or present as a result of soaking the crystals in a 
cryo-protectant solution containing the drug (prior to “freezing” in liquid nitrogen).  
The only non-protein elements that we have been able to confidently assign in our 
model are the aliphatic tails of DDM detergent molecules in the receptor pore, as well 
as chloride and acetate ions (binding to the ECD below the agonist binding C-loop). The 
detergent molecules in the pore are likely to arise as a result of purification and 
crystallization procedures, being of no functional significance (Bocquet et al., 2009). 
However, a functional role for ion (acetate and chloride) binding in the case of GLIC 
remains unclear. Also the presence of chloride ions in the homopentameric human 
GABAA β3 receptor structure, in a spatially equivalent position in the ECD might 
suggest a role in receptor assembly and stabilization (Miller and Aricescu, 2014; Fourati 
et al., 2015).  With regards to a role for chloride coordination, it is notable that kainate 
receptors (of the ionotropic glutamate receptor family) require monovalent anions 
(and cations) for dimer stabilization in the ligand binding domain (Plested and Mayer, 
2007; Plested et al., 2008; Vijayan et al., 2009). This serves to maintain normal 
receptor activity. It will thus be of interest to further study the role of anion binding in 
the ECD of pLGICs.  
Beside these non-protein elements, ambiguous electron density (apparent also as a 




beneath the detergent molecule density at the level of the Ser 6’ M2 residues.This 
density can be interpreted in three ways: 
The first is to speculatively assign this density to bound drug, S97617.This would be 
consistent with computational studies that suggest general anaesthetics can occupy 
multiple pore (block) sites with micromolar affinities in GLIC (LeBard et al., 2012). One 
of these sites notably is at the level of the 6’ and 9’ M2 residues. However, while we 
cannot confirm that the resolution of the map is insufficient to display full density for 
the bound drug, ultimately the shape of the electron density does not adequately fit 
with the contours of S97617. Indeed the only pose in which the drug could be 
orientated with respect to the observed density in our maps would be with the 
pyrimidine ring of the barbituric acid moiety perpendicular to the transmembrane 
helices. Moreover there is no apparent density for the R1, ethyl and R2, 1-methybutyl, 
groups present at position 5 on the pyrimidine ring. Consequently we could not define 
the orientation of S97617, but assume that it occupies a channel site in the open-form 
of GLIC. Generating data with positive anomalous signal for the bromine atom would 
be essential to confirm the presence and precise location of the bound drug. 
The second interpretation would be that in contrast to the consensus view of 
detergent molecule orientation in the pore, the central detergent molecule can indeed 
reside in a “downward” facing orientation (Bocquet et al., 2009). On this basis, the 
maltoside moiety would be positioned approximately at the level of the 6’ serine, and 
could account for the residual density (as modelled in the first crystal structures of 
GLIC).  
Finally, a recent study of ion permeation in GLIC, favoured the argument that a self-
stabilized pentagon of water molecules is located at the 6’ position. This was based 
upon a high-resolution (2.4Å) structure of GLIC and was corroborated through further 
crystallographic studies with Selenium-derived DDM (as introduced previously) to 
discount the second interpretation involving detergent orientation (Sauguet et al., 
2013b). This third interpretation and its applicability to explain similarly observed 




presented here) appears like the most likely candidate for contributing to electron 
density. 
Our own co-crystallographic studies have thus far been unable to generate a high-
resolution structure of a pLGIC in the presence of a barbiturate. However, with our 
collaborators (Marc Delarue, Institut Pasteur) we intend to corroborate our functional 
discoveries through intensive co-crystallization studies of previously reported GLIC 
“channel variants” in the presence of a range of barbiturates. More specifically, we 
hope to explore whether pentobarbital binds preferentially to locally-closed forms of 
GLIC (Prevost et al., 2012). Whilst GLIC crystallization occurs at receptor activating low 
pH conditions, this receptor structure, in terms of the M2 pore lining helix is roughly 
equivalent to the GLIC inactive/resting structure (solved at neutral pH; Appendix Fig 7) 
Such studies would therefore allow assessment of stable barbiturate binding to a 
“resting” inactive form of the receptor (a mechanism that has previously been 
described in functional studies of barbiturate modulation of nAChRs; Hamouda et al., 
2014b).    
5.4. Conclusions 
Pentobarbital inhibits proton-activated currents in the prokaryotic pLGIC GLIC. 
Binding of pentobarbital occurs at a new site and not via the previously identified 
intra-subunit anaesthetic binding cavity. 
A brominated pentobarbital-derivative, S97617, exhibits similar functional properties 
to pentobarbital. 
Crystals of GLIC form in the presence of pentobarbital and S97617. 
The crystal structure of GLIC at 3.3 Å generated in this study does not allow for the 
unambiguous identification of a barbiturate binding site, but confirms features 
previously reported for GLIC channels in an open conformation (in C2 space group 




Chapter 6: A multi-disciplinary structural approach to assessing Pregnenolone 
Sulphate binding at the prokaryotic receptor ELIC 
6.1. Introduction 
In functional studies of GABAA receptor chimera pharmacology we emphasised the role 
that the α1 TMD plays in receptor sensitivity to the inhibitory neurosteroid 
pregnenolone sulphate (PS; Chapter 3). In these studies we observed that in contrast 
to GLIC, a GLIC-GABAAR chimera exhibited profound inhibition at micromolar 
concentrations of PS, in a manner reminiscent of native α1β2 GABAARs. While the 
effects of this inhibitory class of steroids (often typified by the presence of a sulphate-
group) have been extensively studied at GABAA receptors (reviewed in Seljeset et al., 
2015), its binding site and a mechanism of action remain unknown.  
Of interest, these compounds are quite promiscuous (Harteneck, 2013). In addition to 
the effects imparted at GABAARs, sulphonated-steroids (including PS and DHEAS) have 
been shown to have functional effects at other pLGIC family members inhibiting GlyRs 
(and, as shown in chapter 3, the C. elegans GluClα receptor; Fodor et al., 2006). 
Moreover, PS has been shown to induce ligand-dependent potentiation of NMDARs 
(Wu et al., 1991; Malayev et al., 2002) and activating effects at Transient Receptor 
Potential (TRP) channels (Wagner et al., 2008). Regardless of its apparent non-selective 
nature, PS is one of the most abundant neurosteroids in the brain (Robel and Baulieu, 
1994) and is being assessed for its efficacy in treating cognitive and behavioural 
disorders in mental disorders (Smith et al., 2014). Critical to its therapeutic application 
will be a more detailed understanding of the mechanism by which it acts at pLGICs, 
particularly the GABAAR, with new findings potentially assisting rational-based drug 
design around the sulphonated-steroid backbone.  
In this chapter, we have identified an agonist-dependent inhibition of the prokaryotic 
pLGIC ELIC. As in the previous chapter, and without access to an abundance of high-




there are well-characterised purification and crystallization protocols) as a surrogate 
model of a eukaryotic pLGICs (Hilf and Dutzler, 2008) for studying the mechanism of 
binding and action of an inhibitory neurosteroid. In addressing this question we have 
developed a multi-disciplinary experimental approach using native mass spectrometry, 
X-ray crystallography and cryo-electron microscopy.   
Inhibitory steroids, including PS and DHEAS, are major brain ‘inhibitory’ neurosteroids, 
formed during cholesterol metabolism via the precursor pregnenolone (Fig 6.1) 
(Compagnone and Mellon, 2000). In a manner distinct to the potentiating 
neurosteroids, these compounds impart non-competitive antagonist effects at 
GABAARs (Shen et al., 2000; Akk et al., 2001). The two aforementioned examples, PS 
and DHEAS, are structurally distinct to the potentiating neurosteroids by the presence 
of a sulphate group at the C3 position of the steroidal A-ring (Fig 6.1; Gibbs et al., 
2006). Surprisingly however, this distinctive substituent is not critical to the inhibitory 
response (with previous studies showing that similar compounds lacking a charged 
group at this position also inhibit GABAA receptor function; Wang et al., 2002).  
 
 
Figure 6.1 - Chemical structures of pregnenolone and pregnenolone sulphate 
Chemical structures of pregnenolone (potentiating) and pregnenolone sulfate (inhibitory) are shown. 
The charged sulphate group of PS at C3 of the A ring is highlighted by a blue circle. 
 
Besides the differential effects imparted by the compound’s structure, many functional 
studies have sought to understand the mechanism of action of inhibitory steroids at 




neurosteroid-mutant GABAA receptors (at the critical binding Q241 and transduction 
W245 M1 residues) reveal that the inhibitory steroid PS is unlikely to act through 
binding at an overlapping site to that suggested for the potentiating steroids  
(Majewska et al., 1990; Park-Chung et al., 1999; Akk et al., 2008). Indeed in our studies 
of chimeric GABAA α1 TMD receptors this was also apparent (Chapter 3). Additional 
studies have focused on the role of the GABAAR α subunit M2 2’ residue in inhibitory 
steroid sensitivity (Akk et al., 2001; Wang et al., 2006; 2007). Whilst mutation of the α1 
2’ valine (256) to serine was sufficient to reduce sensitivity 30-fold (Wang et al., 2006), 
the lack of voltage sensitivity in the inhibition caused by this sulphated neurosteroid 
does not fit with the properties of a charged compound acting as a (presumed) 
channel blocker (Akk et al., 2001; Eisenman et al., 2003). Further comparative 
structure-function studies using the invertebrate GABA receptor orthologue, UNC-49 
(from C. elegans) have suggested a role for α subunit M1 residues. Residues at the 
extracellular end of M1 in UNC-49C were found to have a dramatic effect on PS 
sensitivity (in studies of chimeric receptors formed from UNC-49B with the more 
sensitive UNC-49C; Wardell et al., 2006; Twede et al., 2007). Given the likely location 
of these residues and their proximity to pre-M1 and M2-M3 loops (both critical 
elements in receptor gating) these appear as potential candidates for binding and/or 
transducing an inhibitory signal. However studies of the equivalent residue positions in 
mammalian GABAARs (composed of α1β2γ2) did not indicate a similar conserved role 
for M1 residues in mediating the inhibitory (sulphated) steroid response (Baker et al., 
2010).  
Evidently, the manner in which inhibitory steroids act at pLGICs, and the GABAA 
receptor in particular is complex. As discussed briefly in Chapter 3, the inhibitory 
steroid PS may show preferential binding to distinct kinetic states of the receptor and 
seems to impart its inhibitory effect by promoting entrance of the receptor into the 
desensitized state (Akk et al., 2001; Eisenman et al., 2003). Moreover, it is not 
implausible that this class of steroids imparts its effects through localised interactions 




In order to address the question of how inhibitory steroids act at the molecular level 
we were keen to take advantage of the apparent promiscuity in the pLGIC family for 
PS. As for studies of anaesthetic binding at GLIC, it might be that binding of PS at a 
homologous receptor is via a site that is conserved through evolution and thus 
relevant to the GABAAR. Whilst GLIC exhibits relative insensitivity to PS, we found that 
ivermectin activated currents at GluCl(α1)cryst were inhibited by micromolar 
concentrations of PS. Though previously crystallized, and thus a strong starting model 
for high-resolution structural analysis of allosteric modulation by PS, crystallographic 
studies of the GluCl receptor are hampered by the necessity of including Fab antibody 
fragments to obtain atomic resolution data (Hibbs and Gouaux, 2011; Althoff et al., 
2014). The response of the prokaryotic pLGIC ELIC to PS has not been reported, and 
thus we were keen to determine whether this receptor (which intriguingly is GABA-
gated) also exhibits sensitivity to steroidal inhibition. By virtue of its amenability to 
receptor purification and crystallization, high-resolution studies of ELIC have identified 
binding sites for a number of inhibitory ligands; divalent cations, the anaesthetic 
bromoform and also the novel Alzheimers’ medication memantine (the binding sites of 
which are summarised in Fig 6.2; Hilf and Dutzler, 2008; Zimmermann et al., 2012; 
Spurny et al., 2013; Ulens et al., 2014).  
We have used electrophysiology to screen ELIC for inhibition by PS for follow-up 
studies using biochemical and structural biology approaches (with purified receptor) 
for the identification of potential inhibitory steroid binding sites. We reason that by 
using mass spectrometry, X-ray crystallography and cryo-EM, this would enable a 
complementary approach to studies of a drug that seems to impart distinct effects in a 







Figure 6.2 - Inhibitory ligand binding sites at the prokaryotic pLGIC ELIC 
The overall structure for ELIC in complex with Ba
2+ 
(red sphere; PDB 2yn6) is shown (central, left top and 
right panel). Ligand bound structures for ELIC-Bromoform and ELIC-Bromo-memantine were aligned and 
ligands (space fill representations) superimposed on to the ELIC-Ba
2+
 structure for comparison. Panel left 
top; A binding site for divalent ions (responsible for mediating inhibition) was identified through barium 
binding (red sphere centre) in the ECD below the ligand-binding pocket (at subunit interfaces), co-
ordinated by the side chains of acidic amino acids. Note bromoform molecule in foreground, binding at 
ECD site. Panel right; close up view of the channel pore (proximal two subunits are removed for clarity) 
revealing additional barium ion binding site at the extracellular end of the channel as well as overlapping 
bromoform and bromo-memantine pore block sites (~16’ in M2). Panel left bottom; shows an 
intersubunit binding site for bromoform molecules formed from a cavity at the intracellular end of the 
TMD.     
 
6.2. Results 
6.2.1. GABA-gated currents are inhibited by Pregnenolone Sulphate 
A previously published screen reported the effects of range of GABAA receptor 




inhibitory class of steroids (Spurny et al., 2012). Of the compounds screened, 
alphaxalone (used at 100 µM in electrophysiological recordings) was the only steroid 
tested of similar chemical structure to the inhibitory steroids and this failed to exhibit 
notable positive or negative allosteric modulatory effects (normally it will potentiate at 
native GABAARs).  
To assess the sensitivity of ELIC to PS, we used TEVC electrophysiology with injected 
oocytes and recorded agonist-induced currents in the presence or absence of PS. GABA 
has been identified as an agonist of ELIC, binding at the orthosteric binding site (as 
determined from crystallographic studies; Spurny et al., 2012). It should be noted that 
divalent cations were included in the recording solution, despite previous observations 
that divalent cations allosterically regulate ELIC in a negative manner (Zimmermann et 
al., 2012). This is most likely to be through ion coordination at a binding site in the 
outer rim of the extracellular domain (between adjacent subunits of ELIC; Fig 6.2). 
Whilst divalent cations (principally Ca2+ and Mg2+) in the recording solution are likely to 
affect ELIC activation by GABA, we reasoned that they were unlikely to alter the 
sensitivity to PS through binding at a competing site (with PS presumably modulating 
at the level of the TMD). Moreover, in absence of divalent cations, ELIC activation is 
dramatically slowed (only reaching peak amplitude in the order of minutes) and 
apparently non-desensitizing during prolonged exposure, making experimental 
recordings difficult. When divalent ions are included in the recording solution ELIC 
activates rapidly upon exposure to GABA, and this response desensitizes during 
prolonged exposure (Fig 6.3 A). Deactivation is relatively fast upon agonist removal. 
Given that this response is most akin to that observed at a GABAA receptor we 
maintained these recording conditions for PS sensitivity experiments.   
After pre-incubation of oocytes in PS and co-application of 30 mM GABA we observed 
a dramatic reduction in the peak current amplitude, which increased with micromolar 
concentrations of PS (Fig 6.3 A and B). At 100 µM PS there was near complete 
inhibition of current (Fig 6.3 A & B). Even at high concentrations, the wash-out of 
steroid is not notably slowed following removal of GABA/PS. In separate experiments 
we also observed inhibition to a similar extent (at 100 µM PS) following ELIC activation 




activation is not dependent on the presence of divalent cations in recording solution. 
For purposes of gauging the relative sensitivity of ELIC to PS, the inhibitory curve sits 
within the range of 10-100 µM (Fig 6.3 B). In this regard there is slight reduction in PS 
sensitivity when compared to eukaryotic GABAA receptors (reported values typically in 
the low micromolar range; Wang et al., 2006; 2007; Sachidanandan and Bera, 2015). 
This may reflect the notable differences in receptor activation kinetics.  
 
 
Figure 6.3 - Electrophysiological studies of ELIC inhibition by PS 
A. Membrane currents elicited by GABA application recorded from oocytes expressing ELIC in the 
absence or presence of pregnenolone sulphate (PS). Note oocytes were pre-incubated in PS prior to 
agonist application. B. PS inhibition curve for ELIC for 30 mM GABA response. Points are normalised to a 
control 30 mM GABA response. Points are mean ± sd from n=4 oocytes. C. Peak normalised response of 
membrane currents recorded from co-application of 30 mM GABA +/- 100 µM PS. Note the faster decay 




In separate studies we assessed the effects of co-applying agonist and PS on ELIC 
function. In a manner reminiscent of that observed at GABAA receptors we observed a 
reduction in the inhibition of the peak current response, however there was an 
apparent increase in the rate of current decay during prolonged exposure (Fig 6.3 C). It 
would appear (from the ‘pre-incubation’ studies; Fig 6.3 A & B) that PS is able to bind 
to the resting state of the receptor, preventing activation upon agonist exposure. In 
the ‘co-application’ of agonist and PS (Fig 6.3 C), it appears that PS promotes 
occupancy in the closed-desensitized state (when considered at the macroscopic 
level). It is difficult to derive the precise kinetic model for PS inhibition of ELIC (and 
extract a precise PS sensitivity) from electrophysiological recordings carried out thus 
far. Crucially however, the inhibitory profile observed is not overtly dissimilar to that 
observed at mammalian GABAA receptors. Thus a potentially common binding site for 
PS may have formed early on in evolution. Therefore we used ELIC as a model for 
structural studies of negative allosteric modulation of a pLGIC by PS.       
 
6.2.2. Biochemical and structural biology approaches 
Having established that the prokaryotic receptor ELIC, like metazoan pLGICs including 
the GABAA receptor, is inhibited by PS, we sought to establish a structural mechanism 
for inhibition. We also aimed to determine a three dimensional binding site for PS. In 
our attempts to do so we employed a range of biochemical and structural biology 
approaches to corroborate functional findings (Fig 6.4). Given the amenability of ELIC 
to high-level bacterial expression for detergent solubilisation, receptor purification and 
crystallization we were keen to assess whether we could generate co-crystal 
complexes of ELIC in the presence of PS (and agonist). Given the restricted nature of 
the crystal form, particularly for ELIC, in determining receptor structure in distinct 
gating states (Cecchini and Changeux, 2014), we were concerned that binding and co-
crystallization of ELIC with PS may be not be favoured.  
To date, in all reported structures of ELIC in the absence and presence of both agonists 




conductive state (Hilf and Dutzler, 2008; Gonzalez-Gutierrez et al., 2012; Spurny et al., 
2012). As to whether this represents the receptor in a closed-inactive or closed-
desensitized state is not immediately clear. Given the likely complex kinetic profile of 
PS inhibition, we were concerned that the propensity for ELIC to crystallize in a single 
form might restrict either PS binding or in the case of successful neurosteroid binding, 
that the receptor might not display a structural state truly reflective of one observed in 
its physiological environment (i.e. in a lipid bilayer). We therefore sought to address 
the question of structure determination in a manner that would be free of the 
potential restraints imposed by the crystal form, namely, electron cryo-microscopy 
(cryo-EM; Fig 6.4). As introduced in previous chapters (and Appendix Primer 1) this 
technique allows for direct imaging of solubilised receptor protein (Cheng et al., 2015), 
and thus is an appealing method for elucidating structures of the same protein in 
distinct conformations – something that has yet to be truly achieved for ELIC. Given 
the proven stability and yield of purified ELIC (in detergent micelles), and the potential 
questions one might address, we reasoned that this might be a perfect candidate 
receptor for optimizing cryo-EM studies of a pLGIC.  
The final approach we have used in our study of PS binding at ELIC is native mass 
spectrometry (nMS; a technique used in previous chapters to define molecular mass of 
intact receptor pentamers). This challenging technique, pioneered by Carol Robinson’s 
group, allows for the characterisation of membrane proteins in various oligomeric 
states devoid of detergent molecules (upon projection into the gas phase) as well as 
the critical assessment of lipid and small molecule binding in the intact protein 
complex (Barrera et al., 2009; Laganowsky et al., 2013; 2014). Furthermore, through 
employing ion-mobility (IM) MS measurements, it is feasible to determine the extent 
to which bound lipids and molecules enhance resistance to gas phase unfolding, and 
thus are stabilizing protein structure (Laganowsky et al., 2014). Through generating 
well resolved mass spectra for protein complexes and their associated charge states, it 
is possible to identify and then distinguish the binding of lipids and small molecules at 
interfacial sites (in an oligomeric complex), as ‘plugs’ in channels or in the bulk lipid 
bilayer (Fig 6.4; Bechara and Robinson, 2015). We reasoned that with sufficient 




association of PS with the pentameric ELIC complex, or whether PS inhibitory effects 
occur in a more transitory manner, through interactions at the receptor periphery with 
the surrounding lipid bilayer.         
 
Figure 6.3 - Integration of biochemical and structural biology techniques to address 
the inhibitory binding site for PS 
We will use three techniques to provide structural information for PS binding to ELIC. Native IM-MS of 
protein complexes can reveal the association of lipids or small molecule with intact protein or distinct 
oligomers. Here ligand (shown as red circles) binds at subunit interfaces and is associated with 
pentameric and a ‘stripped’ tetramer but not with a dissociated monomer of a pLGIC. Cryo-EM and 
crystallography allow for high resolution structural determination (in the absence or presence of 
ligands). A successful combination of all techniques allows for molecular determinants of binding and 




6.2.3. Purification of ELIC 
As for its prokaryotic counterpart (GLIC) a well-established procedure exists for high 
level bacterial expression and purification of ELIC (Hilf and Dutzler, 2008). Once again 
this takes advantage of the stabilizing properties bestowed by the addition of a soluble 
MBP-fusion tag (during initial detergent extraction and affinity purification steps). As 
for GLIC, proteolytic cleavage of the N-terminal (His-) MBP portion of the fusion 
protein is required for isolation of the mature pentameric ELIC-detergent complex for 
further structural analyses.  
Essentially, as described in the previous chapter for crystallographic studies of GLIC 
(and as detailed in Materials and Methods), MBP-ELIC was expressed at high-levels in 
large bacterial cultures. However, for ELIC, detergent extraction and receptor 
purification was carried out in UDM (a similar maltoside-derived detergent). We were 
consistently able to purify upwards of 10 mg of fusion protein. This protein was 
relatively pure and free of contaminating proteins (Fig 6.5 A). Moreover, the high 
stability of the pentameric form of MBP-ELIC in UDM is immediately apparent from 
SEC, where UDM solubilised material, recovered by IMAC, runs in a monodisperse 
state (eluting as single symmetrical peak at approximately 12.7 ml; Fig 6.5 A). SDS-
PAGE and coomassie blue-stain analysis revealed that this peak clearly corresponded 
to the MBP-ELIC fusion protein (migrating as a single homogenous band of ~ 70 kDa). 
After solution-cleavage of the MBP-fusion protein, using a dual-tagged (His- and GST-) 
HRV 3C protease, and “reverse-IMAC purification”, the mature-ELIC (in complex with 
UDM) was obtained. This material is highly stable in the pentameric form as assessed 
by SEC (Fig 6.5 B). Purified receptor material elutes a single symmetrical peak at ~14.8 
ml, consistent with the elution profiles of detergent complexed-pentameric GLIC, 
GluClcryst and chimeric GABAARs. SDS-PAGE confirmed that this peak corresponded to 
the cleaved ELIC, migrating predominantly as a homogenous band of ~30 kDa. The 
higher molecular mass bands most likely correspond to SDS-resistant receptor 
oligomers (Fig 6.5 B). Following analysis, the peak fractions were pooled and 





Figure 6.5 - ELIC forms a stable pentameric complex in UDM 
A. SEC profiles of uncleaved-MBP-ELIC (in UDM). The pentameric fusion protein purifies in a largely 
monodisperse state, with the pentameric complex the predominant species (shaded portion). Inset; SDS 
PAGE of SEC fractions (corresponding to the blue bar below the SEC trace). B. SEC profile of 
(proteolytically) cleaved-ELIC (in UDM). The pentameric complex elutes as a single symmetrical peak 
(shaded portion was pooled and concentrated for crystallization). Inset shows SDS PAGE of SEC fractions 




6.2.4. Crystallization of ELIC in complex with PS (and agonists) 
Given the abundance of purified protein that can be isolated (upwards of 2 mg per 
preparation) and the well-defined crystallization conditions that have been reported 
for ELIC, we first addressed ELIC crystallization in complex with PS. It is notable that of 
the 15 crystal structures reported for ELIC, the vast proportion used identical 
crystallisation conditions (yielding only one crystal form that is not isomorphous to the 
originally reported apo-form). To address crystallization in an unbiased manner, and 
introduction of a new ligand for ELIC (PS), we screened crystallization using membrane 
protein specific-sparse matrix screens (MemStart/Sys, MemGold and MemGold II - 
introduced in Chapter 4). In all previous crystal structures of ELIC, equilibration of the 
receptor in lipids prior to crystallization was apparently essential in generating high-
resolution diffraction data. We therefore pre-equilibrated our protein samples with 
one of two phosphatidylcholine phopsholipids, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). It 
should be noted that the lipid molecules associated with the ELIC receptor have not 
yet been reported in crystallographic data sets, and thus we cannot be sure of the 
manner in which these lipids interact with and stabilize the protein during 
crystallization. The protein was subsequently mixed with PS and crystal drops set in the 
presence or absence of an orthosteric agonist (GABA or propylamine).  We reasoned 
that agonist activation of the receptor in detergent micelles might be necessary for PS 
occupation of its receptor binding site in the crystal form.  
Surprisingly, we found that a large number of conditions supported crystallization (as 
assessed by results from sparse matrix screening). Unsurprisingly, a condition 
previously reported to allow for receptor crystallization (and generation of strongly 
diffracting crystals) was also a crystal growth ‘hit’ in early trials. ELIC crystals typically 
formed large rod or extended rectangular prism crystals (>100µm in longest 
dimension; Fig 6.6). Of more than 10 crystallization conditions assessed for (X-ray) 
diffraction (before further crystal growth optimization) we found that almost all 
exhibited protein diffraction. Typically crystals diffracted maximally to at least 10Å. For 




these hits, diffraction approached 4Å (one of which is shown in Fig 6.6). For these 
crystals we were able to confidently assign a three-dimensional space group to ELIC 
crystals grown in the presence of PS. Crystals were of the space group P21 and in that 
respect were identical to the majority of previously reported ELIC crystal structures. At 
this stage crystal quality was insufficient to collect complete data sets at the maximal 
observed resolution. Whilst it was possible to index and integrate reflections for 
generation of a low-resolution model (by molecular replacement) it is not possible to 
identify specific structural features. The α-helices of the TMD are clear as tube-shaped 
sections of density, and the β-sandwich of the ECD formed a large sheet of density. At 
this resolution we are unable to assign the receptor to a definitive activation state, or 
identify bound ligand or model residue side chains.   
We chose to focus our initial crystal growth optimization on a small number of newly 
identified hits (exhibiting strongest diffraction) as well as a previously reported ELIC 
crystallization condition(Hilf and Dutzler, 2008). Whilst new hits yielded crystal space 
groups identical to that previously reported, we reason that these were more likely to 
represent receptor crystallized in a distinct conformation to that observed in 
previously reported structures. Extensive crystal growth optimization was carried out 
at three temperatures; 4°C, 16°C and 22°C; under two different vapour diffusion 
strategies - hanging and sitting drops; in the presence of a combination of antagonist 
(PS), lipids (DPPC or POPC) and agonist (GABA or propylamine). In agreement with 
results from the initial screens, crystal growth was reproducible and consistently 
observed across a number of optimization screens. Assessing the effects of crystal 
growth optimization in extending the diffraction limit has thus far not yielded further 
success. Never-the-less, we have still to fully determine the importance of varying 
crystal cryo-protection prior to diffraction data collection; the effects of small molecule 
additive screening and the potential use of crystal-seeding (as introduced in chapter 5). 
Ultimately given the long list of diffracting hits in preliminary screens, identifying those 






Figure 6.6 - Diffraction pattern for crystal of ELIC 
X-ray diffraction pattern (0.5° oscillation range) from a crystal (top left panel) of ELIC grown in the 
presence of UDM, lipids and PS using microfocus beamline (Soleil Proxima 2). Resolution rings in the 
main diffraction at 9.6, 4.9 and 3.9Å are shown as blue circles. Lower left panel; magnified section of the 
diffraction image showing spots near to the diffraction limit, ~4.2 Å (resolution rings of 4.9 and 3.9 Å are 
shown in inset as blue circles). Data sets were collected for this crystal (though only complete at lower 
resolution) and indexed successfully as space group P21.  
 
6.2.5. Electron-microscopy of ELIC 
On the basis of the high yields of purified ELIC that could be generated, extensive 
screening of crystallisation was possible. However, what became clear from our efforts 
to co-crystallize GLIC (in Chapter 5) and ELIC, is that the bacterial pLGICs homologs 
should not be viewed as a panacea for rapid progression to high-resolution structural 
solutions. The addition of larger more complex molecules to the receptor-detergent 
complex could disrupt the ordered packing that is observed for receptors in their 




ligands previously crystallised in complex with ELIC and also GLIC. However the large 
macrocyclic lactone, ivermectin, could be crystallised in complex with GluClα (Hibbs 
and Gouaux, 2011). 
We therefore explored structure determination by using alternative means, namely 
cryo-EM. The rapid developments in this technique (as described in the Appendix 
Primer 1) make this a highly appealing technique for structure determination at near- 
atomic resolution, especially for challenging proteins, such integral membrane proteins 
(Liao et al., 2013; Cheng et al., 2015; Bai et al., 2015a). Moreover this technique no 
longer requires the production of large amounts of protein or well-ordered crystals. 
Despite these advantages, cryo-EM has its own set of technical challenges and caveats 
(Cheng et al., 2015). We attempted to optimize ELIC channel preparation for cryo-EM 
with a view to allowing data collection for single-particle cryo-EM (and eventual 
structure determination). We view this not only as an important step in attempting to 
solve the “in-solution” structure of ELIC, but also in establishing quality sample 
preparation that might be applied to alternative pLGICs, namely chimeric GABAARs, for 
single-particle analysis. 
The results of the following section are part of a collaborative project with Dan Kofi-
Clare (and Helen Saibil, Birkbeck); who prepared EM grids, collected electron 
micrographs and carried out initial data analysis. We prepared and optimized protein-
detergent complexes for EM and assisted with image acquisition. An overview of 
experimental procedures and image analysis is provided in the Materials and Methods 
and Appendix.       
ELIC was previously prepared (for X-ray crystallography) in sodium phosphate buffered 
solution, however this buffer displays unfavourable properties in EM studies causing 
high background signal. Receptors were therefore exchanged in to Tris-buffer (and 
UDM) by using SEC prior to EM grid preparation (Fig 6.7 A). ELIC retains its stability as a 
pentameric-detergent complex during this purification step (with SEC profiles 
displaying a sharp symmetrical peak of identical elution volume to that of the receptor 
purified in phosphate buffer). SDS PAGE and coomassie-staining revealed no receptor 





Figure 6.7 - Tris purification, negative stain, symmetry analysis (UDM). 
A. SEC profile for ELIC (in UDM) following exchange in to Tris-buffer (fractions corresponding to the 
shaded section were pooled for EM experiments). Inset shows SDS PAGE analysis of SEC fractions 
(starting material for buffer exchange is labelled as ELIC (NaP)). B. Negative-stain EM images of purified 
ELIC in UDM. Receptors preferentially adsorb to (continuous) carbon-coated grids in “end view” 
orientation. Two typical particle “end views” and one “side view” are highlighted by white boxes and 
shown magnified in side panels (A-C). Scale bar is 160 Å. C. Eigen-image analysis reveals five-fold 




We first needed to establish the sample conformation and compositional 
heterogeneity of ELIC in detergent (i.e. does the receptor form single particles or 
clusters of intact particles) by using negative-stain EM. Diluted samples of ELIC were 
applied to (glow discharged) EM grids with a continuous carbon film, stained with 
uranyl acetate before imaging (on a Tecnai T12 TEM at 67,000x magnification). The 
high contrast of negative stain micrographs revealed that ELIC forms single receptor 
particles, with very few imaged grid regions displaying receptor clustering or 
aggregation (Fig 6.7 B). Grids were largely devoid of significant background staining or 
ambiguous particles, and thus presumably detergent molecules are almost completely 
incorporated into receptor-micelles complexes. What was apparent in negative-stain 
micrographs was the propensity for ELIC to adsorb to carbon films in a preferential 
“end-on” (plan view) orientation (Fig 6.7 B). The vast majority of receptor particles can 
be clearly visualised as prototypical receptor rosettes (formed by the pentameric 
arrangement of subunits around the central pore) with a diameter of ~80Å (Hassaine 
et al., 2014). In most micrographs a small number of particles could be visualized in a 
distinct, presumed, “side-on” orientation. Particles resembling a more rectangular 
structure, with a central invagination, presumably at the border between receptor ECD 
and TMD; Fig 6.7 B) Whilst providing immediate confirmation of receptor structural 
integrity, this high degree of sample homogeneity (with regard to receptor orientation) 
might prove problematic during latter particle picking and image processing for 
structure calculations. 
From the micrographs collected, 1800 particles were picked to confirm that the end-on 
orientations corresponded to the intact pentameric receptor (Fig 6.7 C). Translational 
centering and alignment of particles and eigen image calculations allowed for 
generation of class averages. A second round of eigen image calculation using a subset 
of class averages enabled symmetry analysis of receptor particles. It is clear from 
image processing and analysis that, as expected for a pLGIC, particles in the “end-on” 
orientation display five-fold symmetry around the central axis (Fig 6.7 C).   
While negative stain micrographs display exceptional sample homogeneity (i.e. few 




contrast. The native structure is likely to be distorted by sample dehydration (Saibil, 
2000). Ultimately for structure determination, receptors must be prepared in vitreous 
ice for single-particle cryo-EM. During this vitrification process the sample is applied to 
a holey-carbon coated grid and plunged in to a coolant, typically liquid ethane. The 
result is the generation of a frozen hydrated sample in which native receptors are 
suspended and structure maintained (though particles now exhibit a lower contrast in 
the collected images; Saibil, 2000; Milne et al., 2013).   
In preliminary sample preparation for cryo-EM we observed few particles suspended in 
the amorphous ice layer over EM grid holes (Fig 6.8). Ideally a high degree of protein 
should partition into grid holes in random orientations, which is necessary for image 
collection, particle picking and analysis. What became apparent is that receptor 
particles adsorbed to the carbon-coated grid, resembling train tracks of particles lined 
up along grid lines and projecting out in to ice (Fig 6.8). On the basis of negative-stain 
experiments, it is likely that receptors adsorb to the support film preferentially in an 
“end-on manner”. The detrimental effects of the carbon support on image contrast 
mean that it is not possible to pick particles for image analysis. This phenomenon was 
consistently observed across grid regions and was independent of the thickness of the 
amorphous ice generated during sample vitrification. It is notable that these results are 
reminiscent of those observed in earlier studies of the kainate receptor, GluK2 
(Schauder et al., 2013), on conventional holey-carbon supports (receptor adsorbing 
almost exclusively to carbon in a preferential orientation). For subsequent studies that 
yielded structures of GluK2 (and GluA2) it was necessary to chemically modify the grids 
to “drive” receptors into the grid holes (Meyerson et al., 2014a; 2014b). 
Assessing various “grid supports” including graphene coated (Russo and Passmore, 
2014) and poly-lysine treated grids had no apparent effect on preferential orientation 
and partitioning of apo-ELIC by negative-stain or cryo-EM. Moreover it appeared that 
incubation with agonists (GABA or propylamine) in the absence or presence of PS did 
not alter receptor orientation.  We therefore reasoned that potentially the choice of 
detergent, UDM and its inherent micellar properties might be influencing the 




TRP channels and γ-secretase (allowing for eventual structure determination) found 
that it was essential to exchange detergent solubilised membrane protein in to an 
amphipathic polymer (amphipols, e.g. A8-35 and PMAL-C8; Liao et al., 2013; Cao et al., 
2013b; Paulsen et al., 2015; Bai et al., 2015b). These amphipol surfactants are able to 
exchange with and substitute for detergents used in membrane protein extraction, 
whilst maintaining protein stability (Kleinschmidt and Popot, 2014). Moreover they 
have been found to improve the preparation of membrane proteins in vitreous ice for 
cryo-EM (Althoff et al., 2011; Liao et al., 2014).  
 
 
Figure 6.8 - Preliminary cryo-EM of ELIC in UDM 
Two representative images of frozen-hydrated ELIC in UDM. Carbon segments of grids are regions of 
high contrast and are emphasised by dashed blue lines. Electron dense particles can be clearly seen as 
lines of receptor particles along hole edges and also on top of the carbon grid surface. These are shown 
in greater details in the magnified regions (lower panels). Receptors lining hole edge protruding into the 
ice are indicated by arrows and example of particles packed “on top” of the grid by a white circle. Scale 




ELIC purified in UDM was mixed at varying ratios of protein to the amphipol A8-35 
(ranging from 1:3 to 1:10 protein: A8-35 w/w). During this incubation it is assumed 
that A8-35 exchanges with UDM in the protein-detergent micelle complex, eventually 
surrounding the receptor. Following removal of “free-detergent” molecules (with Bio-
beads), the ELIC-amphipol complex was isolated by a further SEC purification step (in 
detergent-free aqueous solution; Fig 6.9 A). Receptor mixed with A8-35 at a 1:6 ratio 
exhibited a SEC profile with clearly defined peaks. The predominant (symmetrical) 
peak corresponded to the ELIC-amphipol complex, eluting at ~13 ml, and a second 
minor peak likely corresponded to excess free amphipol. We can infer the former from 
SDS PAGE analysis of peak fractions; material migrates predominantly as a band of 
expected mass for the monomeric ELIC receptor subunit; and from the shift in the 
elution profile of the ELIC-amphipol complex when compared to ELIC-UDM. The ELIC-
amphipol complex now elutes earlier from the SEC column, indicative of a complex of 
greater mass (and potentially hydrodynamic radius) when compared to that of ELIC-
UDM. This not surprising given that a single A8-35 molecule is of ~8 kDa (while UDM is 
~0.5 kDa). It is not immediately clear how many molecules of A8-35 associate with the 
pentameric ELIC (of ~185 kDa). It should be noted a small shouldering peak is observed 
with an elution volume roughly equivalent to the mass of ELIC-UDM (~15.5 ml). Given 
that material collected from this peak corresponds to ELIC (as assessed by SDS PAGE 
analysis), it would suggest that this equates to a small portion of ELIC retained in UDM 
(and not exchanged for amphipol). For negative-stain EM characterization we pooled 
the peak fractions presumably corresponding to ELIC-amphipol. 
Sample heterogeneity was assessed by using negative-stain EM (Fig 6.9 B and C). ELIC-
A8-35 complexes were applied to carbon-coated grids. Additionally we tested grids 
which had also been treated with poly-lysine (thereby altering surface charge). Whilst 
ELIC-A8-35 (like the sample in UDM) does not show a propensity to cluster or 
aggregate, existing largely as single particles on the carbon support, in contrast to 
previous observations in UDM, the receptor now displays considerable heterogeneity 
with respect to particle orientation. The number of receptor particles in an “end on” 
orientation is now matched by those in other orientations. Particles of extended length 






Figure 6.9 - Detergent exchange of ELIC in to amphipol, A8-35, and negative-stain EM 
A. SEC profile of ELIC-A8 35 complex (overlaid with ELIC-UDM SEC profile, pale cyan). Pentameric ELIC-
amphipol complex elutes at ~13 ml. Fractions from shaded section were pooled for studies. Inset right: 
peak fractions from SEC (corresponding to the dark red horizontal line in SEC profile) were analysed by 
SDS PAGE. Monomeric ELIC is indicated by a black arrowhead and detergent resistant dimer by blue 
arrowhead. B. and C. Negative-stain EM images of ELIC-A8 35 (on continuous carbon film). Receptor 
particles appear to occupy multiple random orientations in both the absence and presence of additional 
poly-lysine coating to EM grids. Three typical orientations are highlighted in both images; “end view” 
(white circles), “side view” (blue circle) and “tilt angle view” (green view). The tilt angle perspective for 





and “tilted” orientations). We assumed that effects on particle orientation are as a 
result of detergent exchange in to amphipol. Additionally we observed that altering 
the surface charge (through coating grids with poly-lysine) induced further effects on 
particle orientation (most likely an additive effect of altering surface charge and the 
nature of surfactant surrounding protein particle; Fig 6.9C). Given the large size of 
amphipol molecules, it is possible that some remaining free amphipols in the sample 
accumulate to form larger particulates or aggregates that might be of an equivalent 
size to the protein particle. However given the consistency of purified ELIC samples, 
and average particle size we are relatively confident that micrographs taken for ELIC–
amphipol preparations do indeed represent receptor particles in multiple random 
orientations.         
As before, negative stain EM serves only as a quality control step for sample 
preparation optimization and generating 2D averages of a set of particles (i.e. “low 
resolution” sample refinement). For “high resolution” sample refinement we must 
image vitrified samples by cryo-EM. As in previous cryo-EM experiments, ELIC-
amphipol complexes were applied to holey (carbon) EM grids and vitrified by plunging 
in to liquid ethane. In initial imaging experiments we observed that whilst a significant 
proportion of protein was adsorbed on to the carbon, there is a large number of 
protein particles suspended in vitreous ice (partitioned) in the holes of the EM grids 
(Fig 6.10 A). This contrasts with experiments carried out in UDM at equivalent protein 
concentrations (typically 2-3 mg/ml). Moreover, generation of tomograms (through 
reconstruction of 2D tilted images) reveals that the number of particles in the holes is 
too high at this protein concentration, and would likely complicate particle-picking and 
analysis. Due to the inherent low contrast of the samples in ice; the need to collect 
images using a microscope equipped with lower operating acceleration voltages; and 
the use of indirect detection device (for image recording) it was not immediately 
apparent whether particles reside in a preferential orientation in vitreous ice.  At this 
stage grids were prepared without further alteration of the surface charge. 
Having established a high quality sample preparation for cryo-EM, we collected cryo-




a K2 direct electron detector (Fig 6.10). Owing to the improved sample contrast it was 
possible to assess sample heterogeneity in ice. Once again receptors appeared to be 
preferentially orientated in the “end-on” view – easily recognised as a ring of electron 
dense receptor subunits around a central pore. Despite this a number of other particle 
orientations could also be visualized (though not clearly distinguished by eye alone). 
We therefore generated 2D class averages from 4,500 particles (picked from 79 
images; Fig 6.10B). Alignment and 2D classification is a critical step preceding 3D 
reconstruction and allows one to group the major views present in a data set and also 
remove ‘bad particles’ in a data set. Alignment and classification of particles was 
carried out in the software package RELION (REgularised LIkelihood OptimisatioN; 
Scheres, 2012). 
2D class averages of images collected with the K2 direct electron detector revealed a 
number of important factors. Before considering particle orientation one must 
appreciate the greater detail obtained by “direct detection”. “End” views of receptor 
show clear symmetry, and it is even possible to distinguish gross structural features 
(the helical bundle of the TMD). “Side views” reveal clear demarcation between the 
ECD and the TMD, and location of the outer vestibule and pore along the long axis of 
the receptor (Fig 6.10 B). With respects to receptor orientation, there are a number of 
notable observations. Firstly; the “end-on” view is highly populated when compared to 
other views (as indicated by the number of classes in which this orientation is 
observed). Secondly; there are few “bad or junk” classes (in which the nature of the 
particles is not obvious). Thirdly; an additional class of potentially “tilt” viewed 
receptor particles is also apparent. Finally, and most striking, is the presence (in initial 
rounds of alignment and classification) of double complexes resembling an “end view” 
particle associated with an additional “side view” particle. A second round of 
alignment and classification confirms this observation.  
We are currently further assessing particle classification (in parallel to subtle variations 
in sample preparation) to determine the amenability of this data set to initial 3D map 





Figure 6.10 - Cryo-EM images of ELIC - A8-35 complex and 2D class average analysis 
A. Typical images of frozen hydrated ELIC – A8-35 complex recorded on a Polara microscope (operated 
at 200 kV) and equipped with a K2 direct detection camera. Particles are visibly lined up along carbon 
grids and also partitioned in to ice over the grid holes. Right panel shows a magnified region of ice with 
embedded particles. End on views exhibit strong image contrast. Typical particle orientations are 
highlighted by black circles. B. Representative 2D class averages of ELIC particles (4,500 particles were 
used for the analysis). Three classes are indicated by red boxes clearly showing “end views” and “tilt 
views” for ELIC. The left panel shows a magnified end view emphasizing detail detected by K2 camera. 
The symmetry in the particles is emphasized by overlay of circle representing a pentameric arrangement 
of receptor subunits. Blue boxes indicate “doublet” particle classes. These were used in a second round 
of class averaging (shown in the lower panel). Increased detail in the side views is shown in the lower 
right panel (magnified view). Central pore axis is shown by a dashed yellow line and the location of the 




propylamine) in the presence of PS on ELIC receptor orientation and particle picking by 
cryo-EM. In doing so we may obtain data sets capable of generating 3D models for 
subsequent structure solution. This would represent a significant step with regards to 
determining the structures of pLGICs free from the constraints and conformational 
bias of the crystal form.      
 
6.2.6. Native mass spectrometry of ELIC in UDM 
In our integrated biochemical and structural biology approach to addressing PS-
mediated inhibition of the prokaryotic pLGIC ELIC, we also used native (ion mobility) 
mass spectrometry (Uetrecht et al., 2010). By this approach, mass spectra can be 
obtained for intact membrane protein complexes in the gas phase (stripped of 
detergent micelles; Barrera et al., 2008). This method, when coupled to ion mobility 
measurements, can assess the binding strengths and stabilizing effects of small 
molecules and lipids on the receptor (Laganowsky et al., 2014). Moreover the 
generation of high resolution spectra and collision induced dissociation of subunits 
from an oligomeric complex allows for the assessment of oligomeric-state dependent 
association of small molecules and lipids and their likely location of binding on the 
receptor (e.g. at subunit interfaces, plugs, or cavities). Given the lipidic-like nature of 
steroid-derived molecules, we reasoned that native (IM)-MS might also allow for the 
assessment of steroidal molecule binding at pLGICs, such as that of PS binding at of 
ELIC.     
Given the significant technical challenge, we have carried out MS investigation as part 
of a collaboration with Kitty Hendriks and Konstantinos Thalassionos at UCL, who 
acquired and analysed MS data. We prepared protein-detergent complexes for MS and 
assisted with experimental design and data analysis/interpretation.  
For mass spectra generation protein-detergent complexes were ionized by 




are subsequently stripped from the complex by incrementally increasing collisional 
activation energy following transmission into the quadrapole mass analyzer and 
acceleration in to a collision cell. A time-of-flight (TOF) mass analyser is used to then 
separate ions based on their mass: charge ratio (m/z) (Laganowsky et al., 2013). For 
additional IM measurements the drift time of an ion (dependent on size and shape) 
can be deduced. Experiments presented here were performed on a Synapt G1 (Water) 
mass spectrometer.  
Following substantial optimization, high quality mass spectra were generated for ELIC 
in UDM (Fig 6.11). Three distinct charge state distributions could be observed, from 
which experimental mass could be defined for different protein species. The intense 
distributions of lower m/z ratio showed a mass of 37.2 ± 0.013 kDa and likely 
corresponds (with high confidence) to dissociated monomeric ELIC subunit. Two 
further distributions of higher m/z were recorded. The second distribution was 
calculated to have a mass of 185.7 ± 0.042 kDa and the third a mass of 148.6 ± 0.046 
kDa (Fig 6.11). These distributions likely correspond to the pentameric and stripped 
pentamer, or tetrameric, complexes respectively. In the case of the latter, stripping of 
a single subunit occurs with increased collision energy, yielding a tetrameric complex. 
The experimentally derived mass of all species is in strong agreement with calculated 
theoretical masses and would allow for unequivocal assignment of charge distributions 
to oligomeric states of ELIC (Table 6.1).  Given the relatively broad peak corresponding 
to the pentameric state of ELIC, we might conclude that under these experimental 
parameters inefficient removal of detergent models is occurring (resulting in poor 
complex transmission and peak resolution). Nevertheless, the error in determining 
mass is sufficiently small that we might now be able to assess small molecule binding. 
However in order to determine (with high confidence) the identity of bound molecules 







Figure 6.11 - Native mass spectrum of ELIC in UDM 
Mass spectrum of ELIC in UDM. Three distinct charge distributions were observed in the spectraum 
ranging from 1000 to 16000 m/z and which following mass analysis equate to monomeric, pentameric 
and tetrameric ELIC (depicted by green circles above the spectrum). Peaks used to determine masses 
are shown by red, orange and yellow circles and the calculated mass and error are shown top right. Inset 
shows magnified view of the spectrum ranging from 5000 to 16000 m/z. The first distribution (orange 
circles) in this region corresponds to the pentameric form of the protein and the second distribution 
(yellow circles) corresponds to the stripped tetramer.   
 
We therefore carried out MS coupled with IM (IM-MS). Following extensive 
optimization of mass spectrometer parameters, spectra were generated displaying 
three clear charge distributions (as observed under the standard experimental 
conditions described above; Fig 6.12). The first distribution was more poorly defined, 
and peaks of lower intensity compared to those observed under standard conditions. 
The mass calculated from this distribution of 37.1 ± 0.001 kDa is consistent with this 
distribution corresponding to a dissociated monomer. The second and third 
distributions of higher m/z exhibited far greater intensity and resolution under IM 
parameters. The second distribution exhibited a calculated mass of 185.7 ± 0.008 kDa 






Figure 6.12 - Ion-mobility mass spectrum of ELIC in UDM 
IM-Mass spectrum of ELIC in UDM. As before three distinct charge distributions were observed in the 
spectrum ranging from 1000 to 16000 m/z and following mass analysis these equate to monomeric, 
pentameric and tetrameric ELIC (depicted by green circles above the spectrum, red circles suggest 
association and location of bound small molecule). Peaks used to determine the masses are shown by 
red, orange and yellow circles and the calculated mass and error shown top right. Lower panel left; 
shows a magnified view of the spectrum ranging from 5000 to 7000 m/z. This distribution corresponds 
to the pentameric form of ELIC and exhibits a second set of peaks of higher m/z value (indicated by 
asterisks). High m/z peak likely corresponds to protein complexes with associated small molecule. Lower 
panel right; a magnified view of the spectrum ranging from 8000 to 11000 m/z. This distribution 
corresponds to the stripped tetramer and also exhibits a second set of peaks of higher m/z value (also 




ELIC, these distributions corresponded to pentameric and stripped 
pentamer/tetrameric complexes (Table 6.2). More intriguingly, for both pentameric 
and tetrameric charge distributions, we could clearly resolve additional sets of peaks  
of greater m/z values (Fig 6.12: indicated by asterisks on expansion of the charge 
states). Calculation of experimental masses revealed additional values of 721. 49 Da 
and 707.49 Da for the pentameric and tetrameric states of ELIC respectively (Table 
6.2). Crucially this additional mass was not observed for the lower mass dissociated 
monomer.  
Given that measurements by IM-MS exhibit greatly improved transmission and 
resolution of intact oligomeric (principally pentameric) ELIC we can begin to use these 
experimental parameters as a starting point from which to assess the strength (and 
location) of small molecule binding, specifically of PS. Moreover we have been able to 
identify with high confidence an additional mass associated with pentameric and 
(stripped) tetrameric forms of ELIC. We can tentatively assign this to an endogenous 
lipid tightly bound at ELIC throughout the extraction and purification (the most likely 
candidate being phosphatiydlethanolamine, PE, a major E. coli lipid of average mass of 
719.302 Da). This is to our knowledge the first observation of endogenous lipid binding 
at ELIC, a phenomenon which was not observed from crystallographic studies. We 










Table 6.1 Comparison of theoretical and experimental masses of ELIC in UDM as 
determined by MS. 
 






theoretical mass (Da) 
Monomer 37151.68 ± 13.39 37133.58 18.10 
Tetramer 148565.94 ± 45.98 148534.32 31.62 
Pentamer 185748.46 ± 41.51 185667.90 80.56 
 
Note: Theoretical mass of tetramer and pentamer calculated from the mass of a 
monomer 
 
Table 6.2 Comparison of theoretical and experimental masses of ELIC in UDM as 
determined by IM-MS. 
 






theoretical mass (Da) 
Monomer 37142.98 ± 0.9 37133.58 9.34 
Tetramer 148557.50 ± 5.28 148534.32 43.18 
Tetramer * 149284.99 ± 15.41 148534.32 707.49 
Pentamer 185714.85 ± 7.94 185667.90 46.85 
Pentamer * 186436.28 ± 32.82 185667.90 721.49 
 
Note: * corresponds to masses calculated from charge states in Figure 6.12, also 





In this chapter we have identified a previously unreported inhibition of the prokaryotic 
pLGIC ELIC by the sulphonated brain steroid, PS. In efforts to further characterise PS 
binding and its mechanism of action we have carried out X-ray crystallography, cryo-
EM and native IM-MS. Despite each being challenging techniques in their own right, 
we have made significant progress in preparing high quality samples for the generation 
of preliminary data. Through combined use and integration of data from each of these 
techniques we hope to generate a high-resolution unbiased three-dimensional model 
of allosteric inhibition at a pLGIC.     
We are now at a position that we might reasonably implement these techniques for 
directly assessing PS inhibition. Having not yet generated definitive structural or 
binding data for PS, we do not feel it is appropriate to speculate on a mechanism of 
binding and action of PS at ELIC (and other pLGICs). We do however feel it is important 
to further emphasise the relative merits of the functional, biochemical and structural 
biology techniques that we have introduced and how they might assist us in advancing 
our understanding of allosteric modulation at ELIC. Moreover, experimental design in 
the framework of a combination of techniques is likely to prove beneficial to the study 
of other receptors, namely the chimeric GABAA receptors introduced in earlier 
chapters.  
It should initially be noted that further electrophysiological characterisation (beyond 
the extent of that presented here) is essential in further deciphering the underlying 
mechanism of PS inhibition at ELIC. While, reassuringly, PS exhibits allosteric-inhibition 
of agonist activity (as observed for a number of pLGICs, including GABAARs), it is not 
currently clear whether this inhibition is receptor state-dependent. Indeed, a 
consensus mechanism of PS block at native GABAARs is still yet to be reached (Seljeset 
et al., 2015). It was notable in our recordings that by co-application (and not pre-
incubation) of agonist (GABA) and PS, current profiles exhibited an apparent increase 
in the rate of current decay (in a manner akin to that observed at native GABAARs (Akk 




increased occupancy of ELIC in a desensitised state is not fully clear at this stage. With 
recent NMR and DEER spectroscopy experiments (Kinde et al., 2015) revealing that 
ELIC is able to exist in multiple resting and desensitized states, it will be intriguing to 
see if structural studies in the presence of PS will favour occupancy of the receptor in a 
state distinct to that observed in previous crystallographic studies (Hilf and Dutzler, 
2008; Spurny et al., 2012).  
While X-ray crystallography and cryo-EM will ultimately provide the greatest details 
regarding the site for steroid binding, they are reliant on generating strong 
unambiguous density (or signal) for bound ligand (which can be open to 
interpretation). In native (IM-) MS we introduced an alternative technique that can 
provide (lower-resolution) structural information. In line with the lack of consensus 
view regarding the kinetics of PS block, as to where PS binds (at the level of the 
receptor) is far from apparent. Whilst the reasonable assumption is that it likely 
imparts an effect at the level of the TMD, as to whether binding occurs within the 
channel (Wang et al., 2006), through association with the α-helical bundle, or even at 
the periphery of the protein (via lipid-protein interactions) is not clear. Given that in 
each of these scenarios the likely binding strength and number of molecules bound per 
pentamer will vary significantly, we reason that native IM-MS measurements will allow 
for unbiased analysis (i.e. studies of native, non-mutant receptor forms) of these 
variables. Indeed in our own experiments we are able to generate well resolved charge 
distributions and peaks for pentameric (apo-)ELIC that allow for identification of 
additional associated mass, likely corresponding to the endogenous E. coli lipid PE. The 
observation of additional mass at both pentameric and (stripped) tetrameric forms, 
but not dissociated monomers, reveals that this protein-lipid interaction is likely 
formed at the subunit interface (which would not be present in the monomeric form). 
Through binding studies with PS we hope to generate similarly well resolved mass 
spectra for unambiguous assessment of ligand association with pentameric and (gas 
phase) dissociation complexes.   
Of the results presented in this chapter, possibly the most exciting are those for the 




believed that the “size cut-off” for atomic resolution structure determination by cryo-
EM was 300 kDa (Bai et al., 2015a), the rapid development of direct electron detectors 
and image processing tools is continually challenging this limitation. Indeed a recent 
structure of γ-secretase membrane protein (of ~170 kDa) at 3.4Å reveals that these 
cut-off boundaries are already shifting significantly (Bai et al., 2015b). Despite these 
advances, the starting sample must be prepared in such a manner that it allows for 
generation of high resolution data. For a membrane protein extracted and purified in 
detergent this is particularly important. We have been able to clearly show that a 
prototypical pLGIC, ELIC, is stable in an amphipathic polymer (amphipol) known to 
show favourable properties in cryo-EM experiments (when compared to traditional 
detergents). Not only is this ELIC-amphipol complex biochemically stable, but also 
reveals improved properties in preliminary cryo-EM studies (with 2D class average 
images already revealing details of receptor architecture). We are keen to now test the 
size limit of cryo-EM for structure determination of a pLGIC in a non-crystalline 
environment. To date such a feat has only just been achieved for the GlyR (Du et al., 
2015). Moreover, given the quality of sample preparation, we believe this may be 
transferable across similar proteins and intend to assess the stability of chimeric 













Agonist activated currents of ELIC are inhibited by pregnenolone sulphate exhibiting a 
state-dependent mechanism of action. 
Crystals of ELIC can be grown in the presence of pregnenolone sulphate and in the 
presence of lipids and orthosteric agonists.  
Crystals maximally diffract to ~4Å, but do not at current resolution allow for 
unequivocal structural determination. 
ELIC can be detergent exchanged in to the amphipol A8-35, in which it retains 
biochemical stability and can adopt multiple orientations by negative-stain and cryo-
EM. 
IM-MS revealed the binding of small, structurally stabilising, molecules to ELIC, which 





Chapter 7: General Discussion 
For many years, pLGICs, and more specifically the GABAA receptor, proved elusive to 
high-resolution structural studies. The inherent importance of these receptors in 
maintaining normal network function and as significant pharmacological targets 
provides a strong rationale for identifying novel ways to ‘open up’ the GABAA receptor 
family for structural determination. This formed the principal focus of this thesis, 
which was to explore the use of chimeric GABAA receptors as a means to study the 
functional and structural properties of the receptor TMD. On the basis of a previously 
reported chimera between the ECD of the prokaryotic pLGIC GLIC and TMD of the 
human GlyR α1 (Duret et al. 2011), we adopted a similar approach by generating a 
domain chimera between the ECD of GLIC and the TMD of the GABAAR α1 subunit. By 
using a surrogate ECD of a receptor (e.g. GLIC) which is amenableto protein 
crystallization and structure determination, we were keen to determine whether this 
might allow for crystallization of the GABAAR α1 TMD. In doing so we could begin to 
address fundamental questions of how channel gating and allosteric modulation is 
coordinated at the atomic level. 
During the course of this study we have also identified novel interactions of GABAAR 
allosteric modulatory compounds with the prokaryotic pLGIC homologs GLIC and ELIC. 
These have provided the basis for structural studies to elucidate the mechanism of 
binding at these receptors, with a view to determine the evolutionary significance of a 
binding site and how these might relate to allosteric modulation of a native GABAAR 
subtype.  
7.1. The ECD of GLIC can act as a surrogate host for GABAAR subunit TMDs 
As alluded to, it was previously reported that the ECD of GLIC when fused to the TMD 
of the GlyR α1 subunit (a chimera termed as LiLy) formed a functional proton gated 
channel, with a receptor ‘TMD pharmocology’ reminiscent of that of the native α1 GlyR 




with the TMD of the GABAAR α1 or β2 subunit were capable of forming functional 
receptors retaining those properties, with regard to receptor kinetics and 
pharmacology, to be expected of a native GABAAR (Chapter 3). This exciting finding 
provided the starting point for the principal aim of this study, of expressing and 
purifying receptor chimeras for crystallization and subsequent structure 
determination. Ultimately a significant proportion of this study has been committed to 
identifying the expression and purification conditions which allow for the generation of 
a stable homopentameric GLIC-GABA chimera for structural studies (Chapter 4). This is 
somewhat unsurprising given that the purification strategies and structures for the 
homopentameric GABA β3 and LiLy have only recently been reported (Miller and 
Aricescu., 2014; Moraga-Cid et al., 2015). We expanded our approach and have been 
able to purify a chimeric receptor, bearing a single point mutation known to 
profoundly affect receptor desensitization, which allows robust crystal growth and X-
ray diffraction to 9 Å.  
This crucial finding forms the platform from which to advance our efforts of chimeric 
receptor crystallization. In doing so we will implement the array of techniques learnt 
and developed during this study (e.g. CPM fluorescence stability assays) to increase the 
throughput with which we screen new crystallization conditions. Moreover, we are 
beginning to address the question of structure determination by alternative 
approaches, especially cryo-EM, which has seen rapid technical advances in the last 
few years (Cheng et al., 2015). We believe that these approaches can then be applied 
to other receptor chimeras, either of alternative ‘desensitization’ mutants of the GLIC-
GABAAR α1 chimera or a GLIC-GABAAR β2 chimera for example. Given that studies of 
full-length native GABAAR subunits, exhibiting extensive post-translational 
modifications (e.g. glycosylation), will continue to prove challenging, the use of 
receptor chimeras is likely to remain an important one for advancing our 




7.2. GABAA receptor modulators bind at the prokaryotic pLGICs GLIC and ELIC 
Although this was not a major focus of this study, we have identified previously 
unreported inhibitory responses of GABAAR-active compounds at prokaryotic receptor 
homologs, GLIC and ELIC. The barbiturate, pentobarbital, was observed to inhibit a 
proton gated response at GLIC, while the inhibitory neurosteroid, pregnenolone 
sulphate, inhibited GABA-activated currents at ELIC. These observations provided the 
basis for attempts to determine the respective binding sites using X-ray crystallography 
(GLIC and ELIC) and cryo-EM (ELIC).  
 
7.2.1. Pentobarbital inhibition of GLIC 
With regard to the pentobarbital-inhibition of GLIC, it is unclear as to whether a 
barbiturate binding site on GLIC is likely to resemble a conserved binding site for these 
compounds on native GABAARs. Given the complex nature of barbiturate modulation 
of GABAARs (Muroi et al., 2009), and on the basis that we only observed inhibition of 
agonist activity at GLIC, it might be that an identified binding site on GLIC would more 
likely resemble that of a barbiturate binding site on cationic-pLGICs, e.g. nAChRS. 
Indeed, barbiturates have previously been reported to block neuronal and muscle 
nAChRs (Hamouda et al., 2014a). While our efforts to co-crystallize GLIC and 
pentobarbarbital (or a brominated derivative) yielded high-resolution diffraction data, 
allowing for structure determination, we were unable to identify a binding site. 
Ultimately, further efforts, utilizing distinct GLIC-gating mutants (Prevost et al., 2012), 
might assist in determining the molecular basis of pentobarbital binding. From this, 
one might begin to determine whether a binding site resembles one conserved at 





7.2.2. Pregnonlone sulphate inhibition of ELIC 
During this study we also observed that GABA-activated currents through ELIC 
receptors were inhibited by the steroid, pregnenolone sulphate (PS) in a manner 
reminiscent to that observed at native GABAARs (Seljeset et al., 2015). While we have 
yet to fully characterize the kinetic properties on this response, we have however 
begun to address the determinants of binding using a combination of structural 
approaches; X-ray crystallography, cryo-EM and native ion-mobility mass 
spectrometry. This integration of techniques, though challenging, will likely provide the 
most complete picture of how PS binds at and then inhibits receptor activity. During 
the course of this study, we have been able to optimize each of these methodological 
approaches for studies of ELIC and now find ourselves in a position to address the 
underlying basis for PS-mediated inhibition. Of particular note is the study of ELIC by 
cryo-EM. We have identified conditions that allow for the preparation of EM grids 
exhibiting ideal dispersion of ELIC receptor particles in vitrified ice with multiple 
orientations. This sample forms the ideal starting position for high-resolution data 
collection and structure determination by cryo-EM. Moreover, the application of this 
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Primer 1: Electron cryo-microscopy and single particle analysis 
Cryo-EM allows for direct imaging of non-crystalline protein particles. After being 
developed in the 1970’s, the last few years have seen rapid developments in single-
particle cryo-EM that make this technique a genuine competitor to X-ray 
crystallography for high-resolution structure determination (Cheng et al., 2015). This is 
particularly useful for proteins that are inherently refractory to crystallization, 
including membrane proteins (e.g. pLGICs). Moreover, by imaging proteins in a near 
native-state (not necessarily observed in the confines of protein packed into crystal 
form), cryo-EM allows for potential structure solution of a single protein in multiple 
conformational states. This has been highlighted by the recent cryo-EM study of the 
zebrafish α1 Gly receptor, which utilised cryo-EM to generate structures of agonist-, 
antagonist- and agonist/allosteric modulator-bound receptor (Du et al., 2015).  
Below summarises the key steps in sample preparation, imaging and image analysis 
that enables the generation of a 3D model.  
1. Sample Preparation: Purified protein is generated exactly as for protein 
crystallization trials. The amount of protein required is typically less (on the μg rather 
than mg scale). Construct design is also similar, with non-essential or highly flexible 
regions of the protein typically removed (whilst ensuring near-normal receptor 
function). For membrane proteins, additional detergent exchange may be carried out. 
Amphipathic polymers, including Amphipol A8-35 and PMAL-C8, have been used to 
stabilize membrane proteins, improving their qualities for cryo-EM grids when 
compared with proteins in conventional detergents (Cao et al., 2013a; Liao et al., 2014; 
Paulsen et al., 2015).  
2. Sample characterisation by Negative stain EM: Protein is applied to an EM grid and a 
heavy metal stain applied (typically uranyl acetate). During this process the protein 




protein is revealed by negative contrast, though this may be distorted during sample 
dehydration. Negative stain EM is a critical preliminary step in cryo-EM studies for 
structure determination, as it provides details of sample heterogeneity. For example, is 
the protein complex (, e.g. the pentameric assembly of a pLGIC) in the expected 
stoichiometry and does the sample show undesirable aggregation tendencies? 
Additionally the orientation of particles can be assessed; is there a preference towards 
a single or multiple orientations? This will have a bearing on the ability to generate a 
structure. Samples showing favourable properties by negative stain EM can be 
prepared for cryo-EM experiments (Appendix Fig 1).  
3. For cryo-EM the sample is embedded in a layer of vitreous ice (Appendix Fig 1 A). 
This is achieved by applying sample to EM grids that are then rapidly plunged into a 
coolant with high heat conductivity, such as liquid ethane. While the hydrated frozen 
protein retains its native structure, the protein-ice contrast is low compared to that 
observed for negative stain. For this reason, and to maximise contrast, cryo-specimens 
are prepared on grids with holes in the carbon support film. Ideally the protein 
particles are distributed in ice over the grid holes for imaging.  
4. Samples are imaged in the electron microscope (Appendix Fig 1 B).  For structure 
determination (and due to the low protein-ice contrast) images are recorded at high 
electron energies (200-300 kV). Multiple low exposure images (to minimize the 
damaging effects of high energy electron exposure) are collected for a number of grid 
regions containing thousands of particles. The recent developments of direct electron 
detector device (DDD) cameras (where electrons are detected by silicon sensors 
instead of less sensitive charge couple device (CCD) cameras) dramatically improves 
the signal-to-noise ratio in images.   
5. From the acquired images single protein particles are selected (i.e. defined within a 
region of interest). This is performed either manually or in a semi-automated manner 
(depending on sample quality). At this stage, these images represent the (real) 
observed 2D projections of particles. In Appendix Figure 1 C the likely molecular 
architectures of a pLGIC (rendered in iso-surface form) for these 2D projections are 
also shown. Thousands (and in some cases millions) of particles are picked for 




6. Particles are grouped by computational methods (e.g. by classification algorithms in 
the software RELION (Scheres, 2012)) based upon variations in particle orientation and 
structural features. Similar (or related) orientation classes are grouped, forming 2D 
class averages. We have shown 3 idealised classes for a pLGIC; a side view of the 
receptor, a top-down plan view of the ECD and bottom-up view of the TMD (Appendix 
Fig 1 D). Ideally a greater range of orientations would be observed for generating a 3D 
electron density map.  
7. From these 2D projections a 3D density map can be recovered by inverse Fourier 
transformation (Appendix Fig 1 E &F). The Fourier transform of each 2D projection is a 
section through the 3D Fourier transform of the structure. In this case we have 
represented the 3D transform as two intersecting transform sections, derived from the 
side view and end-on (TMD) view of our pLGIC (Appendix Fig 1 E). This is an over 
simplification, and realistically once enough 2D sections spanning a complete range of 
orientations are available, the full 3D transform can be interpolated and an inverse 
Fourier transformation recovers the 3D density map (Appendix Fig 1 F). 
8. Initial 3D maps can be further refined and then a structural model built from the 
electron density maps (as shown for the α1 GlyR, Appendix Fig 1 F) and analysed for 
correct stereochemistry (in a manner similar to that carried out for crystal structure 
model building and refinement).  
Appendix Figure 1 - Structure determination by Cryo-EM 
A. After initial sample characterization by negative stain EM, samples are prepared for single particle 
cryo-EM and structure determination. EM grids can be treated with various substrates to alter the 
surface charge and force particles into the ice over the grid holes. Plunge freezing in liquid ethane can 
be semi-automated using robotic plungers. The quality of freezing has substantial effects on the “ice 
quality” and thickness and subsequent imaging. B. An example of a cryo-EM image is shown for ELIC 
with a number of receptor particles circled. Hypothetical 3D molecular orientations of a pLGIC are 
shown (EM density maps of the α1 GlyR, contour level arbitrarily adjusted, are used as an example; 
EMDB-6344, Du et al., 2015) C. Note the ring of density around the TMD formed by the detergent shell. 
D. Theoretical 2D projections of a pLGIC for side and end views. E. Intersecting sections of side view and 
end view (TMD) are used to represent the 3D transform. F. The EM 3D density map (filtered and 









Primer 2:  Mass spectrometry (MS) reveals modes of lipid and small molecule binding 
to membrane protein complexes.  
While it is not intended to describe in depth the procedure of generating native MS 
data for membrane proteins, it is important to emphasize what can be obtained from 
high quality mass spectra for detergent solubilized pLGICs. This technique can be used 
to generate ‘images’ of how lipids and small molecules (free of additional labels) form 
non-covalent interactions with ion channels. Lipid stabilization and modulation of 
pLGICs is important for maintaining normal function, yet is typically restricted to 
reconstitution studies in proteoliposomes. Such studies do not necessarily provide 
information regarding the direct interaction and affinity of binding of pLGICs for lipids. 
In the case of GABAA receptors it is still far from clear as to the role that lipids play in 
modulating receptor function.  
1. Sample preparation: Mass spectrometry is a highly sensitive technique and while 
requiring less material than crystallography, samples should still be as pure and 
homogenous (Laganowsky et al., 2013).  A range of detergents is compatible with MS 
measurements; however, the ability to generate quality mass spectra is somewhat 
empirical in its derivation and dependent on the choice of detergent. This will also be 
inherently linked to the stability of the protein of interest in a certain detergent.  
2. Instrument parameters: Following ionisation of protein-detergent complexes and 
transfer into the gas phase, detergent molecules surrounding the pLGIC are removed 
by thermal agitation (via collisions with inert gas molecules, Appendix Figure 2; 
Bechara and Robinson, 2015). This releases detergent molecules, gradually exposing 
the transmembrane regions of the protein (Appendix Figs 2 B & C). Evidently 
maintaining the intact protein complex in the native oligomeric state is necessary for 
experimental mass measurements, and thus fine-tuning instruments parameters is 
critical.  Collision cell energies (i.e. varying the acceleration of ions in to a collision cell 
containing inert gas) can be varied to gradually eject the membrane complex from the 
detergent micelles. Here we show that at lower collision energies the pLGIC is trapped 
in the detergent micelle, yielding broad ill-defined mass spectra (Appendix Fig 2 A). 
Gradual loss of detergent molecules is reflected by an increase in the resolution of the 




At higher energies ejection of detergent molecules yields a high-resolution mass 
spectrum of the pentameric complex (Appendix Fig 2 C). Additionally collision-induced 
dissociation of the pentameric complex yields highly charged monomers and 
“stripped” receptor tetramers.  
3. Revealing endogenous lipids: Recent structural data suggests that lipid molecules 
bind at both intra- and intersubunit clefts in pLGICs (Nury et al., 2011; Althoff et al., 
2014). For GluClα, the lipid POPC induced a distinct open-like channel conformation 
when this lipid was added during the crystallization procedure (Althoff et al., 2014). In 
some cases it is possible that endogenous lipids (from the host cell used for protein 
over-expression) may remain tightly bound to receptor following detergent extraction. 
Well-resolved mass spectra of the charged receptor complex should reveal any 
endogenous lipid binding.  
In this example (Appendix Fig 2 D) we have two lipid molecules bound to the pentamer 
at two equivalent subunit interfaces. Expansion of the charge states shows three 
peaks. Deconvolution of these charge states allows the intact mass of the protein-lipid 
complex, and stoichiometry of lipid binding to be deduced. The peak with lowest 
mass/charge (m/z) value corresponds to the lipid free pentamer and peaks of 
increased m/z value correspond to a pentamer with one or two bound lipid molecules 
(Appendix Fig 2 D). With well-resolved spectra the mass of lipids can be determined for 
further analysis. In the example shown, with lipid binding at subunit interfaces, one 
might expect similar charge distributions across the “stripped” tetramer. On this basis, 
lipid association with the monomeric pLGIC subunit, lacking an interfacial site, would 
not be observed. In contrast lipid molecules tightly associated through binding at 
intrasubunit sites would be associated with charge states for all intact and dissociated 
complexes.      
4. Application to exogenous lipid and small molecule binding: By the principles 
introduced above, it should be theoretically possible to assess the mechanism of 
binding of a range of small molecules and lipids (at intrasubunit cavities or subunit 
interfaces). In doing so, specific binding sensitivities, in particular to different lipid 





Appendix Figure 2 - MS reveals detergent stripped-pLGIC and endogenous lipid 
binding 
A-C. Increasing collision cell energy strips detergent molecules from a pLGIC. As more detergent 
molecules are removed, the resolution of the mass spectrum improves (i.e. a narrowing of peaks). At 
optimal settings (C) peaks of charge distributions can be resolved and used for protein mass 
calculations. At high collision energies (C), the pentameric complex is disrupted to yield charged 
monomeric and “stripped” tetrameric species. Lipid and small molecule binding studies can be carried 
out on all species. D. Expansion across the (blue) highlight charge state reveals additional peaks with 
greater m/z value, which can be quantitatively defined as lipid bound complexes. In this example 
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Appendix Figure 3 - Alignment of GABAAR α1, GLIC and GLIC-GABAAR α1 
Alignment of WT mouse GABAAR α1 (red), WT GLIC (blue) and GLIC-GABAAR α1 chimera.  Site of domain 
fusion is at residue 223 of the GABAAR α1 subunit. α-helices of TMD are highlighted grey. Highlighted 
positions show residues lining the channel pore (light green); forming loop 7; M2-M3 loop; responsible 
for neurosteroid (NS) potentiation (teal), transduction (dark green) and activation (yellow); and affecting 
receptor desensitization (purple). 
	
GAbRA1_P62812           4 --------DELKDNTTVFTRILDRLLDG-------YDNRLRPGLGE-------RVTEVKT  
GLIC_3EAM               0 -----------------------------------AQDMVSPPPPIADEP-----LTVNT  
GLICECD GABAa1TMD       0 -----------------------------------AQDMVSPPPPIADEP-----LTVNT  
GLICECD GABAa1TMD ΔICD  0 -----------------------------------AQDMVSPPPPIADEP-----LTVNT  
 
 
GAbRA1_P62812             DIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPM--TVLRLNNLMASKIWTPDTFF  
GLIC_3EAM                 GIYLIECYSLDDKAETFKVNAFLSLSWKDRRLAFDPVRSG--VRVKTYEPEAIWIPEIRF  
GLICECD GABAa1TMD         GIYLIECYSLDDKAETFKVNAFLSLSWKDRRLAFDPVRSG--VRVKTYEPEAIWIPEIRF 
GLICECD GABAa1TMD ΔICD    GIYLIECYSLDDKAETFKVNAFLSLSWKDRRLAFDPVRSG--VRVKTYEPEAIWIPEIRF 
 
  
GAbRA1_P62812             HNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACPLKFGSYA  
GLIC_3EAM                 VNVENARDA----DVVDISVSPDGTVQYLERFSARVLSPLDFRRYPFDSQTLHIYLIVRS  
GLICECD GABAa1TMD         VNVENARDA----DVVDISVSPDGTVQYLERFSARVLSPLDFRRYPFDSQTLHIYLIVRS 
GLICECD GABAa1TMD ΔICD    VNVENARDA----DVVDISVSPDGTVQYLERFSARVLSPLDFRRYPFDSQTLHIYLIVRS 
          Loop 7 
 
GAbRA1_P62812             YTRAEVVYEWTREPARSVVVAE-DGSRLNQYDLLGQTVDSGIVQSST-G-EYVVMTTHFH  
GLIC_3EAM                 VDTRNIVLAVDLEKVG-----KNDDVFLTGWDIESFTAVVKPANFALEDRLESKLDYQLR  
GLICECD GABAa1TMD         VDTRNIVLAVDLEKVG-----KNDDVFLTGWDIESFTAVVKPANFALEDRLESKLDYQLR 
GLICECD GABAa1TMD ΔICD    VDTRNIVLAVDLEKVG-----KNDDVFLTGWDIESFTAVVKPANFALEDRLESKLDYQLR 
 
 
     223                       V251   G258 L263(9’) 
GAbRA1_P62812             LKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP  
GLIC_3EAM                 ISRQYFSYIPNIILPMLFILFISWTAFWS--TSYEANVTLVVSTLIAHIAFNILVETNLP  
GLICECD GABAa1TMD         ISRQYGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP  
GLICECD GABAa1TMD ΔICD    ISRQYGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLP 
                          TM1                           TM2 
                          NS “Activation”            Pore lining Residues 
                          NS Potentiation            Desensitization Residues 
                          NS Transduction 
 
      
GAbRA1_P62812             KVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGVKDPLIKKNNTYAPTATSY  
GLIC_3EAM                 KTPYMTYTGAIIFMIYLFYFVAVIEVTVQHYLKVESQPAR--------------------  
GLICECD GABAa1TMD         KVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGVKDPLIKKNNTYAPTATSY   
GLICECD GABAa1TMD ΔICD    KVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY----------------------- 
                                 TM3 
       M2-M3 Loop  
    
 
GAbRA1_P62812             TPNLARGDPGLATIAKSATIEPKEVKPARGDPGLATIAKSATIEPKEVKP  
GLIC_3EAM                 -------------------------------------------------- 
GLICECD GABAa1TMD         TPNLARGDPGLATIAKSATIEPKEVKPARGDPGLATIAKSATIEPKEVKP 
GLICECD GABAa1TMD ΔICD    ---------------------ATG-------------------------- 
 
        
GAbRA1_P62812             ETKPPEPKKTFNSVSKIDRLSRIAFPLLFGIFNLVYWATYLNREPQLKA  
GLIC_3EAM                 -------------AASITRASRIAFPVVFLLANIILAFLFFGF------ 317 
GLICECD GABAa1TMD         ETKPPEPKKTFNSVSKIDRLSRIAFPLLFGIFNLVYWATYLNREPQLKA 
GLICECD GABAa1TMD ΔICD    ----PEPKKTFNSVSKIDRLSRIAFPLLFGIFNLVYWATYLNREPQLKA 
                      TM4               TM4 
         NS Potentiation 
 
  
GAbRA1_P62812             PTPHQ------------------- 428 
GLIC_3EAM                 ------------------------ 
GLICECD GABAa1TMD         PTPHQ------------------- 428 








Appendix Figure 4 - Trafficking and functional characterisation of a GLIC-GABAAR β2 
chimera. 
A. α-Bungarotoxin labelling of HEK293 cells transfected with EGFP and BBS-tagged GLIC-GABAAR β2 
chimera (eGFP channel green, Alexa555 α-Bgtx channel red and merge with eGFP). B. Proton-gated 
currents for the GLIC-GABAAR β2 chimera (when expressed in oocytes). Currents were small and 







Appendix Figure 5 - SEC profiles of mutant GLIC-GABAAR α1 chimeras following 
extraction and exchange into various detergents 
A. Size exclusion chromatography profile of purified GLIC-GABAAR α1
V251F ∆ICD
His (Extracted: DDM± CHS & 
SEC: DDM). Major peak of pentameric receptor-detergent complex is at an elution volume of ~14.5 ml. 
B. Size exclusion chromatography profile of purified GLIC-GABAAR α1
V251F ∆ICD
His following extraction in 
DMNG + CHS (green) or in DDM +CHS and then exchange into DMNG + CHS(blue) and SEC in DMNG (for 
both). Major peak of pentameric receptor-detergent complex is at an elution volume of ~14.5 ml.C. Size 
exlusion chromatography profile of purified GLIC-GABAAR α1
V251I or G258A ∆ICD
His (extracted in DDM ± CHS 
and SEC in DDM) and comparison with ‘non-mutant’ bearing chimera. Major peak of pentameric 
receptor-detergent complex is at an elution volume of ~14.5 ml. D. B. Size exclusion chromatography 
profile of purified GLIC-GABAAR α1
V251F ∆ICD∆Ct
Hisfollowingextraction inDMNG + CHS (red) or in DDM +CHS 







Appendix Figure 6- Effect of detergents and CHS on GLIC-GABAAR α1
V251 F∆ICDHis 
thermal stability 
A. Melting curves for mild alky-maltoside and MNG detergents in the absence or presence of CHS B. 
Melting curves for less mild detergents: amino oxide (LDAO), ocytl glucoside and maltosides in the 
absence or presence of CHS C. Melting curves for an alky-maltoside (UDM), cycloalkylglycosides (Cymal 






Appendix Figure 7 - Global alignment of activated GLICBrPB at pH 4 (this study) with 
locally closed (pH 4) and resting (pH 7) forms 
Global alignment of the entire GLIC pentamer for active (red; this study), locally closed (LC; green, PDB 
3TLT) and resting (yellow, PDB 4NPQ) forms of GLIC. Active and LC forms were solved at pH 4 while the 
resting form was solved at neutral pH 7. The top panel shows the alignment of two subunits in a 
pentamer with the proximal three subunits removed for clarity. Lower panels show pentameric 
arrangements viewed from the extracellular side at the level of the ECD (left) and TMD (right). The 
relative transitions from resting to active forms are shown by blue arrows. At the level of the TMD, 
bending of the upper portion of M2 towards the channel creates an obstruction to ion flow in the 




Appendix Table 4 Structural alignments of GLIC from this study with equivalent 





Moving structure for alignment (pH & PDB 
ID) 
RMSD of Cα 
atoms (Å) 
GLICBrPB Pentamer GLIC Active (pH 4 4HFI) Pentamer 0.267 
 
GLIC LC (pH 4 3TLT) Pentamer 0.612 
 






Moving structure for alignment (pH & PDB 
ID) 
RMSD of Cα 
atoms (Å) 
GLICBrPB ECD GLIC Active (pH 4 4HFI) ECD 0.214 
 
GLIC LC (pH 4 3TLT) ECD 0.289 
 




Moving structure for alignment (pH & PDB 
ID) 
RMSD of Cα 
atoms (Å) 
GLICBrPB TMD GLIC Active (pH 4 4HFI) TMD 0.260 
 
GLIC LC (pH 4 3TLT) TMD 0.529 
 





Appendix Figure 8 - Difference density maps at high contouring show the likely 
presence of bound ions and detergent molecules 
A-D. Fo-Fc difference density map for the ECD, green, at increasing contour levels reveal peaks at the 
sites of previously identified chloride (white box) and acetate ions (yellow box). E-F. Peaks in 2mFo-DFc 
electron density, blue, and Fo-Fc difference density maps, reveal presence of detergents in the ion 
channel pore. 
